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Abstract 
Introduction: Photodynamic therapy (PDT) is a minimally invasive treatment that requires a light-
activated drug, known as a photosensitiser (PS), light of a specific wavelength and oxygen.  
5,10,15,20-meta-tetra(hydroxyphenyl)chlorin (m-THPC) is one of the most potent PS’s currently 
available for use in PDT, however, its undesirable accumulation in healthy tissues has prompted 
research to improve its uptake and selectivity into tumour tissue for the treatment of certain 
malignant diseases, whilst reducing adverse skin photosensitivity.  In this investigation, a range of 
nanocarriers, eliciting a host of different properties, were developed to achieve more efficient 
delivery of m-THPC in vivo.  These included liposomes, organically modified silica (ORMOSIL) 
nanoparticles (NPs) and polymeric NPs, which were additionally surface modified with a 
biocompatible polymer (PEG) coating to improve blood circulation times and the bioavailability of 
m-THPC.  Further to this, studies investigating the conjugation of ligands, over-expressed on many 
cancers, to the NP surface aimed to increase active m-THPC-delivery via targeted nanocarriers.  
The overall objective of this study was to compare the pharmacokinetics of m-THPC delivery 
between the nanocarrier formulations and standard Foscan®, in normal rat and tumour-bearing 
animal models, to ultimately improve the efficacy of PDT. 
 
Materials & Methods: The biodistribution of m-THPC in its standard formulation (Foscan) 
compared to its incorporation in untargeted and targeted pegylated NPs was assessed through 
quantitative chemical extraction methods and pharmacokinetic analysis.  A range of tissue samples 
were collected over different time periods following i.v. administration of NPs (m-THPC dose 
equivalent) in both healthy and tumour-bearing murine models.  Confocal and fluorescence 
microscopy techniques were employed for in vitro uptake studies and to examine ex vivo tissue 
localisation of encapsulated m-THPC.  Finally PDT and skin photosensitivity studies were carried 
out in vivo to assess the efficacy of treatment to tumours and skin through histological analysis. 
 
Results & Conclusion: Pharmacokinetic data typically indicated an increase in blood plasma t1/2 of 
pegylated NPs in comparison to non-pegylated NPs or Foscan alone, indicative of the stealth 
properties conferred by the PEG corona.  Peak accumulation of m-THPC in tumour tissue occurred 
between 6-24 h via passive uptake with untargeted NPs, attributed to the enhanced permeability 
and retention (EPR) effect.  A significant improvement in tumour uptake, by a factor of three, was 
observed using pegylated liposomes compared to Foscan alone.  Active targeting of NPs 
demonstrated a positive uptake into cells, unfortunately this did not translate to an improvement in 
m-THPC biodistribution or PDT results using in vivo models.  Encouragingly anti-tumour PDT 
effects were observed with all NPs compared to Foscan, but treatment was most effective with 
untargeted pegylated liposomes. 
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1. Photodynamic Therapy 
1.1 Introduction 
Cancer is a leading cause of death worldwide; accountable for 7.6 million deaths in 2008 
(Ferlay J et al. 2008).  With 12.7 million new cases reported in the same year, global 
statistics predict over 20 million people will be diagnosed with cancer by 2030 due to the 
increase in life expectancy and population growth (Boyle, P. &. L. B. 2008).  The demand 
for effective cancer treatments that address the current issues of systemic, conventional 
therapies is ever-increasing.  Photodynamic therapy (PDT) is a minimally invasive, 
powerful tool that can be harnessed to treat a variety of cancers (De Rosa, F. S. et al. 
2000;Veenhuizen, R. et al. 1997;Wang, J. B. et al. 2007;Wang, K. K. et al. 2008;Wang, X. 
H. et al. 2009).  It requires the administration of a non-toxic drug, known as a 
photosensitiser (PS), which only becomes activated when illuminated by a light source at a 
specific wavelength (Kübler, A. C. 2005;Robertson, C. A. et al. 2009).  In oxygenated 
tissues, this leads to the generation of cytotoxic species which consequently induce cell 
death and tissue degradation (Castano, A. P. et al. 2005;Schuitmaker, J. J. et al. 1996).  The 
fundamental specificity of PDT is highly attractive in its application in oncology; however, 
the limited selectivity of the photosensitiser into malignant tissues is a crucial inadequacy, 
which results in adverse prolonged cutaneous photosensitivity.  Additionally, light and 
dosage parameters need to be optimised to enhance its efficacy.  This study aims to reduce 
inter-patient variability of PDT by improving the delivery of a potent PS, meta-
tetra(hydroxyphenyl)chlorin (m-THPC), into ‘target’ tumour tissues in comparison to 
normal tissues by its encapsulation into pegylated nanoparticles (NP). 
 
1.2 History of PDT 
Phototherapy has been known for over 3000 years (Spikes, J. D. 1985) and the use of light 
to treat diseases has been investigated since the beginning of the last century when Niels 
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Rydberg Finsen won the Nobel Prize in 1903 for Physiology-Medicine after treating 800 
patients suffering from skin tuberculosis with phototherapy (Szeimies, R. M. et al. 2001).  
Around the same time, Oscar Raab was investigating the concept of inducing cell death 
through the interaction of light and chemicals under Dr Hermann Von Tappeiner (Raab, O. 
1900).  Using dyes such as acridine and eosin in the presence of light, and crucially oxygen 
(Ledoux-Lebards 1902), it was discovered that paramecia were rapidly killed and the term 
‘photodynamic action’ was introduced (Tappeiner, H. v. et al. 1904).  Porphyrins were the 
first photosensitisers to be identified (Dolmans, D. E. et al. 2003) and tested in humans 
(skin) by Friedrich Meyer-Betz, who observed pain and inflammation (extreme 
photosensitisation) for over 2 months when exposed to light after injecting himself with 
200 mg haematoporphyrin (Meyer-Betz, F. 1913).  Although retention and accumulation of 
haematoporphyrin was observed in neoplastic tissues in 1942 (Auler, H. et al. 1942), PDT, 
was not used to kill cancer cells until 1972 by Diamond et al., (Diamond, I. et al. 1972) in 
rats.  It was soon discovered that deeper regions of the tumour tissue remained viable after 
treatment, which indicated that activation of the photosensitiser was only superficial and 
longer wavelengths of light were required to penetrate tissue further to kill remaining 
cancerous cells.  This was achieved when Dougherty (Dougherty, T. J. et al. 1975) and 
Kelly (Kelly, J. F. et al. 1975) used red light (+ 630 nm) to successfully eradicate tumours 
in mice and humans with the a haematoporphyrin derivative (HPD).  It was found 
numerous PDT treatments could be given to reoccurring malignancies due to its `minimal 
invasiveness in comparison to other available conventional therapies (e.g. surgical 
resection, radiotherapy and chemotherapy), which had previously failed.  Since then, the 
development of new photosensitisers has enhanced the field of PDT, as different sensitisers 
require activation at different wavelengths of light, therefore therapy can be tailored to 
treat a whole range of cancerous tissues, where any damage to surrounding normal tissue is 
within an acceptable or tolerable level from which it can recover; gynaecological (Soergel, 
P. et al. 2008), pancreatic (Bown, S. G. et al. 2002), brain (Popovic, E. A. et al. 1996), 
head and neck (Hopper, C. et al. 2000). 
 
1.3 Photochemistry 
At room temperature almost all molecules are found in their lowest energy (ground) state 
(S0) and electrons are orbitally paired in configuration.  These electronic energy levels are 
dictated by electronic potential energy and are subdivided into (i) vibrational levels, 
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reflecting energy due to oscillations, and (ii) rotational levels (electron spin).  When a 
photon of light is absorbed by the system (chromophore), electrons are excited from low 
energy orbitals (S0) to unoccupied higher energy orbitals (S1).  These excited states are 
more short-lived due to differences in electronic distribution and a lower energetic 
stability; and as a result must release this surplus energy.  This can occur via a number of 
mechanisms, illustrated in the Jablonski diagram (Jablonski, A. 1933) (Fig 1.1). 
 
Figure 1.1. Jablonski diagram illustrating the electronic states of a photosensitiser (S0, S1, Sn, Tn, T1) 
following absorption of a photon, energy transitions between them (IC, VR, ISC) and the production of 
singlet oxygen (1O2).  The states are arranged vertically by energy and horizontally by spin multiplicity 
(Ogilby, P. R. 2010); vibrational ground states are indicated by thick lines, higher rotational states by thinner 
lines, straight arrows show absorption and radiative transitions and curly arrows show non-radiative 
transitions. 
 
Although photochemical reactions may be initiated from higher energy states (Sn), short 
lifetimes (10-9-10-6 s) mean that these processes have low yields, therefore excited electrons 
are quickly converted to their lowest vibrational level (S0 or S1),  through both non-
radiative and radiative transitions (Yaghini, E. 2011) (Fig 1.1). 
 
Non-radiative transitions 
• Vibrational Relaxation (VR), a molecule in a high vibrational level of an excited state 
(Sn) will quickly fall to the lowest vibrational level of this state. 
• Internal Conversion (IC), a molecule can fall from an excited singlet state (S1) to 
ground state (S0) by losing energy in small increments to the environment, cascading 
down through the vibrational levels to S0. 
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• Intersystem Crossing (ISC), ground state (S0) excitation through absorption directly to 
the triplet state (T1) is strictly forbidden in quantum mechanics due to prohibited 
changes in electron spin, from antiparallel ↑↓ (S0) to parallel spin ↑↑ (T1).  This also 
applies for transitions through emission of radiation, from an excited singlet state (S1) 
↑↓ to an excited triplet state (T1) ↑↑ of lower energy.  However, if an electron requires 
a spin inversion to relax and the energy gap between S1 and T1 is small (their wave 
functions have some overlap, Franck-Condon Principle), this leads to favourable spin-
orbit interactions but prolongs radiative decay of the electron.  The probability of this 
process is greater for aromatic compounds.   
 
Radiative transitions 
• Fluorescence, a molecule in its lowest excited singlet state (S1) may fall to a low 
vibrational level of the S0 state (S→S) by giving off energy in the form of light 
(radiative transition, ~10-9 secs).  As emitted photons have a lower energy to that which 
were absorbed, fluorescence emits a longer wavelength of light (λ) than was used to 
excite and consequently emission maxima is red-shifted compared to the absorption 
maxima (Stokes-Lommel’s Law).  This also provides a signal which can be used for 
imaging and dosimetry in PDT. 
• Phosphorescence; a molecule may return to S0 from its lowest excited triplet state (T1) 
by emitting light (or by emitting heat) through ISC (S→T).  As this process is spin 
forbidden it has a slower radiative decay (radiative transition, ~10-3 secs) and the signal 
is weak.  
 
T1 states tend to have longer half-lives than S1 states, as a result of forbidden spin 
processes. 
 
1.4 Mechanism of Action 
Photodynamic therapy consists of two competing oxidative pathways; Type I and Type II 
reactions (Sharman, W. M. et al. 2000).  The process requires three key components in 
order to function, without any one of which, a reaction does not occur; these are light, 
photosensitiser and oxygen.  As with all photochemical reactions, light is initially absorbed 
by a chromophore, however, in photosensitisation reactions, this light activation induces 
chemical changes in additional molecules other than the chromophore itself.   
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Figure 1.2. A schematic diagram of the two oxidation reaction pathways of PDT; Type I and Type II, 
following absorption of photons by a photosensitiser.  Diagram taken from (Dolmans, D. E. et al. 2003). 
 
Once activated, the chromophore promotes electronic excitation to higher energy states.  In 
the case of PDT, when the photosensitiser (P) is exposed to light at a specific wavelength it 
becomes activated from a ground state (0P) to an excited state (nP*).  In the presence of 
oxygen, the photosensitiser can undergo two types of reactions, transferring its energy as it 
returns to ground state (0P).  Intersystem crossing (ISC) from 1P* to the excited triplet state 
(3P*), typically a spin forbidden process, is a therapeutically important relaxation 
mechanism (Yaghini, E. 2011).  Photosensitisers are able to undergo this transition with 
high efficiency due to a shift in energy levels from favourable electron spin-orbit 
interactions.  For example, pi bonds in the aromatic structure of the photosensitiser 
molecule create electron wavefunction overlap, allowing electrons to move from one 
orbital to another more easily (Plaetzer et al., 2009).  In a biological environment the 
excited photosensitiser constantly collides with other molecules, and this provides 3P* with 
alternative relaxation pathways (Hatz, S. et al. 2007).  The first involves transfer of the 
electron to an acceptor molecule (Type I) and the second involves transfer of energy to 
oxygen molecules (Type II) (Foote, C. S. 1991). 
 
In a Type I reaction; 3P* reacts directly with the substrate (S) i.e. components of the cell, 
changing the charge on the photosensitiser molecule to form pairs of neutral radicals (e.g. 
P.- + S.+ or P.+ + S.-) or radical ions (O2.-, superoxide, or .OH. hydroxyl) following hydrogen 
or electron transfer (Calzavara-Pinton, P. G. et al. 2007).  Both the excited photosensitiser 
(3P*) and ground state substrate (S) can act as a hydrogen donor (undergo oxidation) and 
resulting radical species can react with O2 to form peroxyl radicals (SOO.).  Alternatively, 
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semi-reduced forms of photosensitiser (P.-) and substrate (S.-) can also react with O2 to 
generate superoxide radical anions (O2.-).  These, in turn, can both produce and react with 
hydrogen peroxide (H2O2), the latter creating reactive hydroxyl radicals (.OH).  These 
species are toxic and H2O2 is likely more mobile than singlet oxygen (1O2), passing easily 
through intracellular membranes (Bienert, G. P. et al. 2006), creating a greater potential for 
far reaching cellular damage. 
 
Type II reactions are the predominant mechanism for which PDT is thought to occur and 
exert phototoxic effects (Dougherty, T. J. et al. 1976).  In this instance, the photosensitiser 
in its excited triplet state (3P*) is able to transfer energy directly to ground state molecular 
oxygen present in living tissue, as it is naturally found in a triplet state configuration (3O2).  
An electron in 3O2 may be promoted to the singlet excited state (Fig 1.1) upon receipt of 
energy from longer lived 3P*
 
to generate singlet oxygen (1O2) and other reactive oxygen 
species (ROS): 
 
P → 1P* → 3P* + O2 → P + 1O2                                                                             (1.1) 
 
The vast majority of photosensitisers are able to mediate 1O2 production as they possess an 
energy gap exceeding that required to excite 3O2 into its singlet state (>94 kJ mol-1) as they 
absorb light at wavelengths λ < 1260 nm (Plaetzer, K. et al. 2009).  As in its excited 
electronic state (excess energy), singlet oxygen is a potent oxidising agent, reacting 
aggressively with cell components to induce cellular toxicity (Levy, J. G. 1994).  It has an 
extremely short life-time (< 0.04 µs) and a low diffusion constant in biological systems due 
to the presence of various quenchers, which consequently produces a short radius of action 
(< 0.02 µm) (Moan, J. et al. 1991) and compartmentalises photodamage.  However, 1O2 is 
not site-specific and is able to cause a cascade of destruction including lipid peroxidation 
(Rapozzi, V. et al. 2009), photo-oxidation of DNA guanine and damage to membranes and 
the cytoskeleton (Moan, J. et al. 1992) mediating cell death through necrosis and apoptosis 
pathways (Oleinick, N. L. et al. 1998).  Is not site-specific In PDT, this singlet oxygen 
yield ( ) is typically a good indicator of phototoxicity (Chen, W. et al. 2006), however, is 
dependent on a number factors that may limit therapeutic effects clinically, including, the 
diffusion of light and singlet oxygen through different biological tissues and 
photosensitiser aggregation in vivo. 
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1.5 Clinical PDT 
In practice, achieving maximal destruction of tumour tissue can be challenging as the 
processes involved are complex. The availability of oxygen in the tissues is an essential 
PDT parameter.  Vascular damage plays a vital role in PDT efficacy and contributes to 
long-term tumour control (Dougherty, T. J. et al. 1998); however a functional blood supply 
is critical in the delivery of oxygen to tissues, which is required to carry out treatment.  If 
microvascular collapse occurs during the procedure, a photochemical reaction cannot take 
place and the treatment no longer becomes effective due to insufficient oxygen 
concentrations.  It has been found that hypoxic tumour cells in murine RIF-1 tumours have 
been protected from PDT damage in vivo (Henderson, B. W. et al. 1989b) and decreasing 
cell death has been recorded with increasing distance from the vasculature supply 
(Korbelik, M. et al. 1994a).  Therefore it is not preferential to restrict the blood flow to the 
tumour until after completion of PDT treatment which also prevents tumour regrowth.  
This can be achieved by delivering light sequentially over fractionated doses.  A second 
destruction mechanism of PDT involves direct cell kill (Juarranz, A. et al. 2008), whereby 
tumour cells are targeted over the vasculature.  The diffusion of photosensitiser out of the 
vasculature specifically into intracellular compartments of the tumour cells provides a 
killing mechanism, as ROS can only act close to the site of generation (Robertson, C. A. et 
al. 2009) due to the short diffusion distance of singlet oxygen.  It is important to identify an 
optimal subcellular target (Dougherty, T. J. et al. 1998;Kessel, D. 1993) as complete 
tumour eradication by this mechanism is limited by the non-homogenous distribution of 
photosensitisers within the tumour tissue (Dolmans, D. E. et al. 2003).  This will 
additionally prevent unwanted high volumes of photosensitiser distributing into normal 
tissues and is the focus of this investigation. 
 
1.6 Why PDT? 
PDT can be used in a number of applications, ranging from psoriasis, rheumatoid arthritis, 
and microbial infections.  It has been successfully implemented in the treatment of 
diseases, both non-malignant and malignant, including age-related macular degeneration 
and a host of cancers.  Common cancer treatments, currently employed, each have their 
own set of limitations and disadvantages; surgical resections can cause aesthetic 
implications, are costly in time and expense (prolonged hospitalisation) and have long 
recovery/healing periods.  Systemic treatments, such as radiotherapy and chemotherapy, 
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have many unpleasant side-effects including; nausea, exhaustion, digestive problems, 
physical changes (skin, hair) and higher susceptibility to infection during/post-treatment 
due to non-selective uptake in other high-profilerating cells (Cancer Research UK 2014). 
 
PDT is a minimally invasive technique (Allison, R. R. et al. 2009) due to a lack of 
culmulative toxicity and can therefore be applied repeatedly unlike most conventional 
methods where an administrative threshold is reached due to systemic application.  PDT 
treatment periods are short (Mlkvy, P. et al. 1995) resulting in reduced hospital admission 
times (Bown, S. G. et al. 2002) and cost.  The treatment is specific, selective (Alexiades-
Armenakas, M. 2006) and safe, as each of the three components (photosensitiser, light and 
oxygen) have to be present in order for a reaction to occur.  The administration of 
photosensitiser is non-toxic and will only become active once light is introduced to the 
tissue, therefore light can be directed to the exact tumour site.  Although the rapid 
proliferation of tumours is known to result in hypoxic areas within the tissue (Brown, J. M. 
et al. 2004), repeatable PDT treatments mean efficient debulking of the tumour can still 
occur in oxygenated regions (Souza, C. S. et al. 2007).  Furthermore, lymphocytes and 
macrophages may become sensitised as part of an immune response potentiated by PDT, 
which then seek to eliminate small foci of any remaining viable cancer cells under a 
reduced tumour burden (Dougherty, T. J. et al. 1998;Korbelik, M. et al. 1999).  This has 
been reported by multiple studies in vitro documenting macrophage activation factors 
(TNF-β, DBPMAF) and in vivo through immune cell infiltration in murine SCCVII 
tumours (Korbelik, M. et al. 1994b).  Additionally, PDT does not exhibit a thermal effect, 
as the fluence rate of light does not reach sufficient levels to induce heating of the tissue 
(Bown, S. G. 1990), therefore the integrity of underlying structures and connective tissues, 
such as collagen and elastin, are largely preserved (Hopper, C. et al. 2000).  This produces 
very pleasing aesthetic outcomes, as healing is rapid, leading to huge cosmetic advantages 
(Nyst, H. J. et al. 2009).  PDT itself has some remarkable benefits but can be particularly 
effective when used in combination with conventional and novel therapies, especially if the 
patient is already in a weakened state or these treatments have previously failed (Nathan, 
T. R. et al. 2002).  Photochemical Internalisation (PCI) is a new technique, which exploits 
the mechanisms of PDT at a subcellular level to augment the intracellular delivery of 
endocytosed, biologically active macromolecules, such as cytotoxic chemotherapeutic 
agents to potentiate cell death.  Its success in vivo has led to its progression into Phase II 
clinical trials and offers exciting potential. 
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1.7 Photosensitisers 
Photosensitisers are archetypally planar, aromatic compounds with a core macrocycle 
composed of pyrrole rings.  These rings are linked by either azone bridges 
(phthalocyanine) or methine bridges (porphin, chlorin, bacteriochlorin), which are all fully 
conjugated with double bonds (Fig 1.3). 
 
 
22 pi-electrons 20 pi-electrons 18 pi-electrons 18 pi-electrons 
λ ~630 nm λ ~650 nm λ ~670 nm λ ~670 nm 
 
Figure 1.3. Basic structures of porphyrin, chlorin, bacteriocholrin and phthalocyanine with their 
corresponding pi-electrons and emission wavelengths (λ) (Bonnett, R. et al. 1999). 
 
The extensive pi-conjugation system within these aromatic structures allows these 
photomolecules to absorb light in the visible region of the spectrum (λ = 350-750 nm), 
producing similar absorption spectra.  Characteristically, porphyrins exhibit a strong 
absorption peak in the near-ultraviolet region ~400 nm (Soret Band) as a result of a strong 
transition from the ground state to higher excited states (S0→Sn) and a weaker absorption 
peak between ~600-800 nm (Q band) from a weak transition to the first excited state 
(S0→S1).  Despite the reduction in absorption, this secondary weaker peak is more 
preferable in clinical applications due to the greater penetration depth of red light (longer 
λ) into biological tissues in comparison to blue light (shorter λ), which is strongly absorbed 
or scattered by haemoglobins in the blood and other proteins (Bechet, D. et al. 2008).  This 
pi-conjugation system also potentiates a reduction in the transition energy (∆E) between 
molecular excitation states, resulting in absorption of longer wavelengths of light (lower 
energy).  Porphyrins have a greater number of pi-electrons (22) due to the greater number 
of saturated double bonds in their structure (Fig 1.3) in comparison to chlorins (1 reduced 
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double bond, 20 pi-e) and bacteriochlorin/phthalocyanine (2 reduced double bonds, 18 pi-e).  
As a result, the absorption maxima of the Q band progressively increases in wavelength (λ) 
between each compound due to the loss of symmetry in the molecule and the lower level of 
energy required to induce transitional changes (Fig 1.3).   
 
The disadvantages associated with PDT are largely attributed to the localisation and uptake 
of the photosensitiser.  For example, prolonged photosensitivity of the skin and eyes is a 
result of undesirable accumulation in these tissues, which can lead to swelling, sunburn 
and blistering if exposed to bright light (Chatterjee, D. K. et al. 2008a) for several days or 
even weeks after treatment (depending on the PS).  In both the clinic and animal models, 
hydrophilic photosensitisers (e.g. haematoporphyrin, tetrasulphonated porphyrins and 
phthalocyanines) are largely transported by albumin and globulins, whereas hydrophobic 
photosensitisers (porphyrin esters and chlorins) are preferentially incorporated into the 
lipid interior of lipoproteins (Jori, G. 1989).  The systemic administration of more 
hydrophobic photosensitisers (non-polar molecules) through intravenous injection can 
create preliminary problems, due to the formation of aggregates in physiological aqueous 
conditions (Chen, B. et al. 2005).  Their hydrophobicity may also lead to interactions with 
other circulating PS molecules, which can affect the photophysical properties of the PS, 
such as the production of singlet oxygen ( ) (Bechet, D. et al. 2008).  Furthermore, the 
stimulated binding of plasma proteins to hydrophobic aggregate-complexes can lead to 
rapid PS elimination from circulation and preferential uptake by cells of the 
reticuloendothelial system (RES), such as the Kupffer cells of liver, followed by the spleen 
and the lungs (Brannon-Peppas, L. et al. 2004).   
 
FDA approved photosensitisers absorb in visible regions of the spectrum (< 700 nm), 
which can be restrictive clinically, as light penetration is limited (mm) and therefore only 
superficial lesions can be treated (without the use of fibre-optic scopes).  In addition, 
technical difficulties in the application of PDT to a wide range of oncological diseases, can 
lead to high inter-patient variability with many photosensitisers in terms of PDT treatment 
response.  However, tissues irradiated at wavelengths exceeding this (>700 nm) may not 
generate adequate levels of energy to produce ROS.  Finally, and perhaps more 
importantly, selectivity of the photosensitiser to diseased tissue may not sufficiently 
outweigh that of normal tissue.   
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Ideal photosensitisers should fulfil several requirements (Bonnett, R. et al. 1989a) for use 
in clinical applications, established by Bonnett et al.,: 
 Chemically pure with stable composition 
 Strong absorption in the red region of the visible spectrum (> 650 nm) 
 High quantum yield in triplet formation (3P*) (energy > 94 kJ mol-1) for high 
production of singlet oxygen and greater phototoxicity 
 Minimal dark toxicity 
 High tumour selectivity over normal host tissue 
 Good pharmacokinetic clearance profile 
 
In 1993 PDT was first approved for the treatment of bladder cancer in Canada (Dolmans, 
D. E. et al. 2003), which was carried out using the PS, Photofrin® (PII).  PII is partially 
purified haematoporphyrin derivate (HpD), that contains the porphyrin moiety.  Porphyrins 
are comprised of four pyrrole rings interconnected by methine bridges to form a 
heterocyclic structure.  Upon the introduction of light, these alternating single and double 
bonds in the ring chains of the molecule, allow activated electrons to circulate around 
them, retaining and transferring energy from one molecule to another non-energised 
molecule (Wald, G. 1959).  Porphyrins were named the first generation photosensitisers.  
They have been approved for a range of cancer treatments over the last 20 years (Brown, S. 
B. et al. 2004) having never produced any serious side-effects indicating good long-term 
safety and repeatability.  However, PII is not a pure compound and is synthesised in a 
complex mixture of porphyrin dimers and oligomers (Fadel, M. et al. 2010;Verma, S. et al. 
2007).  Its maximal absorption wavelength is 630 nm, at the lower end of the therapeutic 
window, producing limited penetration depth of light.  It also possesses poor tumour 
selectivity, which can lead to skin photosensitivity lasting for several weeks (Moriwaki, S. 
I. et al. 2001).   
 
Second generation photosensitisers including; phthalocynanines, napthalocyanine and 
chlorins, are porphyrin derivatives developed to try and overcome some of the limitations 
and unfavourable properties of porphyrins (Chatterjee, D. K. et al. 2008a).  Temoporfin, 
also known as 5,10,15,20-meta-tetra(hydroxyphenyl)chlorin (m-THPC) (Fig 1.4) or trade 
name formulation, Foscan®, is a second generation photosensitiser (Bonnett, R. et al. 
2002) and was approved in the European Union and Japan for the treatment of head and 
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neck cancers in 2001 (Brown, S. B. et al. 2004).  Since this time, it has been used to treat 
early squamous cell carcinomas (Copper, M. P. et al. 2003), basal cell carcinomas (Baas, 
P. et al. 2001), prostate (Moore, C. M. et al. 2006) and pancreatic cancer (Bown, S. G. et 
al. 2002).  m-THPC was synthesised as a stable ‘m’ isomer, based on the ‘meta’ position of 
the hydroxy group on the benzene ring (Fig 1.4), and was found to be the most active 
isomer in in vivo assays (Bonnett, R. et al. 1989b).  It was derived from porphyrin 
(Bonnett, R. et al. 1989b)  and as a result is ≥98% chemically pure (Glanzmann, T. et al. 
1998).  It is a potent photosensitiser and has an exceptionally strong phototoxcity, as it 
produces high quantum yields of singlet oxygen (0.87) (Hopper, C. et al. 2000) due to its 
longer half-life in the excited triplet state  and its effectiveness in PDT has been reported as 
being ~200-fold higher than that of PII (Ball, D. J. et al. 1999;Sharman, W. M. et al. 
1999;Vangeel, I. P. J. et al. 1995).  This implies lower PDT light exposures (10 j cm-2) 
(Ris, H. B. et al. 1991) and lower photosensitiser drug doses can be administered in order 
to elicit a similar PDT response; typically 0.15-0.3 mg kg-1 compared to 10 mg kg-1 for PII 
(Dougherty, T. J. et al. 1998;Jones, H. J. et al. 2003), even for large surface treatment.  m-
THPC also has a strong absorption peak in the far red region of the visible spectrum (λ = 
652 nm) and a molar extinction coefficient of 29,600 M-1 cm-1 at this wavelength (PII = 
1170 M-1 cm-1).  This longer wavelength of light can penetrate biological tissues at a depth 
greater than PII of approximately 7 mm (Dougherty, T. J. et al. 1998;Palumbo, G. 2007) at 
relatively low light fluencies.   
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Table 1.1. Drugs approved for PDT in oncology, diagnosis and non-malignant disease and drugs in clinical trials. 
Active Drug Product name Application Approved 
 
Haematoporphyrin derivative (HpD), 
porfimer sodium  
 
Photofrin® (Axcan 
Pharm) 
 
Lung, oesophageal adenocarcinoma, 
cervical, gastric, bladder cancer 
 
Selected countries worldwide, 
1993 
meta-tetra(hydroxyphenyl)chlorin (m-
THPC) 
Foscan® (Biolitec 
Pharma) 
Head and neck cancer EU, Norway, Iceland, Japan, 
2001 
5-aminolevulinate (ALA) precursor to 
Protoporphyrin (Pp) IX 
Levulan® (DUSA 
Pharma) 
Topical; actinic keratosis  US, 1999 
Methyl aminolevulinate Metvixia® (Photocure) Topical; actinic keratosis, basal-cell 
carcinoma 
EU, Australia, 2001 
mono-L-aspartyl chlorin e6 
(Talaporfin) 
Laserphyrin® (Meiji Seika 
Pharma) 
Lung cancer Japan, 2004 
Aluminium sulfonated phthalocyanine 
(AlPcS) 
Photosense® (NIOPIK) Head and neck cancer Russia, 1995 
Hexyl aminoevulinate Hexvix Diagnosis Sweden, EU, 2005 
Benzoporphyrin derivative (BPD), 
Verteporfin 
Visudyne® (Novartis) Age-related macular degeneration ≥70 countries worldwide, 2001 
2-(1-Hexyloxyethyl)-2-devinyl 
pyropheophorbide-a (HPPH) 
Photochlor Lung cancer Phase II clinical trials, 2011 
Motexafin lutetium Antrin Topical, prostate cancer, 
photoangioplasty 
Phase I clinical trials, 2009 
Hexylaminolevulinate (HAL) Cevira Precancerous cervical lesions (HPV) Phase II clinical trials, 2012 
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Figure 1.4. Structure of 5,10,15,20-meta-tetra(hydroxyphenyl)chlorin (m-THPC) and the meta (m), para (p) 
and ortho (o) isomers of the hydroxyphenyl substituent. 
 
When administered systemically through intravenous injection in its standard Foscan® 
formulation (m-THPC in buffer; 30% PEG 400: 20% ethanol: 50% H2O), the 
biodistribution of m-THPC in vivo has been shown to change over time in murine models, 
which also differ to clinical data, due to the binding of various available serum proteins 
that exist in different concentrations, i.e. low density lipoproteins (LDL) (Jori, G. et al. 
1993;Triesscheijn, M. et al. 2007) and albumins (Verma, S. et al. 2007).  In vitro studies 
carried out with HT29 human colon adenocarcinoma cells using m-THPC show a good 
uptake and distribution of the photosensitiser intracellularly after short incubation periods 
of 3 h (Melnikova, V. O. et al. 1999b).  Marchal et al., also demonstrated m-THPC 
localisation in the nuclear envelope in human MCF-7 breast cancer cells, however, it was 
suggested m-THPC predominantly localised in the ER and Golgi apparatus (Marchal, S. et 
al. 2007;Melnikova, V. O. et al. 1999b) as these were the primary sites of PDT-induced 
damage.  ER localisation supports apoptotic cell death as it improves the photoactivation of 
the caspase-7 pathway but both apoptotic and necrotic pathways are implicated in PDT cell 
death (Marchal, S. et al. 2007).  Binding of serum proteins in foetal calf serum (FCS) in 
vitro has shown to monomerise hydrophobic aggregates of m-THPC in myeloid leukaemia 
cells (Chen, J. Y. et al. 2000) and facilitate its cellular uptake via receptor mediated 
endocytosis (Palumbo, G. 2007;Verma, S. et al. 2007).  m-THPC has been found to be a 
moderately photolabile compound, susceptible to changes under the influence of radiant 
energy.  Kinetic analysis shows two types of aggregated species, dimers and higher 
aggregates, each with distinct disaggregation rate constants that significantly increase with 
higher temperatures (Hopkinson, H. J. et al. 1999).  Further in vivo studies show unusual 
pharmacokinetics with human plasma, as following intravenous injection, m-THPC 
initially binds to an unknown protein in large quantities before being redistributed to 
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lipoproteins (Hopkinson, H. J. et al. 1999).  Secondary m-THPC concentration peaks in the 
plasma are produced at 6 and 10 h, indicating very slow m-THPC release kinetics 
(Glanzmann, T. et al. 1998).  LDL is up-regulated on the surface of cancers due to their 
increased cell proliferation (Misawa, J. et al. 2005), which is thought to aid in the 
accumulation of m-THPC in tumour tissues over normal tissues (Lin, C. W. et al. 1991), as 
hydrophobic PSs are preferentially bound by lipoproteins (Jori, G. 1989).  Although 
similar findings of m-THPC binding to various protein fractions in rat models have been 
observed in vivo, the identification of hydrophobic molecules in the plasma by the host 
immune system, result in opsonisation of m-THPC, where major loss of the photosensitiser 
from circulation is observed, as it is directly distributed to the cells of the RES for 
clearance i.e. residing macrophages in the liver, spleen, kidneys (Kudinova, N. V. et al. 
2009;Peng, Q. et al. 1995).   
 
During PDT treatment, the production of reactive oxygen species (ROS) and intermediates 
react not only with biological substrates but the photosensitiser itself, causing 
transformation changes or destruction of the photosensitiser molecule, known as 
photobleaching.  Comparisons in vivo using a Balb/c mouse model show the rate of 
photobleaching for m-THPC was ~20 less than a similar porphyrin derivative, m-THPBC, 
5,10,15,20-meta-tetra(hydroxyphenyl)bacteriochlorin (Rovers, J. P. et al. 2000).  This 
photobleaching rate was increased further to ~90 fold when in solution (methanol-water, 
3:2) compared to m-THPC.  However, at high m-THPC concentrations, self-quenching of 
the triplet states is believed to result in a loss of photosensitising efficiency (Sasnouski, S. 
et al. 2007). 
 
Figure 1.5.  A schematic diagram of the mechanisms involved in photobleaching during Type I and Type II 
reactions following absorption of photons by a photosensitiser (P). 
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Although m-THPC creates great promise in enhancing PDT, issues associated with its 
hydrophobic nature generate several drawbacks. For example, its residual photosensitivity 
is unfortunately not much lower than some first generation photosensitisers (Moriwaki, S. 
I. et al. 2001), showing little selectivity between normal and malignant tissues in vivo 
(Braichotte, D. et al. 1996;Brown, S. B. et al. 2004), resulting in a large range of tissue 
responses in patients despite identical treatment parameters.  This poor selectivity also 
leads to long drug-light treatment intervals, where patients must be protected from light for 
up to 3 days before PDT treatment due to its unusual pharmacokinetic profile in human 
plasma (Triesscheijn, M. et al. 2007).  Therefore third generation photosensitisers have 
been developed, whereby encapsulation of the photosensitiser into novel ‘nano vehicles’ 
have been to designed to improve photosensitiser delivery and uptake into malignant 
tissues.  A range of materials and different techniques can be used to incorporate 
photosensitisers into nano-sized particles, in order to obtain highly desirable properties 
(Tallury, P. et al. 2008).  The size, composition and surface characteristics have been well 
documented in determining the biodistribution profile and stability of the nanoparticles in 
the body (Alexis, F. et al. 2008) and they can be multifunctionalised, integrating several 
modalities within a single particle, i.e. imaging agent, targeting molecule and photoactive 
drug (Tallury, P. et al. 2008).  Ultimately, improving devliery of the photosensitiser should 
increase its accumulation in target tumourous tissue and with this higher tissue uptake, a 
greater intracellular localisation of PS within the tumour cells is expected.  These factors 
are believed to positively contribute towards the destruction of tumour cells and efficacy of 
PDT treatment, which we wish to established through this investigation. 
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2. Nanotechnology 
2.1 Introduction 
Nanotechnology incorporates the design, characterisation, synthesis and application of 
materials which have nanoscale structural properties, i.e. one billionth of a metre 
(Birrenbach, G. et al. 1976).  A fast evolving area of science and engineering, 
nanotechnology has become integrated into the design and manufacture of functional 
systems in a vast range of applications.  Due to their size, nanoparticles exhibit a range of 
unique properties, not observed with macro or micro-particles, offering multiple 
advantageous characteristics and prompting extensive research into the assembly and 
fabrication of nanometre-sized colloid structures.   
 
Figure 2.1. The in vivo applications of nanotechnology in the field of biomedicine (Choi J et al. 2011). 
 
Among other areas of research, the use of nanoparticles have been widely implemented in 
medicine (Fig 2.1), referred to as ‘nanomedicine’ (Liu, Y. Y. et al. 2007;Zhang, L. et al. 
2008).  Their use extends to drug delivery (Farokhzad, O. C. 2008), targeted cancer 
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therapy (Gu, F. et al. 2009), cell biomanipulation (Desai, J. P. et al. 2007) and as novel 
analytical devices (biosensors) (Luz R et al. 2013) and diagnostic tools (Fan, Z. et al. 
2013).  The popularity of their utilisation in biomedicine has been heavily reflected in the 
literature in the past decade (Doane, T. L. et al. 2012;Kawasaki, E. S. et al. 2005;Zhang, L. 
et al. 2008).  In 2006, it was reported that over 150 companies were developing nanoscale 
therapeutics in Europe and currently more than 20 nanoparticle-based products are 
available on the pharmaceutical market (Wagner V et al. 2006).  Although some 
pioneering nanotherapeutics have been approved for clinical use and have shown success, 
the long-term safety associated with nanotechnology, particularly in in vivo applications, 
has yet to be clearly defined (Choi J et al. 2011).   
 
Nanoparticles can be tailored to their purpose and designed to obtain highly desirable 
properties, such as; high sensitivity, stability, imageability, biocompatibility and 
targetability (Tallury, P. et al. 2008).  As a result they have been applied to almost every 
branch of medicine, from oncology to dentistry (Farokhzad, O. C. et al. 2006;Farokhzad, 
O. C. et al. 2009).  Due to the broad spectrum of applications encompassed in this ever-
expanding field, this chapter will predominantly focus on the utilisation of nanotechnology 
in PDT. 
 
2.2 The Role of Nanotechnology in PDT 
When designing nanoparticles for use in PDT, several key considerations must be taken 
into account in order to obtain effective treatment outcomes (Box 2.1). 
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Nanoparticles have been developed in the field of PDT to improve the bioavailability and 
selective delivery of photosensitisers in vivo to malignant tissues.  Issues associated with 
systemic photosensitiser administration and a lack of selectivity at tumour sites has proved 
problematic, as successful PDT to solid tumours requires specific delivery of light-
sensitive agents to establish dosimetric parameters and ensure local drug activation by 
irradiation (Master, A. et al. 2013).  Undesirable PS accumulation in healthy tissues can 
cause irritation to areas easily exposed to ambient light, such as the eyes and skin, resulting 
in prolonged phototoxicity and photosensitivity in patients, which has to be continually 
managed, particularly following multiple PS doses (Hopper, C. 2000).  Presently, clinical 
PDT is predominantly used to treat malignant and pre-malignant topical lesions that are 
easily accessible owing to the delivery of the PS (Master, A. et al. 2013).  While 
advancements in the design of laser technologies have improved selective activation of 
photosensitive drugs through the delivery of light via novel image-guided pathways and 
fibre-optics interstitially and intra-tumourally, nanomedicine can further enhance 
selectivity by providing an effective way to resolve challenges associated with both the 
systemic intravenous administration of PS and its accumulation in deep tissue tumours. 
 
Nanoparticles synthesised from an array of materials and via various manufacturing 
techniques have been used to incorporate hydrophobic, insoluble photosensitisers in order 
to improve drug delivery.  This encapsulation increases PS solubility and prolongs its half-
life in systemic circulation by reducing protein binding and rapid uptake via the 
reticuloendothelial system (RES), which may occur before the PS has had time to elicit a 
therapeutic effect.  By reducing unfavourable accumulation in healthy tissues, adverse 
side-effects associated with non-specific localisation can be minimised.  Despite these 
improvements through nanoparticle encapsulation, modifications at the particle surface can 
be made via the conjugation of biocompatible polymers, such as polyethylene glycol 
(PEG), to combat further delivery issues such as fast PS drug release rates, 
immunogenicity, non-specific biodistribution and fast clearance of nanoparticles.  These 
highly hydrated flexible PEG polymer chains have been used to enhance the 
pharmacokinetic parameters of many nanoparticle formulations and positive results have 
prompted the fabrication of PEG-coated drugs for use in the clinic both within the field of 
PDT (Table 4.1 Chpt 4; Table 5.1 Chpt 5; Table 6.2 Chpt 6, Table 7.3 Chpt 7) and 
outside (e.g. Adagen, Macugen, Pegasys and Oncaspar).  Furthermore, the extremely small 
size (nm) of nanoparticles provides a unique high surface-area-to-volume ratio (Bechet, D. 
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et al. 2008;Peer, D. et al. 2007), facilitating the attachment of specific targeting ligands at 
high surface densities to direct PS uptake into cancer cells.  Finally, particles can be 
multifunctional, possessing more than one modality.  Imaging agents, targeting molecules 
and photoactive drugs can be integrated within a single particle for combinational therapies 
(Tallury, P. et al. 2008).   
 
The efficacy of PDT is primarily related to the production of the reactive oxygen species 
(ROS), largely singlet oxygen, generated from the activation of accumulated PS in tissue.  
Therefore in designing nanocarrier systems the synthesis and release of these ROS is 
crucial.  Photosensitisers are highly planar molecules, which can be physically entrapped 
through strong hydrophobic interactions or chemically linked (i.e. covalent bonding) 
within nanoparticles.  Unlike other therapeutic agents (i.e. chemotherapeutics) it is not 
essential that the active drug molecule be released from the nanoparticle to elicit a 
therapeutic effect only that ROS are able to escape into surrounding tissue.  The two most 
commonly adopted approaches used to achieve this are incorporation of PS inside 
biodegradable and non-biodegradable nanoparticles.  Each system has its own advantage; 
biodegradable nanoparticles are able to release the PS once the matrix has broken down, 
which can then be irradiated to generate singlet oxygen.  This is attractive in ensuring the 
case material does not cause any long-term toxicity itself, but leaching and premature loss 
of the PS through degradation can occur (Jain, R. K. et al. 2010).  Simple physical 
entrapment of the PS within non-biodegradable nanoparticle can also result in PS transfer 
to serum proteins and significant leakage (Compagnin, C. et al. 2009).  Conversely, its 
chemical linkage inside non-biodegradable particles can help to overcome these problems.  
Whilst excited singlet oxygen molecules can diffuse in and out of porous nanoparticle 
matrices freely to exert phototoxic effects, the consequence of adopting non-biodegradable 
materials may lead to potential in vivo toxicity from sustained accumulation (Bechet, D. et 
al. 2008).  In either nanocarrier example, the intrinsic PS concentration must also be 
considered in order to calculate sufficient PS loading within the nanoparticle to produce 
maximal ROS but simultaneously reduce aggregation and self-quenching of the PS for 
efficacious PDT.   
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i. Micelles/Liposomes 
Micelles and liposomes are examples of biodegradable nanocarrier drug-delivery systems 
formed by phospholipids molecules, similar to biological membranes, generating closed, 
spherical structures (Hofheinz, R. D. et al. 2005).  The former, micelles, are detergent-like 
molecules comprised of a fatty acid core due to the arrangement of phospholipid 
monolayers, in comparison to liposomes which contain an internal aqueous hydrophilic 
compartment and a hydrophobic shell as a result of their closed spherical phospholipid 
bilayer structure (Fig 2.2).  Although micelles have shown application in drug delivery 
(Kato, K. et al. 2012;Matsumura, Y. et al. 2004), liposomes are typically favoured, as 
greater concentrations of hydrophobic drug molecules, such as photosensitisers, can be 
‘packaged’ into their larger shell (Torchilin, V. P. 2005) and amphiphilic molecules can 
partially reside in lipo- or hydrophilic regions (Frederiksen, L. et al. 1997).  As a result, 
liposomes account for more than 80% of the nanoscale therapeutic products currently 
available on the market (along with polymer-drug conjugates) and can be synthesised from 
various lipidic compositions in a range of sizes and lamellarity (number of bilayers) 
(Zhang, L. et al. 2008).  They are typically classified into three categories; (i) small 
unilamellar vesicles or oligo-lamellar, (ii) large unilamellar vesicles and (iii) multilamellar 
vesicles. 
 
 
Figure 2.2. The structure of liposomes contain an internal aqueous compartment as a result of their closed 
spherical phospholipid bilayer structure.  Micelles lack an aqueous core due to their formation through closed 
phospholipid monolayers therefore contain a fatty acid core.  Taken from (Pharmainfo.net 2014). 
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Conventional liposomes (unmodified) carrying photosensitisers, however, are not able to 
enhance tumour-to-normal tissue ratios alone, as they are swiftly degraded (mins) upon 
entering the blood circulation (Derycke, A. S. et al. 2004).  Long-circulating or ‘Stealth’® 
liposomes have been developed, through PEG modification at the liposome surface (Allen, 
T. M. et al. 1995;Klibanov, A. L. et al. 1990;Oku, N. et al. 1994) to minimising protein 
binding when in systemic circulation and increase the probability of accumulation in 
tumour tissues (Li, S. D. et al. 2008).  The use of these nanocarriers in drug delivery and 
PDT is investigated and discussed at greater depth in Chapter 4: Liposomes. 
 
ii. Polymeric nanoparticles 
Alternatively, polymeric nanoparticles are the most commonly investigated materials for 
use as biodegradable nanocarrier systems due to the comprehensive catalogue of polymers 
available and numerous combinations for nanoparticle fabrication (Fig 2.3).  Their use as 
anticancer drug carriers was originally reported in 1979 by Couvrer et al., and 
doxorubicin-loaded nanoparticles entered clinical trials in the mid-1980s (Couvreur, P. et 
al. 1982).  In recent years they have been the focus of many studies due to the multitude of 
positive characteristics they elicit.  These include high drug loading, unique designs in 
chemical composition, architecture and surface properties, biocompatibility of a large 
variety of materials, and the controlled release of drugs through targeting components and 
polymer degradation (Chatterjee, D. K. et al. 2008a).  Polymeric nanoparticles can be 
constructed from synthetic and natural polymers.  In the former instance, two of the most 
commonly utilised polymers are poly(lactic acid) (PLA) and the co-polymer poly(lactide-
co-glycolide) (PLGA), both of which are FDA approved (Hrkach, J. S. et al. 1997).  In the 
latter, examples include chitosan (Agnihotri, S. A. et al. 2004;Calvo, P. et al. 1997) 
albumin (Kratz, F. 2008) and collagen (El-Samaligy, M. S. et al. 1983), which can be used 
to encapsulate drug molecules without the need for chemical modification.  Controlled 
degradation for the release of therapeutics can occur in response to the local environment 
via surface or bulk erosion, diffusion of the drug through the polymer matrix or swelling 
followed by diffusion (see Chapter 6: Polymeric Nanoparticles) (Peer, D. et al. 2007). 
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Figure 2.3. 200 nm nanoparticles (A) polystyrene and (B) poly(lactic-co-glycolic acid) PLGA.  Taken from 
(Fraikin, J. L. et al. 2011;Tang, K. S. et al. 2013). 
 
These attractive characteristics have prompted much interest and research into polymeric 
nanoparticle utilisation.  In PDT, the different ratios of polymers from which the 
nanoparticles are composed, have been suggested to strongly affect the photodynamic 
activity through differences in degradation, carrier uptake and intracellular localisation, 
which is dependent on their hydrophilic nature (Chatterjee, D. K. et al. 2008a).  Increasing 
the percentage of more hydrophilic glycolic acid polymers (PLGA) in 200 nm PLGA: PLA 
has been shown to increase the biodegradation rate and phototoxicity of encapsulated 
meso-tetra(p-hydroxyphenyl) porphyrin (p-THPP) in vitro in EMT-6 mouse tumour cells 
(Konan, Y. N. et al. 2003).  A significant photodynamic activity was demonstrated again in 
vitro in P388-D1 cells with zinc phthalocyanine (ZnPc)-loaded PLGA NPs, which showed 
encapsulated PS was able to retain its photophysical properties (Ricci-Junior, E. et al. 
2006).  More recent studies with the same ZnPC-loaded NPs (374 nm and 200 nm) carried 
out in vivo in tumour-bearing mice showed a significant increase in tumour growth delay 
studies and smaller mean tumour size (Fadel, M. et al. 2010).  Additionally, smaller PLGA 
NPs (~167 nm) loaded with verteporfin have demonstrated a rapid diminishment in 
cutaneous photosensitivity from early to longer light exposure time points (Konan-
Kouakou, Y. N. et al. 2005) and temoporfin delivered to mice via pegylated PLGA 
nanoparticles have exhibited therapeutically favourable tissue distribution (Rojnik, M. et 
al. 2012).  These promising results are encouraging for PLGA nanoparticle applications in 
PDT but concerns have arisen involving the structural heterogeneity of polymers (high 
polydispersity indices), internal drug distribution and homogenous size distribution of 
nanoparticles.  These issues and a more extensive literature review into the use of other 
polymeric nanoparticles for applications in PDT are discussed at greater depth in Chapter 
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6: Polymeric Nanoparticles, along with in vivo investigations into the use of pegylated 
poly(D, L-lactide-co-glycolide) (PLGA) nanoparticles (~250 nm). 
 
iii. Dendrimers 
Dendrimers are comprised of synthetic, highly branched, repetitive polymer molecules that 
can be further divided into sub branches along a carbon atom backbone (Fig 2.4).  Unlike 
classic polymeric nanoparticles, their structure has a high degree of molecular uniformity 
and they represent a relatively new field in polymer chemistry (Peer, D. et al. 2007).  Their 
well-defined structure enables nanoparticles of a narrow size distribution, shape and size to 
be produced.  
 
Figure 2.4. Chemical structures of (A) dendrimer porphyrin (DP) and (B) dendrimer phthalocyanine (DPc).  
Taken from (Nishiyama, N. et al. 2009b). 
 
Dendrimers have been used to deliver various photosensitisers increasing their solubility to 
improve drug selectivity and phototoxic effects in tumours (Huang YY et al. 2012).  The 
spatial alignment between branches of the dendrimer ensures the PS at the central core is 
less likely to form aggregates, as it is more sterically stable.  Nishiyama et al., 
demonstrated a great improvement in tumour PDT efficacy both in vitro (A549) and in 
corresponding in vivo models (A549 tumours in nude mice) with dendrimer 
phthalocyanine-loaded micelles (Fig 2.4), whilst a simultaneous reduction in skin 
phototoxicity was observed (Nishiyama, N. et al. 2009a).  The addition of a poly-L-lysine 
PEG (PEG-PLL) complex on the dendrimer surface formed 50 nm micelles and was found 
to positively correlate to PDT tumour necrosis.  Furthermore, in vitro studies using ALA-
dendrimers have shown these nanocarriers helped to enhance cell uptake of ALA in A431 
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cells and murine keratinocytes.  The precursor (ALA) to the natural synthesis of porphyrin 
(via the haem pathway) was able to produce porphyrin more efficiently when incorporated 
in dendrimers compared to free ALA (Battah, S. et al. 2007).  The simple conjugation of 
targeting molecules, imaging agents and drugs has led to their further pre-clinical 
development (Gillies, E. R. et al. 2005), however, their costly and multi-step synthesis, in 
comparison to other nanoparticles, has posed challenges in large-scale commercial 
production (Peer, D. et al. 2007). 
 
iv. Ceramic nanoparticles 
Non-biodegradable nanocarrier systems have shown to be equally successful in their 
application in PDT (Bechet, D. et al. 2008;Chatterjee, D. K. et al. 2008a) through the 
encapsulation or chemical linkage of photosensitisers in organic or inorganic materials.  
Ceramic-based, mesoporous particles are inorganic systems that include silica (Fig 2.5), 
titania and alumina.  They have recently emerged as suitable drug vehicles as they offer 
multiple benefits over biodegradable nanoparticles (Cherian, A. K. et al. 2000) and their 
properties have led to the development of mesoporous silica nanoparticles entering the 
preclinical stage in targeted cancer therapy (Rosenholm, J. M. et al. 2012).  In PDT, their 
optically transparent matrices, porosity (ROS diffusion), protective casing, water 
dispersity, general inertness, resistance to microbial attack, or extreme pH/temperatures 
and reported increase in PS photostability from encapsulation are particularly attractive 
(Tallury, P. et al. 2008).  However, one of the main concerns is their inability to break 
down into biologically inert components, facilitating their accumulation in the body and 
thus potentially causing undesirable effects (Gupta, A. K. et al. 2005).  Ideally particle size 
needs to be controlled to ensure as small a size as possible in order to avoid RES uptake 
and encourage clearance from the body via renal filtration (≤ 5.5 nm) (Choi, H. S. et al. 
2007). 
 
Figure 2.5. Examples of mesoporous silica nanoparticles. Taken from (Nandiyanto, A. B. D. et al. 2009). 
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Various studies have shown photosensitisers physically entrapped (non-covalently bound) 
within nanoparticles have photocytotoxic effects, as singlet oxygen generation and its 
diffusion through porous particles is maintained, eliciting oxidative damage to cells (Roy, 
I. et al. 2003).  However, the method of incorporation of PS into these porous particles is 
inadequate, as serum proteins in vivo can cause PS leakage into the plasma, which 
consequently results in a loss of the PDT agent, non-specific accumulation and uptake into 
macrophages before particles reach target tissues (Compagnin, C. et al. 2009).  Organically 
modified silica (ORMOSIL) nanoparticles (NP) have been developed which form self-
assembling micelles during the oil-in-water microemulsion preparation process through the 
presence of both hydrophilic and hydrophobic groups whilst helping to improve 
biocompatibility and reduce RES uptake of particles.  Additionally the PS can be 
immobilised within particles through covalent binding (Ohulchanskyy, T. Y. et al. 2007).  
Despite chemical linkage to anchor the PS to the internal silica matrix, covalently 
incorporated photosensitisers have been shown to retain their spectroscopic and functional 
properties, producing high quantum yields of singlet oxygen upon illumination (Roy 
2003).  These nanoparticles are also stable in aqueous environments and can be synthesised 
at small sizes (~20 nm).  In vitro studies of ORMOSIL NPs incorporating 2-Devinyl-2-(1-
hexyloxyethyl) pyropheophorbide (HPPH) demonstrated a high uptake into the cytosol of 
tumour cells, which enhanced cytotoxic effects with PDT treatment (Ohulchanskyy, T. Y. 
et al. 2007;Roy, I. et al. 2003).  Studies with MB (Tang, W. et al. 2005), PpIX (Qian, J. et 
al. 2009;Simon, V. et al. 2010), m-THPC (Compagnin, C. et al. 2009;Yan, F. et al. 2003); 
and HA (Zhou, L. et al. 2010) have also been carried out in vitro and showed effective 
singlet oxygen generation compared to free PS in the latter cases.  Primary biodistribution 
studies in vivo with ORMOSIL NPs showed greater accumulation of these particles in the 
liver, spleen and stomach, indicating they are cleared by the hepatobiliary excretion 
pathway but no toxicity or abnormalities in tissues were observed after 15 days (Kumar, R. 
et al. 2010).  Chen et al., also demonstrated their potential as multifunctional platforms, 
incorporating MB and an Fe2+/Fe3+ magnetic core within the silica matrix to enhance anti-
tumour effects through targeted PDT (Chen, Z. L. et al. 2009).  The use of these 
nanocarriers in PDT is investigated and discussed at greater depth in Chapter 5: 
ORMOSIL nanoparticles. 
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v. Metallic nanoparticles 
Metallic particles possess highly favourable optical and chemical properties for biomedical 
imaging (diagnostic) and therapeutic applications (Hirsch, L. R. et al. 2006).  Metallic 
nanoparticles have versatile surfaces, distinguishing photo-properties and are easily 
tuneable in size.  Those that incorporate metallic ions within their cores (i.e. iron oxide) are 
classed as superparamagnetic agents and are particularly valuable in MRI imaging.  Their 
surfaces can be coated with biological molecules such as dextran, phospholipids or 
polymers (PEG) to inhibit aggregation and enhance stability.  The adopted use of different 
metallic nanoparticles is largely dependent on the application, for example, silver 
nanoparticles (AgNPs) are used for their antibacterial and fungicidal capabilities whereas 
gold nanoparticles are exploited for their catalytic, conductive and colouring properties 
(Fig 2.6).   
 
 
Figure 2.6. Different metallic nanoparticles in solution; Silver (Ag), Gold (Au), Ruthenium (Ru) and 
Platinum (Pt).  Right, gold nanoparticle functionalised with carboxyl groups on the surface. Taken from (Kim, 
B. et al. 2010). 
 
Gold nanoparticles (AuNPs) can induce changes in their optical properties due to the 
confinement/arrangement of surface electrons (plasmon resonance effect) on account of 
their small size, producing quantum effects which can be exploited for use in diagnostic 
tools, such as novel nano-optic biosensors e.g. where a conjugate might be cleaved to 
provoke a colour change (Huang YY et al. 2012).  When dispersed, they are red in 
solution, however, upon aggregation the electrons delocalise over two nanoparticles, 
causing a colour shift to blue (Kim, T. et al. 2008).  AuNPs have also been studied 
extensively for applications in PDT based on their distinctive characteristics.  They can be 
used as effective PS-delivery vehicles through surface conjugation of molecules (covalent 
or non-covalent), similar to other inorganic nanoparticles.  PEG-coated AuNPs have been 
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used in vivo to successfully penetrate tumour tissue to deliver non-covalent Pc4 (Cheng, Y. 
et al. 2011b).  Similarly, effective results have also been obtained with AuNP-modified 
porphyrin-brucine conjugates in vivo with complete tumour regression observed in 
comparison to free PS (Zaruba, K. et al. 2010), whilst in vitro studies with 
hematoporphyrin-nanogold showed more effective PDT with larger AuNPs (45 versus 15 
nm) due to the increase in porphyrin transported to tumour cells (Gamaleia, N. F. et al. 
2010).  AuNPs have been used in photo-thermal tumour ablation, which involves laser 
irradiation, taking advantage of the strong near infrared (NIR) absorption of gold 
nanoshells to destroy tissues through heat.  Although proven effective in the destruction of 
tumour tissue in vivo, with mice appearing tumour free >90 days, unlike PDT, the thermal 
activity means loss of structural integrity in normal tissues, leading to functionality and 
aesthetic complications. 
 
vi. Quantum Dots 
Quantum dots (QDs) are semiconductor crystals that have become popular in recent years 
on account of their small size (<10 nm), which dictates their unique fluorescence 
properties, making them powerful diagnostic imaging tools.  Their tuneable size regulates 
the band-gap (energy level between the highest valence band and lowest conduction band) 
and their fluorescence spectra, producing narrow emission peaks (Fig 2.7).  Upon 
absorption of light, QDs can transfer energy to surrounding O2, forming ROS and causing 
toxicity to cells. 
 
Figure 2.7. (A) Quantum dots in solutions fine-tuned to various sizes to absorb light across the colour 
spectrum and (B) structure of a quantum dot with a heavy metal CdS core and ZnSe coating.  Taken from 
(Pietryga, J. M. et al. 2004). 
 
As such, QDs can act as photosensitisers on their own; however, inefficient generation of 
ROS e.g. 1O2 for effective PDT has promoted the covalent attachment of photosensitisers 
on to the QD surface.  This improves the excitation properties of the PS by acting as a 
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primary energy donor via Forster resonance energy transfer (FRET), yielding higher ROS 
production.  QDs have been developed in this capacity to activate the PS, Pc4, chemically 
linked to the particle surface, using shorter wavelengths of light.  Unfortunately, this 
produced ineffective results as singlet oxygen generation was low (He, J. et al. 1997).  In 
vitro studies have shown QD fluorescence in cells is quenched due to accumulation in 
acidic endocytic vesicles (Generalov, R. et al. 2011).  Conversely, in vivo studies have 
found their small size (≥5 nm) is beneficial in promoting renal clearance and in attempting 
to overcome long-term accumulation but their heavy metal ion cores (i.e. cadmium 
selenide (CdSe), cadmium sulphide (CdS) and indium phosphide (InP)) (Fig 2.7) pose 
potential toxicity problems due to risks associated with heavy metal leaching in vivo 
(Weng, J. et al. 2006).  This, combined with low water solubility, means for use in 
biological applications it is crucial quantum dots be coated with other organic materials to 
allow for dispersion and prevent such leakage (Medina, C. et al. 2007).  Moreover, efforts 
to synthesis Cadmium- or heavy metal-free QDs are currently under way to address some 
of these issues.  
 
vii. Carbon Nanotubes 
Working with materials on a nanoscopic level results in the production of a hugely diverse 
range of products.  This is perhaps best demonstrated by the various arrangements of 
identical single carbon atoms which form a variety of naturally occurring structures; 
diamond (cubic), graphite (planar) or soot (amorphous).  Combined with technological 
advancements, carbon atom alignment can be manipulated further to manufacture artificial 
structures, such as fullerenes and carbon nanotubes (Fig 2.8), which have been reviewed 
extensively for use in PDT (Huang YY et al. 2012).  Fullerenes are novel carbon allotropes 
with a polygonal structure made up exclusively by 60 carbon atoms.  These nanoparticles 
are characterized by having numerous points of attachment and whose surfaces can also be 
functionalized for tissue binding (Bosi, S. et al. 2003).  Remarkably, fullerenes act as pro-
oxidants under illumination and antioxidants in the absence of light.  Their application in 
PDT is limited by their extreme hydrophobicity and absorption in the blue/green regions of 
the visible spectrum, where penetration of light into biological tissue is poor (Huang YY et 
al. 2012).  Carbon nanotubes have been extensively studied due their ability to produce 
light-weight materials with high electrical conductivity and great strength.  Carbon 
nanotubes can be formed from a single sheet of graphite rolled to form a seamless cylinder 
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and exist in two classes, single-walled (SWCNT) and multi-walled (MWCNT). MWCNTs 
are larger and consist of many single-walled tubes stacked one inside the other. 
Functionalised carbon nanotubes have emerged as novel components in nanoformulations 
for the delivery of therapeutic molecules (Pagona, G. et al. 2006) and their large surface 
area allows for greater packaging of hydrophobic drugs, such as doxorubicin (Zhang, L. et 
al. 2010) and photosensitisers. 
 
Figure 2.8. Single walled carbon nanotubes (SWCNTs) from left to right; armchair, zigzag and chiral 
structures forming concentric cylinders.  Taken from(Chemical, B. &. M. E. C. 2008). 
 
In PDT, sophisticated techniques have been used to selectively deliver the PS and enhance 
local singlet oxygen production using aptamers (Han, D. et al. 2013;Zhu, Z. et al. 2008), 
coating polymers (Erbas, S. et al. 2009) and polysaccharides (Shiraki, T. et al. 2011).  In 
vitro, PDT kill has been significant (Huang, P. et al. 2011a;Tian, B. et al. 2011), however, 
there has been much confusion regarding the safety of CNTs in vivo in recent years due to 
conflicting evidence on their reported toxicity. It is thought that their biodistribution and 
pharmacokinetic behaviour is predominantly associated with their surface coating, route of 
administration and shape and/or size rather than the base material (Yang, K. et al. 2012). 
 
viii. Size and shape 
Unlike larger molecules (macro or micro), nanoparticles exhibit a greater total surface area 
to volume ratio therefore surface atoms dominate the properties of the material.  
Compounds deemed previously inert in bulk, may become catalysts on at the nanoscale 
level.  The size, composition and surface characteristics have been well documented in 
determining the biodistribution profile and stability of the nanoparticles in the body 
(Alexis, F. et al. 2008). 
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Figure 2.9. Nanoparticles of varying shapes and size (A) square (B) cylindrical (C) hexagonal and (D) star-
shaped.  Taken from (Peng, Z. et al. 2009). 
 
Naturally occurring biological molecules in the nanometre-size range follow design rules 
and have evolved into well-defined structures of specific shapes, sizes and chemistry for 
optimal functionality.  For example, virus particles (virions) occur as icosahedrals, rods or 
spheres and their geometries dictate their infection efficacy (Albanese, A. et al. 2012).  The 
size and shape of the nanocarrier plays a particularly important role regarding its 
intracellular uptake and penetration into tissues (Chatterjee, D. K. et al. 2008a;Decuzzi, P. 
et al. 2010).  Rod shaped particles have demonstrated the highest uptake rate, followed by 
spheres, cylinders and cubes (Fig 2.9) potentially due to their larger surface area and 
presentation to the cell in two different orientations (short or long axis), increasing uptake 
(Gratton, S. E. et al. 2008).  However below 100 nm, spherical nanoparticles have proved 
more advantageous than rods, which is likely due to their unique surface area to volume 
ratio and subsequent properties at smaller sizes.  Star-shaped nanoparticles create potential 
for controlling ligand presentation and increase the surface area of particles, but may also 
increase exposure to circulating blood proteins and inflammatory factors (Albanese, A. et 
al. 2010).  
 
Smaller particle sizes are considered superior for delivery of photosensitisers on account of 
enhanced endocytosis and have been shown to improve a number of critical factors 
associated with PDT, including reduced toxicity, improved drug clearance, reduced skin 
sensitivity and improved PDT efficacy from greater singlet oxygen diffusion and 
phototoxic capability (Jori, G. et al. 1993).  The benefits of adopting smaller particles in 
vivo are largely due to achieving optimal size thresholds for clearance pathways i.e. renal 
filtration, and deeper penetration into the unique structure of tumour tissue (Choi, H. S. et 
al. 2007).  However, the effect of small nanoparticles on the permeability and integrity of 
the blood-brain barrier (BBB) are of toxicological concern, as despite an upper pore size 
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limit of <1 nm; particles with a diameter of several nanometres can cross the BBB by 
carrier-mediated transport (Sharma, H. S. et al. 2010).  It should also be considered, much 
of this nanoparticle size-efficacy work has been carried out in cancerous (HeLa) cell lines, 
as opposed to primary cell lines.  As each cell line expresses different levels of receptors 
and unique phenotypes, optimal nanoparticle uptake may be dependent on the cell line 
being investigated and internalisation mechanisms are likely to vary between cell types. 
 
In the literature, Chatterjee et al., (Chatterjee, D. K. et al. 2008a) have reported preferable 
sub-50 nm silica NP size (maximum diameters ≤ 100 nm) for effective phototoxic 
treatment albeit only in vitro, which was supported by studies using 30 nm silica-based 
particles by Roy et al., (Roy, I. et al. 2003).  Liu et al investigated the biodistribution of 
liposomes (30-400 nm in size) in mice and found 60% of the injected dose of 100-200 nm 
particles were found in the blood compared to liposomes smaller or greater than this size.  
This correlated closely to tumour uptake, which demonstrated a four-fold increase in 
accumulation of these 100 nm liposomes, compared to >300 nm and <50 nm liposomes 
(Liu, D. et al. 1992).  In the delivery of therapeutic agents to solid tumours, nanoparticles 
between 30-200 nm are deemed more desirable due their longer circulation half-life and 
the related probability of passively accumulating in tumour tissue (Jain, R. K. et al. 2010).  
Smaller nanoparticles (20 nm) are also believed to penetrate tumours more effectively, as 
they are able to navigate between the tumour interstitium following extravasation from 
leaky tumour vessels but are not retained beyond 24 h (Albanese, A. et al. 2012).  
Conversely, larger nanoparticles (100 nm) are unable to permeate far beyond the blood 
vessels but remain trapped in the extracellular matrix (ECM) between cells (Albanese, A. 
et al. 2012;Jain, R. K. 1994;Stylianopoulos, T. et al. 2010), thus creating a caveat in 
optimising particle size. 
 
ix. Charge 
The surface charge of nanoparticles (zeta-potential, ζ) has proved equally important in 
establishing their fate.  In systemic circulation, surface charge plays a pivotal role in 
nanoparticle distribution, metabolism, clearance, immunogenicity and uptake due to 
interactions with blood serum proteins, such as, immunoglobulins, lipoproteins, 
coagulation factors, metal- or sugar-binding proteins (Cedervall, T. et al. 2007).  
Nanoparticles with a neutral surface charge have been established as having a reduced 
2. Nanotechnology 
- 50 - 
 
plasma absorption and uptake into macrophages, demonstrating a high blood half-life 
(Gbadamosi, J. K. et al. 2002).  In comparison to both neutral and negatively charged 
nanoparticles, positively charged nanoparticles have shown a much faster clearance from 
the blood and an increase in the rate of non-specific tissue uptake, with higher 
accumulation in organs of the reticuloendothelial i.e. lungs (Arvizo, R. R. et al. 
2010;Thorek, D. L. et al. 2008).  This is thought to be due to cellular membranes having a 
slightly negative charge, which drives ionic/electrostatic interactions (Foged, C. et al. 
2005;Jin, H. et al. 2009).  As a result negatively charged nanoparticles are believed to 
promote local gelation at the lipid membrane, whereas positively charged nanoparticles 
augment fluidity (Albanese, A. et al. 2012).  In biological environments the surface of 
nanoparticles is quickly coated in multiple proteins layers, known as a ‘corona’.  The 
corona is affected by surface charge and consists of two layers; a hard layer of strongly 
adsorbed proteins lies in direct contact with the particle surface and an exterior soft layer 
of serum proteins that weakly interact with the hard layer.  The soft layer is much more 
dynamic as a result and can change over time, ultimately determining the nanoparticles fate 
(Lynch, I. et al. 2009).  Positively charged nanoparticles experience this phenomenon more 
intensely, with rapid adsorption of serum proteins that identify them for removal by the 
RES (Albanese, A. et al. 2012).  The addition of PEG groups can significantly reduce 
opsonisation by creating a more neutral particle surface charge. 
 
x. Miscellaneous nanoparticles 
In recent years, novel classes of nanoparticles have emerged for direct application in PDT.  
Upconversion (UC) nanoparticles represent a class of particles that can be efficiently 
excited at low excitation densities to improve the penetration depth of light into tissues 
(Haase, M. et al. 2011).  This occurs through the emission of shorter wavelengths of light 
(higher energy) than those used to excite the particles (anti-Stokes-type emission), 
following the absorption of two or more photons (Huang YY et al. 2012).  The UCNs 
achieve this through one of three quantum processes; energy transfer upconversion (ETU), 
excited-state absorption (ESA) and photon avalanche (PA).  In the clinic this translates into 
a ‘nanotransducer’ converting deeply penetrating near-infrared (NIR) light of low energy 
into visible light of shorter wavelengths and higher energy to activate PS deep within 
tumour tissue, generating singlet oxygen for PDT (Chatterjee, D. K. et al. 2008b).  This 
mechanism also has applications in biomedical imaging as greater penetration of tissue, 
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free from auto-fluorescence background, creates high sensitivity and better images (Cheng, 
L. et al. 2013).  Some of the first PDT studies in vivo using mesoporous-silica–coated 
upconversion fluorescent nanoparticles (UCNs) with dual-photosensitisers conjugated to 
their surface (ZnPc and MC540) have shown successful tumour growth inhibition (Idris, N. 
M. et al. 2012). 
 
In direct contrast to UCNs, simultaneous two-photon excitation nanoparticles require 
extremely high energy densities to induce excitation facilitated by a laser.  As excitation 
with NIR light (λ>780 nm) of longer wavelengths is able to penetrate biological tissue but 
is of too low photon energy to activate most photosensitisers by one-photon excitation, 
two-photon absorption (TPA) is able to combine the energies of two identical photons 
arriving at the PS at the same time.  Alternatively, the energy of one photon is provided at 
half the wavelength producing enough energy to activate the PS (Bhawalkar, J. D. et al. 
1997).  TPA-PDT has been demonstrated in vivo with mesoporous silica nanoparticles 
encapsulating porphyrin to treat tumours in mice with effect.  Results showed a tumour 
growth delay thirty days after treatment compared to controls (Gary-Bobo, M. et al. 2011). 
 
Finally, self-illuminating nanoparticles combine radiation therapy and PDT to induce Self 
Lighting Photodynamic Therapy (SLPDT) (Chen, W. et al. 2006).  Here, scintillating or 
luminescent (light-emitting) particles are able to activate photosensitisers whose absorption 
spectrum matches that of the light emitted i.e. porphyrins, following exposure to ionising 
radiation.  This produces singlet oxygen to enhance the killing of cancer cells.  As X-rays 
can easily penetrate through tissues (X-ray photons), unlike visible light, they can activate 
photo-sensitive agents deep in tumour tissue through the use of these self-illuminating 
particles.  Furthermore, combined with a PDT effect, lower doses of systemic radiation can 
be applied to stimulate tumour regression.  In this capacity, quantum dots and other 
nanoparticles have been explored for their employment in treating internal tumours with 
this type of combination therapy (Juzenas, P. et al. 2008). 
 
xi. Targeted nanocarriers 
The nanomedicine approach provides a promising step towards enhanced control of 
photosensitiser biodistribution and tumour-selective delivery in PDT.  The future of 
nanotechnology in clinical oncology is moving in the direction of creating multifunctional 
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particles, adapting nanoparticles for use as drug carriers, imaging agents and diagnostic 
tools for targeted cancer therapy (Liu, Y. Y. et al. 2007).  This has been achieved through 
the fabrication of targeted nanoparticles, whereby ligands are attached to the surface of the 
particle, which are highly selective and bind with great affinity to complementary receptors 
over expressed or up regulated on cancer cells, in order to exploit active mechanisms of 
uptake into malignant cells (Fig 2.10) (Peer, D. et al. 2007).   
 
 
Figure 2.10. Multifunctional targeted nanoparticle. Taken from (Aalto University 2012). 
 
Pegylation of nanoparticles to improve stability and circulation half-life has been shown to 
simultaneously weaken interactions between particles and cells due to steric hindrance, 
which may cause inefficient intracellular delivery (Li, S. D. et al. 2008).  To solve this 
problem, polymer conjugation has been combined with functionalisation of nanoparticles 
through the further addition of specific targeting agents to help prevent immune system 
recognition and increase the efficiency of drug delivery.  Surface modifications to particles 
include the conjugation of ligands, antibodies, vitamins, hormones and growth factors.  
Tumours, for example, display a variety of receptors that are unregulated on their surface, 
largely due to the rate at which they proliferate, but are found at much low numbers on 
normal cell surfaces.  This has been exploited in cancer therapy as the ligand and the 
receptor have a high specificity and affinity for one another and bind tightly as a result.  
This, in turn, triggers signal transduction cascades and loaded nanoparticles may be 
internalised through target-mediated endocytosis.  The utilisation of targeted nanoparticles 
in medical applications and PDT will be explored at greater depth in Chapter 7: Targeted 
Nanoparticles. 
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2.3 Tumour Biology 
i. Enhanced Permeability and Retention (EPR) Effect 
In PDT, common in vivo challenges include site-selectivity of drugs, light delivery and 
additional variability in tumour heterogeneity, including vascular perfusion, antigen 
expression and oxygen levels (hypoxia).  These factors not only influence the delivery of 
therapeutics but also dictate PDT efficacy. 
 
 
Figure 2.11. Vasculature in normal healthy tissue and tumour tissue.  Diagram taken from (Brown, J. M. et 
al. 2004). 
 
The biology, physiology and composition of tumour tissue is fundamentally different to 
that of normal tissue (Fig 2.11) (Wong, C. et al. 2011).  These differences can be exploited 
when designing and implementing nanocarriers for passive targeting of anti-cancer 
therapeutics (Jori, G. 1996).  In comparison to surrounding normal tissue, tumour tissue 
typically possess tortuous, abnormal vasculature (Brown, J. M. et al. 2004), acidic 
microenvironments (higher pH) and up regulated expression of specific cell surface 
receptors, including, glycoproteins i.e. folic acid (FA) (Leamon, C. P. 2008), growth 
factors (GFs) i.e. epidermal (EGF) or vascular epidermal growth factor (VEGF) 
(Yotsumoto, F. et al. 2009);(Kuwai, T. et al. 2008), signalling peptides and low density 
lipoproteins (LDLs) (Jori, G. et al. 1993).  In the latter example, circulating hydrophobic 
PS-complexes, preferentially bound by lipoproteins, may be endocytosed by tumour cells 
through specific LDL receptor-mediated pathways, increasing the passive accumulation of 
the PS in neoplastic tissues (Jori, G. 1989). 
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Figure 2.12. The Enhanced Permeability and Retention (EPR) effect in tumour tissue.  Diagram taken from 
(Peer, D. et al. 2007). 
 
The architecture of tumour vasculature is characteristic of rapid angiogenesis to serve fast-
growing cancers compared to more hierarchically organised healthy blood vessels (Fig 
2.11) (Brown, J. M. et al. 2004).  Leaky tumour vessels allow nanoparticles to extravasate 
into tumour tissue through hyperpermeable, discontinuous endothelial walls (larger 
fenestrae), which combined with poor clearance mechanisms from a dysfunctional 
lymphatic drainage system, facilitates their accumulation in tumour tissue (Peer, D. et al. 
2007).  This is known as the ‘enhanced permeability and retention’ (EPR) effect (Maeda, 
H. et al. 2000;Yokoyama, M. et al. 1998) (Fig 2.12).  Furthermore, the density of collagen 
fibres within the tumour may cause the compression of intratumoral blood vessels, 
affecting hydrostatic pressure, preventing the delivery of NPs within the tumour interior 
and reducing NP penetration through the collagen matrix (Tong, R. et al. 2013).  
 
Data from numerous studies indicate the EPR effect favours the passive accumulation of 
sub-500 nm particles for optimum penetration through the tumour interstitium following 
delivery via blood vessels and retention in the parenchyma from poor lymphatic clearance 
(Couvreur, P. et al. 2006;Roy, I. et al. 2003;Torchilin, V. P. 2005;Yuan, F. et al. 
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1994;Yuan, F. et al. 1995).  The size of the tumour fenestrae (100 – 1200 nm) (Moreira, J. 
N. et al. 2001) enhances vascular permeability and passive accumulation; creating high 
tumour-to-normal tissue ratios, providing the particles circulate for sufficient periods of 
time in the blood (Takeuchi, H. et al. 2001).  However, Jain et al., have found that not all 
solid tumours exhibit the EPR effect and the permeability of vessels may differ throughout 
a single tumour (Jain, R. K. 1994). 
 
ii. Tumour hypoxia and PDT 
Hypoxia in tumours is a result of an inadequate supply of oxygen (O2) reaching tissues on 
account of malignant propagation, which compromises biological functions.  The disorder 
in the structure and function of the tumour microcirculation leads to pathophysiological 
deterioration causing hypoxic areas in tissue, with oxygen partial pressure up to two orders 
of magnitude lower than healthy tissues (Freitas, I. 1985).  This in turn results in a 
signalling increase for hypoxia inducible transcription factor (HIF-1α) in order to restore 
oxygen homeostasis (Kunz, M. et al. 2003).  Oxygen deficient regions are strongly 
resistance to therapies and, as such, have become a central issue in cancer treatment.  This 
causes fundamental problems for the treatment of solid tumours with PDT, as sufficient 
tissue oxygenation is required to generate ROS via interaction with the PS.  Without the 
presence of oxygen, the PDT effect is abolished.  It is thought hypoxic tumour cells are 
resistant to PDT and a site for possible tumour recurrence post-irradiation (Master, A. et al. 
2013).  Strategies to reoxygenate heterogeneous tissues during or pre-treatment have been 
investigated, including molecular inhibition of HIF, hyperbaric oxygen therapy, ozone 
therapy and other combinational therapies (Muzykantov, V. R. et al. 2012), as well as 
destruction of hypoxic cells through hyperthermia (Sun, X. et al. 2010).  Research into 
improving the penetration, uniformity and distribution of nanocarriers within tumour tissue 
aims to compound these results. 
 
2.4 Future of Nanotechnology 
Nanotechnology is playing an increasingly important role in the development of many 
areas of biomedicine, especially drug delivery.  First generation nanoparticles were 
synthesised to demonstrate the capabilities of these novel materials for applications in 
biomedical research, using non-stealth particles as proof of concept for cellular uptake and 
safety in vivo.  Since then, second generation nanoparticles have been developed to create 
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long-circulating particles that can be actively targeted to increase selective uptake.  
Currently, third generation multifunctional nanoparticles are being generated for use in 
combinational therapies.  Alongside ‘intelligent’ particles that are able to respond to 
surrounding environments to exert their therapeutic effect, particles that enhance the 
photophysical properties of photosensitisers for PDT are being investigated in an attempt 
to overcome previous limitations.  With continued research into this field and a growing 
number of nanoparticle-based therapeutics entering clinical trials, the impact of this 
technology in the clinic is only set to rise.  This investigation seeks to explore the use of 
nanoparticles for application in PDT to treat solid tumours. 
 
3. Aims of Thesis 
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3. Aims of Thesis 
The aim of this investigation was to determine whether encapsulation of the 
photosensitiser, m-THPC, into different nanocarriers altered its delivery to target tissues 
and improved photodynamic therapeutic efficacy.  This was predominantly achieved 
through normal (healthy) and cancerous in vivo rodent models. 
 
The first objective of this work was to investigate the in vivo biodistribution and 
accumulation of m-THPC when incorporated into pegylated nanoparticles.  These 
nanocarrier delivery vehicles were composed of different materials and varied in size, 
degradability and surface ligands.  Each was directly compared to the uptake of standard 
micellular clinical m-THPC formulation, Foscan®, following intravenously administered; 
- liposomes (~ 100-120 nm) 
- polymeric (PLGA) nanoparticles (~ 150-250 nm) 
- organically modified silica (ORMOSIL) nanoparticles (~ 20-100 nm)  
+ cRGD peptide 
 
The major methodology employed to obtain pharmacokinetic data was chemical extraction 
of m-THPC from tissues, followed by spectrofluorimetric analysis.  The resultant 
pharmacokinetic data were analysed through both compartmental and non-compartmental 
models. 
 
The second objective was to determine whether specific nano-formulations of m-THPC 
and corresponding tumour uptake resulted in improved efficacy of PDT to tumours, and 
simultaneously, whether this reduced adverse effects in normal tissues using similar in vivo 
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models.  Effects on efficacy of dose and light parameters were included.  The central 
methodology employed was post mortem histological analysis to determine the extent of 
tumour PDT necrosis.  Normal tissue damage was assessed through selected skin 
photosensitivity studies with biodegradable liposomal nanocarriers and toxicology studies 
in organs involved in major clearance pathways with non-biodegradable silica 
nanoparticles. 
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4. Liposomes 
4.1 Introduction 
The application of nanoparticles in medicine has become an attractive avenue in recent 
years due to their potential benefits in clinical practice.  They offer solutions to some of the 
current limitations faced in the diagnosis and treatment of disease, such as improved 
pharmacokinetic properties, selective accumulation, controlled release of drugs and 
reduced systemic toxicity.  In 2008, liposomal drugs and polymer-drug conjugates 
accounted for more than 80% of the total nanotechnology-based therapeutic products 
approved for clinical use (Farokhzad, O. C. 2008). 
 
Liposomes, first discovered by Bangham in 1965, are inert, biodegradable nanocarrier 
systems.  They are closed, spherical phospholipid bilayer structures composed of natural or 
synthetic amphiphilic lipid molecules, producing a hydrophilic aqueous core and a 
hydrophobic lipid shell.  The suitability of their biological properties has made them a 
popular choice as pharmaceutical carries during the past decade, aiming to increase the 
therapeutic index whilst minimising adverse side-affects (Box 4.1). 
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Liposomal membranes consist of parallel components, such as phospholipids and 
cholesterol; the net properties of which determine their physical and chemical 
characteristics, including size, stability, fluidity, hydrophobicity, charge density and steric 
hindrance (Bawarski, W. E. et al. 2008).  Liposome formation is spontaneous due to 
naturally occurring interactions between water molecules and the amphiphilic 
phospholipids, self-assembling into bilayers. 
 
Liposomes, used as nanoparticles, typically measure 1-100 nm in diameter (Malam, Y. et 
al. 2009).  In recent years, different manufacturing processes have been used to 
successfully incorporate a variety of drugs and dyes into their structure.  Depending on 
their hydro- or lipophilic properties, different molecules occupy different liposome regions 
due to the hydrophilic head groups and hydrophobic chains of the phospholipids 
(Kozlowska, M. K. et al. 2009), determining drug distribution.  Hydrophobic drugs 
penetrate the lipidic bilayer, whilst hydrophilic drugs usually localise to the surface or 
aqueous compartment of liposomes near the polar heads (Angeli, N. G. et al. 2000). 
 
Figure 4.1. (Left) Schematic diagram of bilaminar liposome (Malam, Y. et al. 2009).  Left: Drugs are either 
trapped in aqueous core or packaged into hydrophobic shell.  Outer surface can be functionalised with active 
targeting ligands and/or pegylated. Top right: 3D model cross-section of liposome. Bottom right: Cryo-TEM 
image of liposomes (courtesy of Dr Scheglmann, Biolitec, Germany). 
 
Packaging therapeutics into liposomes can protect molecules from degradation and the 
physical-chemical properties of liposomes can determine uptake and localisation in vivo, 
emphasising the importance of particle design.  Lipid membrane components can be 
200 um 
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manipulated to improve their stability in vivo through modification of the bilayer fluidity 
(Damen, J. et al. 1981).  Cholesterol is renowned for its effect on membrane fluidity and 
has repeatedly been shown to increase liposome stability and reduce the permeability of 
the encapsulated drug molecules from the liposomal membrane (Vemuri, S. et al. 1995).  
Particle size can have a significant influence on uptake, with larger particles more likely to 
be eliminated from the blood circulation than smaller ones, due to the increase in 
cellular/tissue uptake of sterically favoured smaller particles (Senior, J. et al. 1982).  This 
has been confirmed in vitro using EMT-6 mammary tumour cells, which showed a higher 
intracellular uptake of smaller nanoparticles via cellular endocytosis, along with a higher 
drug release rate once internalised, due to a corresponding increase in the total particle 
surface area exposed to the leaching medium (Konan-Kouakou, Y. N. et al. 2005).  
Liposome size can be used to passively target organs that have fenestrae (GI tract, kidneys) 
or a discontinuous endothelium (liver, spleen, bone marrow).  The pores or gaps in the 
endothelial cells lining capillaries allow the passage of bulkier molecules, such as large 
proteins and liposomes, to pass through from the blood due to a lack (sinusoidal 
capillaries) or loosening in tight junctions between cells.  These anatomical features can be 
beneficial or deleterious depending on the application.  For example, it may be 
advantageous to passively target anti-parasitic or microbial drugs to organs of the 
reticuloendothelial system (liver, spleen) to treat infections (Basu, M. K. et al. 2004), 
however, for toxic chemotherapeutic or anti-cancer drugs, accumulation in the liver is 
undesirable.  Often, a compromise exists between decreasing particle size and increasing 
the drug load to deliver sufficient quantities of drug to target tissues.  Recently, Zheng et 
al., demonstrated that porphyrin molecules may be directly substituted into the lipid bilayer 
during formation of self-assembling lipid structures in order to conserve low particle size 
without compromising on drug loading (Lovell, J. F. et al. 2011).   
 
Surface charge can affect liposome distribution and efficacy in vivo.  Major problems 
associated with cationic liposomes, designed for gene delivery, have been observed as a 
result of their strong interactions with blood components and subsequent swift removal 
from circulation, dramatically lowering their transfection efficiency in an SK-1 mouse liver 
model (Senior, J. H. 1987;Zelphati, O. et al. 1998).  Anionic (negatively charged) 
liposomes face similar problems, with a shorter half-life in circulation than those with a 
neutral net surface charge (Funato, K. et al. 1992).  A linear relationship between the 
particle zeta potential and phagocytosis was recognised following surface modifications to 
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polystyrene microspheres.  Upon neutralising their surface charge, a reduction in both 
plasma absorption and uptake into J774 A1 macrophage-like cells was observed 
(Gbadamosi, J. K. et al. 2002).   
 
Liposomes can enter cells through a number of different mechanisms (Fig 4.2).  This 
occurs through either; non-targeted (A) or targeted (B) delivery and leads to liposomal 
degradation and intracellular drug release.  With non-targeted delivery, liposomes can be 
absorbed on to the cell surface or fuse to the plasma membrane, as they are formed of 
similar phospholipid constituents, to release their drug-load by micropinocytosis.  
Alternatively, they can undergo endocytosis through non-targeted or targeted delivery.  
Here, the whole liposome enters the cell via endosomes where they are either chemically 
degraded through hydrolytic enzymatic digestion following delivery to lysosomes, or they 
induce endosome destabilisation en route to lysosomes; both resulting in the release of 
encapsulated drugs into the cellular cytoplasm.   
 
 
Figure 4.2. Entrance pathways of (A) untargeted liposomes and (B) targeted liposomes into a cell.  Diagram 
taken from Nature Reviews (Torchilin, V. P. 2005). 
 
It appears conventional liposomes (unmodified), are not able to enhance tumour-to-normal 
tissue drug ratios alone, as they are swiftly degraded (mins) upon entering the blood 
circulation (Derycke, A. S. et al. 2004).  This can occur through a number of mechanisms 
(Fig 4.3).  The first relates to the instability of the liposomes in plasma and their interaction 
with high (HDL) and low density (LDL) lipoproteins (Allison, B. A. et al. 1997).  
Irreversible disintegration through lipid exchange between the liposomes and lipoproteins 
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causes rapid release of the encapsulated drug.  Although there is evidence to suggest LDL 
lipoproteins may help to enhance the tumoural uptake of liposome-released drugs (as 
discussed in Chpt 1 & 2).  As the expression of LDL receptors is elevated on the surface 
of rapidly proliferating tumour cells due to the increased demand for cholesterol, required 
for membrane synthesis, this may dually facilitate the uptake of liposome-released 
hydrophobic drugs, bound to the lipid core of LDL lipoproteins, into tumour cells via 
LDL-receptor-mediated endocytosis (Renno, R. Z. et al. 2001).  However, the localisation 
of drug-loaded liposomes within tumour tissue is thought to be more favourable in terms of 
therapeutic efficacy.  The second method is through opsonisation of the liposomes from 
blood serum proteins, resulting in their removal from circulation and uptake into cells of 
the mononuclear phagocytic system (MPS), also known as the RES (Hoedemakers, R. M. 
et al. 1993).  In this instance, the liposomes themselves are not recognised by the MPS but 
upon exposure to blood they become coated with plasma proteins (opsonins), which can 
take the form of immunoglobulins, fibronectin and glycoproteins (Patel, H. M. 1992), and 
determine the recognition and subsequent fate of the liposome by the MPS.  Lastly, the 
host’s immune system uses ‘complement components’ as a natural defence mechanism 
against invading pathogens.  Membrane attack complexes (MAC) initiate cell membrane 
lysis by producing lytic pores.  In the case of liposomes, this causes instability and release 
of their content, enhancing uptake by the MPS. 
 
Figure 4.3.  In vivo behaviour of different liposomes; (1) macrophage uptake, (2) lipid exchange between 
plasma proteins, (2) release of PS, (2’) plasma protein association or (2”) entry of free PS ino tumour cells 
via LDL-receptor mediate endocytosis, (3) direct internalisation of liposomes into tumour cells. Passive 
targeting into tumour interstitium or active targeting (I) non-internalising target or (II) endocytosis.  Diagram 
taken from Advanced Drug Delivery Reviews (Derycke, A.S. and De Witte, P.A., 2004). 
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Long-circulating or Stealth® liposomes have been synthesised through modification of the 
liposome surface (Allen, T. M. et al. 1995;Klibanov, A. L. et al. 1990;Oku, N. et al. 1994), 
however, this cannot be achieved through the substitution of saturated phospholipids and 
cholesterol alone.  For many nanoparticles, minimising protein binding is vital for 
developing long-circulating nanoparticles (Li, S. D. et al. 2008).  This typically involves 
attaching a biocompatible polymer to the surface of the liposome to increase its 
hydrophilicity and discourage opsonisation.  This can be achieved in several ways: (i) 
physically adsorbing the polymer on to the external shell surface, (ii) incorporating the pre-
fabricated polymer-lipid conjugates during preparation or (iii) covalently attaching reactive 
groups to the surface of the liposome (Immordino, M. L. et al. 2006).  The evidence for the 
effect of such polymers on increasing particle longevity is apparent, irrespective of their 
surface charge or addition of stabilising agents such as cholesterol (Immordino, M. L. et al. 
2003). 
 
Polyethylene glycol (PEG) is an uncharged, biocompatible polymer with low 
immunogenicity and toxicity which is readily incorporated onto the liposomal surface 
(pegylation) via a number of mechanisms (Dreborg, S. et al. 1990).  In the current 
investigation, PEG is anchored to the liposomal surface via a cross-linker lipid, 
distearoylphosphatidylethanolamine (DSPE), to which it can be conjugated (DSPE-PEG).  
Typically in commercially PEG-modified liposomes, a more stable carbamate bond is used 
to conjugate PEG to DSPE, as used here, as esters are more prone to cleavage at certain 
pHs.  As a linear polyether diol, soluble in aqueous and organic solutions (Powell GM et 
al. 1980), PEG helps to increase the hydrophilicity of the liposomes, whilst simultaneously 
providing good steric hindrance for the prevention of serum protein binding (opsonisation) 
(Blume, G. et al. 1993).  This consequently enables particles to avoid recognition by 
scavenger receptors present on the macrophage cell surface (MPS/RES) and subsequent 
internalisation, degradation and removal from circulation, aiding in increasing their 
longevity and bioavailability to target tissues (Opanasopit, P. et al. 2002) (Zamboni, W. C. 
2005).  The chain length (or molecular weight) and surface graft density of PEG can be 
freely modulated and determine the degree of surface coverage, having a significant effect 
on particle biodistribution.  Although shown to improve vesicle stability and prevent 
aggregation through promoting strong interbilayer repulsion (Needham, D. et al. 1992), 
higher concentrations of PEG attached to the surface of a liposome can jeopardise the 
stability of the lipid-based nanocarrier as the dense polymer chains can disrupt the integrity 
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of the phospholipid membrane (Dos, S. N. et al. 2007).  Moreover, high pegylation can 
also weaken interactions between particles and cells, which can cause inefficient 
intracellular delivery (Li, S. D. et al. 2008). 
 
 
 
Figure 4.4. Left: Chemical structures of distearoylphophatidylcholine (DSPC), 
distearoylphophatidylethanolamine after conjugation with poly-(ethylene glycol) (PEG) (DSPE-PEG) and 
DSPE-PEG linked with a targeting moiety. Right: The behaviour of PEG when attached to the liposome 
surface, dependent on the graft density and molecular mass of the polymer which in turn determines surface 
coverage, distance between graft sites and polymer chain interaction creating (i) brush mode <8 mol% (ii) 
mushroom conformation <4 mol% & (iii) pancake, with DSPE-PEG 2000, as proposed by DeGennes, 1980. 
 
PEG chains are highly flexible and water-soluble and can extend to give a hydrodynamic 
radius ~5–10 times greater than that of a globular protein of equivalent molecular weight.  
Owing to its high degree of hydration, the polymer chain helps to mask the surface to 
which it is bound by effectively forming a ‘water shell’ (Duncan, R. 2006).  When 
polymer-coated surfaces come into contact with one another they experience repulsive 
forces (Helm, C. A. et al. 1992).  At low surface polymer coverage, polymer chains can 
interact with the opposite surface independently of one another.  As surface coverage 
increases, so does the probability of the polymer chains coming into contact with one 
another, forcing them to adopt extended configurations (see Fig 4.4).  These interactions 
increase the thickness of the polymer layer and are believed to simultaneously increase 
steric stabilisation efficiency within this extended region (Helm, C. A. et al. 1992).  
Although there has been much evidence to suggest a reduction in particle aggregation and 
an increase in circulation times as a result of these properties, PEG has also been shown to 
interfere with cell interaction and intracellular trafficking (Xu, L. et al. 2011). 
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Numerous studies demonstrate the positive impact of pegylation on delivering cancer 
targeted drugs (Dadashzadeh, S. et al. 2008;Ichikawa, K. et al. 2004;Konan-Kouakou, Y. 
N. et al. 2005;Oku, N. et al. 1997;Park, J. W. 2002;Pegaz, B. et al. 2006;Symon, Z. et al. 
1999;Zamboni, W. C. 2005) as a reduction in MPS uptake allows for passive accumulation 
in other tissues.  In contrast to normal tissue vasculature, with tight junctions between 
capillary endothelial cells, malignant tumour vasculature is characterised by rapid 
angiogenesis, producing leaky vessels with large fenestrae.  This facilitates the 
extravasation of liposomes into the interstitial space where they are allowed to passively 
accumulate due to a dysfunctional lymphatic drainage system via the enhanced 
permeability and retention (EPR) effect (Maeda, H. et al. 2000).  However, the degree to 
which the active drug molecule is taken up and released into the interior of the tumour cell 
is unknown and the two mechanisms are not mutually exclusively.  It has also been 
suggested that intracellular uptake and subsequent subcellular distribution of drugs within 
tumour cells has a great therapeutic effect than extravasation into the tumour interstitium 
alone (Richter, A. M. et al. 1993).  
 
New generations of liposomes for passive targeting to tumour tissue have been created 
using intelligent design to improve selectivity.  In addition to modifications at the liposome 
surface, the carriers incorporate specific trigger release mechanisms tailored to their target 
tissue environment in order to release their drug content and allow liberated molecules to 
interact with their surroundings.  Examples include;  
i. Thermo-sensitive liposomes; when the target tissue is heated above the phase-
transition temperature of the liposomal membrane, the drug molecules are released 
as a result of membrane lipid disorder and an increase in the permeability of the 
membrane.  Ideal candidates are liposomes composed of lipids that have a phase-
transition temperature just above normal body temperature (37°C) that are triggered 
by local heating of tumour tissue.  This treatment, however, may affect the integrity 
of surrounding normal tissue as heating causes destruction of structural collagen 
fibres (Gaber, M. H. et al. 1995) therefore may only be suitable for topical cancers. 
ii. Fusogenic liposomes; viral proteins with fusogenic properties (e.g. Sendai virus 
coat-proteins) have been coupled to the surface of liposomes to create virosomes.  
These are used to deliver the contents of liposomes into the cytosol upon fusing 
with the cell membrane via non-internalising receptors.  Drawbacks to this system 
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include the lack of tumour selectivity, as viral proteins dictate which cells are 
targeted (Metselaar, J. M. et al. 2002). 
iii. pH sensitive liposomes; the microenvironment of tumour tissue (interstitial space) 
and tumour cells (endosomes/lysosomes) has a lower pH compared to the 
physiological pH of normal tissue, making it slightly acidic.  This can be exploited 
by designing liposomes that incorporate acid-sensitive molecules which are 
charged at neutral pH but uncharged at acidic pH.  This would cause liposomes to 
collapse in a low pH environment as protonation results in a reduction in 
interbilayer repulsion, releasing drug molecules into tumour tissue (Aicher, A. et al. 
1994).  Studies in vivo have shown that additional incorporation of modifying 
molecules, such as PEG, used to increase blood circulation times in rats, can reduce 
the pH sensitivity of these liposomes (Slepushkin, V. A. et al. 1997).  In order to 
combat this, other studies have encouraged the detachment of PEG in local 
pathological conditions, i.e. low pH of tumours, to release their therapeutic load 
(Torchilin, V. P. 2005). 
As previously discussed, the clinical utility of many therapeutics has been limited by their 
inability to localise in target tissues at sufficient concentrations or impairment by 
severe/harmful side-effects to normal tissues.  Liposomes were first employed as drug 
delivery vectors in 1995 when Doxil® (Table 4.1) was the first liposomal pharmaceutical 
product to be approved for use the treatment of Kaposi’s sarcoma (AIDS-related).  It 
contains the chemotherapeutic drug Doxorubicin, which causes major cardiotoxicity (e.g. 
strongly binds to cardiolipin) when administered freely.  Liposomes were developed to 
enhance the therapeutic index by reducing doxorubicin-related toxicity (Myocet®) and it 
was discovered the addition of PEG groups (Doxil®) and alterations in liposomal 
composition (LipoDox®) increased blood circulation times (stability) and improved the 
safety profile; as evidence suggests Doxil is metabolised by a different mechanism to 
doxorubicin from patient studies (Malam, Y. et al. 2009).  Despite a reduction in severe 
cardiac events, new symptoms such as stomatitis (inflammation of mucosal lining) became 
the dose-limiting side-effect and the number of incidences increased with pegylated 
formulations, paradoxically, as a result of their longer half-life (Hong RL 2004;O'Brien, 
M. E. et al. 2004) .  Since then, liposomes have been used in other applications including, 
but not limited to, ophthalmology, pain management, infections, vaccinations and further 
expansion into the effectiveness of anti-cancer drugs (Table 4.1) of which many have been 
either clinically approved or entered into Phase III clinical trials. 
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Table 4.1. Liposomal drugs approved for clinical application (market) or undergoing clinical evaluation (Phase III clinical trials*) (Chang, H. I. et al. 2012). 
Active drug Product name Modified Lipid composition (molar ratio) Treatment 
Amikacin* Arikace pegylated DPPC, cholesterol Lung infections 
Amphoteracin B Ambisome Non- pegylated HSPC, DSPG, cholesterol, Amp B (2:0.8:1:0.4) Fungal infection 
Cisplatin LipoPlatin pegylated SPC, DPPG, cholesterol, mPEG 2000-DSPE  Epithelial malignancies 
Cytarabine DepoCyt Non- pegylated Cholesterol, triolein, DOPC, DPPG (11:1:7:1) Lymphomatous meningitis 
Daunorubicin DaunoXome Non- pegylated DSPC, cholesterol (2:1) Kaposi’s sarcoma 
Doxorubicin Myocet Non- pegylated EPC, cholesterol (55: 45) Recurrent breast cancer 
Doxorubicin Doxil/Caelyx pegylated HSPC, cholesterol, PEG 2000-DSPE (56:39:5) Kaposi’s sarcoma, breast, ovarian 
Doxorubicin LipoDox pegylated DSPC, cholesterol, PEG 2000-DSPE (56:39:5) Kaposi’s sarcoma, breast, ovarian 
Doxorubicin* Thermodox pegylated DPPC, MSPC, PEG 2000-DSPE (90:10:4) Primary liver cancer 
Inactivated virus Epaxal Non- pegylated DOPC, DOPE Hepatitis A vaccine 
Inactivated virus Inflexal V Non- pegylated DOPC, DOPE Influenza vaccine 
Verteporfin Visudyne Non- pegylated EPG, DMPC (3:5) Wet- macular degeneration 
Vincristine Marqibo Non- pegylated Cholesterol, egg sphingomyelin (45:55) Non-Hodgkin’s lymphoma 
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Applications in PDT 
Drug delivery systems for photosensitising agents ideally should be soluble in aqueous 
solutions, in order to ensure suitability for administration via intravenous injection.  In 
addition, they should be able to demonstrate increased selectivity towards tumours.  
Although many photosensitisers possess hydrophobic properties, which enable them to 
penetrate through the cell membrane, their hydrophobicity also causes delivery problems 
due to the strong aggregation of molecules in aqueous environments.  Aggregated forms of 
photosensitisers are much less photoactive and bind strongly to certain serum proteins 
(Triesscheijn, M. et al. 2007).  It has been shown, particularly for porphyrins, that their 
photophysical properties are dramatically altered upon aggregation, causing a decrease in 
the absorption coefficient and a reduction in the fluorescence yield and lifetime (Boyle, R. 
W. et al. 1996), largely in the triplet state, reducing singlet oxygen formation (Ricchelli, F. 
et al. 1998).  Porphyrins, for example, exist in two aggregation formations; face-to-face 
aggregates (H-aggregate) (Hunter, C. A. et al. 1990) and edge-to-edge aggregates (J-
aggregate) (Ribo, J. M. et al. 1994).  Although liposomes do not completely prevent 
dimerisation of photosensitiser molecules they help to promote monomerisation along with 
the formation of possible planar aggregates, capable of photosensitising ability, thereby 
significantly increasing photoactivity and oxygen consumption (Derycke, A. S. et al. 
2004;Ricchelli, F. 1995).  This is known as the ‘monomerisation effect’ and occurs as a 
result of the localisation of the photosensitiser molecules within hydrophobic bilayers 
(Angeli, N. G. et al. 2000).  A second contributing factor is the ‘concentration effect’, as 
liposomes are able to incorporate large quantities of drugs, the local concentration of 
photosensitiser inside a vesicle is several orders of magnitude greater than that in the 
solvent solution.  This can lead to a structurally controlled aggregation process in the 
liposomal bilayer (Borovkov, V. V. et al. 1996).  Finally, the photosensitiser is located in a 
structured microenvironment within the liposome.  An increase in microviscosity slows 
down internal movements of the embedded molecule, restricting their diffusion motion and 
as a result reducing collisional quenching of fluorophores in excited states (Gottfried, V. et 
al. 1988), known as the ‘viscosity effect’.  Other contributing factors that may influence the 
photophysical properties of the liposomal encapsulated photosensitiser include the degree 
of rotational freedom of embedded molecules in the membrane, affecting quantum yields 
and singlet oxygen formation, and photobleaching inside the lipid bilayer (Gottfried, V. et 
al. 1988). 
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In PDT, problems associated with the biodistribution of PS to normal tissues and its 
clearance can result in residual cutaneous photosensitivity which must be managed until 
the drug is eliminated (Hopper, C. 2000).  The selectivity of tumour uptake with PDT 
photosensitisers is also marginal.  Liposomes have been used in recent years due to their 
suitability for packaging large quantities of hydrophobic photosensitisers into their lipid 
shells (Buchholz, J. et al. 2005;Lassalle, H. P. et al. 2009) and their ability to accumulate in 
tumour tissue through the enhanced permeability and retention (EPR) effect as a result of 
their size, as demonstrated numerous in vivo models (Maeda, H. et al. 2000).  This 
selectivity, however, is also largely dictated by the plasma half-life and pharmacokinetics 
of the liposomes, therefore PEG can be used to coat the outer surface of the liposome to 
reduce susceptibility to the host's immune system and rapid uptake into the RES 
(Torchilin, V. P. 2005), hindering the loss of the liposome from circulation (Dos, S. N. et 
al. 2007).  It is also essential that the photosensitiser be released from the liposome prior to 
irradiation with light, due to the short diffusion distance and half-life of singlet oxygen.  
Although excited photosensitiser may be able to oxidatively break down the liposomal 
carrier itself to release molecules, it may simultaneously prevent migration of reactive 
oxygen species into the local environment, limiting therapeutic effect (Derycke, A. S. et al. 
2004). 
 
Currently, Photofrin® (porfimer sodium), Visudyne® (verteporfin), Levulan® (5-
aminolevulinic acid, 5-ALA) and Metvixia® (methyl aminolevulinic acid) have been 
approved for use as PDT drugs by the Food and Drug Administration in the US.  Foscan® 
(m-THPC) has also been approved to treat head and neck cancers in the European Union 
and Japan (Hopper, C. et al. 2000).  All other clinically approved PDT drugs are 
porphyrin-based molecules, with the exception of 5-ALA, and are hydrophobic with 
intrinsically low water solubilities, therefore excipient molecules, such as lipid mixtures 
(e.g. in Visudyne) and ethanol/poly(propylene glycol) (e.g. in Foscan), are used to 
solubilise these agents for systemic intravenous injections (Ding, H. et al. 2011). 
 
Visudyne® is a successful, commercially available liposomal photosensitiser (non-
pegylated) approved for clinical PDT since 2004 (Table 4.1).  The active compound is the 
hydrophobic photosensitiser verteporfin, which is a benzoporphyrin derivative with a 
chlorin-like structure, activated upon illumination with 693 nm light (Bressler, N. M. et al. 
2000).  It was shown to be highly effective as a PDT agent in vivo from primate to murine 
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models, however, its low solubility in aqueous environments, means it typically undergoes 
self-aggregation, limiting its bioavailability.  Liposomes were used as a means to inject 
verteporfin intravenously in its monomeric form (Visudyne).  Visudyne was able to 
prevent the growth of destructive blood vessels (angiogenesis) without injury to 
surrounding tissues in patients due to its apparent selectivity to the vasculature and as such 
was used to treat wet age-related macular degeneration (AMD) with PDT, for which it is 
currently the only drug approved by the FDA (Chang, H. I. et al. 2012).  12 months post 
treatment patients had statistically better visual activity (67%) due to a reduction in the 
growth of abnormal blood vessels in the back of the eye (macular region) (Study Group 
1999). 
 
The photosensitiser, m-THPC, is similar to that of verteporfin.  It is a highly potent, second 
generation PS that exhibits several favourable characteristics for PDT (Bonnett, R. et al. 
1999).  Being a chlorin it exhibits stronger absorption than porphyrins at longer 
wavelengths (652 nm); however, it is hydrophobic and prone to aggregation, which 
presents problems in optimising its formulation (Redmond, R. W. et al. 1985).  The 
aggregated form of m-THPC is less photoactive and binds strongly to serum proteins 
(Triesscheijn, M. et al. 2007).  High inter-patient variability of the current micellular m-
THPC formulation, Foscan (Glanzmann, T. et al. 1998) is attributed to rapid uptake of PS-
aggregates into cells of the reticuloendothelial system (RES) and poorer accumulation in 
tumour tissue.  The unique microenvironment of solid tumours also limits PS delivery and 
distribution within cancerous tissue (Minchinton, A. I. et al. 2006), further contributing to 
differences in PDT response (Blant, S. A. et al. 2002).   
 
The aim of the present study was to investigate the in vivo biodistribution and 
accumulation of two pegylated liposomal m-THPC formulations (FosPEG 2% and FosPEG 
8%), in comparison to standard Foscan (m-THPC alone) (Table 4.2 & Fig 4.5).  Linear 
clearance patterns of therapeutics are rarely observed in biological systems therefore 
theoretical mathematical compartmental and non-compartmental approaches were applied 
to obtain a host of pharmacokinetic parameters.  Pharmacokinetic analysis was carried out 
in both normal Wistar rats and Hooded Lister rat models.  The latter model having been 
subcutaneously implanted with a syngeneic fibrosarcoma cell line (MC28), which has been 
successfully used in previous m-THPC (Foscan) studies (Tsutsui, H. et al. 2002).   
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m-THPC Foscan® FosPEG 
  
m-THPC 4.0 mg/mL m-THPC 1.5 mg/mL 
DPPC - DPPC 18.0 mg/mL 
DPPG - DPPG 2.0 mg/mL 
DSPE-PEG 
2000 - 
DSPE-PEG 2000 
(2 or 8 mol%) 
2.0 or 8.0 
mg/mL 
Ethanol 20% 
Glucose in 10 mM 
histidine buffer        
pH 6.5 
50 mg/mL PEG 400 30% 
dH20 50% 
Table 4.2. Foscan and FosPEG constituents and the molecular structure of m-THPC.  FosPEG is composed 
of two phospholipids DPPC (Dipalmitoylphosphatidylcholine) and DPPG (dipalmitoylphosphatidylglycerol) 
in a liposome structure with varying degrees of PEG 2000-DSPE (distearoylphosphatidyl ethanolamine).  
Information courtesy of Biolitec, Jena, Germany. 
 
Pharmacokinetic parameters obtained helped to deduce the in vivo behaviour of m-THPC 
in terms of its uptake and retention in different tissues over a selected time series.  The 
uptake of m-THPC when incorporated in pegylated liposomes was then correlated with 
measurements of tumour PDT efficacy and skin photosensitivity in comparison to Foscan. 
 
 
Figure 4.5. Schematic diagram illustrating the different liposomal nanocarrier formulations loaded with m-
THPC.  Liposome structure is formed with two phospholipids DPPC and DPPG.  The diameter of the 
unilamellar liposomes are ~105 - 125 nm, loaded with ~20 000 m-THPC molecules per liposome.  Foslip 
lacks a PEG coating and was not used in this study.  FosPEG formulations are coated with either 2% mol 
(FosPEG 2%) or 8% mol (FosPEG 8%) PEG (polyethylene glycol). Diagram courtesy of Biolitec, Jena, 
Germany. 
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4.2 Materials & Methods 
4.2.1 Chemicals and Photosensitisers 
Biolitec AG (Jena, Germany) kindly provided all m-THPC formulations (Dr Dietrich 
Scheglmann).  Foscan® was supplied in its standard formulation (m-THPC in 
ethanol/propylene glycol) at a stock concentration of 4 mg mL−1.  Liposomal formulations 
of m-THPC, FosPEG 2% and FosPEG 8%, were prepared as a 9:1 mixture of 
dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylglycerol (DPPG) 
using a conventional film method (Compagnin, C. et al. 2011).  The degree of pegylation 
was 2% and 8% (molar equivalent ratio) using 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[amino (polyethylene glycol)-2000] (DSPE-PEG2000) (Table 
4,2).  These were provided as stock solutions containing a molar equivalent concentration 
of 2.21 mM (or 1.5 mg mL−1) m-THPC in 10 mM histidine buffer, containing 50 mg mL−1 
glucose at pH 6.5.  The mean number of m-THPC molecules in the hydrophobic 
phospholipid shell was estimated at 2 × 104 per liposome, based on the 9:1 molar ratio of 
lipid to m-THPC determined after extrusion (~10 % m-THPC).  Mean particle size 
distribution and particle characterisation measurements were assessed using photon 
correlation spectroscopy, differential scanning calorimetry and cryo-TEM following 
extrusion and after storage.  The mean particle diameter of liposomal formulations was 
between 105-125 nm (z-average) and polydispersity indices (PCI) were between 0.04 and 
0.15, indicating narrow size distributions.  All formulations remained stable in size for up 
to 12 months in storage buffer and upon dilution (slight decrease in size ~5%), with no 
changes in optical appearance and no drug precipitates or aggregates observed.  Solvable™ 
(Perkin-Elmer, UK), which is a commercially available aqueous-based alkaline solvent, 
was used to dissolve animal tissues and release m-THPC in its monomeric form for 
spectrofluorimetric analysis, as aggregated photosensitisers cause dramatic changes in their 
absorption and fluorescence properties (Bonnett, R. et al. 1999). 
 
4.2.2 Absorbance spectra 
The absorbance spectra of m-THPC was measured for Foscan and each liposomal 
formulation in their equivalent buffers at 1 µM concentrations using a Lambda 25-UV/Vis 
spectrophotometer (Perkin-Elmer, UK).  Absorbance spectra were recorded between 300 – 
700 nm light wavelengths at 1 nm intervals.  Spectra were obtained at a scanning speed of 
480 nm min-1 and recorded through UV Winlab software®.  Pure m-THPC powder (Scotia 
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Pharmaceuticals, UK) was additionally dissolved in ethanol and diluted into working stock 
solutions of 1 µM as a reference.  In a separate group, absorbance of m-THPC was 
measured for all formulations at 1 µM concentrations when diluted in Solvable™ 
following incubation in Solvable™ at 50°C for 2 h, in order to replicate tissue chemical 
extraction conditions.  This was to assess potential shifts in maximum absorbance peaks 
(λmax) following extraction and ensure absorbance of m-THPC was not altered for 
spectrofluorimetric analysis.  Optimal wavelengths at the highest sensitivity (minimise 
deviations from Beer’s Law, A = ε l c) were set to obtain measurements (m-THPC λexc = 
423 nm, λem = 652 nm).  Absorbance measurements of each solution were taken in quartz 
cuvettes with a light path-length of 1 cm (Pye Unicam, UK). Cuvettes were rinsed with 
ethanol (Sigma, UK) before each reading.  Spectra were normalised with background 
absorbance values of Solvable™, ethanol and formulation buffers. 
 
4.2.3 Fluorescence spectra 
The fluorescence emission spectra of m-THPC in liposomal formulations, FosPEG 2% and 
FosPEG 8%, were measured in histidine loading buffer or DMSO (dissolution) at m-THPC 
concentrations of approximately 0.5 µM in 96 well plates (averaged).  Fluorescence 
emission spectra of known concentrations of m-THPC formulations in Solvable were 
measured to construct calibration curves for pharmacokinetic studies.  Control solutions of 
m-THPC in DMSO/Solvable only were run simultaneously (as m-THPC is insoluble in 
aqueous buffer).  An LS50B Perkin-Elmer spectrofluorimeter (Perkin-Elmer, UK) was 
used to obtain fluorescence spectra.  Spectra were acquired using a multimode bifurcated 
fibre-optic probe to provide front surface excitation/detection geometry, which is 
unaffected by polarisation effects, unlike the conventional orthogonal excitation/detection 
configuration.  The intensity of the fluorescence emission spectrum of m-THPC 
formulations was recorded between the 600 – 700 nm range after excitation (m-THPC λexc 
= 423 nm) using FL Winlab software.  Fluorescence spectra were normalised with control 
readings from background wells. 
 
4.2.4 Confocal microscopy in vitro 
The intracellular localisation of m-THPC in MC28 (rat fibrosarcoma) cells was determined 
through confocal fluorescence microscopy taking advantage of its red fluorescence.  1 x 
104 MC28 cells were seeded in 35 mm diameter glass-bottomed fluorodishes (WPI, UK).  
These were incubated over night to encourage adherence and optimal subconfluent cell 
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spreading for imaging.   After 24 h, MC28 cells were incubated with fresh Dulbecco’s 
modified Eagles Medium (DMEM) containing L-glutamine, 4.5 g/L glucose 
(BioWhittaker, Lonza, Verviers Belgium), supplemented with 10% (v/v) foetal calf serum 
(FCS) (Sigma-Aldrich), 100 U/mL penicillin and 100 µg/mL streptomycin at 37ºC in a 
humidified, 6% CO2 incubator under dark conditions for either 1 h or 6 h with 1 µM m-
THPC (Foscan) or m-THPC liposomal formulation (FosPEG 2%).  Following incubation, 
cells were washed twice with PBS before fresh media (minus serum and phenol red) was 
added.  This is because FCS is known to interfere with cellular drug uptake (Jori, G. et al. 
1984;Siboni, G. et al. 2002) and m-THPC emission is detected in the red region of the 
spectrum (Zguris, J. et al. 2006) (see Appendix I – A.3 Preparation of Fluorodishes: 
Foscan® and FosPEG2%).  Cells were observed using an inverted Olympus Fluoview 
1000 confocal laser scanning microscope to determine intracellular localisation of m-
THPC.  Fluorescence confocal images obtained with 60x 1.4 NA oil immersion objective 
(Olympus) were analysed with Fluoview FV1000 (Olympus) and Image J software.  m-
THPC fluorescence was detected using a 405 nm laser and a set of detection filters with 
400 nm excitation and 640-80 nm emission.  Laser voltage, Gain and Offset were kept 
consistent throughout imaging. 
 
4.2.5 Animals and tumour model 
All animal experiments were carried out under the authority of project and personal 
licences granted by the UK Home Office and with reference to NCRI (National Cancer 
Research Institute) guidelines for the Welfare of Animals in Experimental Neoplasia 
(2010). All procedures were performed under general anaesthesia with inhaled isofluorane 
(Abbott Laboratories Ltd, Kent, UK). Buprenorphine hydrochloride (Reckitt & Colman 
Products Ltd, Hull, UK) was given subcutaneously for postoperative analgesia where 
necessary. 
 
Female Wistar rats (180–220 g) were used for in vivo normal tissue pharmacokinetic 
studies and skin photosensitivity studies, since skin pigmentation is minimal. The same 
model was used previously by Weersink et al., in studies with a different photosensitiser 
(Weersink, R. A. et al. 2005).  Each formulation was administered intravenously via a tail 
vein injection at a dose of 0.3 mg kg−1 m-THPC (see Appendix I –A.1 Dosage 
Calculations). At a specified time point between 2 and 168 h, animals were killed by 
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cervical dislocation. For plasma readings, animals were killed immediately after injection 
at an estimated time of ≤ 5 min. 
 
The Wistar rat model was additionally chosen due to the large volume of literature 
published on PDT to normal tissues in these animals (i.e. liver and colon); therefore 
comparisons could be drawn with other available photosensitisers e.g.  Palladium 
bateriopheophorbide (Tookad) (Woodhams, J. H. et al. 2006), Phthalocyanine (Pc) 
(Woodhams, J. H. et al. 2003), aminolevulinic acid (ALA) (Messmann, H. et al. 1995) and 
ATX-S10Na(II) (Harada, M. et al. 2005).   
 
A methylcholanthrene-induced fibrosarcoma cell line (MC28), syngeneic and 
transplantable to Hooded Lister (HL) rats (Ashraf, S. et al. 1997;Tsutsui, H. et al. 2002) 
was cultured in Dulbecco’s modified Eagles Medium (DMEM) containing L-glutamine, 4.5 
g/L glucose and phenol red (BioWhittaker, Lonza, Verviers Belgium).  Media was 
supplemented with 10% (v/v) foetal calf serum (FCS) (Sigma-Aldrich), 100 U/mL 
penicillin and 100 µg/mL streptomycin (Sigma-Aldrich).  Cells were cultured under 
aseptic conditions in monolayers and maintained at 37ºC in a humidified, 6% CO2 
incubator (LEEC Research CO2  Incubator).  At 80-90% confluence (~ 1-2 x 106 cells/T-
150 flask),ells were passaged routinely; washing twice with phosphate buffered saline 
(PBS) (BioWhittaker, Lonza) before trypsinisation (0.05% Trypsin in 0.02% PBS/ EDTA) 
with 3 mL Trypsin-EDTA (ethylene diamine tetra-acetic acid, EDTA, calcium chelator) 
for 0.5 - 1 mins, to ensure cell detachment.  Trypsin was neutralised with serum enriched 
culture medium and the cell suspension was centrifuged (5 mins, 17600 g RCF).  Cells 
were resuspended in fresh media and re-plated at an optimal growth seeding density of 
5000 cells/cm² (see Appendix I –A.2 Cell Counts and Calculations). 
 
Female HL rats (150–220 g) were inoculated subcutaneously in the lower flank, where 
influence of respiratory movement is minimal, with approximately 1–2 × 106 MC28 cells 
in 0.1 mL injection volume (Ashraf, S. et al. 1997;Murphy, P. et al. 1986).  Tumours were 
monitored continuously and reached an optimal size of approximately 10 mm3 after 7–10 
days at which point they were selected for studies. For longer time points (≥72 h) animals 
were recruited earlier to studies to account for continual tumour growth.  This size was 
chosen based on previous publications which showed no evidence of spontaneous necrosis 
in tumours ≤10 mm in diameter in this model (Tsutsui, H. et al. 2002). 
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4.2.6 Pharmacokinetic study 
Tissue samples selected for pharmacokinetic analysis included muscle, skin (right 
abdominal wall), liver, spleen, kidneys, lung, blood serum and tumour, taken from three 
animals at each time point.  Immediately post-mortem tissues were removed under 
subdued lighting at 2, 4, 6, 18, 24, 72, 96 and 168 h from normal Wistar rats after 
intravenous administration of each m-THPC formulation at 0.3 mg kg−1.  For HL tumour 
rats, time points of 2, 4, 6, 24 and 72 h were chosen for intravenous administration of each 
m-THPC formulation at the same dose (0.3 mg kg−1) due to maximal tumour growth 
threshold being attained by 72 h.  Blood samples (~3 mL) were also taken immediately 
after injection at an additional ≤5 min interval and left to stand for 20 mins before 
centrifuging to separate the serum at 2000 rpm (~300 g RCF) for 10 min for 
pharmacokinetic analysis.  Negative control animals at 0 h were run simultaneously.  
Samples were stored in the dark at −80 °C. 
 
m-THPC accumulation in tissues was measured through a chemical extraction method 
combined with spectrofluorimetric analysis of m-THPC in the extract, adapted from 
Kascakova et al., (Kascakova, S. et al. 2008).  Tissue samples of approximately 0.1 g wet 
weight were run in triplicate.  These were incubated in 2 mL of 100% Solvable™, an 
aqueous-based alkaline solvent containing a mixture of dodecyldimethylamine oxide (2.5–
10%), secondary alcohol ethoxylate (2.5–10%) and sodium  hydroxide (≤2.5%)  in water 
(Perkin-Elmer, UK).  Samples were incubated for approximately 2 h at 50 °C in a shaking 
water bath, until completely dissolved without any visible tissue residue to ensure 
complete monomerisation of m-THPC (no binding of m-THPC to residual tissue).  
Fluorescence detection was used to construct a linear standard curve of known m-THPC 
concentrations (0–5 µM) from control tissues for each organ, prepared under identical 
conditions and diluted in the same solvent (Solvable™) as test samples (Table 4.3).  The 
solubilised tissues were aliquoted (300 µL) into a 96 well plate.  The fluorescence signal 
from each well was detected using a Perkin-Elmer LS 50B fluorescence spectrometer 
(Perkin-Elmer, UK) linked to a plate reader.  Front surface excitation/detection was 
employed using a fibre-optic probe which minimises reabsorption and polarisation 
artefacts.  Excitation and emission wavelengths for m-THPC fluorescence measurements 
were set at 423 nm and ~652 nm respectively, as determined by m-THPC absorbance 
spectra maxima.  Slit widths, that select the band of incident light, were set at 10 nm for 
excitation/emission entry/exit with an additional internal 515 nm long-pass filter for 
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emission.  Fluorescence was measured and recorded through Win lab® software.  
Fluorescence readings were used to calculate the mean tissue concentration of m-THPC.  
Readings from negative control samples (without m-THPC) were deducted to correct for 
the autofluorescence (endogenous fluorophores) of each organ. The mean and the standard 
deviation (SD) for all three animals at each time point were calculated (± s.d., n = 3). The 
blood pharmacokinetics were analysed by compartmental and non-compartmental 
mathematical methods (Clark B et al. 1981) (Yamaoka, K. et al. 1978). 
 
 Rat 1 Rat 2 Rat 3 Control Rat 
 3 samples 3 samples 3 samples 3 samples 
 1 2 3 4 5 6 7 8 9 10 11 12 
A             
B             
C             
D             
E             
F             
G             
H             
Std C     0      0.001   0.005    0.01     0.02     0.05       0.1      0.2       0.5         1          2      5(µM) 
Table 4.3. Illustration of the well plate loading of tissue samples for spectrofluorimetric analysis. e.g.  Tissue 
sample = liver, at time point = 2 h, drug = Foscan.  Tissue removed from 3 separate animals (Rat 1 – 3) + 
negative control animal (Control Rat: m-THPC free) and extraction carried out in triplicate (Rows A-D: 
Columns 1-3 ■ , 4-6 ■, 7-9 ■, 10-12 □).  A standard curve of known m-THPC concentrations (µM) was 
additionally constructed using control tissue (Rows E – H: Columns 1 – 12). 
 
Raw data were collected in micro molar units of concentration (µM) and subsequently 
converted into micrograms per gram (µg g-1) (see Appendix I – A.4 Chemical Extraction: 
Raw Data Calculations).  All data were represented as mean±SD.  Statistical analysis was 
carried out using a Student's t –test, where P≤0.05 was considered statistically significant.   
 
This method is based on previously published work on alkaline hydrolysis of ex vivo tissue 
for photosensitiser quantification (Wilson, B. C. et al. 1997).  It has since been refined, 
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removing/adding steps to establish optimal solvent concentrations, pH and incubation 
periods specifically for m-THPC quantification (Kascakova, S. et al. 2008), which have 
been adopted here.   
 
4.2.7 Photodynamic therapy on MC28 tumours 
Treatment with each m-THPC formulation was initiated when tumours had reached an 
optimal diameter of 10 mm.  Clinical m-THPC doses of 0.3 mg kg−1 (high), 0.1 mg kg-1 
and 0.05 mg kg−1 (low) (Betz, C. S. et al. 2008) were administered to two groups of 
animals prior to light delivery.  A DLI of 24 h was chosen for PDT studies based on 
chemical extraction data of tumour tissue.  Tumours were irradiated with red laser light 
interstitially from a 652 nm diode laser (Diomed, Cambridge, UK) using a 400 µm bare 
cleaved tip optical fibre inserted approximately 1 mm into the tumour capsule via a small 
incision in the overlying skin and in the MC28 tumour capsule.  This irradiation method 
has been used in previous studies with m-THPC in the same tumour model (Tsutsui, H. et 
al. 2002) within our laboratories and mimics interstitial clinical PDT with Foscan, 
predominantly carried out on head and neck tumours whereby the laser fibre is inserted 
into the tumour.  A total energy of either 2 J or 10 J of light at 100 mW (20 or 100 s) was 
delivered to each tumour.  Each treatment group consisted of five animals.  Animals were 
killed 24 h after treatment by cervical dislocation and whole tumours resected for 
histological analysis.
 
 
4.2.8 Skin photosensitivity studies 
Skin photosensitivity studies required shaving, depilating (Neet™) and cleaning an area on 
the lower flank in a separate group of female Wistar rats (180–220 g).  Following m-THPC 
i.v. administration of either 0.3 mg kg−1 or 0.1 mg kg-1, 4 circular areas of skin measuring 
0.5 cm in diameter and 1 cm apart (grid design) were exposed sequentially to either 0 (0 J), 
5 (30 J), 15 (90 J) or 30 min (180 J) of 100 mW cm−2 of light (1 sun=solar equivalent 
spectrum) from a solar simulator source (Olympus CLV-S30, Cambridge, UK) at drug-
light intervals (DLI) of either 96 and 168 h (Fig 4.6).  
 
This system incorporated a 300W (Olympus Endoscopic) xenon lamp, providing a uniform 
2 cm diameter beam at the skin surface.  Surrounding skin tissue was protected from light 
using a light impenetrable fabric.  Illuminated areas were marked adjacently.  Light power 
was measured using a laser power metre (Gentec, UK) and was calibrated before and after 
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each treatment.  A spectra of the solar simulator light was also taken to ensure it correlated 
to the observed spectra of sunlight (see Appendix I – A.10 Skin Photosensitivity Studies: 
Solar Simulator Spectra).  Although this does not result in a perfect reproduction of the 
true solar spectrum, due to a lack of UV (< 400 nm) and infra-red (> 750 nm) regions of 
the spectrum, it should be sufficient for quantitative assessment of skin response for 
guiding clinical use of m-THPC. 
 
   
Fig.4.6. Experimental set-up for skin photosensitivity studies using female Wistar rats.  Bare skin was 
irradiated with artificial sunlight from a solar simulator source (Olympus CLV-S30) for up to 30 mins.  
(Controls received either no PS or no light).  The light source was calibrated before each treatment to ensure 
the power (100 mW) was constant and energy of light administered was accurate.  The total diameter of the 
light beam was 25 mm, which was positioned 1.5 cm above the skin surface. 
 
Treatments were carried out in a climate controlled room to prevent overheating of the 
skin.  Visual assessment of skin reactions were carried out 24 h post-treatment and digital 
images taken.  Imaged areas were then assessed by two independent scorers using a 
blinded grading model, previously established by Weersink et al., (Weersink, R. A. et al. 
2005) (see Appendix I – A.11 Skin Photosensitivity Studies: Skin scoring model).  
Grading was carried out on all images at one time to ensure subjective analysis across the 
data set was relative between animals.  Each m-THPC formulation was allocated an ordinal 
value (0–8) and scores were averaged over each exposure time.  Areas of skin treated at 0 
min (no light control) and 30 min were removed for histological analysis.  A separate 
group of animals that received no PS was also treated with 30 min of light to ensure skin 
effects were a result of the presence of PS, not light exposure. 
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4.2.9 Histology and measuring necrosis (Hamamatsu nanozoomer) 
Whole tumours and skin tissue samples removed post-mortem were immersed in 4% 
neutral formalin buffer (4% w/v formaldehyde in phosphate buffered saline) for a 
minimum of 24 h at 20 °C. Samples were processed by routine histological methods.  The 
tumours were cut in half (parallel to the laser fibre) and skin samples were cut through the 
centre of the treatment area, and adjacent halves of the tissue were embedded face down in 
paraffin wax blocks.  Four-micrometre sections were cut and mounted on Vectabond 
(Vecta laboratories, UK) treated glass slides.  Three sections were taken from each of the 
tissue halves. Slides were stained with Harris haematoxylin and eosin.  Whole slides were 
scanned with the Hamamatsu Nanozoomer (Hamamatsu Photonics UK Ltd).  Hamamatsu 
virtual microscopy imaging software was used to observe markers indicative of skin 
photosensitivity i.e. erythema and oedema. PDT damage in tumour tissue was assessed by 
measuring the surface area of necrosis from each section, as used previously in m-THPC 
PDT (Garrier, J. et al. 2010).  The damage was calculated from each tumour as a 
percentage of the whole tumour surface area due to variability in tumour size and 
heterogeneity of tissue (see Appendix I –A.15 PDT: Hamamatsu Nanozoomer: 
Calculating the Area of Necrosis).  Six sections were averaged per tumour (3 from each 
tumour half).  The mean percentage surface area of tumour necrosis was calculated through 
blind analysis per group of five identically treated animals and all data were represented as 
mean±SD. 
 
4.2.10 Statistical analysis 
Mean and standard deviation was calculated for each animal group (±SD, n=3–5). All data 
were represented as mean±SD.  Statistical analysis was carried out using a two-tailed 
Student's t-test and a Mann–Whitney U test for PDT data. p≤0.05 was considered 
statistically significant, unless stated otherwise. 
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4.3 Results 
i. Absorption spectra 
An absorbance spectrum of Foscan and each pegylated liposomal m-THPC nanocarrier 
formulation, FosPEG 2% and 8%, was taken in its corresponding buffer, as when 
administered in animals, to deduce peak absorbance wavelengths. 
 
 
Figure 4.7. Absorbance spectra of Foscan (m-THPC in buffer: PEG 400 (3): EtOH (2): dH2O (5)) and 
pegylated liposomal m-THPC, FosPEG 2% and FosPEG 8% in corresponding histidine loading buffer 
prepared at ~1 µM concentrations (A) inset: Soret band, (B) inset: Q band. 
 
The absorbance spectra of Foscan (m-THPC in PEG buffer solvent system, PEG 400: 
EtOH: dH2O) demonstrated two strong absorbance peaks (Fig 4.7), which showed 
absorption maxima at ~ 419 nm (Soret band) and ~651 nm (Q band).  This is characteristic 
of the absorption peaks observed for chlorin-type compounds and corresponds to the 
literature (Kascakova, S. et al. 2008) (Bonnett, R. et al. 1999).  Over a concentration range 
(c = 0–5 µM m-THPC) there was no evidence of spectral broadening or shifts in 
absorbance maxima with Foscan (data not shown) and solutions accurately followed Beer-
Lambert’s law.  This suggests that the same photoactive species of m-THPC were present.  
The shoulder observed on the Soret band of Foscan is indicative of highly conjugated 
systems and is common for these chromophores, often solvent dependent.  Absorbance 
A 
B 
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spectra of FosPEG formulations (liposomal m-THPC) demonstrates a bathochromatic shift 
(red shift) in the Soret band to longer wavelengths (λ = 423 nm), compared to Foscan, 
characteristic of J-aggregate formations.  These changes in spectra are less pronounced in 
the Q band (~650 nm) for each m-THPC formulation. 
 
Absorbance spectra of all m-THPC formulations were additionally taken following a 2 h 
incubation period in 100% Solvable (aqueous-based alkaline solvent) to mimic chemical 
extraction conditions when dissolving tissues and to ensure the spectrofluorimetric 
properties of m-THPC were not changed.  Foscan and FosPEG formulations exhibited 
identical absorbance spectra in Solvable (c = 1 µM) with no detectable differences in the 
Soret or Q absorption bands (Fig 4.8).   
 
 
Figure 4.8. Absorbance spectra of Foscan (m-THPC in buffer: PEG 400 (3): EtOH (2): dH2O (5)) and 
pegylated liposomal m-THPC, FosPEG 2% and FosPEG 8% in corresponding histidine loading buffer 
diluted to ~1 µM concentrations in Solvable™. (A) inset: Soret band, (B) inset: Q band. 
 
When comparing the m-THPC spectra acquired in aqueous buffered solutions (Fig 4.7) to 
those of Solvable (Fig 4.8), there appear to be only small bathochromic shifts in the Soret 
and Q band with FosPEG solutions.  Foscan also undergoes a red shift in the presence of 
Solvable, however, the most significant change in spectra observed is the loss of the 
shoulder on the Soret peak between solutions.  These results correspond to the literature for 
A 
B 
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the spectroscopic properties of m-THPC (Foscan) in Solvable (Kascakova, S. et al. 2008).  
Slight differences in absorbance maxima at 423 and 652 nm may be due to experimental 
error in preparing m-THPC solutions. 
 
ii. Fluorescence spectra 
Fluorescence spectra were carried out in 100% Solvable with m-THPC (c = 0-0.5 µM) and 
FosPEG formulations (data not shown) to construct corresponding calibration curves of 
known m-THPC concentrations for pharmacokinetic studies. 
 
Figure 4.9. Fluorescence emission spectra (m-THPC λexc = 423 nm) of m-THPC diluted in Solvable and 
corresponding calibration curve (0-0.5 µM concentration range). 
 
The fluorescence spectrum of m-THPC (Fig 4.9) in 100% Solvable was the same for all m-
THPC formulations with increasing concentration.  A slight shift from ~652 nm, when 
diluted in loading buffer (data not shown), to ~655 nm in Solvable was observed.  This is 
in accordance with the literature (Kascakova, S. et al. 2008). 
 
The fluorescence emission spectra of m-THPC were recorded for liposomes, FosPEG 2% 
and FosPEG 8%, in DMSO and in their loading (histidine) buffer.  The peak emission, 
using 423 nm excitation, was recorded at 652 nm in each case but interestingly a higher 
peak intensity was observed with FosPEG 8% in its loading buffer (Fig 4.10) compared to 
FosPEG 2% (ratio of 1.25).  Following complete dissolution of liposomes in DMSO, the 
fluorescence intensity almost doubled for both pegylated m-THPC liposomes, with little 
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difference in peak intensities between formulations.  m-THPC is known to emit a 
negligible fluorescence in aqueous buffer (Kascakova, S. et al. 2008), therefore a control 
solution of m-THPC in DMSO, run in parallel, gave an identical fluorescence peak at 652 
nm (data not shown).   
 
Corresponding lifetime fluorescence data of these pegylated liposomes (histidine buffer) 
showed multi-exponential decays with significantly shorter lifetimes, in comparison to m-
THPC in DMSO (9.6 ns) (Compagnin, C. et al. 2011):  FosPEG 2%; 7.3, 2.5 & 0.9 ns and 
FosPEG 8%; 9.8, 1.1 & 3.0 ns (see Chpt 6: Fluorescence lifetime equations). 
 
 
Figure 4.10. Fluorescence emission spectra of m-THPC in pegylated liposomes, FosPEG 2% and FosPEG 
8%, either in their loading buffer or when dissolved in DMSO using an excitation wavelength of 423 nm. 
Peak emission was recorded at 652 nm. 
 
4. Liposomes 
- 86 - 
iii. Confocal microscopy in vitro 
 
Figure 4.11. Confocal microscopy images of MC28 tumour cells following incubation with 1 µM m-THPC 
(Foscan) or m-THPC liposomal formulation (FosPEG2%) at different time intervals to determine cellular 
localisation.  (A) Negative control MC28 cells no drug, (B) Foscan 1 h, (C) FosPEG 2% 1 h, (D) FosPEG 2% 
1h (magnified), (E) Foscan 6 h and (F) FosPEG 2% 6 h. 
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Qualitative confocal microscopy results in vitro (Fig 4.11) show a greater uptake of m-
THPC into MC28 tumour cells when delivered by both Foscan and FosPEG 2% after 6 h 
incubation time at 37°C  in comparison to 1 h with m-THPC concentrations of 1 µM 
(FosPEG 8% solutions were not used in these studies).  This is indicated by an increase in 
fluorescence of MC28 cells at 652 nm (Fig 4.11 E & F) in comparison to negative control 
cells (Fig 4.11 A), which received no drug.  Although m-THPC fluorescence appears to be 
much lower following shorter incubation periods, at 1 h the images suggest there is a slight 
increase in the uptake of m-THPC when delivered by pegylated liposomal nanocarriers 
(FosPEG 2%) in comparison to Foscan (Fig 4.11 B & C) by a corresponding increase in 
fluorescence intensity.  After 6 h incubation, m-THPC fluorescence reveals a more intense 
and uniform localisation pattern in cells, compared to 1 h incubation whereby m-THPC 
fluorescence is diffuse but sequestered to intracytoplasmic vesicles, illustrated by bright 
spots.  Uptake of m-THPC appears to be localised to the cytoplasm and the perinuclear 
area of tumour cells with both m-THPC formulations, sparing the nucleotic centre, which 
remains dark and clearly visible at both times points (Fig 4.11 D).  It is also important to 
note, although these cells were imaged in serum-free media, they were subjected to prior 
incubation with 10 % FCS supplemented media in the presence of each m-THPC 
formulations (1 or 6 h).   
 
iv. Pharmacokinetics of m-THPC (Foscan versus FosPEG 2% and 8%) 
Pharmacokinetic studies with m-THPC in untargeted pegylated liposomal nanocarrier 
formulations, FosPEG 2% and FosPEG 8%, were carried out in reference to standard 
Foscan formulation.  Doses of 0.3 mg kg-1 (m-THPC drug equivalent) were employed in 
rats for a time series analysis to quantify m-THPC distribution in vivo (µg g-1) by 
measuring uptake in different tissues through a chemical extraction method (also see 
Appendix I - A.21 %ID/g of liposomal m-THPC in different tissues in vivo).   
 
For the investigation in normal tissues, a range of organs were selected for 
pharmacokinetic analysis to compare relative uptake of m-THPC to that of tumour tissue.  
These tissues were selected for their primary role and participation in therapeutic 
circulation (blood), evasion or recognition by the host’s immune system (RES; liver, 
spleen, lungs) and subsequent clearance or retention in the body (kidneys, colon, skin).   
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m-THPC was administered via a bolus intravenous injection into the tail vein and therefore 
introduced directly into the blood (central compartment).  In order to study the distribution 
and elimination of m-THPC, blood serum was taken over a time course of 96 h. 
 
 
Figure 4.12. Semi-log plot of mean m-THPC concentration in blood serum after intravenous administration 
of 0.3 mg kg-1 m-THPC in Foscan, FosPEG2% or FosPEG8% liposomal formulation into female Wistar rats.  
This plot is fitted according to a three compartmental model.  Data points show the mean ± SD, n = 3. 
 
Figure 4.12 shows the blood clearance after a single i.v. injection of 0.3 mg kg-1 m-THPC 
in Foscan, FosPEG 2% and 8% formulations into the normal Wistar rat model between ≤5 
min and 96 h.  m-THPC delivery through Foscan was observed at the lowest concentration 
and was cleared most rapidly from the blood serum (Fig 4.12) in comparison to both 
untargeted liposomal nanocarriers.  Serum concentrations peaked at approximately 0.5 µg 
mL-1 ≤ 5 mins and fell to ≤ 0.01 µg mL-1 by 96 h (Foscan).  FosPEG 2% and FosPEG 8% 
m-THPC was observed at concentrations approximately 11-fold higher than Foscan at t=0 
and remained significantly higher up to 96 h.  This demonstrates a positive correlation 
between increased pegylation of the nanocarrier and increased blood circulation time of the 
m-THPC. 
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Pharmacokinetic parameter Foscan FosPEG 2% FosPEG 8% 
Three compartmental model    
Initial dosage (Do, mg kg-1) 0.3 0.3 0.3 
Initial concentration (Co, µg mL-1, t=0) 0.7 8.7 16.9 
Initial volume of distribution (Vd, mL kg-1) 407.4 34.6 17.7 
Vd of first compartment (mL kg-1) 1373.9 71.1 21.8 
Vd of second compartment (mL kg-1) 640.1 69.5 100.9 
Vd of third compartment (mL kg-1) 6086.2 2231.8 1505.8 
t1/2 of first compartment (h-1) 0.9 1.0 0.6 
t1/2 of second compartment (h-1) 3.3 2.3 5.5 
t1/2 of third compartment (h-1) 90.0 99.0 138.6 
    
Non-compartmental model    
Blood clearance (Cl, mg kg-1 h-1) 30.0 6.41 3.21 
Mean residence time (MRT, h-1) 61.9 72.5 90.3 
Volume of distribution (Vd, mL kg-1) 1875.7 464.2 289.5 
Half-life (t1/2, h-1) 42.9 50.2 62.6 
Elimination rate constant (Kel, h-1) 0.016 0.014 0.011 
Table 4.4. Blood pharmacokinetic parameters of m-THPC after i.v. injected dose of 0.3 m kg-1 m-THPC in 
Foscan and each liposomal formulation in Wistar rats, calculated using the exponential equations of the three 
compartment model ( A e_αt+Be_βt+Ce_γt), and the non-compartmental method. 
 
Following intravenous injection, m-THPC serum concentrations peaked at the earliest time 
point for each formulation and appeared to decline exponentially.  Since m-THPC 
clearance from serum fitted multiple exponential decays; therefore data were analysed  
using both a compartmental (Clark B et al. 1981) and  non-compartmental approach 
(Yamaoka, K. et al. 1978). 
 
Using a compartmental approach (Table 4.4), the data best fit a tri-exponential decay 
curve, described by the equation C = A e-αt + Be-βt + Ce-γt (whereby C = concentration, A, 
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B, C = y-intercepts (at t = 0), and α, β, γ = elimination rate constants), which describes the 
rate of drug flow into and out of the central compartment and gave three compartmental 
half-lives (t1/2) and elimination rate constants for Foscan, FosPEG 2% and 8% (Table 4.4) 
(see Appendix I – A.5 Pharmacokinetic Analysis: Compartmental Approach). 
Foscan®, C = 0.22e-0.78t + 0.47e-0.21t + 0.05e-0.008t, t1/2 = 0.9, 3.3 & 90 h.               (4.1) 
FosPEG 2%, C = 4.22e-0.72t + 4.32e-0.30t + 0.13e-0.007t, t1/2 = 1.0, 2.3 & 99 h.          (4.2) 
FosPEG 8%, C = 13.7e-1.18t +2.97e-0.13t + 0.20e-0.005t, t1/2 = 0.6, 5.5 & 138.6 h.     (4.3) 
The biological half-live (t1/2) of the third compartments (log/linear phase) show a 1.5-fold 
increase between Foscan and FosPEG 8%, 90 h vs. 138.6 h, which is confirmed by figures 
obtained  through non-compartmental analysis (42.9 h vs. 62.6 h, Table 4.4) and suggests 
increased longevity of circulating m-THPC through liposomal encapsulation and 
increasing pegylation. 
 
The non-compartmental model was also used to additionally calculate other 
pharmacokinetic parameters such as clearance and bioavailability, which can be directly 
determined from the area under the curve (AUC) of the serum-time concentration curve 
(Shargel, L. et al. 2005) (see Appendix I – A.6 Pharmacokinetic Analysis: Non-
Compartmental Approach). 
 
The non-compartment model (Table 4.4) gives half-lives of 42.9 h for Foscan, 50.2 h for 
FosPEG 2% and 62.6 h for FosPEG 8%, with elimination rate constants of 0.016 h-1, 0.014 
h-1 and 0.011 h-1, respectively.  The compartmental model estimates the initial volume of 
distribution (Vd) from the central compartment as 407 mL kg-1 for Foscan®, 34.6 mL kg-1 
for FosPEG 2% and 17.7 mL kg-1 for FosPEG 8%.  However, the volume of distribution 
(Vd) for each formulation in each of the three compartments is much lower for FosPEG 2% 
and 8% than Foscan.   
 
Bio-distribution of m-THPC (Foscan®, FosPEG 2% and 8%) 
In normal tissues of the Wistar rat, the highest m-THPC concentrations were observed in 
the highly perfused tissues, such as the liver, spleen and lungs (Fig. 4.13-4.15) and show 
exponential decays.  Concentrations of m-THPC for all drug formulations peak at the 
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earliest time points between 2 and 4 h, following i.v. injection.  This ranges from 
approximately 2.5±3.5 µg g-1 in the liver (Fig 4.13) and 1.0±2.5 µg g-1 in the spleen (Fig 
4.14) (see Appendix I – A.7 Time and Concentration of Maximal m-THPC Levels).  
Concentrations of Foscan are significantly reduced in the spleen by 168 h, however, 
remain at approximately 0.5 µg g-1 in the liver after 72 h.  FosPEG 2% displays favorably 
low accumulation in the liver (Fig 4.13), nearly half that of Foscan at the concentration 
maxima, and less than 1 µg g-1 in the spleen after 40 h, with complete clearance from both 
organs by ~96 h.  FosPEG 8% encouragingly accumulates at low concentrations in the 
spleen, not exceeding 1 µg g-1, and is almost absent after 168 h.  However, unlike FosPEG 
2%, remain at elevated concentrations in the liver (~ 3.5 µg g-1), along with Foscan. 
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Figure 4.13. Concentration of m-THPC (µg g-1) in the liver of the Wistar rat as a function of time following 
an intravenous injection of 0.3 mg kg-1 m-THPC in standard Foscan, FosPEG2% and FosPEG8% 
formulations.  Data corrected for negative control tissue.  Data points show the mean ± SD, 3≤ n ≤ 4. 
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Figure 4.14. Concentration of m-THPC (µg g-1) in the spleen of the Wistar rat as a function of time 
following an intravenous injection of 0.3 mg kg-1 m-THPC in standard Foscan, FosPEG2% and FosPEG8% 
formulations.  Data corrected for negative control tissue.  Data points show the mean ± SD, 3≤ n ≤ 4. 
 
FosPEG 8% also displays slower distribution kinetics, with a lower Vd and a higher mean 
residence time (MRT) and half-life (t1/2) in the serum compared to FosPEG 2% and 
Foscan.  In the spleen FosPEG 8% accumulates at the lowest concentrations, not exceeding 
1 µg g-1.  By 168 h, both FosPEG formulations are almost absent from the spleen, whereas 
there appears to be a slight retention of Foscan at this time. 
 
The slower distribution kinetics of FosPEG 8% are also demonstrated in the lung tissue 
(Fig 4.15), where FosPEG 8% remains consistently higher than Foscan (~6 fold) and 
FosPEG 2% (~2-3 fold) over 168 h, which are both cleared by this time, indicating they are 
not being unfavorably retained.  This clearance pattern correlates very closely to the blood 
serum pharmacokinetics (Fig 4.12).  
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Figure 4.15. Concentration of m-THPC (µg g-1) in the lung of the Wistar rat as a function of time following 
an intravenous injection of 0.3 mg kg-1 m-THPC in standard Foscan, FosPEG2% and FosPEG8% 
formulations.  Data corrected for negative control tissue.  Data points show the mean ± SD, 3≤ n ≤ 4. 
 
Foscan is found at the lowest concentration in the lungs over 168 h and at the earliest time 
points (t = 0-2 h) in comparison to liposomal m-THPC, measuring approximately 0.5 µg g-
1
.  This parallels its concentration in the serum at this time, ~0.5 µg mL-1.  Again, although 
FosPEG 2% and 8% appear to accumulate at greater concentrations in the lung tissue at t= 
0-2 h, relative to blood serum concentrations at this time, they are taken up between 3-4 
times less than Foscan from the central blood compartment.  At ~6 h, all m-THPC 
formulations appear to peak in concentration before exponential decay occurs.   
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Figure 4.16. Concentration of m-THPC (µg g-1) in the kidney of the Wistar rat as a function of time 
following an intravenous injection of 0.3 mg kg-1 m-THPC in standard Foscan, FosPEG2% and FosPEG8% 
formulations.  Data corrected for negative control tissue.  Data points show the mean ± SD, 3≤ n ≤ 4. 
 
In the kidneys (Fig 4.16) little variation in m-THPC uptake exists within the given time 
period for each individual formulation, which plateau from 2 – 168 h.  However, the 
difference in m-THPC uptake between degrees of pegylation for each formulation, rather 
than m-THPC encapsulation alone, is significant.  When delivered by FosPEG 8% the 
concentration of m-THPC remained at a consistently low level, typically < 0.2 µg g-1 
versus ≤ 0.5 - 0.7 µg g-1 for Foscan and FosPEG 2%.   
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Figure 4.17. Concentration of m-THPC (µg g-1) in the skin of the Wistar rat as a function of time following 
an intravenous injection of 0.3 mg kg-1 m-THPC in standard Foscan, FosPEG2% and FosPEG8% 
formulations.  Data corrected for negative control tissue.  Data points show the mean ± SD, 3≤ n ≤ 4. 
 
Skin tissue (Fig 4.17) displays the lowest concentrations of m-THPC in each formulation 
in comparison to all other tissues.  Foscan and FosPEG 2% have highly similar kinetic 
profile patterns in the skin.  The initial (≤ 5 mins) and final time points (72-168 h) indicate 
the concentration of Foscan and FosPEG 2% was approximately 0.02 µg g-1, however, 
FosPEG8% showed continual elevated accumulation from 96 h, approximately 3-fold 
greater, at 0.07 µg g-1.   
4. Liposomes 
- 96 - 
MUSCLE
Time (h)
0 20 40 60 80 100 120 140 160
Co
n
ce
n
tra
tio
n
 
o
f p
ho
to
se
n
si
tis
e
r 
(µg
 
g-
1 )
0.0
0.1
0.2
0.3
0.4
0.5 Foscan
FosPEG 2%
FosPEG 8%
 
Figure 4.18. Concentration of m-THPC (µg g-1) in the muscle of the Wistar rat as a function of time 
following an intravenous injection of 0.3 mg kg-1 m-THPC in standard Foscan, FosPEG2% and FosPEG8% 
formulations.  Data corrected for negative control tissue.  Data points show the mean ± SD, 3≤ n ≤ 4. 
 
In the muscle tissue (Fig 4.18), m-THPC uptake does not exceed 1.5 µg g-1 for all m-THPC 
formulations.  There were no clear differences in the uptake of m-THPC between Foscan 
and FosPEG formulations by 168 h.  Despite final concentrations of m-THPC being 
similar, FosPEG 8% appeared to clear more rapidly from muscle tissue between 24 and 
168 h.  Both muscle and skin tissues accumulate the least amount of m-THPC for all 
formulations compared to other tissues.  Over the time course of this pharmacokinetic 
study, an elimination phase did not occur therefore m-THPC half-lives could not be 
calculated for muscle or skin. 
 
Chemical extraction data of the colon indicated slower distribution kinetics for all m-
THPC formulations with a gradual increase in the uptake of m-THPC (of approximately 
0.25 µg g-1) over 168 h, where it peaked.  Although m-THPC in FosPEG 8% had a much 
higher uptake at the earliest time point (approximately 3-fold), there appeared to be no 
significant difference between each formulation for the remainder of the time series (see 
Appendix I – A.8 Chemical Extraction: Colon Accumulation). 
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Tumour Accumulation of m-THPC (Foscan®, FosPEG 2% and 8%) 
There is a significant increase in maximal m-THPC uptake in tumour tissue of the HL rat 
between 6 and 24 h with FosPEG 2% and 8%, in comparison to Foscan (p≤0.001) of 
approximately three-fold (~1.14 ± 0.98 vs. 0.33 µg g-1) (Fig 2.10A).  Although there is no 
significant difference in accumulation between the two FosPEG formulations over the 
majority of the time series, FosPEG 8% administration results in higher accumulation in 
the tumour tissue for up to 72 h post injection.  At this time period it remains at more than 
four times the concentration obtained using Foscan (0.62 vs. 0.14 µg g-1).  By 24 h, all m-
THPC formulations enter a linear, terminal phase of elimination from tumour tissue (Fig 
4.19A). 
 
Mean concentration ratios of tumour to skin tissue from the HL rat model were calculated 
for all m-THPC formulations (Fig 4.19B), as clinical m-THPC, Foscan, is known to cause 
prolonged skin photosensitivity in patients.  The greatest difference in m-THPC uptake 
between the two tissue types was ~6 h.  FosPEG 2% elicits a concentration ratio almost 5 
times greater than that found with Foscan, whilst FosPEG 8% is slightly slower. 
 
Blood serum pharmacokinetic data demonstrated there was an increase in m-THPC 
circulation time when incorporated into liposomal nanocarrier formulations in comparison 
to standard Foscan over 72 h.  This corresponds to the pattern observed for m-THPC 
uptake in tumour tissue (Fig 4.19A).  FosPEG formulations increase the concentration and 
therefore bioavailability of m-THPC in the blood greatly (≥4 fold), which simultaneously 
increases the concentration of m-THPC in tumour tissue (≥3 fold), due to 
encapsulation/pegylation, compared to Foscan.  Although FosPEG formulations may not 
preferentially accumulate in tumour tissue from the blood (see Appendix I – Fig A.9 
Concentration of m-THPC in blood plasma versus tumour from HL rat tissues: Foscan, 
FosPEG 2% and 8%), they improve the uptake between tumour and normal skin tissue 
(concentration ratios) in this fibrosarcoma model (≥3 fold).   
 
Fig 4.19 indicates maximum tumour to skin m-THPC concentration ratios at 6 h, this 
presented an optimal drug light interval (DLI) at which to treat tumours with PDT.  
However, Fig 4.12 still shows high concentrations of m-THPC in the blood plasma by 6 h 
for all formulations, relative to m-THPC accumulation in tumour tissue (Fig 5A).   
4. Liposomes 
- 98 - 
 
 
 
Figure 4.19. (A) Concentration of m-THPC in MC28 tumour tissue of female Hooded Lister rat as a function 
of time following an intravenous injection of 0.3 mg kg−1 m-THPC in standard Foscan, FosPEG 2% and 
FosPEG 8% formulations. (B) Mean concentration ratio of tumour to skin in female Hooded Lister rats over 
a time series following intravenous injection of 0.3 mg kg−1 m-THPC in Foscan, FosPEG2%, FosPEG 8% 
formulations. Data points show the mean ± SD, n = 4.  Taken from published work (Bovis, M.J. et al., 2011). 
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 Foscan FosPEG 2% FosPEG 8% 
Tissue 
Elimination 
Rate Constant 
(x10-3 h-1) 
Half-Life 
(h) 
Elimination 
Rate Constant 
(x10-3 h-1) 
Half-Life 
(h) 
Elimination 
Rate Constant 
(x10-3 h-1) 
Half-Life 
(h) 
Serum 7.7 90.0 7.0 99.0 5.0 138.6 
Tumour 13.2 52.5 8.5 81.5 9.4 73.7 
Liver 6.8 101.9 35.8 19.4 8.9 77.9 
Spleen 5.7 121.6 62.4 11.1 14.5 47.8 
Kidney 4.5 154.0 2.8 247.6 11.7 59.2 
Table 4.5. Elimination rate constants and half-lives of the terminal phase of elimination in selected tissues 
with each m-THPC formulation; Foscan, FosPEG 2% or FosPEG8%, after 0.3 mg kg-1 injected dose. 
 
Compartments refer to the organs and tissues for which the rate of uptake and subsequent 
clearance of m-THPC are similar (Clark B et al. 1981).  The elimination rates for all the 
different tissues are shown in Table 4.5 and were calculated from the log concentration 
versus time graphs (data not shown) using the terminal three data points (72, 96 and 168 
h).  These were similar in some tissues, indicating they could be part of one compartment.  
Through this method, tissues could essentially be grouped into three theoretical 
compartments taking into account their elimination rate constants and half-lives.  Foscan 
had the fastest clearance from tumour tissue with a short half-life and high elimination rate 
constant (Table 4.5), therefore was placed in its own compartment (red).  The blood serum 
and liver, however, had similar half-lives and elimination rate constants, therefore could be 
grouped into a second compartment (blue), much like the spleen and kidney, into a final 
third compartment (black).  Compartments varied for each m-THPC formulation 
depending on their clearance, mean residence time, volume of distribution and half-life.   
 
v. Tumour PDT response with m-THPC (Foscan, FosPEG 2% and 8%) 
PDT studies were carried out in an MC28 tumour rat model to assess whether an increase 
in m-THPC uptake through the pegylated liposomal nanocarriers improved the efficacy of 
PDT treatment. H&E stained MC28 tumour sections were scanned with the Hamamatsu 
Nanozoomer to observe the extent of PDT damage with m-THPC, measured by the area of 
necrosis, using a 24 h drug: light interval (DLI), based on chemical extraction data.  0.3 mg 
kg-1 of m-THPC in Foscan (FS) and pegylated liposomal formulations (FosPEG 2% and 
FosPEG 8%) was injected intravenously into the tail vein of the rat.  Control tissues 
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received light treatment with no drug.  PDT was initially performed using clinical doses of 
m-THPC (0.3 mg kg−1) and light was delivered at a total energy of either 2 J or 10 J at 100 
mW interstitially to tumours.  Subsequently m-THPC doses were lowered to 0.1 mg kg-1 
and 0.05 mg kg−1.   
Figure 4.20. Histological analysis: H&E stained MC28 tumour sections scanned with the Hamamatsu 
Nanozoomer to observe the extent of PDT damage, measured by the area of necrosis (dotted perimeter), after 
24 h DLI: 0.3 mg kg-1 of m-THPC in Foscan (FS) and pegylated liposomal formulations (FP 2% and FP 8%) 
was injected i.v.  Negative control tissues received light and no drug (Control).  Permission for the use of 
histological images of PDT for liposomal m-THPC was granted courtesy of Dr Josephine Woodhams. 
H&E tumour sections of control MC28 tumour tissue (received light and no drug) were 
stained a deep purple colour, indicative of the presence of ‘healthy’ tumour cells from 
intact nuclei.  The damage to tumour tissue at 24 h with PDT (10 J of light at 100 mW) 
with all 3 m-THPC formulations was very similar and more than 60 % of total tumour 
tissue surface area showed signs of necrosis (Fig 4.20).  With Foscan, a large necrotic area 
(pink) induced by PDT damage was clearly visible.  Tumour sections of FosPEG 2% 
displayed an undamaged tumour capsule periphery and a well-defined boundary between 
necrotic (pink) and‘healthy’ (purple) tumour tissue.  Finally, with FosPEG 8%, the damage 
was much more irregular, occurring sporadically through, which may have been a 
consequence of the heterogeneous composition of the tumour tissue itself and the resulting 
m-THPC uptake.  (Images shown are representative of multiple animals treated). 
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Although a high level of necrosis was observed with all m-THPC formulations, there did 
not appear to be an immediate or obvious variation in tumour damage between Foscan and 
pegylated liposomal m-THPC through qualitative histological examination of PDT.  
Hamamatsu Nanozoomer software was therefore employed to obtain quantitative results by 
calculating an estimated area of necrosis as a percentage of total tumour tissue (see 
Appendix I – A.15 Hamamatsu Nanozoomer: Calculating the Area of Necrosis). 
 
All formulations of m-THPC cause significant tumour necrosis, expressed as a percentage 
of the total tumour tissue (Fig. 4.21), in comparison to the control treatment group which 
received light without drug (p≥0.001).  For each of the three variable treatment groups 
there is also a significant difference in percentage tumour necrosis between Foscan versus 
FosPEG formulations (p≤0.001).  When exposed to 10 J of light following administration 
of 0.3 mg kg−1 of m-THPC, percentage tumour necrosis with FosPEG formulations is 
slightly lower than that with Foscan (Fig. 4.21).  In contrast, with either low dose m-THPC 
(0.05 mg kg−1) or low light energy (2 J), both FosPEG 2% and 8% produced a significantly 
greater percentage of tumour necrosis in response to PDT compared to Foscan, by either 
10% or 20% (p≥0.001). 
 
Fig. 4.21. The percentage area of PDT tumour necrosis following administration of either  2 J or 10 J of light 
to female Hooded Lister rats at a DLI of 24 h, after intravenous injection of 0.3 or 0.05 mg kg−1 m-THPC in 
■ Foscan, ■ FosPEG2%, and ■ FosPEG 8% formulations.  Control group received light treatment, 10 J, with 
no drug.  Data points show the mean±SD, n=4. 
* 
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PDT was performed to tumours also using a 0.1 mg kg-1 dose of m-THPC at the same DLI 
(24 h) using a light dose of 10 J.  As chemical extraction data at 24 h indicated a three-fold 
increase in the uptake of pegylated liposomal m-THPC compared to Foscan, the 
administered dose was reduced by a factor of three, to one third of the original 
photosensitiser concentration (0.1 mg kg-1).  This was to deduce whether the higher 
accumulating m-THPC in pegylated liposomes produced the same PDT effect (percentage 
tumour necrosis) compared to Foscan.  There was an increase in percentage tumour 
necrosis following PDT (10 J) with FosPEG formulations administered at 0.1 mg kg-1 
compared to Foscan, however, overall, this was not significant when compared to necrosis 
exhibited by all m-THPC formulations at higher doses of 0.3 mg kg-1 m-THPC (see 
Appendix I –A.16 PDT to MC28 tumours using 0.1 mgkg-1 m-THPC dose). 
 
vi. Skin photosensitivity studies 
Skin photosensitivity caused by m-THPC, following i.v. administration of either Foscan, 
FosPEG 2% and FosPEG 8% at clinical m-THPC doses of 0.3 and 0.1 mg kg-1, were 
evaluated in female Wistar rats.  These animals were exposed to either 0 (0 J), 5 (30 J), 15 
(90 J) or 30 min (180 J) of 100 mW cm−2 of light (1 sun=solar equivalent spectrum) from a 
solar simulator source (Olympus CLV-S30) at drug-light intervals (DLIs) of either 96 or 
168 h.  Wistar rats were chosen as an appropriate in vivo model based on previous skin 
photosensitivity studies (Weersink, R. A. et al. 2005), due to the lack of skin pigmentation.  
Comparisons could also be drawn from quantitative m-THPC data collected through 
chemical extraction studies in Wistar rat normal tissues.  Light power (100 mW) was kept 
consistent with PDT studies carried out here using Foscan and pegylated liposomal m-
THPC.  Longer DLIs were chosen as complete clearance of m-THPC was not observed for 
either m-THPC formulation (Foscan, FosPEG 2% and FosPEG 8%) by 96 h, therefore 
measuring any prolonged photosensitivity effects in the skin after this time were deemed 
appropriate for assessment.  
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Fig. 4.22. (A) Wistar rats exposed to 0, 5, 15 or 30 min of 100 mW cm−2 (1 sun=solar equivalent spectrum) 
of light from a solar simulator source at drug-light intervals (DLI) of 96 and 168 h, following an intravenous 
injection of 0.3 mg kg−1 or (B) 0.1 mg kg-1 m-THPC in Foscan, FosPEG2% and FosPEG 8%. (C) Visual 
assessment of skin reactions carried out 24 h post-treatment and imaged areas scored by a double-blind 
grading model. Scores were averaged over each exposure time for each m-THPC formulation. 
 
The results in Figure 4.22 A+B display a positive correlation between the length of light 
exposure (0 to 30 min) and observable photosensitive effects from graded skin analysis for 
both m-THPC doses, 0.3 and 0.1 mg kg-1.  Visually, for 0.3 mg kg-1 m-THPC doses, 
Foscan evoked greater cutaneous photosensitivity over time in comparison to milder 
effects observed with FosPEG 2%, which displays the lowest levels of skin 
photosensitivity at both DLIs at 30 min exposure (Fig 4.22A).  FosPEG 8% demonstrates a 
slightly higher degree of skin photosensitivity at 96 h in comparison to both Foscan and 
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FosPEG 2%, as a result of greater skin damage observed between 15 and 30 min light 
exposure.  This supports chemical extraction data of FosPEG 8% in skin tissue at this time 
(Fig. 4.17).  However by 168 h, Foscan scored highest at a light exposure time of 30 min 
(Fig 4.22A) (see Appendix I – A.12 Skin Photosensitivity Studies: Raw skin scoring data 
0.3 mg kg-1).  At 0.1 mg kg-1 m-THPC doses, grading analysis shows an overall reduction 
in skin photosensitivity with each formulation of approximately 3-folds, which directly 
corresponds to the reduction in m-THPC dosage (Fig 4.22B).  Foscan and FosPEG 2% 
show an increase in photosensitivity over 30 mins at a DLI of 96 h, however at the longer 
DLI, Foscan scores positively lower in sensitivity across all light exposure times whereas 
FosPEG 2% increases.  FosPEG 8% appears to show the least amount of sensitivity at both 
DLIs over the 30 min exposure time (see Appendix I – A.13 Skin Photosensitivity Studies: 
Raw skin scoring data 0.1 mg kg-1).  No blistering or necrosis (Score 8) of skin tissue was 
observed visually with any m-THPC formulation at the doses used in this study.  Control 
tissue exposed to 0 min light was unaffected (Score 0), as were animals that only received 
light (no PS).  Fig. 8 illustrates typical photosensitivity observed in histological rat skin 
sections from the same animal treatment groups at 0 min (control) and 30 min light 
exposure with 0.3 mg kg-1 m-THPC doses.  Qualitative differences exist between m-THPC 
formulations, with Foscan eliciting extensive superficial damage to the epidermis at DLI of 
96 h, illustrated by mass cell death, in comparison to FosPEG formulations which are 
slightly milder.  At a DLI of 168 h, photoinduced damage is reduce with FosPEG 2%, 
showing no signs of sensitivity, whereas Foscan and FosPEG 8% demonstrate localised 
damage to regions of the epidermis and dermis respectively.  No photosensitive effects to 
skin are detected at 0 min of light exposure (Fig. 4.23) and no damage was observed with 
those animals that were exposed to light but did not receive m-THPC (data not shown) (see 
Appendix I – A.14 Skin Photosensitivity Studies: control skin tissues). 
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Fig.4.23. Histological sections of skin tissue removed from the animal 24 h after light treatment with 0.3 mg 
kg-1 m-THPC. Skin control samples at 0 min (no light) and treated samples at maximal exposure of 30 min 
were collected and cut through the centre of the treatment area. Adjacent halves of the skin tissue were 
sectioned (4 µm), stained with H&E and were observed with the Hamamatsu Nanozoomer. M—muscle, 
Ad—adipocytes, D—dermis, HF—hair follicle, ED—epidermis. 
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4.4 Discussion 
The outcome of PDT treatment is dependent on a number of critical factors, each of which 
need to be optimised to improve its efficacy.  The photosensitiser plays a fundamental role 
in this process as its potency (quantum yield of singlet oxygen production) and distribution 
determines the light dose, light wavelength (activation) and drug-light interval.  m-THPC 
is currently approved for the palliative treatment of selected cancers with PDT (Brown, S. 
B. et al. 2004), however steps are being taken to reduce adverse skin photosensitivity 
through improving delivery of the PS to tumour tissues by its encapsulation into novel 
nano-vehicles.   
 
Liposomes were chosen as a suitable model based on their biocompatibility and, following 
surface pegylation, have been reported to increase circulating m-THPC in feline and avian 
chorioallantoic membrane (CAM) models in vivo by reducing RES uptake (Buchholz, J. et 
al. 2005;Pegaz, B. et al. 2006).  It is hypothesised that this subsequent improvement in m-
THPC bioavailability increases the probability of uptake into tumour tissue.  These studies 
aimed to correlate m-THPC pharmacokinetics of the standard clinical formulation, Foscan, 
and pegylated liposomal nanocarriers with PDT efficacy and skin photosensitivity in rat 
models.  Through assessment of m-THPC uptake and its selective accumulation in tissues 
by different liposomal nanocarrier formulations in vivo, the maximal normal skin to 
tumour tissue ratio of m-THPC was deduced.  This gave a strong indication as to the 
optimal treatment time and m-THPC dose in which to elicit the greatest tumour PDT 
response. 
 
Photophysical studies: Liposomes 
In this investigation, m-THPC was packaged into the fatty acid bilayer of unilamellar 
liposome shells (Torchilin, V. P. 2005).  The distribution of m-THPC to the lipidic bilayer 
is influenced by its insolubility and hydrophobic properties.  Pegylation of the liposome 
surface is further believed to inhibit the premature release of such hydrophobic compounds 
by minimising the adsorption of serum proteins, which can result in drug leaching (Satomi, 
T. et al. 2007).  Varying, but defined, degrees of liposomal pegylation were used in this 
study to assess the effect of increased pegylation on m-THPC biodistribution.  Two 
pegylated liposomal m-THPC formulations that displayed surface PEG (2000 Mw) polymer 
chains at concentrations of 2% mol (FosPEG 2%) and 8% mol (FosPEG 8%) were 
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investigated in vivo to compare the difference in accumulation and distribution of m-THPC 
in normal tissues and tumour tissue of rats, versus Foscan (Table 4.2).  These liposomes 
were developed from Foslip formulations, which lack a stealth polymer coating (Fig 4.5), 
and have previously been tested in tumour-bearing murine models in vivo with some 
success (Garrier, J. et al. 2011;Lassalle, H. P. et al. 2009).  Furthermore, veterinary studies 
in cats using other pegylated liposomal m-THPC formulations demonstrated improved 
distribution patterns in the plasma, tumour and skin, however, the degree of pegylation 
(2.5–5%) was not precisely defined (Buchholz, J. et al. 2005).   
 
In this study, pegylations of 2% and 8% (molar equivalent) were chosen as the lower and 
upper limits since higher percentages of PEG are known to disrupt the integrity of the 
liposome membrane (Li, S. D. et al. 2008).  The PEG chain length and degree of PEG 
surface coverage of the liposomes was dictated by the polydispersity index (PDI) and z-
average measurements.  It was established that longer PEG chains (e.g. 5000) with higher 
surface coverage (8% mol) were unstable and produced liposomes of inconsistent size, 
shape and mass distribution (high PDI) and as a result, despite their greater chain length, 
showed a reduction in mean particle diameter, likely due to the production of smaller 
subpopulations (data not shown).  Similarly, shorter PEG lengths (eg. 750) with high 
surface coverage (8% mol) showed the greatest variation in particle size and m-THPC 
content following a 40 day storage period from the time of preparation, suggesting lower 
stability (data not shown). 
 
Absorbance Properties 
Spectroscopic changes provide a means of investigating sensitiser incorporation and 
distribution in liposomes.  It has been reported that the corresponding absorption bands of 
porphyrins incorporated into liposomes undergo a red shift (approx. 10-20 nm) and their 
fluorescence intensities increase (Brault, D. et al. 1986) as a result of their hydrophobicity 
and subsequent local distribution within liposomes.  These larger red shifts are thought to 
be attributed to the monomerisation of aggregates.  m-THPC’s hydrophobic chlorin 
structure suggests it would behaviour similarly, however, no significant red shift in 
absorption was observed following incorporation into pegylated liposomes (FosPEG) in 
either their loading buffer (histidine) (Fig 4.7) or 100% Solvable (solubiliser) solution (Fig 
4.8).  This indicates that m-THPC was predominantly confined to the lipidic bilayer as its 
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microenvironment did not change following interaction with DPPC/DPPG liposomes 
(Ricchelli, F. et al. 1986).  Direct comparisons in aqueous media (e.g. PBS) with free m-
THPC could not be tested to confirm this due to the poor solubility of m-THPC.  However, 
absorbance measurements with Foscan (m-THPC) showed a detectable bathochromatic 
shift in the Soret band between different solvents (PEG system; λ = 419 nm, 100% 
Solvable; λ = 423 nm).  These results correspond to the literature for the spectroscopic 
properties of m-THPC (Foscan) in Solvable (Kascakova, S. et al. 2008).  Bathochromatic 
shifts in the Soret band, to longer light wavelengths, are usually indicative of conjugation 
of PS molecules.  Like many photosensitisers, m-THPC is a highly hydrophobic molecule 
and has been described as forming almost non-fluorescent aggregates in aqueous 
environments, producing broadening of both bands (Soret and Q) due to stacking of its 
chlorin rings (J-aggregates) (Bonnett, R. et al. 2002).  However, there was no detectable 
difference in half height bandwidths (~500 nm) between the PEG buffer and 100% 
Solvable to suggest the formation of dimers.  As Solvable is an alkaline based solvent, 
known to realise m-THPC in its monomeric form, this was expected.  No evidence of 
aggregate formation was detected through variations in absorption maxima, spectral peak 
broadening or deviations from Beer’s law to account for this shift.  Moreover, the shoulder 
observed on the Soret peak of m-THPC (Foscan) is indicative of highly conjugated 
systems and is common for these chromophores.  This is often solvent dependent and as 
such disappeared upon incubation with 100% Solvable. 
 
Fluorescence Properties 
The fluorescence spectrum of increasing m-THPC concentrations (Fig 4.9) in 100% 
Solvable was the same for all m-THPC formulations.  A slight shift from ~652 nm, when 
diluted in loading buffer (data not shown), to ~655 nm in 100% Solvable was observed.  
This has been attributed to the increase in the basicity of the environment with 100% 
Solvable (pH ~12.7) compared to the PEG solvent solution of Foscan (pH ~4.3) 
(Kascakova, S. et al. 2008).  However, no significant changes in absorption and 
fluorescence intenisty of m-THPC were detected in 100% Solvable (Fig 4.8 & 4.9), which 
excludes possible chemical bleaching of m-THPC. 
 
Recently, in a joint study with our laboratory, the photophysical properties of the same 
liposomes were investigated through fluorescence lifetime data studies (Compagnin, C. et 
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al. 2011).  These studies revealed the period of time (ns) a photosensitiser remains in the 
activated, excited triplet state (i.e. the time in which the initial fluorescence intensity of the 
fluorophore decays).  Fluorescence lifetime measurements of FosPEG formulations were 
carried out in aqueous histidine buffer and following incubation in DMSO (solvent).  Data 
suggested m-THPC was aggregated when incorporated in pegylated liposomes (FosPEG 
2% and 8%), since m-THPC fluorescence was strongly quenched and produced multi-
exponential decays (histidine buffer) in comparison to monomeric m-THPC, which 
exhibited a longer mono-exponential lifetime of 9.6 ns in DMSO.  This was thought to 
occur due to m-THPC dimerisation, in combination with energy-transfer between adjacent 
m-THPC monomers and weakly fluorescent aggregates within the liposomes, as a result of 
high m-THPC loading and close proximity of PS molecules in the lipid bilayer.  
Furthermore, the fluorescence intensity of m-THPC increased two-fold following 
dissolution of liposomes in DMSO in fluorescence spectra (Fig 4.10).  This is in 
accordance with Reshetov et al., (Reshetov, V. et al. 2011), who observed lower 
fluorescence yields of m-THPC when incorporated into identical pegylated liposomes 
(FosPEG 2%) and in non-pegylated liposomes (Foslip) in human serum in vitro.  
Interestingly, this group observed slightly higher fluorescence intensities for FosPEG 8% 
in comparison to FosPEG 2% (ratio 1.25).  Although m-THPC is water-insoluble and 
should reside within the liposomal membrane, it has been suggested there may be some 
partioning of m-THPC to the PEG layer of the liposomes, explaining the higher 
fluorescence efficiency of FosPEG 8%, as this formulation favours partioning of m-THPC 
(at 25°C), creating changes in its microenvironment (Compagnin, C. et al. 2011).  These 
m-THPC molecules may exist as aggregates or monomers in the pegylated layer.  Finally, 
despite no large bathochromic shifts being observed here in the absorbance spectra of 
FosPEG formulations between aqueous histidine buffer and Solvable (solvent) to account 
for these changes in m-THPC state, discrepancies may be attributed to differences in the 
water content between the two solvents used in each study (DMSO versus Solvable) and 
also high underlying background absorbance scatter from the liposomes.  Regardless of the 
apparent aggregation of m-THPC within pegylated liposomes, Compagnin et al., 
demonstrated rapid degradation of liposomes following cellular uptake in vitro in human 
adenocarcinoma alveolar basal epithelial (A549) cells and release of m-THPC in its 
monomeric photoactive form inside the cell producing effective cell kill under 
illumination. 
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Liposome Stability 
It is important to measure the stability of drug-loaded liposomes when in serum and when 
stored for prolonged periods.  Serum proteins can exert an inhibitory effect with regards to 
therapeutic delivery, as they can bind to the particle surface and cause structural 
reorganisation, aggregation, drug leaching and/or dissociation of the delivery vehicle 
(Drummond, D. C. et al. 1999).  Cationic liposomes have shown to strongly bind to blood 
components (Zelphati, O. et al. 1998) and increase uptake in the lungs.  Redistribution of 
liposome-released photosensitiser by lipoproteins in circulation can in turn lead to tumour 
accumulation due to the elevated number of LDL-receptors expressed on tumour cells 
(Allison, B. A. et al. 1997) (Reddi, E. 1997), however, where selective delivery of a drug 
to a solid tumour is desired, there must be a substantial proportion of drug retained in the 
liposome while in circulation (Senior, J. H. 1987).  This is not only to increase 
concentrations in tumour tissue but also to reduce adverse drug uptake in normal tissues.   
 
Our collaborators (Scheglmann et al., unpublished data) have shown liposomes used in 
studies here remain stable over 28 h in high concentrations (90%) of serum (see Appendix 
I –A.18).  When studying m-THPC transfer from different liposomes in the presence of 
serum proteins, almost 100% transfer of m-THPC from cationic pegylated liposomes 
(PEG-DSPE+DOTAP+DPPC) was observed in <45 mins in 5% FCS in comparison to 
pegylated (PEG-DSPE+DPPC+DPPG) and non-pegylated liposomes (DPPC+DPPG) alone 
(data not shown).  Further collaborative studies demonstrated a greater transfer of m-THPC 
from FosPEG with increasing FCS (10%>50%>90%) over 2 h (see Appendix I –A.17) and 
in vitro studies showed a decrease in intracellular fluorescence with the same liposomes in 
A549 cells with increasing FBS (0%>3%>10%), suggesting possible release of m-THPC 
from pegylated liposomes (Compagnin, C. et al. 2011).  These finding were corroborated 
in vitro, in human plasma, where a proportion of mTHPC was released much faster from 
pegylated liposomes compared to conventional liposomes (Foslip) (Reshetov, V. et al. 
2011;Reshetov, V. et al. 2012), which may have been due to partioning of m-THPC into 
the PEG layer.  However, the opposite was found to be true in later in vivo studies using 
the same liopsomal formulations in nude mice, demonstrating a 10% faster m-THPC 
release from Foslip in mouse plasma compared to FosPEG, with only half of i.v. injected 
liposomes intact after 24 h (Reshetov, V. et al. 2013).  FosPEG formulations are composed 
of DPPC lipids, with a phase transition temperature of 41°C, therefore liposomes may 
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remain in their gel phase at lower temperatures (in vivo).  Although, following 
incorporation of m-THPC into pegylated liposomes, their phase transition temperature is 
thought to decrease to 37°C, suggesting heavy leaching of m-THPC in the presence of 
serum proteins due to an increase in lipid fluidity (see Appendix I –A.17 & A.19).  Pegaz 
et al., (Pegaz, B. et al. 2006) observed slow leakage of m-THPC from FosPEG liposomes 
(lipid compositions of similar phase transition properties) in studies in vivo on a chick 
chorioallantoic membrane model in comparison to Visudyne (verteporfin in non-pegylated 
liposomes), thought to delay transfer to serum proteins.  This has also been observed by 
collaborators with FosPEG formulations in vitro through FACS analysis, whereby the 
presence of ≥10% FBS significantly reduced m-THPC fluorescence intensity within human 
normal fibroblasts (CCD-34Lu) and A549 cells by almost 3-fold, compared to no serum 
(0%) (Compagnin, C. et al. 2011).  This may explain the biphasic uptake of FosPEG, 
which was reported to be slower than that of free m-THPC, as the modality of cell 
internalisation may have been through the formation of serum protein complexes.   
 
In vitro: liposomal m-THPC uptake 
Confocal microscopy studies here indicated there was little difference between the 
intracellular uptake of m-THPC with either Foscan or FosPEG 2% into MC28 cells over 6 
h, following prior incubation with 10% FCS (Fig 4.11), as both formulations demonstrated 
high levels of m-THPC fluorescence in the cytosol.  These cell studies are in good 
agreement with the literature, which shows diffuse cellular distribution of m-THPC 
(Marchal, S. et al. 2007;Melnikova, V. O. et al. 1999a).  Kiesslich et al., observed similar 
findings with Foslip, suggesting m-THPC attached to serum components to mediated 
cellular uptake (Kiesslich, T. et al. 2007).  Although the addition of the PEG layer 
(FosPEG) should reduce serum interactions and enhance liposomal internalisation, transfer 
of m-THPC from liposomes to serum, as previously described, may facilitate 
internalisation.  It has been demonstrated in other tumour cell lines that m-THPC 
accumulation becomes significantly greater with longer incubation periods, high m-THPC 
concentrations and increased cell surface area (Teiten, M. H. et al. 2001).  The intracellular 
localisation of m-THPC was restricted to the cytoplasm for both formulations employed 
here, however, at the earliest incubation time (1 h) m-THPC appeared to accumulate in 
intracytoplasmic vesicles that resemble lysosomes in localisation and size.  Using identical 
FosPEG formulations, Compagnin et al., showed, following liposomal internalisation, m-
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THPC is promptly released and the major sites of localisation are the Golgi apparatus and 
endoplasmic reticulum (Compagnin, C. et al. 2011) at short (≤5 h at 37°C) and longer 
incubation periods (≥24 h at 37°C) at similar m-THPC concentrations (1.5 µM) in A549 
cells.  However, a 30-40% reduction in the cellular uptake of FosPEG was observed in 
comparison to m-THPC (Foscan), causing a corresponding reduction in photocytotoxicity 
but simultaneously reducing dark cytotoxicity.  Lassalle et al., demonstrated that Foscan 
and non-pegylated m-THPC liposomes (Foslip) enter HeLa cells via a similar mechanism 
and behave in a similar fashion once they have entered the cell, but at longer incubation 
times (≥24 h) may locate to different intracellular sites (Lassalle, H. P. et al. 2009).  
Compagnin et al., also showed FosPEG uptake occurred primarily through endocytosis due 
to complete inhibition of cellular uptake from 37°C to 4°C incubation temperature and a 
negative correlation between increasing concentrations of FBS and decreasing m-THPC 
fluorescence intensity.  This was demonstrated in A549 cells following incubation of 
pegylated liposomes (FosPEG 8%) with 0%, 3% or 10% FBS; concluding the presence of 
FBS inhibits the uptake of m-THPC when delivered by FosPEG through either competition 
for m-THPC binding, interactions between liposomes and serum complexes or possible 
release of m-THPC to serum components before cellular internalisation (Compagnin, C. et 
al. 2011).   
 
The intracellular localisation of a specific photosensitiser is believed to be dependent on its 
properties, which make an important contribution to the effectiveness of its photocytotoxic 
outcome due to the short half-life and reactive radius of singlet oxygen (Moan, J. et al. 
1991).  m-THPC self-quenching observed with FosPEG formulations could create 
fundamental drawbacks in the application of these nanocarriers in PDT, however, it has 
been hypothesised, upon liposomal degradation inside cells, m-THPC is released into the 
cytosol in its monomeric form.  Hydrophobic drugs, such as m-THPC, and cationic 
compounds are known to trigger an overexpression of P-glycoprotein (P-gp) efflux protein 
pumps on the cell surface as a means to expel internal excessive of these drugs (Teiten, M. 
H. et al. 2001), which can lead to a multidrug resistance (MDR) phenotype.  Despite its 
hydrophobicity, it was shown that m-THPC was not a transport substrate for the P-gp 
pump, as similar m-THPC localisation patterns and concentrations were found at short and 
long cell incubation periods (Compagnin, C. et al. 2011).  Ball et al., also showed m-THPC 
is tightly sequestered upon entering cells and released very slowly regardless of the 
presence of serum components (Ball, D. J. et al. 1999).  This is unlike first generation 
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porphyrin derived photosensitisers, such as Photofrin (anionic), and showed an impaired 
cellular uptake (Sharkey, S. M. et al. 1993).   
 
In vivo: liposomal m-THPC uptake 
To date, studies using m-THPC (Foscan) have been carried out in the clinic and in different 
in vivo models including murine, feline and avian CAM, demonstrating significant 
variations in uptake and distribution.  In this investigation, pharmacokinetic studies with 
m-THPC in untargeted pegylated liposomal nanocarrier formulations, FosPEG 2% and 
FosPEG 8%, were carried out in reference to standard Foscan (m-THPC) formulation in rat 
models.  Doses of 0.3 mg kg-1 (m-THPC drug equivalent) were employed for a time series 
analysis to quantify m-THPC distribution in vivo by measuring uptake in different tissues.  
A chemical extraction method was chosen, as other quantification methods, such as, 
radiolabeling (Jones, H. J. et al. 2003), chromatographic analysis (HPLC chromatography) 
(Cramers, P. et al. 2003;Morlet, L. et al. 1995) and optical absorption (Bellnier, D. A. et al. 
1996;Henderson, B. W. et al. 1995) are more technically demanding, expensive and/or 
hazardous.  A commercially available tissue solubiliser, Solvable™, was used to dissolve 
tissues and release m-THPC monomerically prior to fluorescence spectroscopic analysis.  
In formative studies, it was found that absorption and fluorescence spectroscopic properties 
of dissolved tissues changed with incubation time (Kascakova, S. et al. 2008), therefore all 
samples were corrected for background fluorescence of native tissues, having undergone 
the same experimental conditions, to obtain accurate m-THPC concentrations.   
 
Pharmacokinetic analysis of liposomal m-THPC 
Compartmental model 
The serum clearance pharmacokinetics of the in vivo rat animal model presented here 
followed first-order elimination kinetics and best fit three exponential decays, based on 
compartmental grouping of m-THPC elimination from each tissue.  This was similar to 
previous pharmacokinetic studies carried out with Foscan (Jones, H. J. et al. 2003) and a 
non-pegylated liposomal formulation, Foslip (Lassalle, H. P. et al. 2009), in other murine 
models.  Studies with m-THPC (Foscan) in vitro in human plasma, demonstrated slow, 
steady-state distribution kinetics of m-THPC, owing to the hydrophobic nature of m-THPC 
causing high serum protein binding (i.e. LDL proteins) and prolonging the time at which 
patients could be treated (Triesscheijn, M. et al. 2007).   
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Each phase of decay represented a different route of elimination; as it takes different 
lengths of time for the drug to reach equilibrium in various tissues of the body, so will it 
affect its distribution.  Initially, directly after an intravenous bolus injection of 0.3 mg kg-1 
m-THPC into the tail vein, each formulation produced an instantaneous peak and a rapid 
linear distribution into a highly perfused central compartment (vasculature: blood plasma) 
(Veenhuizen, R. et al. 1997), representing the first phase of elimination.  Following this, a 
less rapid distribution of drug uptake into a second compartment was observed, before a 
terminal elimination phase into a third, or deep tissue, compartment (Shargel, L. et al. 
2005).  The compartments refer to the organs and tissues for which the rate of uptake and 
subsequent clearance of m-THPC are similar (Clark B et al. 1981).  Through this method, 
tissues could essentially be grouped into three theoretical compartments taking into 
account their elimination rate constants and half-lives (Table 4.5).  Compartments varied 
for each m-THPC formulation depending on their clearance, volumes of distribution and 
half-lives.  The accumulation and distribution of each m-THPC formulation to every organ 
was most probably due to their hydrophobicity, size, encapsulation and/or degree of 
pegylation, which determined the rate at which they moved from the blood into other 
tissues before being cleared by these organs, leading to expulsion from the body.  The half-
lives obtained for Foscan for each elimination phase (0.9, 3.3 and 90.0 h) (Table 2.2) are 
very close to the data of Jones et al., (0.46, 6.91 and 82.5 h), carried out in LSBD1 
fibrosarcomas implanted into BDIX rats with C-14 radiolabelled m-THPC (Jones, H. J. et 
al. 2003).  Studies in felines using an earlier FosPEG formulation by Buchholz et al,. 
(Buchholz, J. et al. 2005) revealed equal peak plasma concentrations of Foscan (~ 0.45 µg 
mL−1) at ≤ 5 min–2 h, as illustrated here (Fig 4.12), but found maximal plasma 
concentrations of FosPEG were only ~ 3.5 times higher than Foscan compared to >15-fold 
greater found here with FosPEG 8%.  However, in the latter study few details were 
provided on liposome composition and the degree of pegylation. 
 
Compartmental analysis (Table 4.4) demonstrated an initial volume of distribution of 407 
mL kg−1 with Foscan, which is extremely high given the blood volume of a rat ~ 50–70 mL 
kg−1.  This indicates that the initial retention of Foscan in the blood is very low and it 
preferentially diffuses and accumulates out of the central compartment, where it is 
selectively retained in different tissues.  This is perhaps as a result of Foscan being rapidly 
bound by serum proteins in the blood and taken up by phagocytosis.  In contrast, FosPEG 
2% and 8% have a low initial volume of distribution of 34.6 and 17.7 mL kg−1 
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respectively.  It is believed the PEG polymer coating sterically stabilises the liposomal 
particle, and prevents rapid uptake into macrophages at the earliest time points, thus 
increasing the longevity and accumulation of m-THPC in circulation, increasing its 
confinement to the vasculature.  The extended m-THPC half-lives of FosPEG 2% (99.0 h) 
and FosPEG 8% (138.6 h), however, exhibit only moderate differences compared to 
Foscan (90.0 h) (Table 4.4).  It is possible that by 96 h the liposomes have broken down in 
vivo so that only free m-THPC is being measured in the terminal phase of elimination (72-
96 h), resulting in similar half-lives.  However, evidence suggests the PEG coating may 
improve liposomes stability in serum and reduce drug release, as demonstrated using a 
similar pegylated liposomal composition (DPPC:DPPG, 9:1) (Crosasso, P. et al. 2000).  A 
reduction in the release of a hydrophobic drug (paclitaxel) from pegylated liposomes was 
observed over 96 h when incubated at 37 °C in human serum (35% of initial encapsulated 
drug) compared to non-pegylated liposomes (72%).  The same conclusion was reached by 
collaborators in in vitro studies using FosPEG, which demonstrated a reduction in m-
THPC transfer to serum proteins (~2.1%) in 10% FCS compared to ~40% m-THPC release 
in 90% FCS when incubated for 2 h at 37°C (see Appendix I – A.17).  
 
Non-compartmental model 
The non-compartmental approach was used as it compensates for individual data being 
collected from a number of animals, and is believed to give a more reliable measure of 
bioavailability, as it is directly proportional to the total amount of unchanged drug that 
reaches systemic circulation (Jones, H. J. et al. 2003).  The advantage of this method is that 
no assumptions are made regarding specific tissue compartments therefore each m-THPC 
formulation can be analysed over the entire time series as a whole compartment.  For 
Foscan versus pegylated liposomal m-THPC nanocarriers, FosPEG 2% and FosPEG 8%, a 
non-compartmental analysis gave m-THPC plasma clearance rates of 30, 6.4 and 3.2 mg 
kg-1 h-1 and t1/2 lives of, 42.9 h, 50.2 h and 62.6 h.  This decrease in m-THPC blood serum 
clearance rates and increase in t1/2 values between formulations implies that with 
encapsulation and increasing pegylation, m-THPC remains in circulation for prolonged 
periods of time, due to a reduction in nanoparticle internalisation by macrophages 
(Opanasopit, P. et al. 2002).  These macrophages are an essential component of the MPS 
and largely reside in the tissues of the liver (Kupffer cells), spleen (reticular cells) and bone 
marrow (Li, S. D. et al. 2008), however can also be found in a number of different organs, 
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such as, the lungs (alveolar cells), the blood (monocytes) and the kidneys (Kasravi, F. B. et 
al. 1995).   
 
Non-compartmental analysis gave an average volume of distribution (Vd) of 1875.7 mL kg-
1
 for Foscan, 464.2 mL kg-1 for FosPEG 2% and 289.5 mL kg-1 for FosPEG 8%.  This 
shows Foscan had a Vd six-fold greater than FosPEG 8%.  Foslip studies gave a volume of 
distribution of 709 mL kg-1, comparatively, in EMT6 xenografted nude mice (Lassalle, H. 
P. et al. 2009).  This suggests m-THPC-loaded pegylated liposomes are more confined to 
the vasculature due to their much lower volume of distribution, which continues to 
decrease with further pegylation.  This suggests, combined with mean residence times 
(MRT) of 61.9 h for Foscan versus 72.5 h for FosPEG 2% and 90.3 h for FosPEG 8%, that 
encapsulated m-THPC are less likely to be taken up into normal tissues to the same extent 
as Foscan within the same time frame.  This, in turn, increases the probability of m-THPC 
being extravasated into tumour tissues through passive uptake from the blood when 
incorporated in pegylated liposomes.  Foscan (m-THPC) is also a much smaller molecule 
than the 100 nm liposomes, therefore is able to diffuse out of normal blood vessels more 
easily, where it can distribute to other tissues.  Other distribution factors include cardiac 
output/blood flow, permeability and perfusion of membranes, disease and plasma protein 
binding.  Foscan’s high Vd is more likely due to the latter, as m-THPC is a highly 
hydrophobic molecule, making it prone to rapid serum binding and the formation of m-
THPC-serum complexes.  This may subsequently lead to removal of m-THPC upon 
entering the blood stream, before redistribution to tissues for clearance, indicated by 
Foscan’s reduced half-life and mean residence time in the plasma.   
 
In these analyses, the volume of distribution (Vd) is not a physiological value but a 
theoretical volume that a drug needs to occupy in order to equal its concentration in the 
blood, based on a uniform distribution.  Table 4.6 displays human blood volume 
concentrations (mL kg-1) and total blood volume (L) based on an average 70 kg person.  
The total body water volume (L) is comprised of the extracellular volume (including blood 
serum and interstitial volume) and intracellular volumes (L) (Guzman, F. 2009).  The same 
parameters are identified for a 200 g rat in Table 4.6 (Lee, H. B. et al. 1985). 
 
This information, combined with calculated volumes of distribution from pharmacokinetic 
models can be used to interpret the distribution of a drug.  For example, in a rat model (200 
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g), if the Vd for a drug is approximately equal to the total blood volume, 13 mL (65 mL kg-
1), it would suggest excessive binding to serum proteins and greater confinement to the 
central vascular compartment (Table 4.6).  In the same model, a Vd between 13-43 mL 
(~65-215 mL kg-1) indicates retention in the extracellular fluid, characteristic of 
hydrophilic drugs, and a Vd between 43-90 mL (~215-450 mL kg-1), implies drug 
distribution to the interstitial volume.  A Vd equal to the total body water volume or greater 
(>90 mL or >450 mL kg-1), suggests diffusion to intracellular fluid or strong drug binding 
to tissues. 
 
Parameter   Human Rat 
Total body weight (kg) 70  0.2 
Blood Volume (mL kg-1)  ~70 ~65 
Total blood volume (L)  ~8 ~0.013 
55 % blood serum (L)  ~5 ~0.008 
Total body water volume (L) 42 (100%) ~0.135 
Extracellular volume (L) Blood plasma ~4 (10 %) ~0.013 
Interstitial volume ~10 (23%) ~0.03 
Intracellular volume (L) ~28 (66%) ~0.09 
Table 4.6. Illustrates the relative size of various distribution volumes in average humans (Guzman, F. 2009) 
versus rats (Lee, H. B. et al. 1985).  Distribution volumes are related to certain parameters, such as, blood 
volume (mL kg-1) and total body water volume (L), giving an indication of drug distribution following 
systemic administration. 
 
In this investigation, Foscan has a Vd of ~1876 mL kg-1.  In a 200 g rat model this equates 
to ~375 mL, which supersedes the total body water volume and indicates strong m-THPC 
binding to tissues.  Vd calculated for FosPEG 2% and FosPEG 8% give values of ~93 mL 
and ~58 mL respectively.  The first indicates distribution to the intracellular volume and/or 
binding to tissues, whilst the latter suggests distribution to the interstitial volume.  This is 
possibly due to the increasing hydrophilicity of the liposomes with increasing pegylation.   
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Liposomal m-THPC biodistribution in vivo: normal tissues 
A large number of studies have documented the uptake of m-THPC (Foscan) at high 
concentrations into the RES using murine models; (Alian, W. et al. 1994;Cramers, P. et al. 
2003;Jones, H. J. et al. 2003;Peng, Q. et al. 1995;Whelpton, R. et al. 1996) and although 
the PEG coating on the surface of the liposome reduces their rate of uptake into these 
tissues, it does not completely prevent it (Zamboni, W. C. 2005).  The clearance of 
therapeutics from the blood is an important process for the removal of substances which 
could cause harmful side effects if retained in the body for long periods.  However, rapid 
clearance of a drug may lead to its removal from circulation before adequate time has 
passed for it to elicit a therapeutic effect in target tissues.  Fundamentally, it is crucial to 
establish a balance between clearance and adverse drug uptake into non-target tissues, 
however, this proves to be a difficult and on-going challenge. 
 
Liver/Spleen 
In this investigation, all formulations were found to show peak m-THPC levels at the 
earliest time points (Fig 4.13-15) in the liver, spleen and lungs.  These tissues are highly 
vascularised and will receive a high blood flow from the total cardiac output and as a 
result, increase the probability of exposure to circulating therapeutics.  These organs also 
constitute the RES and as such are involved in clearance pathways by acting as 
immunological filters of the blood (Yan, X. et al. 2005).  The liver is known to contain 
~20% of the total rat blood volume at any one time (~2.5 mL in 200 g rat) (Lee, H. B. et al. 
1985), which may further contribute to these results.  The liposomal encapsulation of m-
THPC and PEG coating of the particle surface, led to significant differences in m-THPC 
uptake in the liver.  Data from the liver show similar m-THPC concentrations at t≤2 h for 
both Foscan (~4 µg g-1) and FosPEG 8% (~3.5 µg g-1), m-THPC concentrations in the 
blood serum have to be taken into account in the same time frame.  For example, Foscan is 
measured at ~0.5 µg mL-1 in the blood at t≤2 h and FosPEG 8% at ~5.8 µg mL-1 (Fig 4.12).  
This demonstrates that Foscan is almost immediately and extensively removed from the 
blood at the earliest time points, accumulating in the liver at a concentration 8 times greater 
than that of the blood serum (Fig 4.13).  FosPEG 8%, however, shows little over half has 
been removed from the blood and distributed to the liver at this time.  This pattern of m-
THPC uptake corresponds to previous in vivo studies carried out in rats with Foscan 
(Jones, H. J. et al. 2003) and Foslip (Lassalle, H. P. et al. 2009) and in nude mice with 
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FosPEG (Reshetov, V. et al. 2013).  This confirms a greater and prolonged accumulation 
of m-THPC in FosPEG formulations in the central blood compartment.  The encapsulation 
of m-THPC and higher degrees of pegylation, may contribute to suppressed uptake into 
macrophages and organs of the RES (Alian, W. et al. 1994), such as the Kupffer cells of 
the liver, or stimulation of lymphocytes in the spleen (Bourdon, O. et al. 2002;Woodle, M. 
C. et al. 1992). 
 
Lungs 
Interestingly, the biodistribution of m-THPC formulations in the lung tissue (Fig. 4.15) 
correlated closely to the blood serum pharmacokinetics (Fig. 4.12), as lung uptake of m-
THPC increased with liposomal pegylation.  Following i.v. injection, the lungs are the first 
tissue to be perfused (Whelpton, R. et al. 1995).  Combined with the high density of 
permeating blood vessels and the large surface area of endothelial cells it can be speculated 
that circulating, residual blood may still have been present in the extracted tissue, as it was 
not not possible to flush prior to removal, resulting in a similar pattern of m-THPC 
accumulation.  Foscan results confirm this, as a 1:1 ratio of m-THPC in lung tissue: blood 
serum was observed.  Complete removal of Foscan and FosPEG 2% from the lungs was 
observed by 168 h; indicating they were not being unfavorably retained, however a slower 
clearance rate was found for FosPEG8%, suggesting longer periods of time are required for 
their clearance.  These slow distribution changes in the liver and lung could be the result of 
corresponding increased blood serum levels of FosPEG 8%, as nanocarriers are 
redistributed to different tissues of the RES through macrophage uptake (Xie, G. et al. 
2010).  Quantitative Foscan studies with lung tissue have been investigated in vivo (Peng, 
Q. et al. 1995;Svensson, J. et al. 2007;Whelpton, R. et al. 1995).  Fielding et al., have 
demonstrated localisation of m-THPC in the macrophages of lung tissue at 72 h (Fielding, 
D. I. et al. 1999).  To date, no studies have focused on the cumulative deposition of m-
THPC-loaded pegylated liposomes in normal lung tissue, but findings such as these offer 
exciting potential in treating diseased or cancerous lung tissue with PDT, as it is 
notoriously difficult to access.  Other studies using comparable nanocarriers have indicated 
similar capabilities and applications.  Schiffelers et al., used pegylated liposomes to deliver 
antibiotics in vivo to treat pneumonia in lung tissue of RP/AEur/RijHsd strain albino rats.  
It was found, the liposomes preferentially accumulated in infected lung compared to the 
contralateral non-infected lung and, as discovered here, a reduction in surface PEG density 
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resulted in a higher uptake by the RES and lower blood circulation time (Schiffelers, R. M. 
et al. 1999).  Similarly, Zhang et al., used 100 nm pegylated nanostructured lipid carriers to 
improve the delivery of an anti-tumour agent which targets nuclear enzymes (HCPT), in 
nude mice bearing human A549 tumours.  Biodistribution studies demonstrated an increase 
in HCPT circulation time, a reduction in RES uptake and superior tumour treatment 
efficacy in comparison to non-pegylated NPs and free HCPT (Zhang, X. et al. 2008).  
More recently, non-biodegradable polystyrene NPs were directly adsorbed onto the surface 
of red blood cells in Balb/C nude mice to improve NP accumulation in the lungs, whilst 
simultaneously reduce liver/spleen uptake. 
 
Kidneys 
Drugs and their metabolites are excreted primarily via the kidneys into urine, however, 
hydrophobic molecules, such as m-THPC, are thought to become rapidly bound by serum 
proteins upon entering the blood circulation, which contributes to their higher uptake and 
distribution to the RES, where they are transformated into hydrophilic liver metabolites 
(Li, S. D. et al. 2008).  According to the literature, hydrophilic drugs (PEG) undergo less 
protein binding, therefore are eliminated quickly from the blood by renal filtration into the 
urine.  In spite of the hydrophilic PEG coating of the liposomes, it is unlikely they are 
cleared significantly through the renal pathway due to their size.  Accumulation of m-
THPC may be on account of residing RES cells in the kidneys, as it is expected by 168 h 
that m-THPC may have leached from FosPEG formulations or they are likely to have been 
degraded.  The kidneys receive 25% of the total cardiac output (Dawson, T. R. 2002) and 
also contain RES cells.  Clearance of particles through the urinary system is more 
favorable with regards to toxicity as it reduces cumulative drug effects in the liver, and in 
the case of photosensitisers, prolonged cutaneous photosensitivity.  Choi et al., have 
demonstrated a 13% retention of injected drug doses in vivo up to two years post i.v. 
administration for even the smallest nano-drug molecules (Choi, H. S. et al. 2007), 
indicating 100% maximum clearance for the majority of nanoparticles is unobtainable.  
Research carried out by Burns et al., (Burns, A. A. et al. 2009), showed very small 
nanoparticles of 3-6 nm could be successfully cleared from animals through renal excretion 
in the kidneys, while studies using quantum dots by Choi et al., suggests the cut-off size 
for renal clearance is 5.5 nm (Choi, H. S. et al. 2007).  The liposomal nanocarriers used in 
our study were much larger than this (105-125 nm), suggesting ineffective clearance 
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through size dependent glomerular filtration.  Although decreased drug excretion rates and 
long-term retention can lead to potential problems with associated toxicity in the liver from 
incomplete biodegradation of particles into biologically benign components (Choi, H. S. et 
al. 2007), an initial reduction in renal clearance of encapsulated m-THPC in NPs can result 
in an increase in blood circulation time and therefore increased probability of accumulation 
in target tissues.  The uptake for all m-THPC formulations was much lower in the kidneys 
in comparison to the major organs of the RES (Fig. 4.16).  FosPEG 8% accumulates at the 
lowest concentrations in the kidneys over 168 h (≤ 0.1 µg g-1) following intravenous 
injection and may be on account of its prolonged circulation time.  Its clearance is in 
accordance with the pattern of excretion via the hepatobiliary pathway (Kumar, R. et al. 
2010;Lassalle, H. P. et al. 2009) but cannot be confirmed, as metabolic experiments were 
not carried out in this investigation for urine or fecal collection.  Bio-optical imaging by 
collaborators, however, indicated high levels of m-THPC fluorescence in fecal matter in ex 
vivo colon tissue with pegylated liposomes (Dr Wijnand Helfrich, NL – data not shown).  
Similar pharmacokinetic studies show corresponding results, with clearance closely related 
to uptake into the RES (Jones, H. J. et al. 2003;Kumar, R. et al. 2010;Lassalle, H. P. et al. 
2009;Whelpton, R. et al. 1995) and excretion via the hepatobiliary mechanism (Kumar, R. 
et al. 2010), however, these studies used non-biodegradable nanocarrier systems.   
 
Skin 
It was essential to examine the uptake and retention of m-THPC in skin tissue due to its 
well documented prolonged cutaneous photosensitivity post-PDT and subsequent 
complications with patient management.  Despite being highly vascularised, skin tissue has 
a low blood flow (5 mL/100 g tissue per min) relative to its percent of body weight (7 %) 
in comparison to the liver, which makes up 2% of total body weight and has a blood flow 
of 140-170 mL/100 g tissue per min in humans (Leiberman, D. P. et al. 1978;Shargel, L. et 
al. 2005).  In addition, large levels of macrophages reside in the RES therefore 
redistribution of m-THPC to these organs may occur, unlike the skin, which explains the 
low m-THPC uptake at early time points in the skin (non-exponential) compared to the 
liver, lungs or spleen.  The concentration of m-THPC in the skin tissue plateaus over 168 h 
(Fig 4.17) and may be accounted for by the same phenomena, as under normal steady state 
conditions only a small number of monocytes (precursors of macrophages) migrate to the 
skin (Vanfurth, R. et al. 1979).  This reduced rate of phagocytosis suggests m-THPC may 
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not be efficiently cleared from the skin upon entering, it is essential to ensure m-THPC 
uptake into the skin is kept to a minimum.  Skin tissue was found to accumulate the lowest 
concentrations of m-THPC (≤0.1 µg g−1) here and when compared to previous studies 
(Jones, H. J. et al. 2003;Lassalle, H. P. et al. 2009;Whelpton, R. et al. 1996).  Regrettably, 
Foscan and FosPEG 2% elicited similar kinetic profiles (Fig. 4.17) in the skin and slightly 
elevated concentrations of FosPEG 8% were observed.  Like the skin, muscle is a 
peripheral tissue and elicited similar m-THPC kinetics.  However, skin to tumour tissue 
ratios (~1.4 versus 6) (Fig. 4.19B), suggest pegylated liposomal m-THPC uptake may be 
sufficient to reduce DLIs and drug doses without detriment to PDT efficacy and patient 
treatment to overcome this problem.  Reshetov et al., also found improved tumour to skin 
ratios in nude mice with highly similar FosPEG formulations in comparison to Foslip 
(Reshetov, V. et al. 2013). 
 
Other tissues 
Drug uptake in brain tissue was not measured in these studies; however, successful 
treatment with liposomal therapeutics has been shown.  Although there has been little 
documented on the uptake of m-THPC into neurons, preliminary studies in our group 
(unpublished) have shown no evidence of accumulation in these cells and preservation of 
nerve tissue during clinical PDT treatment.  Based on the size of nanocarriers investigated 
here (~100 nm), it is highly unlikely they are able to cross the walls of non-sinusoidal non-
fenestrated blood capillaries of blood-brain barrier (BBB), which have a physiologic upper 
limit pore size of <1 nm (Sarin, H. 2010).  However, may be altered for targeted brain 
treatments, therefore any acute associated toxicity must not be ruled out. 
 
Liposomal m-THPC biodistribution in vivo: tumour tissue  
The pharmacokinetic data for tumour tissue (Fig. 4.19A) displayed a peak in m-THPC 
accumulation with all formulations between 6 and 24 h following the administration of 
clinical doses of m-THPC (0.3 mg kg−1).  This is in agreement with Foscan studies carried 
out by Jones et al., (Jones, H. J. et al. 2003), which show an m-THPC peak around 18–24 h 
in LSBD1 tumours in the BDIX rat along with Cramers et al., in H-MESO1 tumour-
bearing mice after equal injected doses of m-THPC (Cramers, P. et al. 2003).  More 
recently, Garrier et al., (Garrier, J. et al. 2010) found maximal Foscan uptake at 24 h in 
EMT6 tumour-bearing mouse models, comparable to Lassalle et al., (Lassalle, H. P. et al. 
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2009) who observed similar concentrations at time periods between 6 and 15 h with Foslip 
in the same model and m-THPC dose (0.3 mg kg−1).  Reshetov et al., found maximal 
tumour accumulation in nude mice over the same time periods following 0.15 mg kg-1 i.v. 
injection of either Foslip or FosPEG (~10% mol), but minimal differences in maximum m-
THPC concentrations between formulations.  It was speculated this may have been due to 
insufficient liposomal drug concentration in the plasma after 6 h (Reshetov, V. et al. 2013).  
By comparison, approximately 90% more m-THPC accumulated in tumour tissue using 
similar FosPEG formulations in studies presented here (Foslip ~0.1 µg g−1 vs. FosPEG ~1 
µg g−1).  Furthermore, studies carried out in felines by Buchholz et al., (Buchholz, J. et al. 
2005) showed peak tumour-to-skin ratios at similar times (7 h) with m-THPC-loaded 
FosPEG (2.5% or 5%) versus Foscan, using lower administered dose of m-THPC (0.15 mg 
kg-1).  Despite differences in administered m-THPC doses, quantification techniques and 
tumour species/models, it is apparent there are distinct differences in the tumour 
pharmacokinetics of m-THPC when delivered by liposomes with or without the addition of 
an inert PEG polymer coating.  This has been well documented since the introduction of 
Stealth® liposomes (Allen, T. M. et al. 1995;Papahadjopoulos, D. et al. 1991;van Vlerken, 
L. E. et al. 2007).  The inherent accumulation of nanoparticles such as liposomes in tumour 
tissue can further be attributed to the EPR effect, since leaky tumour vasculature, 
characterised by rapid angiogenesis (Brannon-Peppas, L. et al. 2004), increases 
permeability of pegylated liposomes allowing them to extravasate into the surrounding 
tumour tissue where they are retained due to a dysfunctional lymphatic drainage system 
(Maeda, H. et al. 2000).  Combined with prolonged periods in blood circulation, this is 
believed to aid their passive uptake into tumour tissue compared to normal tissue (Brown, 
J. M. et al. 2004).  The dynamics are likely to be more complex, since m-THPC can also be 
slowly released from liposomes through binding to serum proteins in circulation prior to 
reaching their tumour tissue (D'Hallewin, M. A. et al. 2008;Lassalle, H. P. et al. 
2009;Reshetov, V. et al. 2011).  However, following cellular uptake, liposomes are 
degraded to release encapsulated photosensitiser in its monomeric and photoactive form 
(Lassalle, H. P. et al. 2009).  Steric hindrance from bulky PEG groups at the nano-bio 
interface may explain why the relationship between increased uptake in tumour tissues of 
m-THPC incorporated into pegylated liposomal nanocarriers (2% mol) and increased 
pegylation of liposomes (8% mol) is non-linear and similarly why in vitro studies with 
some cell lines using these liposomes cause inefficient intracellular delivery (Li, S. D. et al. 
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2008).  Differences in tumour uptake may also be a consequence of the heterogeneity of 
the tumour tissue between animals. 
 
Summary: Biodistribution 
The PEG polymer coating appears to offer the liposome a degree of protection from 
recognition by the host’s immune system, increasing the longevity of m-THPC in the blood 
stream and its passive uptake into tumour tissue compared to Foscan in vivo.  Low skin to 
tumour tissue ratios observed with FosPEG formulations could be advantageous for PDT.  
 
PDT  
PDT studies were carried out in subcutaneous rat tumour (MC28 fibrosarcoma) models 
following administration of either FosPEG formulation versus Foscan in order to assess 
differences in PDT treatment response.  Drug: light intervals of 24 h were chosen based on 
the greatest uptake of m-THPC observed in vivo from pharmacokinetic data and optimal 
tumour: skin concentration ratios.   
 
In PDT studies, tumour necrosis was measured as a percentage of whole tumour surface 
area from histological sections, as carried out previously (Garrier, J. et al. 2010).  At m-
THPC doses of 0.3mg kg−1 and exposure to 10 J of light, a high percentage of tumour 
necrosis was found for all formulations although no significant differences were evident, 
despite the greater m-THPC concentration in tumour tissue using the liposomal-m-THPC 
formulations (Fig. 4.19A).  This may simply be due to the much larger light dose required 
to kill tissue at the tumour periphery, which may mask concentration differences, 
considering the complex dosimetry of interstitial light delivery (Berg, K. et al. 
2011;Wilson, B. C. et al. 1997).  A further factor is that the tumour periphery in sub-
cutaneous models has been observed to be more resistant to PDT (Berg, K. et al. 2011).  
However, when either light energy or m-THPC doses were lowered to ≤20% of their 
original dose (2 J or 0.05 mg kg−1 m-THPC) a significant difference (p≤0.001) in 
percentage area tumour necrosis between Foscan versus FosPEG 2% and 8% was observed 
(Fig. 4.21) from ~30% necrosis to ≥40–50% necrosis.  This implies not only that treatment 
times could be reduced, but also more importantly, that much lower doses of pegylated 
liposomal m-THPC may be administered in comparison to Foscan in order to elicit the 
same PDT effect witnessed at higher m-THPC doses.  This pattern of PDT efficacy has 
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also been observed in the treatment of arthritic joints (Hansch, A. et al. 2008) with 
pegylated liposomal m-THPC and in spontaneous squamous cell carcinomas in felines 
(Buchholz, J. et al. 2007).   
 
It is not feasible to discriminate clearly from these studies m-THPC damage to the 
vasculature and direct tumour cell kill.  It is likely that damage to the tumour vasculature, 
due to the increased levels of the FosPEG formulations in the circulation, makes an 
important contribution.  We note also that histological examination showed signs of 
haemorrhagic damage.  Tumour cell damage may then arise primarily through the 
accumulative effect of blood vessel collapse and hypoxia, with a lesser extent of direct 
tumour cell damage (Cramers, P. et al. 2003;Veenhuizen, R. et al. 1997).  A similar 
mechanism was proposed by Lassalle et al., using a Foslip formulation and more recent 
work by this group also attributed longer DLIs (≥15 h) and improved intratumoral 
localisation, throughout the tumour parenchyma and vasculature, to culminate in more 
effective PDT with FosPEG (Lassalle, H. P. et al. 2009;Reshetov, V. et al. 2013).  
Although both FosPEG formulations used here are effective, at this stage it is unclear as to 
which FosPEG formulation is optimum for tumour PDT and would be dependent upon the 
application owing to the complex dosimetry of different tissues.  
 
PDT performed to tumours using an intermediate dose of m-THPC (0.1 mg kg-1) at the 
same DLI (24 h) with a light dose of 10 J, showed an increase in the percentage tumour 
necrosis with FosPEG formulations (2% and 8%) compared to Foscan.  However, 
statistical analysis revealed this was not significant between percentage PDT tumour 
necrosis induces with higher dose of 0.3 mg kg-1 m-THPC (see Appendix I –A.16 PDT to 
MC28 tumours using 0.1 mgkg-1 m-THPC dose) therefore a further reduction in drug 
dosage was employed (0.05 mg kg-1). 
 
Many reports have suggested that a PDT damage threshold could be a consequence of 
vasculature collapse, as PDT efficacy is dependent on the availability of oxygen in the 
tissues, delivered by a functional blood supply (Dougherty, T. J. et al. 1998).  Therefore if 
significant vasculature damage occurs during treatment, the photochemical reaction cannot 
take place and treatment no longer becomes effective, as anoxic environments and hypoxic 
cells are protected from PDT damage (Henderson, B. W. et al. 1989a;Henderson, B. W. et 
al. 1989b).  However, our study found when m-THPC drug doses were significantly 
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reduced (0.1 mg kg-1 or 0.05 mg kg-1) and light parameters were fixed (10 J), an increase in 
percentage tumour tissue necrosis with PDT, at a DLI of 24 h, was observed with FosPEG 
formulations compared to Foscan.  This suggests the extent of phototoxic damage elicited 
by m-THPC in FosPEG formulations was maintained at similar levels to those observed 
with higher m-THPC doses.  One could argue, passive uptake of m-THPC into tumour 
tissues is more effective when m-THPC is delivered by nanocarriers (FosPEG), over 
standard formulation (Foscan), and therefore PDT response may also be attributed to PS 
extravasation and accumulation in tumour tissues rather than acting solely on the 
vasculature (Schacht, V. et al. 2006).  Vascular-mediate effects have been heavily 
associated with m-THPC in many studies, which have been correlated with plasma drug 
levels at the time of irradiation, rather than tumour levels (Triesscheijn, M. et al. 2005).  
Veenhuizen et al., (Veenhuizen, R. et al. 1997) and Cramers et al., (Cramers, P. et al. 
2003) showed PDT efficacy with Foscan paralleled m-THPC concentrations in the plasma.  
PDT damage here, however, shows an inverse relationship between m-THPC 
concentration and PDT response.  For example, as i.v. injected m-THPC doses are reduced, 
an increase in PDT response is observed with FosPEG formulations compared to Foscan.   
 
PDT efficacy is not only dependent on the bulk PS tumour concentration but also the 
spatial intratumoral localisation, therefore increasing specific tumour cell uptake following 
passive accumulation of NPs in tumour tissue is the focus for much research into future 
drug delivery strategies, targeting receptor-mediated uptake mechanisms overexpressed on 
many cancers.  There is also evidence to suggest that PDT efficacy could potentially be 
improved further with FosPEG formulations if the light fluence rate was lowered to reduce 
oxygen consumption rates (Seshadri, M. et al. 2008) or PDT light delivery was fractionated 
to allow re-oxygenation of tissue (Pogue, B. W. et al. 1997), as destruction of blood vessels 
feeding rapid-proliferating tumour tissues may help aid in long-term tumour regression 
(Dougherty, T. J. et al. 1998). 
 
Summary: PDT 
In order to understand in vivo interactions of m-THPC and perhaps even its intracellular 
distribution, the PDT effect has to be correlated to photosensitiser levels and tumour 
localisation.  Through encapsulation of m-THPC into pegylated liposomes the 
accumulation of photosensitiser in tumour tissues was improved and this was reflected in 
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PDT damage, whereby one sixth of the original administered dose resulted in maximal 
levels of tumour tissue necrosis, in comparison to standard formulation, Foscan. 
 
Skin photosensitivity 
The biodistribution of photosensitisers can lead to unfavourable uptake and retention in 
normal tissues, notably the skin.  In the case of m-THPC, this uptake is likely due to its 
hydrophobicity and non-selectivity.  Patients treated with PDT are advised to keep out of 
direct sunlight or strong indoor lighting in order to avoid common side-effects such as, 
skin blistering, sunburn, erythema and oedema.  With Foscan (m-THPC) this prolonged 
cutaneous photosensitivity has been documented to last for up to several weeks post-
treatment, complicating patient management (Wagnieres, G. et al. 1998).   
 
Skin photosensitivity studies revealed extensive superficial damage to skin tissue with 0.3 
mg kg–1 Foscan (i.v.) over the treatment area (5 mm2) after 30 min of light exposure at 100 
mW cm–2 (sun light equivalent) with a DLI of 96 h.  This was illustrated through 
histological examination by the thickening of the epidermis due to mass cell death at this 
site and an infiltration of inflammatory cells (indicated by arrows) (Fig. 4.23), indicative of 
severe erythema.  The histological effects of light exposure (30 min) were slightly milder 
when using FosPEG 2% and 8%, confirming damage to the epidermis at 96 h (Fig. 4.23).  
Visual assessment of skin effects at 96 h using FosPEG 8% (Fig. 4.22) correlated to 
chemical extraction results (Fig. 4.17), whereby elevated accumulation of FosPEG 8% in 
skin tissue was reflected in higher skin photodamage grading.  However, disparities 
between histological data were thought to be due to differences in the cellular localisation 
of m-THPC within skin tissue, which primarily determined the site and outcome of 
photoinduced damage (Moor, A. C. 2000).  Histologically there appeared to be less skin 
damage at a DLI of 168 h with all m-THPC formulations (Fig. 4.23).  Foscan appeared to 
elicit the most severe symptoms, in accordance with visual assessment (Fig. 4.22); 
however damage was more sporadic and occurred in isolated areas of the epidermis.  No 
further effects were observed with FosPEG 2%.  The skin histology for FosPEG 8% 
showed an infiltration of mast cells and neutrophils into the dermis (Fig. 4.23); however in 
one animal, widespread damage to the epidermis was detected (data not shown).  This 
correlated to m-THPC accumulation for FosPEG 8% at 168 h obtained through chemical 
extraction but the irregularity probably accounts for the increase in photosensitive grading 
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observed upon visual assessment.  This was believed to be due to inter-animal variation, 
m-THPC localisation and small sampling size.  All control skin samples including those 
that received no light (0 min exposure) and/or without m-THPC (data not shown) 
displayed no signs of cutaneous photosensitivity (Fig. 4.23). Recently, a reduction in skin 
photosensitivity has also been demonstrated using m-THPC encapsulation in micelles 
(Shieh, M. J. et al. 2010).  At reduced m-THPC doses (0.1 mg kg-1) grading analysis 
showed an overall reduction in skin photosensitivity with each formulation of 
approximately 3-fold, which directly corresponded to the reduction in m-THPC dosage 
(Fig 7B).  Foscan and FosPEG 2% showed an increase in photosensitivity over 30 mins at 
a DLI of 96 h, however at the longer DLI, Foscan scored positively lower in sensitivity 
across all light exposure times.  FosPEG 8% appeared to show the least amount of 
sensitivity at both DLIs over the 30 min exposure time, although cellular damage through 
histological examination was not carried out to confirm this.   
 
Summary: Photosensitivity 
Overall, there appeared to be a 2-3 fold reduction in skin photosensitivity over most light 
exposure times (0-30 mins) when the m-THPC dose was reduced but there did not seem to 
be a significant difference between FosPEGs and Foscan or DLIs.   
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4.5 Conclusions 
Novel pegylated liposomal nanocarrier delivery systems (FosPEG) have been developed in 
this chapter to improve the uptake of a second generation photosensitiser, m-THPC, into 
tumour tissues.  This was investigated by studying the biodistribution and accumulation of 
encapsulated m-THPC in comparison to standard formulation, Foscan, through in vivo 
pharmacokinetic analysis, which was then correlated with measurements of PDT efficacy 
and skin photosensitivity. 
 
Our study has shown that improved tumour uptake of FosPEG formulations (FosPEG 2% 
and 8%) in comparison to Foscan.  An increase in blood circulation half-life, combined 
with the influence of the tumour microenvironment (EPR effect), are believed to contribute 
to enhanced passive tumour uptake of m-THPC.  Improved maximal tumour to skin ratios 
at≤24 h with both FosPEG formulations indicate that significantly reduced administered 
doses of m-THPC could be employed over Foscan to produce the same PDT treatment 
efficacy.  This could be improved further still with the attachment of targeting ligands to 
the liposome surface, capable of recognising tumour-associated receptors over-expressed 
on the surface of many cancers.   
 
In a clinical setting, using lower administered m-THPC doses to achieve the same PDT 
anti-tumour response could reduce adverse prolonged skin photosensitivity, improve 
patient quality of life and significantly cut therapeutic costs. 
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5. Polymeric Nanoparticles 
5.1 Introduction 
Polymeric nanoparticles can be degraded into biocompatible, non-toxic products that can 
be cleared from the body.  The polymer composition of the nanoparticle can help 
determine the rate of its degradation, mechanical strength, solubility and pore size.  
Polymeric nanoparticles can be prepared from a range of polymers that exist naturally 
including, collagen and complex sugars (chitosan, hyaluronan and saccharides) or 
fabricated synthetically (α-hydroxy acids, polyanhydrides and others). 
 
PLGA poly(lactic-co-glycolic acid) is a synthetic, amorphous copolymer of two cyclic 
dimers, lactic acid (LA) and glycolic acid (GA), and is one of the most successfully 
developed biocompatible and biodegradable polymers owing to the production of 
endogenous metabolites (LA, GA), and their reabsorpability through natural pathways, 
following PLGA degradation (Danhier, F. et al. 2012).  Lactic acid is converted into 
pyruvate and glycolate enters the tricarboxylic acid cycle (TCA or Kreb’s cycle) and is 
eliminated from the body as carbon dioxide (CO2) and water (Crotts, G. et al. 1998).  
Glycolic acid may be excreted via the same process or as an unchanged molecule via renal 
clearance (Crotts, G. et al. 1998).  This minimal associated toxicity has rendered PLGA a 
promising biomaterial and has led to extensive research into its application in medicine, 
including micro- and nanoparticles, grafts, sutures, implants and prosthetic devices.  As a 
result, PLGA has been approved by the US Food and Drug Administration (FDA) and 
European Medicine Agency (EMA) for various drug delivery systems since 1989 (Duncan, 
R. 2006). 
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Figure 5.1.  Lactic acid (LA) can undergo a condensation (dehydration) reaction with glycolic acid (GA) to 
form lactic-co-glycolic acid via ester linkages.  Polymerisation of alternate repeating LA and GA units form 
the polymer, PLGA (x is the number of repeating lactic acid units and y the number of glycolide units).  
Taken from (Makadia, H. K. et al. 2011). 
 
In aqueous environments, degradation of the PLGA copolymer matrix is the collective 
process of (i) bulk diffusion (from water penetration), (ii) surface diffusion, (iii) bulk 
erosion and (iv) surface erosion predominantly through the hydrolysis of ester bonds 
between monomer subunits.  Furthermore, the biodegradation process autocatalyses due to 
the increasing number of carboxylic end groups available during degradation.  The rate of 
polymer degradation is thought to be largely affected by pH, through the 
protonation/deprotonation of ester bonds in acidic/basic environments and additional 
enzymatic cleavage is believed to be a contributing factor in vivo due to differences in drug 
release rates in comparative in vitro studies (Alexis, F. et al. 2008).  It has been shown by 
Makadia et al., that the degradation of PLGA is predominantly related to the composition 
of the polymer, specifically, the molar ratio of each monomer (LA:GA).  It was found the 
higher the ratio of glycolide units, the faster the degradation rate of PLGA.  This is due to 
the absence of hydrophobic methyl groups on glycolide units.  This increases the 
hydrophilicity of PLGA molecules with a higher percentage GA.  The presence of methyl 
groups on lactic acid monomer units means PLGA copolymers are able to absorb less 
water and therefore degrade more slowly (Makadia, H. K. et al. 2011).  The molecular 
weight (Mw) of the polymer has also been shown to positively correlate with the 
mechanical properties of the material (higher Mw increases polymer strength) and 
therefore its physical breakdown (Kranz, H. et al. 2000).  The degree of crystallinity within 
the polymer structure, which is directly related to its molecular weight, can also dictate its 
mechanical strength, rate of hydrolysis and subsequent degradation, with a reduction in 
crystallinity causing an increase in the rate of hydration/hydrolysis of PLGA (Makadia, H. 
K. et al. 2011).  The degree of PLGA crystallinity is dependent on the poly lactic acid 
(PLA) enantiomer incorporated (D or L); as PLA exists in two forms due to the presence of 
an asymmetric α-carbon.  PLLA occurs in a highly crystalline form whereas PDLA is 
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completely amorphous due to disordered polymer chains (Makadia, H. K. et al. 2011).  
Despite this, the physicochemical properties of optically active PDLA and PLLA are very 
similar.  (PLGA is generally an acronym for poly D,L-lactic-co-glycolic acid where D- and 
L- lactic acid enantiomer forms are in equal ratio).  Polymers of glycolic acid (PGA) are 
void of any methyl side groups, which ensure a highly crystalline structure; however, with 
a simultaneous increase in hydrophilicity, a higher ratio of GA monomers promotes a 
faster rate of PLGA degradation (Makadia, H. K. et al. 2011). 
 
Nanoparticles made of polymers (poly(alkylcyanoacrylate) were first described in 1977 by 
Couvreur et al., but were precluded from clinical applications as drug carriers until the 
mid-1990s owing to their limited circulation half-life (Olivier, J. C. 2005).  Several 
methods have since been proposed to increase the half-life of polymeric NPs in aqueous 
environments (Esmaeili, F. et al. 2008).  Polymers end-capped with esters prevent the 
exposure of free carboxyl groups at the terminal ends of PLGA chains to reduce hydrolysis 
and polymer degradation.  The addition of other biocompatible polymers, such as non-
ionic polymers, Poloxamers (poly(oxypropylene/oxyethylene)), or hydrophilic PEG 
groups, prevents precipitation of the copolymer molecules (Makadia, H. K. et al. 2011).  
PLGA/PEG block copolymers have been processed as diblock molecules (PLGA-PEG) 
and are readily commercially available.  The hydrophobic regions of PLGA (LA) form 
associative crosslinks and the hydrophilic PEG regions allow the copolymer molecules to 
stay in solution (Teply, B. A. et al. 2008).  As with previously described nanoparticles, the 
layer of PEG can act as a protective barrier from rapid RES uptake, however, is also 
thought to reduce the encapsulation efficiency of certain drugs in PLGA NPs.  The precise 
mechanism for this effect is unclear but is likely due to steric interference of drug-polymer 
interaction by the PEG chains (Makadia, H. K. et al. 2011).  Complex and simple sugars, 
such as chitosan and trehalose, have also been studied for PLGA surface modification 
(Jain, A. K. et al. 2011).  Each of these conjugated groups can reduce the electrostatic and 
hydrophobic interactions that enable opsonins to bind to the particle surface for clearance 
via the RES.   
 
Drug encapsulation into polymeric nanoparticles can occur through a number of different 
techniques with varying encapsulation efficacies, largely dependent on the drug being 
incorporated.  Inclusion of the drug can be made during the polymerisation process or by 
direct adsorption onto preformed nanoparticles.  In the first instance, chemical reactions 
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may occur between drugs and polymer monomers, inhibiting their function (Guise, V. et 
al. 1990).  If adsorbed directly onto the particle surface, drugs may be susceptible to serum 
protein competition of binding sites when in the blood or during subsequent surface 
modification steps, which may result in a reduction in nanoparticle stability and polymer 
degradation (Olivier, J. C. 2005).  Alternatively a rapid, one-step nanoprecipitation 
method, first described by Fessi et al., (Fessi, H. et al. 1989), can be used to incorporate 
drugs, following their dispersion in solvent during nanoparticle synthesis, in an attempt to 
overcome some of these drawbacks (Bilati, U. et al. 2005).  The method requires two 
miscible solvents; the first dissolves both the polymer and the drug (the solvent), whereas 
the second dissolves the polymer only (the non-solvent).  The removal of the solvent from 
the polymer material in solution (desolvation) via the addition of the non-solvent causes 
nanoprecipitation.  This process occurs rapidly upon diffusion of the polymer-containing 
solvent into the dispersing medium, causing immediate drug entrapment in polymer 
precipitates.  Nanoprecipitation enables the production of small nanoparticles (100–300 
nm) with narrow unimodal distribution from a wide range of preformed, commercially 
available polymers (Bilati, U. et al. 2005).  Additionally, the procedure does not require 
toxic organic solvents, high temperatures or pH steps, which may modify drugs or denature 
proteins being incorporated.  The nanoprecipitation method is more suitable for loading of 
hydrophobic, poorly soluble drugs into PLGA NPs, as opposed to water soluble drugs, due 
to the initial drug-polymer solvent dissolving phase, which promotes high encapsulation 
efficiency and prevents hydrophobic drug leakage (see Appendix I – B.1 
Nanoprecipitation method: PLGA NPs) (Barichello, J. M. et al. 1999;Fessi, H. et al. 
1989;Govender, T. et al. 1999).  100% encapsulation of hydrophobic Paclitaxel into PLGA 
NPs was demonstrated by Fonseca et al., using this method (Fonseca, C. et al. 2002).  
Consequently, this method has been used to produce PLGA and PEG-PLGA particles 
incorporating m-THPC in these studies.   
 
There is extensive research being carried out on the use of PLGA nanoparticles as drug 
delivery systems (targeted and untargeted) for use in various clinical applications, which is 
reflected in the literature (Table 5.1).  Many examples described in Table 5.1 encapsulate 
various anti-cancer agents such as paclitaxel (Fonseca, C. et al. 2002), 9-nitrocamptothecin 
(Derakhshandeh, K. et al. 2007), cisplatin (Dhar, S. et al. 2008), doxorubicin (Park, J. W. 
2002) etc. but a large proportion of PLGA NPs are also being developed for vaccinations 
and cerebral diseases (Danhier, F. et al. 2012).  All of these examples are currently in the 
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experimental or pre-clinical stage.  Despite improvements on polymeric NP stealth 
properties, issues associated with potential toxicity from dose dumping (initial drug burst), 
inconsistent drug release rates and in vivo drug-polymer interactions need to be evaluated 
(Makadia, H. K. et al. 2011). 
 
Table 5.1.  PLGA-based nanoparticles currently being developed as drug delivery systems for various 
clinical applications.  Taken from (Danhier, F. et al. 2012). 
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Drug release rates from polymeric nanoparticles are thought to be more complex than 
polymer degradation (Fig 5.2) and one can be independent from the other, as recent studies 
have found that the type of drug incorporated within the polymer delivery vehicle may also 
play a role in regulating release rates (Siegel, S. J. et al. 2006).  Drug release from PLGA 
nanoparticles (NPs) may occur via drug diffusion through the polymer matrix and/or 
through erosion of the polymer material.  This process is influenced by a combination of 
factors including (i) surface modification of NPs, (ii) method of NP preparation, (iii) 
particle size, (iv) molecular weight of encapsulated drug and (v) the ratio of lactide to 
glycolide (LA:GA) moieties (Makadia, H. K. et al. 2011).  Drug release patterns over time 
can be variable; high-performance liquid chromatography (HPLC) studies with PLGA 
microspheres incorporating protein (BSA) have shown non-linear and dose-dependent 
release profiles (Yang, Y. Y. et al. 2001).   
 
Drug release as a result of polymer degradation is believed to be an autocatalytic process, 
as the number of carboxylic end groups increases during hydrolytic biodegradation.  Drug 
release from PLGA NP biodegradation exhibits a biphasic curve pattern: 
(1) Initial burst of drug release (dose dumping) is related to drug compound, concentration 
and hydrophobicity.  Drug is released as a function of solubility and penetration of water 
into polymer matrix.  Random hydrolysis of PLGA chains significantly decreases 
polymer Mw, but no appreciable weight loss or production of soluble polymer monomers. 
 
(2) In the second phase, drug is released progressively through further depletion of polymer.  
Water inside the matrix hydrolyses polymer into soluble oligo- or monomeric products, 
creating a passage for diffusion of drug and further exposure for polymer erosion. Drug 
type plays an important role in attracting the aqueous phase into the matrix. 
 
Figure 5.2.  PLGA nanoparticle erosion over time; from left to right at 0 day, 1 week, 2 weeks and 5 weeks 
in PBS incubation media, pH 7.4.  Particles prepared using the emulsification solvent evaporation method. 
Particle size increased from 150 to 345 nm during this period.  Taken from (Jain, A. K. et al. 2011). 
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In vitro PLGA-nanoparticles are thought to enter cells either through fluid phase non-
specific pinocytosis and/or through clathrin-mediated endocytosis (Vasir, J. K. et al. 2006).  
Vasir et al., have demonstrated rapid internalisation of PLGA NPs, which are able to 
escape endo-lysosomes due to transient and localised destabilisation of vesicular 
membranes, entering the cytoplasm within 10 min of incubation (Vasir, J. K. et al. 2006).  
As discussed in Chapter 2: Nanotechnology, NP surface charge plays an important role in 
their interaction with cells and subsequent intracellular uptake.  Ionic interactions between 
positively charged particles and negatively charged cell membranes are believed to 
enhance non-phagocytic cellular uptake (Frohlich, E. 2012).  Cationic nanoparticles have 
also shown an ability to escape from lysosomes and exhibit perinuclear localisation, 
whereas negatively or neutrally charged nanoparticles prefer to co-localise with lysosomes 
(Yue, Z. G. et al. 2011).  However, non-specific uptake into macrophages (RES) in vivo, 
with untargeted pegylated positively charged NPs was higher compared to neutral particles 
on account of these properties (Yu, S. S. et al. 2012).  PLGA nanoparticles used here have 
a slightly negative surface charge (ζ potential) which increases their colloidal stability due 
to dispersion by electrostatic repulsion (de Paula, C. S. et al. 2013) but particles with high 
anionicity also demonstrate greater non-specific uptake into macrophages (Raynal, I. et al. 
2004;Yu, S. S. et al. 2012);.  Surface modifications, such as pegylation or chitosan coating 
can alter particle surface charge to render particles less prone to opsonisation (Tahara, K. et 
al. 2009).  However, macrophage uptake is believed to be more NP size-dependent, with 
studies carried out on a sub-100 nm pegylated polymeric NP range with different ζ 
potentials (between -9.0 mV and -3.5 mV), showing uptake was up to 42% more sensitive 
to particle size than charge (Yu, S. S. et al. 2012). 
 
Figure 5.3.  Schematic representation of intracellular uptake of PLGA nanoparticle (Acharya, S. et al. 2011). 
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Applications in PDT 
Polymeric nanoparticles have been used with success for applications in PDT, 
incorporating various photosensitisers into different polymers and copolymers.  Particles 
discussed here will largely focus on the utilisation of PLGA as the primary nanocomposite 
material (Table 5.2).  Amphiphilic photosensitisers such as Hypericin and 5-aminolevulinic 
(ALA) have been encapsulated into the copolymer matrix of PLGA NPs.  Recently, ALA 
PLGA NPs of ~65 nm diameter, with a PS encapsulation efficiency of 65%, have been 
studied in vitro in human skin squamous carcinoma cells (Shi, L. et al. 2013).  This yielded 
positive results, with ALA uptake observed in the cell cytoplasm and more effective PDT 
to tumour cells (% cell survival) following 24 h incubation with loaded NPs than with free 
ALA alone at the same concentration (Shi, L. et al. 2013).  Due to their insolubility in 
water, hydrophobic photosensitisers, such as AlClPc, ZnPc, ICG, Verteporfin, m-THPC, p-
THPP have also been packaged into PLGA NPs for improved systemic administration 
(Table 5.2).  Recently, Silva de Paula et al., observed a significant phototoxic effect of 
≥80% cell kill in human fibroblasts at low laser light doses (3 J/cm2) with AlClPc 
incorporated in nanocapsules comprised of either PLGA, PLA or PEG-PLA NPs (140-270 
nm in diameter, ~60-90% encapsulation efficiency) compared to free AlClPc (de Paula, C. 
S. et al. 2013).  PLA-PEG and PLGA NPs also showed the lowest AlClPc drug release in 
vitro compared to PLA.  m-THPC-loaded PLGA NPs were found to completely eradicate 
dark toxicity effects of m-THPC in vitro in human colon carcinoma cells (HT29) (Low, K. 
et al. 2011) compared to free drug.  In other studies performed with PLGA and PEG-
PLGA NPs encapsulating m-THPC, a faster and greater release of m-THPC in 10% FBS 
was detected through ultracentrifugation with PEG-PLGA NPs but a significant reduction 
in m-THPC uptake into A549, MCF10A neoT and U937 cell lines was observed with 
pegylated NPs compared to PLGA NPs, demonstrating their stealth properties.  
Bioluminescence imaging in vivo (athymic nude-Foxn1 mice) of whole organs, with 
similar PLGA NPs as used in studies here, did not show any significant difference in m-
THPC uptake in various tissues at 24 h post i.v. injection (0.3 mg kg-1 m-THPC) between 
pegylated and non-pegylated PLGA NPs, however, this was partially dependent on the 
optical properties of each tissue (Rojnik, M. et al. 2012).   
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Photosensitiser NP polymer Publication
5-aminolevulinic acid (ALA) PLGA Shi L, 2013
Chloro(29H,31H-phthalocyaninato)aluminium (AlClPc) PLGA Silva de Paula C, 2013
PLA
PEG-PLA
meta-tetra(hydroxyphenyl)chlorin (m-THPC) PLGA Rojnik, 2011
PEG-PLGA
Zinc (II) phthalocyanine (ZnPc) PLGA Fadel, 2009
Hypericin (Hy) PLGA Zeisser-Labouebe, 2006
PLA
Indocyanine green (ICG) PLGA Gomes A, 2006
Verteporfin (Visudyne) PLGA Konan-Kouakou, 2005
Bacteriochlorophyll-a (BChl-a) PLGA Gomes A, 2005
meso-tetra(hydroxyphenyl)porphyrin (p-THPP) PLGA Konan, 2003
PLA
 
Table 5.2. PLGA-based nanoparticles currently being developed for the delivery of photosensitisers for PDT.  
Further details can be found in (Chatterjee, D. K. et al. 2008a). 
 
The aim of the present study was to investigate the in vivo biodistribution, accumulation 
and photodynamic efficacy of m-THPC when non-covalently incorporated into 
biodegradable polymeric nanoparticles in comparison to standard Foscan (m-THPC).  
Nanoparticles were synthesised and characterised by collaborators at the University of 
Ljubljana using a commercially available diblock copolymer, PEG-PLGA, and a non-
pegylated PLGA copolymer.  As with liposomal studies, m-THPC tissue accumulation was 
assessed in subcutaneous syngeneic fibrosarcoma (MC28) Hooded Lister rat models at 
selected time points.  These results were correlated with PDT efficacy to tumours in vivo 
using identical time periods for selected drug to light intervals for PDT treatment.  To our 
knowledge, these are the first in vivo PDT studies to be carried out incorporating m-THPC 
in PLGA NPs. 
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5.2 Materials & Methods 
5.2.1 Chemicals and Photosensitisers 
Poly(lactic-co-glycolic acid) (PLGA) and pegylated (PEG) PLGA NPs were prepared and 
supplied by Dr Kos’ group at the University of Ljubljana using a modified 
nanoprecipitation method (Kocbek, P. et al. 2010) (see Appendix I – B.1 
Nanoprecipitation method: PLGA NPs).  Brief preparation protocol as described by 
(Rojnik, M. et al. 2012): 45 mg of PLGA (Resomer RG 503H, Boehringer, Germany) and 
5 mg of m-THPC (Biolitec AG, Germany) were dissolved in 1 ml acetone and the solution 
was slowly injected into 50 ml of 0.25% (w/v) poloxamer 188 (Lutrol F68, Sigma, UK) 
water solution with moderate magnetic stirring.  The resulting NP dispersion was stirred 
for 15 min at RT and centrifuged at 15,000 rpm for 15 min to separate NPs from non-
incorporated m-THPC and excess stabiliser.  NPs were washed with 20 ml of distilled 
water, centrifuged at 15,000 rpm for 15 min, and dispersed in 10 ml of 5% (w/v) aqueous 
trehalose (Sigma, UK) solution.  The NPs were freeze-dried at RT and 0.090 mbar for 24 h 
(Christ Beta 18–K, Germany) for storage and shipment.  Pegylated NPs were prepared by 
the same procedure.  A 1:1 weight ratio of PLGA (Resomer RG 503H) and PEG-PLGA 
(Resomer RGP d 50155) was used for preparation of pegylated NPs.  NPs were 
characterised at the University of Ljubljana through photon correlation spectroscopy (PCS) 
using a Zetasizer Nano ZS (Malvern Instruments, Worcestershire, UK) to determine 
polydispersity index (PDI) and mean particle diameter (Table 5.3).  Particle charge was 
quantified as ζ-potential by laser Doppler anemometry using a Zetasizer Nano ZS 
(Malvern).  The total amount of m-THPC entrapped in NPs was measured by fluorescence 
spectroscopy after complete dissolution of the NPs in DMSO (Sigma, UK).  m-THPC 
fluorescence was detected at λexc = 423 nm, λem = 652 nm. 
 
Immediately prior to experiments, 1 mg of lyophilised PLGA and PEG-PLGA NPs 
supplied were re-suspended in 1 mL phosphate buffered saline (PBS) and transferred 
between a vortex and water bath ultrasonicator for 10 mins to obtain a homologous 
dispersion (avoid aggregation and sedimentation). 
 
5.2.2 Absorbance spectra 
The absorbance spectra of m-THPC in Foscan, PLGA and PEG-PLGA NPs were recorded 
using a Lambda 25-UV/Vis spectrophotometer (Perkin-Elmer, UK) as described in 
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Chapter 4: Liposomes.  Samples were diluted in either PBS (saline) or solvent (dimethyl 
sulfoxide (DMSO), Sigma, UK) at equivalent m-THPC concentrations (10 µM) to ensure 
the characteristics of the absorbance spectrum of m-THPC had not been altered following 
encapsulation and release.   
 
5.2.3 Fluorescence spectra 
The fluorescence emission spectrum of noncovalently entrapped m-THPC in the 
copolymer matrix of PLGA and PEG-PLGA NPs (and that partially bound to the particle 
surface) was measured in stock solutions of PBS (pH 7.4) or DMSO (dissolution) at 
equivalent m-THPC concentrations.  Additionally, fluorescence emission spectra of m-
THPC formulations in Solvable were measured to construct calibration curves for 
pharmacokinetic studies (data not shown) as described in Chapter 4: Liposomes.   
 
In a separate group of animals (no tumour) to those used in pharmacokinetic studies, ex 
vivo fluorescence emission spectra of m-THPC were taken from freshly excised rat liver 
tissue using a USB4000 Ocean Optics fibre-optic CCD spectrometer (Ocean Optics, U.K).  
Measurements were obtained from liver tissue removed immediately post-mortem at either 
10 mins, 30 mins or 24 h (Table 5.2) following an intravenous tail vein injection of 0.3 mg 
kg-1 m-THPC for either Foscan, PLGA or PEG-PLGA NPs.  Excitation was provided by a 
405 nm blue emitting diode laser (Photonic Products, U.K.) and light was delivered via an 
optical fibre held in direct contact with the surface of the rat liver tissue.  A second fibre 
was coupled to the spectrophotometer and a CCD capture transferred to a PC for 
fluorescence spectrum acquisition.  Fluorescence measurements were recorded at three 
different sites in triplicate.  Control groups did not receive an injection of m-THPC. 
 
5.2.4 Confocal microscopy in vitro 
For visualisation of m-THPC uptake and intracellular localisation following encapsulation 
in PLGA NPs, confocal microscopy was employed.  1 x 104 MC28 (rat fibrosarcoma) cells 
were prepared using identical incubation conditions and fluorodish seeding methods as 
described in Chapter 4: Liposomes.  Cells were incubated for 4 h with either: 1 µM m-
THPC (Foscan), 1 µM m-THPC in PLGA NPs or PEG-PLGA NPs (- FCS) or 1 µM m-
THPC in PLGA NPs or PEG-PLGA (+ 10% FCS).  Control cells were incubated without 
m-THPC.  Following incubation, cells were washed twice with PBS before fresh media 
(minus serum and phenol red) was added. 
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5.2.5 Animals and tumour model 
Female Hooded Lister (HL) rats (150–220 g) were used for all PLGA NP in vivo studies.  
The methylcholanthrene-induced fibrosarcoma cell line (MC28) was cultured and 
transplantaed into animals as described in Chapter 4: Liposomes.  Following obtainment 
of sufficient tumour size between 7-10 days, m-THPC loaded PLGA or PEG-PLGA NPs 
were administered intravenously via a tail vein injection at a dose of 0.3 mg kg−1 m-THPC 
(see Appendix I – A.1 Dosage Calculations).  Animals were killed by cervical dislocation. 
 
5.2.6 Biodistribution studies 
Tissue samples selected for biodistribution studies were as described in Chapter 4: 
Liposomes.  Immediately post-mortem tissues were removed under subdued lighting at 24 
and 72 h from HL rats after intravenous administration of 0.3 mg kg−1 m-THPC in each 
PLGA NP formulation.  m-THPC extraction from tissues and detection was acquired using 
the same equipment, under identical conditions, following the same methodologies and 
mathematical models as described in Chapter 4: Liposomes.   
 
5.2.7 Confocal microscopy ex vivo 
Confocal microscopy was used to obtained images of m-THPC localisation in fresh ex vivo 
liver tissue from HL rats (no tumour) following intravenous administration of 0.3 mg kg-1 
m-THPC in either PLGA or PEG-PLGA NPS.  Tissue samples were removed and 
observed immediately post-mortem using an inverted Olympus Fluoview 1000 confocal 
laser scanning microscope.  Fluorescence confocal images were obtained using x60 
magnification using an oil immersion objective (Olympus).  Fluoview FV1000 (Olympus) 
and Image J software were used to analyse images.  m-THPC fluorescence was detected 
between 640-80 nm following excitation with a blue 405 nm laser (m-THPC λexc = 423 
nm, λem = 652 nm).  Laser voltage, Gain and Offset were kept consistent throughout 
imaging. 
 
5.2.8 Fluorescence lifetime studies 
The fluorescence lifetimes of non-covalently entrapped m-THPC in PLGA and PEG-
PLGA NPs were measured in stock solutions of PBS (pH 7.4) or following NP dissolution 
in DMSO at equivalent m-THPC concentrations (as described in 5.2.3 Fluorescence 
Spectra) in quartz cuvettes with a light path-length of 1 cm (Pye Unicam, UK).  Control 
5. Polymeric Nanoparticles 
- 142 - 
solutions of m-THPC in DMSO only were run simultaneously but no lifetime data was 
recorded for m-THPC in PBS as m-THPC is insoluble in aqueous buffer.   
 
Ex vivo fluorescence lifetime measurements of m-THPC were taken from freshly excised 
rat liver tissue (as described in 5.2.3 Fluorescence Spectra).  Measurements were obtained 
from liver tissue removed immediately post-mortem at either 10 mins, 30 mins or 24 h 
(Table 5.2) following an intravenous tail vein injection of 0.3 mg kg-1 m-THPC in either 
Foscan, PLGA or PEG-PLGA NPs.  Fluorescence lifetime data were obtained using time 
correlated single photon counting (TCSPC) (PC-mounted TimeHarp 100 board, Picoquant, 
Germany).  The light source was a 405 nm pulsed laser diode (ELP-405, Edinburgh 
Instruments, UK) with a pulse duration of 90 picoseconds and a 5 MHz repetition rate.  
Samples were excited using a fibre-optically coupled picosecond 405 nm laser diode and 
fluorescence was detected using a fast multi-alkali photomultiplier (H5773-04, Hamamatsu 
Photonics K.K., U.K.) via a monochromator (M300, Bentham Instruments, U.K.) and 
longpass filter (OG510, Schott, U.K.).  An Instrument Response Function (IRF) was also 
recorded to determine the temporal response of the detection system.  For ex vivo samples 
a fibre probe was placed and fixed in direct contact with the surface of the tissue to deliver 
a uniform distribution of light (power density: 2 mW cm-2).  The fibre was cleaned with 
alcohol between measurements to remove traces of blood and tissue, which may have 
given rise to false positive readings.  Approximately five measurements were taken for 
each sample and readings averaged.  Results were analysed with Picoquant Fluofit 
Software (Picoquant, Germany) to obtain lifetimes. 
 
Derivations of fluorescence lifetimes 
The time-resolved fluorescence intensity decays d(t) were fitted to a sum of exponentials, 
as described in equation 5.1. 
 
                                                                                                (5.1) 
The definition of the fitting parameters is as follows: 
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Ai; Amplitude of the ith component in counts (also as the pre-exponential factor).  
Therefore for the 50:50 mixture of two species, the values of A for each component would 
be 0.5. 
 
τi: Lifetime of the ith component 
 
To obtain the time-integrated signal d(int), i.e. over the whole decay, for a bi-exponential 
fit (two fluorescence lifetimes) the equations 5.2 and 5.3 were used: 
 
d(t) = A1 exp(-t/ τ1) + A2 exp(-t/ τ2)                                                                                  (5.2) 
d(int) = A1τ1 + A2τ2                                                                                                           (5.3) 
 
The integrated fluorescence is proportional to the weighted average of the lifetimes which 
is mathematically equivalent to the ‘mean’ lifetime.  Fluorescence decays were analysed 
using proprietary fitting software (Fluofit, Picoquant GmbH). 
 
5.2.9 Fluorescence microscopy (frozen tissue sections) 
Animal tissues were removed post-mortem and snap frozen in liquid nitrogen under 
isopentane (VWR, UK) 24 h and 72 h post-intravenous injection with 0.3 mg kg-1 m-THPC 
in PLGA and PEG-PLGA NPs.  10 micron frozen sections of liver, spleen, lung, kidney 
and tumour tissue were cut using a cryostat and mounted on polylysine treated glass slides 
(VWR, UK).  On average ten sections were taken per tissue sample from three animals.  
Sections were exposed to blue light for 10 secs using a 405 nm laser (3 mW) to excite m-
THPC and detect fluorescence in tissues.  CCD false coloured fluorescence microscopy 
images (512 pixels) were obtained with a PIXI 512 CCD camera (Princeton Instruments, 
USA) coupled to an inverted Olympus IMT-2 microscope (Olympus).  This system was 
equipped with a dichroic mirror (505DCLP, Omega) and filters were set as follows: 660 
nm DF33 bandpass filter, 595 nm long pass filter and 500 nm ACSP short pass filter.  
Sections were imaged at x10 magnification and analysed through WinSpec32 software 
(Roper Science Software).  The image resolution was 512 x 512 pixels, corresponding to 
557 x 557 microns. 
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5.2.10 Photodynamic therapy on MC28 tumours 
Injected doses of 0.3 mg kg-1 of m-THPC in PLGA or PEG-PLGA NPS were administered 
to HL tumour animals prior to light delivery.  Drug-light intervals of 24 h and 72 h were 
chosen based on pharmacokinetic data.  Tumours were irradiated with red light using a 400 
µm bare-cleaved tip optical fibre inserted approximately 1 mm into the tumour capsule via 
a small incision in the overlying skin and tumour capsule, to mimic interstitial clinical PDT 
with Foscan.  A total of 10 J of light at 100 mW for 100 s was delivered from a 652 nm 
diode laser.  Treatment with each m-THPC formulation was initiated when tumours had 
reached an optimal diameter of 10 mm.  Each treatment group consisted of four animals.  
Animals were killed 24 h after treatment by cervical dislocation and whole tumours 
resected for histological analysis. 
 
5.2.11 Histology and measuring necrosis (Hamamatsu Nanozoomer) 
Treated tumour tissue samples were removed post-mortem and prepared by routine 
methods for histological analysis as described in Chapter 4: Liposomes.  The damage was 
calculated from each tumour as a percentage of the whole tumour surface area.  Six 
sections were averaged per tumour (3 from each tumour half).  The mean percentage 
surface area of tumour necrosis was calculated through blind analysis per group of four 
identically treated animals and all data were represented as mean±SD. 
 
5.2.12 Statistical analysis 
Mean and standard deviation was calculated for each animal group (±SD, n=3–5). All data 
were represented as mean±SD.  Statistical analysis was carried out using a two-tailed 
Student's t-test and a Mann–Whitney U test for PDT data. p≤0.05 was considered 
statistically significant, unless stated otherwise. 
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5.3 Results 
5.3.1 Polymeric Nanocarriers 
 
Table 5.3. Specifications of m-THPC loaded PLGA and pegylated PLGA NPs used in this investigation. 
 
i. Absorption spectra 
An absorbance spectrum of m-THPC in Foscan, PLGA and PEG-PLGA NPs was taken in 
PBS (dilution buffer), as when administered in animals (Fig 5.4) to deduce peak 
absorbance wavelengths. 
 
 
Figure 5.4. Absorbance spectra of m-THPC in Foscan and noncovalently incorporated in PLGA and 
pegylated PLGA nanoparticles in PBS.  All solutions prepared at 10 µM m-THPC concentrations. 
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As described in the previous chapter (Chpt 4: Liposomes), Foscan demonstrated two 
strong absorbance peaks (Fig 5.4) with absorption maxima at ~ 423 nm (Soret band) and 
652 nm (Q band), characteristic of m-THPC (Bonnett, R. et al. 1989b).  When non-
covalently incorporated in PLGA and PEG-PLGA polymer matrices, m-THPC 
demonstrated a slight peak broadening and small bathochromic shifts for both absorbance 
peaks; m-THPC λexc = 425 nm, λem = 654 nm, in comparison to Foscan.  An absorbance 
spectrum could not be taken for pure m-THPC in PBS due to its hydrophobicity.   
 
Figure 5.5. Absorbance spectra of m-THPC in Foscan and noncovalently incorporated in PLGA and 
pegylated PLGA nanoparticles in dimethyl sulfoxide (DMSO).  All solutions prepared at 0.5 µM m-THPC 
concentrations. 
 
Dimethyl sulfoxide (DMSO) is a solvent used for its ability to dissolve a wide range of 
analytes.  DMSO disrupts PLGA polymer chains and causes NP collapse, releasing and 
solubilising m-THPC into its monomeric form.  It was employed for absorbance spectra 
measurements and corresponding fluorescence spectra lifetime studies (Table 5.4) of m-
THPC in Foscan, PLGA and PEG-PLGA NPs (also see Appendix I – B.2 Absorbance 
spectra of PLGA NPs in MeOD).  No spectral shift or peak broadening was detected for 
m-THPC in PLGA and PEG-PLGA NPs compared to Foscan in DMSO (Fig 5.5).  
Absorbance maxima for all m-THPC formulations in DMSO were recorded at 423 nm and 
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652 nm, respectively.  There was an absence of light scattering between 300-400 nm 
compared to spectra taken in PBS, suggesting complete disruption of polymer NPs and m-
THPC micelles (Foscan).  Slight differences in absorbance maxima (Ab = εcl) may be due 
to experimental error in preparing solutions (c = concentration). 
 
Absorbance measurements of m-THPC in PLGA and PEG-PLGA NPs in Solvable 
displayed similar spectra (data not shown), with a less pronounced shoulder on the Soret 
peak (~423 nm), as observed with m-THPC incorporated in liposomes (Chpt 4: 
Liposomes). 
 
ii. Fluorescence spectra 
 
Figure 5.6. Fluorescence emission spectra of m-THPC in PLGA and pegylated PLGA NPs in loading buffer 
(PBS) or when dissolved in DMSO, using an excitation wavelength of 423 nm. Peak emission was recorded 
at 652 nm. 
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The fluorescence emission spectrum of m-THPC was recorded for PLGA and PEG-PLGA 
NPs in DMSO or loading buffer (PBS).  Peak m-THPC fluorescence emission, using 423 
nm light excitation, was recorded at 652 nm in PBS for PLGA and PEG-PLGA NPs but a 
small red-shift to 654 nm was observed for both NPs in DMSO.  A large reduction in m-
THPC fluorescence intensity was observed with PLGA and PEG-PLGA NPs in PBS 
loading buffer in comparison to DMSO (dissolution), by factors of 11 and 21, respectively 
(Fig 5.6).  The Soret band (~423 nm) was also noticeably broader for NPs in DMSO (data 
not shown).  m-THPC loading was similar for both NPs: 6.9% w/w PLGA and 6.7% w/w 
PEG-PLGA (Rojnik, M. et al. 2012). 
 
Corresponding fluorescence lifetime data of m-THPC in Foscan, PLGA and PEG-PLGA 
NPs was taken in the same solutions (PBS and DMSO) and in ex vivo liver following 
intravenous injection of 0.3 mg kg-1 m-THPC in each formulation (Fig 5.10-12) at shorter 
(10-30 mins) and longer time (24 h) intervals (Table 5.4). 
 
iii. Confocal microscopy in vitro 
Confocal microscopy was used to image MC28 tumour cells following 4 h incubation with 
1 µM m-THPC in Foscan, PLGA or PEG-PLGA NPs, either in the presence or absence of 
10% FCS.  Confocal images showed a strong uptake of m-THPC into the cytoplasm of 
healthy dividing tumour cells with Foscan (Fig 5.7 B), determined by a strong fluorescence 
intensity (white) and a dark nucleus.  For both PLGA and PEG-PLGA NPs, m-THPC 
fluorescence is greater than the control group (without m-THPC), however, the presence of 
frequent bright white spots indicative of particle precipitation, aggregation and/or 
sedimentation can be observed in the absence of FCS (Fig 5.7 C & D) in comparison to the 
presence of 10% FCS (Fig 5.7 E & F).  Control cells showed a low background level of 
autofluorescence (Fig 5.7 A).   
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Figure 5.7. Confocal microscopy imaging: Qualitative uptake and localisation of m-THPC in vitro in MC28 cells of different formulations after 4 hours incubation. (A) Control MC28 cells 
(no m-THPC), (B) 1 µM Foscan (+) FCS, (C) 1 µM PLGA NPs (-) FCS, (D) 1 µM PEG-PLGA NPs (-) FCS, (E) 1 µM PLGA (+) 10% FCS, (F) 1 µM PEG-PLGA (+) 10% FCS. 
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iv. Biodistribution studies 
Uptake and Distribution of Photosensitiser in Tissues 
Biodistribution studies with m-THPC in non-pegylated PLGA or pegylated PLGA NPs 
were carried out with reference to standard Foscan formulation.  Doses of 0.3 mg kg-1 (m-
THPC drug equivalent) were administered in Hooded Lister rats implanted with 
subcutaneous tumours for analysis over selected time periods to measure levels of m-
THPC in tissues using chemical extraction.  Time intervals were chosen based on previous 
data from biodegradable pegylated nanocarrier systems (Chpt 4: Liposomes) in order to 
reduce animal numbers. 
A range of organs were selected for quantitative analysis to compare the relative uptake of 
m-THPC to that of tumour tissue when delivered by PLGA NP formulations versus 
standard Foscan.  At 24 h, m-THPC concentrations in the blood serum were more than 
four-fold lower when administered in Foscan (0.05 µg mL-1) compared to its encapsulation 
in either PLGA or PEG-PLGA NPs (0.3-0.4 µg mL-1) (Fig 5.8 A).  By 72 h traces of m-
THPC (Foscan) and in PLGA NPs are still detectable in the blood serum (Fig 5.8 B).  The 
highest m-THPC concentrations were observed in the liver and spleen for all m-THPC 
formulations at 24 h.  In both organs a much greater uptake of m-THPC in PLGA (~1.8 µg 
g-1) and PEG-PLGA NPs (~1.5 µg g-1) was observed in comparison to Foscan (~1.2 µg g-1) 
but these concentrations were greatly reduced to levels below that of Foscan in the liver by 
72 h.  The m-THPC concentration for PLGA and PEG-PLGA NPs was almost 10 times 
greater (~1.5 µg g-1) in the lung compared to Foscan (~0.15 µg g-1) at 24 h, however, as 
observed in the liver and spleen, this was dramatically reduced by 72 h (≥0.25 µg g-1).  The 
biodistribution kinetics of m-THPC in the kidney showed some unexpected results.  
Foscan was observed at a higher concentration (~0.5 µg g-1) than m-THPC-loaded NPs 
(~0.15 µg g-1) in the kidneys which continues to increase by 72 h (~0.75 µg g-1).  
Accumulation of m-THPC in skin tissue showed an increase in m-THPC accumulation 
with PLGA and PEG-PLGA NPs (~0.15 µg g-1) in comparison to Foscan (~0.05 µg g-1), 
which appears to be retained over 72 h.  In tumour tissue an increase in m-THPC uptake 
was observed with both PLGA NPs (~0.8 µg g-1) of more than two-fold in comparison to 
Foscan (~0.25 µg g-1) at 24 h, however, this was not significant with PLGA NPs.  By 72 h, 
m-THPC in PLGA NPs (~0.6 µg g-1) remains significantly higher than Foscan (~0.15 µg g-
1), by approximately four-fold, whereas PEG-PLGA m-THPC concentrations are similar to 
that of Foscan (also see Appendix I – B.4 %ID/g of m-THPC in polymeric NPs in vivo). 
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Fig 5.8. Concentration of m-THPC in selected tissues of the Hooded Lister rat following an intravenous 
injection of 0.3 mg kg-1 m-THPC in Foscan, PLGA and PEG-PLGA nanoparticles at (A) 24 h and (B) 72 h.  
Data points show the mean ± s.d., n = 4. 
A 
B 
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v. Confocal microscopy ex vivo 
 
Fig 5.9. Confocal microscopy of m-THPC in ex vivo rat liver tissue at 24 h following an intravenous injection 
of 0.3 mg kg-1 m-THPC in Foscan (micellular), PLGA or PEG-PLGA NPs, CNT (control; without m-THPC). 
 
Confocal microscopy images of ex vivo rat liver tissue following i.v. administration of 0.3 
mg kg-1 m-THPC in either Foscan, PLGA or PEG-PLGA NPs (Fig 5.9) shows the presence 
of large hepatocytes (green autofluorescence) with a dark nucleus and yellow fluorescence, 
indicative of m-THPC fluorescence, at 24 h.  This fluorescence appears in discrete bright 
yellow spots and may suggest localisation in the cytoplasm of hepatocytes in endo-
lysosomal compartments.  These images appear to show a greater distribution of Foscan in 
comparison to polymeric NPs at 24 h.  Control images (without m-THPC) demonstrated a 
slight green autofluorescence from liver tissue. 
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vi. Fluorescence lifetime ex vivo studies 
Following excitation, m-THPC decays back to a ground state (S0) through a number of 
different (radiative and/or non-radiative) decay pathways, the rate of which can be 
measured from fluorescence lifetime.  Fluorescence lifetime studies were carried out to 
investigate the decay rate of m-THPC fluorescence when non-covalently incorporated in 
PLGA and PEG-PLGA NPs in different solutions (PBS and DMSO) and in ex vivo rat liver 
tissue following intravenous injection of 0.3 mg kg-1 m-THPC equivalent (Table 5.4).  As 
observed with fluorescence emission spectra of m-THPC encapsulated in PLGA and PEG-
PLGA NPs (Fig 5.6), a large reduction in m-THPC fluorescence intensity was observed in 
PBS (loading buffer) in comparison to DMSO (dissolution), by factors of 11 and 21, 
respectively (Fig 5.6).  This corresponded to fluorescence lifetime data (Table 5.4), which 
showed a significant change in fluorescence lifetimes (τ) between the two solvents.  In 
DMSO, all m-THPC formulations demonstrated mono-exponential decays (A1) with 
identical lifetimes (~9.5 ns), however, in PBS, multi-exponential decays (A1 + A2) with 
significantly shorter lifetimes were observed for both the polymeric NPs.  Using bi-
exponential fitting, the lifetimes of PEG-PLGA NPs in PBS were shorter (3.2 and 1.4 ns) 
than for PLGA NPs (6.2 and 2.3 ns).  Lifetime data for m-THPC was collected in DMSO 
only due to its insolublity in PBS (Table 5.4).  
 
Table 5.4. Fluorescence lifetimes (τ) of m-THPC in pegylated (PEG-PLGA) and non-pegylated (PLGA) NPs 
in PBS (loading buffer) and dimethyl sulfoxide (DMSO) solution, with pre-exponentional factors (A), and in 
ex vivo rat liver tissue following an intravenous injection of 0.3 mg kg-1 m-THPC equivalent at 10 or 30 mins 
and 24 h.  Results part-published in (Rojnik, M. et al. 2012). 
Formulation τ1 (ns) A1 (%) τ2 (ns) A2 (%) 
     
PLGA in PBS 6.2 67 2.3 32 
PEG-PLGA in PBS 3.2 27 1.4 73 
m-THPC in DMSO 9.6 100 - - 
PLGA in DMSO 9.5 100 - - 
PEG-PLGA in DMSO 9.5 100 - - 
     
PLGA LIVER 10 mins 6.1 43 1.0 57 
PLGA LIVER 24 h 9.5 63 0.8 37 
     
PEG-PLGA LIVER 10 mins 7.8 66 1.4 34 
PEG-PLGA LIVER 24 h 8.4 100 - - 
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The fluorescence lifetimes of m-THPC (Table 5.4, Fig 5.10-12 A) and corresponding 
fluorescence emission spectra were also recorded on the outer surface of freshly excised ex 
vivo rat liver tissue following intravenous administration of 0.3 mg kg-1 m-THPC in PLGA 
(Fig 5.10 C) and PEG-PLGA NPs (Fig 5.11 C) at either 10 mins or 24 h.  m-THPC in 
PLGA NPs exhibit multi-exponential decays at both time points in ex vivo liver (Table 
5.4), but the fluorescence lifetime is longer at 24 h, paralleling that of m-THPC in DMSO 
(~9.5 ns) and similar to PLGA NPs in PBS at 10 mins (6.1 ns) following a bi-exponential 
fit (Fig 5.10 A + B).  This longer fluorescence lifetime, consistent with less self-quenching, 
is also reflected in the fluorescence spectra, which shows a 2-fold increase of m-THPC 
fluorescence between 650-660 nm at 24 h versus 10 mins (Fig 5.10 C).  In PEG-PLGA 
NPs, m-THPC shows a mono-exponential decay in liver at 24 h (Table 5.4) but a shorter 
fluorescence lifetime than PLGA NPs (~8.4 ns).  A similar fluorescence lifetime is 
observed at 10 mins (~7.8 ns) (Fig 5.11 A + B). 
 
               
Fig 5.10. Fluorescence lifetime (A) linear scale (B) log scale of m-THPC in ex vivo rat liver tissue at 10 min 
and 24 h following an intravenous injection of 0.3 mg kg-1 m-THPC in PLGA nanoparticles (C) fluorescence 
emission spectra (620-690 nm) of m-THPC on the same ex vivo tissue. 
 
Foscan demonstrated identical monoexponential decays in ex vivo liver tissue at both 30 
mins and 24 h following intravenous injection of 0.3 mg kg-1 m-THPC (Fig 5.12 A + B).  
Fluorescence lifetimes of Foscan in liver tissue were the same as m-THPC in DMSO (~9.5 
ns) (data not shown). 
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Fig 5.11. Fluorescence lifetime (A) linear scale (B) log scale of m-THPC in ex vivo rat liver tissue at 10 min 
and 24 h following an intravenous injection of 0.3 mg kg-1 m-THPC in PEG-PLGA nanoparticles (C) 
fluorescence emission spectra (620-690 nm) of m-THPC on the same ex vivo tissue. 
 
                   
Fig 5.12. Fluorescence lifetime (A) linear scale (B) log scale of m-THPC in ex vivo rat liver tissue at 30 min 
and 24 h following an intravenous injection of 0.3 mg kg-1 m-THPC in Foscan. 
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vii. Fluorescence microscopy frozen sections 
False colour fluorescence CCD images generally indicate higher m-THPC fluorescence 
intensity in all tissues at 24 h following intravenous administration of m-THPC-loaded 
PLGA NPs in comparison to PEG-PLGA NPs (Fig 5.13).  Intense bright fluorescence 
spots, suggestive of high m-THPC uptake were observed in the greatest number in the 
liver, spleen and lungs for both nanoparticles at 24 h.  m-THPC localisation in these organs 
was predominantly around blood vessels in the liver and distributed throughout spleen and 
lung tissue.  Furthermore, PLGA NPs also showed m-THPC fluorescence in the kidneys 
compared to pegylated PLGA NPs, which appears to be focused around the glomeruli.  
The lowest fluorescence was observed in tumour tissue for both particles at this time.   
 
At 72 h m-THPC fluorescence in liver tissue remains high with PLGA NPs and 
concentrated around blood vessels, however, is much lower with PEG-PLGA NPs (Fig 
5.14).  Foscan shows an even m-THPC fluorescence distribution throughout liver tissue 
between parenchyma cells, suggesting uptake in Kupffer cells.  There is a reduction of 
intense bright m-THPC fluorescence spots with PLGA NPs at 72 h compared to 24 h in the 
spleen, however, uptake is greater for both polymeric NPs compared to Foscan.  Lung 
tissue also shows bright m-THPC fluorescence spots with PEG-PLGA NPs but was more 
uniformly distributed throughout tissue and around blood vessels at a greater intensity with 
Foscan and PLGA NPs.  Finally, in tumour tissue a higher fluorescence intensity was 
observed at 72 h for all m-THPC formulations in comparison to 24 h, but noticeably more 
with PLGA NPs, which corresponds to chemical extraction data at this time (Fig 5.8). 
 
The histological structure of each tissue was determined by H&E staining of corresponding 
frozen tissue sections used for fluorescence microscopy (Fig 5.13).  Lung tissue revealed a 
sponge-like appearance due to its composition of thin-walled alveoli, comprising a single 
layer of squamous epithelium between which lies a thin layer of connective tissue and 
capillaries.  Hexagonal liver lobules formed of large hepatocytes (parenchymal cells) can 
be observed in liver with larger blood vessels clearly visible in tissue.  H&E staining of 
spleen tissue demonstrates a clear boundary between white and red pulp structures.  In the 
kidneys, red parenchymal tissue is punctuated by discrete bundles of cells, with nuclei 
stained purple, illustrating the presence of glomeruli and tumour tissue is typically 
heterogeneous (Fig 5.13). 
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Fig 5.13. CCD false coloured fluorescence microscopy images of m-THPC in 10 micron thick tissue sections following an intravenous injection of 0.3 mg kg-1 m-THPC in either PLGA 
(top) and PEG-PLGA nanoparticles (middle) at 24 h. (Bottom) equivalent frozen tissue sections stained with H&E for histological analysis.  100 micron scale bar on each image and the 
fluorescence intensity scale, top, increases from black (background/no fluorescence) through to white (max. fluorescence). 
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Fig 5.14. CCD false coloured fluorescence microscopy images of m-THPC in 10 micron thick tissue sections following an intravenous injection of 0.3 mg kg-1 m-THPC in either PLGA 
(top) and PEG-PLGA nanoparticles (middle) at 72 h. (Bottom) equivalent frozen tissue sections stained with H&E for histological analysis.  100 micron scale bar on each image and the 
fluorescence intensity scale, top, increases from black (background/no fluorescence) through to white (max. fluorescence). 
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viii. PDT 
The second part of this investigation involved assessing the PDT efficacy to tumours in 
vivo with m-THPC-loaded PLGA and PEG-PLGA NPs in comparison to Foscan.  In order 
to help establish optimal PDT parameters required for maximal tumour necrosis, two DLIs 
were chosen to perform PDT to subcutaneous MC28 fibrosarcomas in Hooded Lister rats. 
 
H&E stained MC28 tumour sections were scanned with the Hamamatsu Nanozoomer 
following intravenous administration of 0.3 mg kg-1 m-THPC in either Foscan (FS), PLGA 
or PEG-PLGA NPs, prior to PDT treatment at 24 h (Fig 5.15) and 72 h with 10 J of light at 
100 mW, in order to observe the extent of PDT damage, measured by the percentage area 
of necrosis.  Control tissues received no drug or light. 
 
 
Figure 5.15. Examples of H&E stained MC28 tumour sections scanned with the Hamamatsu Nanozoomer to 
observe the extent of PDT damage with m-THPC, measured by the area of necrosis (dotted perimeter), after 
24 h post i.v. injection of 0.3 mg kg-1 of m-THPC in Foscan (FS), PLGA or PEG-PLGA NPs.  Negative 
control tissues received no drug or light (Control). 
 
Control MC28 tumour tissue was typically heterogeneous in structure and stained dark 
purple with H&E, indicative of ‘healthy’ (non-necrotic) tumour cells.  The PDT damage to 
tumour tissue at 24 h with Foscan appeared slightly greater than for m-THPC-loaded 
PLGA and PEG-PLGA NPs, with similar percentage necrosis exhibit between both 
formulations (Fig 5.15).  Signs of necrosis, including haemorrhagic damage and condensed 
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cellular nuclei were observed with all m-THPC formulations, in addition to the presence of 
a more resistant tumour periphery.  
 
When histologically analysed sections of MC28 tumour tissue were quantified to assess the 
percentage of MC28 tumour necrosis induced following PDT at 24 h and 72 h, there did 
not appear to be any significant difference between each m-THPC formulation (Foscan, 
PLGA or PEG-PLGA NPs) at either time point after a 0.3 mg kg-1 m-THPC (Fig 5.16).  
Results showed a greater percentage area of necrosis induced with PDT at 24 h following 
the administration of Foscan (55%) of approximately 5%, in comparison to PLGA (50%) 
and pegylated PLGA NPs (46%).  At a 72 h drug light interval, PDT induced tumour 
necrosis appeared to fall by 13% with Foscan (42%) but the percentage area of necrosis 
remained identical for both PLGA formulations.  Control tumour tissue, which received 
light treatment but no administration of m-THPC showed negligible levels of induced 
necrosis.   
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Figure 5.16. The percentage of MC28 tumour tissue necrosis (%) induced by PDT with 10 J of light at 100 mW following intravenous injection of 0.3 mg kg-1 of m-THPC in either Foscan, 
PLGA and pegylated PLGA NPs at drug:light intervals of (A) 24 h and (B) 72 h. 
A B 
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5.4 Discussion 
The aim of this study was to investigate whether incorporation of m-THPC into an 
alternative biodegradable nano-vehicle system could facilitate its passive delivery into 
tumour tissue in vivo and improve PDT tumour efficacy.  Pegylated and non-pegylated 
poly(lactide-co-glycolide) nanoparticles, PEG-PLGA and PLGA NPs, were used in these 
studies to encapsulate m-THPC and were prepared via a nanoprecipitation method (Rojnik, 
M. et al. 2012).  Polymeric nanoparticles were supplied by the University of Ljubljana as 
freeze dried particles following their synthesis.  To increase their long-term stability and 
improve their dispersion/reduce sedimentation upon resuspension in PBS (loading buffer), 
they were supplemented with trehalose (sugar) (see Appendix I – B.1 Nanoprecipitation 
method: PLGA NPs).  Characterisation studies in vitro and in vivo with these particles 
have previously been published (Rojnik, M. et al. 2012). 
 
The particle diameter of polymeric particles used in these studies was 144.7±2.0 nm for 
PEG-PLGA NPs and 179.0±0.3 nm for PLGA NPs (Table 5.3).  Interestingly, the addition 
of PEG groups decreased particle size and was thought to be due to the incorporation of 
more hydrophilic PEG chains in the hydrophobic PLGA polymer.  Rojnik et al., reported 
covalently linked hydrophilic PEG blocks can change the physicochemical properties of 
PLGA polymers, enabling the formation of smaller particles (Rojnik, M. et al. 2012).  
Furthermore, the addition of trehalose as a stabilising agent was thought to contribute to an 
increase in nanoparticle diameter due to the attachment of bulky carbohydrates.  The 
greater negative ζ-potential of PLGA NPs compared with PEG-PLGA NPs was attributed 
to the presence of a larger number of free carboxyl groups on the PLGA NP surface and a 
lack of uncharged PEG chains (Rojnik, M. et al. 2012).  Both NP formulations, however, 
generally showed a low polydispersity index (PDI) and a low negative surface charge (≤-
5.5 mV).  A low surface charge of these NPs has indicated low stability, resulting in their 
aggregation/sedimentation from aqueous dispersions but a simultaneous reduction in 
macrophage uptake compared to highly anionic particles (≥-9 mV) (Yu, S. S. et al. 2012).   
 
Loading efficiency 
In colloidal systems, such as these, determining the precise drug content of NPs is 
challenging, however, ultracentrifugation can be employed to separate nanoparticles from 
non-encapsulated or non-adsorbed drug.  This can help to determine the concentration of 
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drug remaining inside the polymeric NPs, as binding to serum proteins is only possible 
following drug release from the polymer matrix (Kumari, A. et al. 2010).  While PLGA-
based NPs often present high encapsulation efficiencies, drug loading has been described 
as generally poor, usually equating ~1% weight/weight (%, w/w) (Kumari, A. et al. 2010).  
This typically means that 1 mg of active drug is available per 100 mg of polymer in the 
nanoparticle.  These terms have been described by Tripathi A et al., as the following 
(Tripathi, A. et al. 2010):  
 
 
Equations 5.4.  Equations describing drug encapsulation efficiency and drug loading efficiency in polymeric 
nanoparticles.  Taken from (Tripathi, A. et al. 2010). 
 
PEG-PLGA and PLGA NPs developed here had drug loadings of 6.7% and 6.9% (w/w), 
respectively (Table 5.3).  In NP preparation, 50 mg of polymer and 5 mg of m-THPC were 
dissolved in acetone solution.  The maximum m-THPC encapsulation efficiency 
achievable in this system is 9.1% (w/w): 5 mg of m-THPC/ (50 mg of polymer + 5 mg of 
m-THPC).  The encapsulation efficiency of m-THPC in polymeric NPs, developed here, 
was ~75% (6.7-6.9%/9.1%).  These values show that PEG chains did not drastically affect 
m-THPC loading through steric interference of drug-polymer interactions, as reported by 
Makadia et al., due to similar drug loadings for both NPs (Makadia, H. K. et al. 2011). 
 
A ‘high burst’ drug release rate is also characteristic of polymeric nanoparticles, referred to 
as ‘dose dumping’.  This rapid initial release creates localised drug toxicity issues, whilst 
reducing the ability of therapeutics to reach target tissue or cells, leading to a loss of 
therapeutic efficacy.  This has been attributed to the immediate release of a fraction of 
partially adsorbed drugs on the NP surface on account of their hydrophobicity and 
incompatibility with hydrophilic PEG chains (Kumari, A. et al. 2010).  This has been 
observed by Compagnin et al., with m-THPC in pegylated liposomes (Compagnin, C. et al. 
2011) and by Rojnik et al., with non-covalently entrapped m-THPC in PEG-PLGA NPs, 
similar to those used in studies here (Rojnik, M. et al. 2012).  In the latter example, m-
THPC demonstrated a faster release from PEG-PLGA NPs in 10% FBS compared to 
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PLGA NPs through ultracentrifugation.  With PLGA NPs the rate of m-THPC release was 
believed to be directly proportional to the rate of polymer degradation but the mechanism 
of release for PEG-PLGA NPs followed a more biphasic pattern, with an initial burst 
release of 30% (w/w) m-THPC.  Despite a more sustained released of m-THPC from 
PLGA NPs over 24 h in 10% FBS, ~68% m-THPC was still detectable at this time (24 h) 
in comparison to ~45% m-THPC in PEG-PLGA NPs as a result of the initial m-THPC 
burst release (Rojnik, M. et al. 2012) (see Appendix I – B.3 Rate of m-THPC release from 
polymeric NPs). 
 
Photophysical studies: polymeric NPs 
Aggregates of porphyrin-based photosensitisers, such as m-THPC, are well known to 
possess inferior fluorescence properties with regards to shorter fluorescence lifetimes, 
lower triplet state yields, and thus poorer photodynamic efficiency than monomeric m-
THPC (Bezdetnaya, L. et al. 1996).  Fluorescence lifetime data (Table 5.4) and 
fluorescence emission spectra (Fig 5.6) indicated m-THPC fluorescence is strongly 
quenched when encapsulated in PEG-PLGA and PLGA NPs, in comparison to monomeric 
m-THPC.  Monomerisation was achieved by disrupting polymeric NPs in DMSO to 
release m-THPC from particles and resulted in a significant increase in fluorescence 
intensity and lifetime in comparison to intact m-THPC-loaded particles suspended in their 
loading buffer (PBS).  These results are consistent with the occurrence of fluorescence 
self-quenching due to the aggregation of m-THPC within NPs.  The degree of quenching 
appeared to be greater for PEG-PLGA NPs versus PLGA NPs, despite comparable m-
THPC loading (Table 5.3).  This could be explained by the smaller size of PEG-PLGA 
NPs resulting in a higher local m-THPC concentration and a greater propensity for PS 
aggregation.  Similar fluorescence quenching results have also been observed following the 
incorporation of m-THPC into liposomes.  In liposomal studies, the fluorescence lifetime 
of encapsulated m-THPC was reduced to 1 ns from 20 ns (free m-THPC), which was 
attributed to aggregation (Lassalle, H. P. et al. 2009;Moan, J. et al. 1991;Vargas, A. et al. 
2008).  Absorbance spectra of the same PLGA and PEG-PLGA NPs demonstrated small 
spectral changes of m-THPC, including a slight peak broadening and small bathochromic 
shifts in PBS (Fig 5.4) compared to DMSO (Fig 5.5).  This is likely due to the 
incorporation of m-THPC into polymer matrices and the formation of dimers, as 
Glanzmann et al., reported broadening of both m-THPC bands due to dimerisation (such as 
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stacking of its chlorin rings) in aqueous environments (Glanzmann, T. et al. 1998).  
However, it should be noted, differences between monomeric and dimerised forms of m-
THPC are less easy to interpret through this method.  The most noticeable difference in 
absorbance spectra was between 300-400 nm (outside of m-THPC absorbance range), 
suggesting a reduction in NP light scattering from complete disruption of NP polymer 
chains when in a solvent.   
 
Despite data indicating the presence of m-THPC forming aggregates when entrapped 
inside PLGA NPs, it has been shown these aggregates are able to dissociate to monomeric 
forms following their release from the NPs and transfer to plasma proteins when reaching 
tumour sites (Konan-Kouakou, Y. N. et al. 2005); (Hopkinson, H. J. et al. 1999); 
(Sasnouski, S. et al. 2007).  This is preferable for ROS production and effective PDT 
(Triesscheijn, M. et al. 2007).  The rate of m-THPC monomerisation is dependent on the 
rate of polymer degradation and release of m-THPC from the NP, affecting its availability 
and photo-activity (Rojnik, M. et al. 2012).   
 
Fluorescence lifetime: ex vivo 
The fluorescence lifetimes of m-THPC and corresponding fluorescence emission spectra 
were also recorded on the outer surface of freshly excised ex vivo rat liver tissue following 
intravenous administration of 0.3 mg kg-1 m-THPC in PLGA and PEG-PLGA NPs at either 
short (10 mins) or longer (24 h) time periods (Table 5.4, Fig 5.10-11 A).  At shorter 
administration times, m-THPC in both PLGA NPs had multi-exponential decays, 
displaying sub-populations with much shorter fluorescence lifetimes that comprised a 
significant percentage (%).  This suggests self-quenching of m-THPC through the 
formation of weak aggregates.  At 24 h, m-THPC in PLGA NPs has a much greater 
population with longer fluorescence lifetimes, paralleling that of m-THPC in DMSO (~9.5 
ns).  In addition, m-THPC in PEG-PLGA NPs shows a mono-exponential decay in ex vivo 
liver by this time (Table 5.4).  This demonstrates more monomerically active m-THPC, 
likely following the degradation and release of m-THPC from NPs at longer time points 
and its subsequent binding by serum proteins (Rojnik, M. et al. 2012).  Foscan 
demonstrated identical monoexponential decays in ex vivo liver tissue at both 30 mins and 
24 h following intravenous injection of 0.3 mg kg-1 m-THPC and fluorescence lifetimes 
were the same as m-THPC in DMSO.  This suggests m-THPC in Foscan is present in its 
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monomeric active form in the liver due to the binding of serum proteins (Triesscheijn, M. 
et al. 2007). 
 
In vitro: polymeric m-THPC uptake  
Confocal microscopy was used to image MC28 tumour cells following 4 h incubation with 
1 µM m-THPC in either Foscan, PLGA or PEG-PLGA NPs in the presence or absence of 
10% FCS (Fig 5.7).  Confocal images showed a strong uptake of m-THPC in the 
cytoplasm of tumour cells following incubation with micellular Foscan (+ 10% FCS).  The 
association of m-THPC with various serum proteins has previously been shown in the 
literature to improve intracellular uptake of monomerised m-THPC (Hopkinson, H. J. et al. 
1999); (Sasnouski, S. et al. 2007).  Dissociation of m-THPC from polymeric NPs may 
occur before or after cellular uptake of particles, thus m-THPC released prior to NP 
internalisation may also contribute to intracellular fluorescence activity (Rojnik, M. et al. 
2012).  In this case, the observed fluorescence intensity of m-THPC was to a lesser degree 
with PLGA and PEG-PLGA NPs than free m-THPC (Foscan) in the cytoplasm.  This 
would need to be confirmed with a Lysotracker in vitro to ensure this fluorescence is 
intracellular, however, a reduction in intracellular fluorescence may be attributed to the 
larger size of NPs being internalised (~150-180 nm), hindering m-THPC uptake efficiency 
through steric hinderance at the nanobio-interface, in comparison to Foscan over a 4 h 
period.  According to Segat et al., PLGA NP size was said to increase further still, by 
almost two-fold, in the presence of 10% FCS due to protein binding (Segat, D. et al. 2011).  
Furthermore, m-THPC concentrations may decrease in continuously dividing cells (20 
mins – 24 h cell cycle) reducing intracellular fluorescence (Compagnin, C. et al. 2009).  In 
the absence of FCS, m-THPC uptake with both NPs demonstrated the presence of 
numerous bright white spots (Fig 5.7).  This was thought to be indicative of particle 
precipitation, aggregation and/or sedimentation due to the lack of serum proteins available.  
Rojnik et al., supplemented PBS (loading buffer) with 10% FBS upon resuspension of 
freeze dried NPs prior to measurements in order to improve their dispersion and 
stabilisation.  This appeared to be confirmed with confocal images (Fig 5.7). 
 
Studies by collaborators showed intracellular localisation of m-THPC displayed similar 
distribution patterns throughout the cytoplasm of human-transformed breast cancer cells 
(MCF10A neoT) following incubation at 1, 3, 6 and 10 h (Rojnik, M. et al. 2012) with m-
THPC-loaded PLGA or PEG-PLGA NPs.  Red m-THPC fluorescence following cellular 
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incubation with both polymeric NPs was predominantly localised around the endoplasmic 
reticulum (ER) and Golgi apparatus, as demonstrated with m-THPC-loaded ORMOSIL 
NPs and liposomal-m-THPC with different (immortalised) cell lines in vitro (Compagnin, 
C. et al. 2009;Compagnin, C. et al. 2011).  This localisation was believed to be due to m-
THPC released from NPs prior to their internalisation.  At longer incubation periods (10 h) 
an increase in the appearance of bright red spots was attributed to accumulation of m-
THPC in lysosomal-endosomal compartments, as a result of intact NPs internalised via 
clathrin dependent endocytosis.  The rate of PLGA degradation is expected to increase in 
acidic environments, such as the cytoplasmic vesicles of cells, due to acid-catalysed 
hydrolysis of ester bonds between LA and GA monomeric units, which may contribute to 
this observed fluorescence pattern (Alexis, F. et al. 2008).   
 
Rojnik et al., also demonstrated a significant reduction of m-THPC uptake in vitro through 
flow cytometry (FACS) using A549 cells, MCF10A neoT cells and differentiated human 
promonocytic U937 cells (macrophages), with PEG-PLGA NPs compared to PLGA NPs 
(as used here) (Rojnik, M. et al. 2012).  It was proposed that these results demonstrated the 
stealth-like properties of PEG-PLGA NPs, owing to the reduction of m-THPC fluorescence 
observed in all cells line, and particularly in phagocytotic cells (U937), compared to PLGA 
NPs.  Furthermore, the faster initial release rate of m-THPC from pegylated PLGA NPs 
into the cell medium may have contributed to the loss in intracellular fluorescence 
observed through FACS.  However, it should be noted, fluorescence measurements for m-
THPC in these studies were recorded at wavelengths of λexc = 488 nm, λem = 670 nm, 
which is far from optimum for m-THPC (λexc = 423 nm, λem = 652 nm). 
 
Ex vivo: polymeric m-THPC uptake 
Confocal microscopy images of freshly excised ex vivo rat liver tissue were taken 
following 0.3 mg kg-1 intravenous administration of m-THPC in either PEG-PLGA or 
PLGA NPs (Fig 5.9) at 24 h in order to determine m-THPC distribution through 
fluorescence.  m-THPC fluorescence appeared to be localised in the cytoplasm of large 
hepatocytes due to the presence of a dark nucleus.  Fluorescence was detected as discrete 
bright yellow spots, suggesting uptake into lysosomal-endosomal compartments, which 
may affect the site and efficacy of photoactive damage.  As previously discussed, this is 
likely to have been on account of their size, which has shown to strongly affect stealth 
properties and macrophage uptake in vitro (Yu, S. S. et al. 2012).  Despite their larger size, 
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PLGA NPs (~150-180 nm), no detectable m-THPC uptake was observed in liver 
macorphages (Kupffer cells), which reside between hepatocytes, in comparison to smaller, 
non-biodegradable ORMOSIL NPs (~20-100 nm) discussed in Chpt 6: ORMOSIL.  This 
could be due to the biodegradable nature of polymeric NPs.  The fluorescence signal is 
generally weak in confocal images, with a yellow fluorescence observed for m-THPC, 
rather than red.  This could also be on account of the strong green autofluorescence of liver 
tissue itself.  The presence of m-THPC appears to be slightly greater with PEG-PLGAs 
compared to PLGA NPs in the liver at 24 h, however, these differences may be due to the 
confocal technique whereby fluorescence images depict a single plane of tissue (non-
stacked).  This produces a less powerful signal than fluorescence microscopy, which is 
cumulative for the depth of the tissue section. 
 
Polymeric m-THPC biodistribution in vivo: normal tissue 
m-THPC biodistribution was assessed by chemical extraction following complete 
dissolution of whole tissues and through fluorescence microscopy of frozen tissue sections 
at 24 h and 72 h following i.v. administration of 0.3 mg kg-1 m-THPC in either Foscan, 
PLGA and PEG-PLGA NPs.  The average ~150 nm size of each NP aimed to target 
tumour tissue through passive accumulation via the EPR effect and promote NP 
internalisation into tumour cells (Maeda, H. et al. 2000).  The addition of PEG polymer 
chains further aimed to prolong the blood circulation time of m-THPC-loaded NPs by 
preventing the adhesion of opsonins to the NP surface and discourage their removal 
through circulating macrophages (Whelpton, R. et al. 1996).  Despite these predictions, 
chemical extraction results showed there was no detectable trace of m-THPC-loaded PEG-
PLGA NPs in the blood serum by 72 h in comparison to PLGA NPs and Foscan (Fig 5.8).  
However, at both 24 and 72 h PLGA NPs demonstrated a greater retention in the blood 
serum, superseding that of Foscan by almost six-fold.  This may have been due to the high 
initial burst release rate of m-THPC observed from PEG-PLGA NPs.  Rojnik et al., 
indicated a difference of almost 23% drug loading between PLGA NPs at 24 h regardless 
of similar loading efficiencies (~6.7-6.9%) (Rojnik, M. et al. 2012).  
 
Liver/spleen/lungs 
The greatest uptake of Foscan (m-THPC) was observed in the liver and in both the liver 
and spleen for polymeric NPs at 24 h.  This is concordant with previous studies presented 
in this investigation with biodegradable liposomal m-THPC (Chpt 4), which illustrates that 
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although the surface PEG coating can reduced the rate of NP/m-THPC uptake into these 
tissues, it does not completely prevent it (Zamboni, W. C. 2005).  However, despite a 
much greater initial uptake of m-THPC-loaded polymeric NPs in the lungs and spleen at 24 
h, m-THPC appears to be cleared from the lungs, liver and spleen at a much faster rate 
when non-covalently incorporated in polymeric NPs than Foscan.  A significant reduction 
in m-THPC concentration of approximately three-fold was observed in these organs 
between 24-72 h, whereas Foscan remained at similar concentrations in the lung and spleen 
over this period (Fig 5.8).  As demonstrated with m-THPC-loaded liposomes (Chpt 4), the 
biodistribution of m-THPC in the lungs correlated closely to that of the blood serum.   
 
False coloured fluorescence CCD microscopy images corresponded to chemical extraction 
data, with the greatest m-THPC uptake observed in the liver, lung and spleen at 24 h (Fig 
5.13).  Intense bright fluorescence spots, suggestive of high m-THPC uptake were 
observed at the greatest number in these organs.  Fluorescence was predominantly 
observed in the connective tissue, epithelium and capillaries of the lung and around the 
blood vessels in the liver and remained high over 72 h with PLGA NPs compared to PEG-
PLGA NPs and Foscan (Fig 5.14).  m-THPC accumulation is generally harder to determine 
in spleen tissue due to the difference in fluorescence properties of red and white pulp 
(splenic cords) (Bourdon, O. et al. 2002) but frozen sections appeared to show m-THPC 
fluorescence throughout the spleen, as concentrated bright spots, and uptake was greater 
for both m-THPC-loaded PLGA NPs compared to Foscan.  High m-THPC uptake into 
these organs is likely due to the high number of macrophages that reside in these tissues 
(Li, S. D. et al. 2008), however, specific intracellular uptake could not be determined from 
these studies.  The proinflammatory effects of these particles has been determined by Segat 
et al., who showed moderate capture of PLGA-NPs by different types of leukocytes and 
the effects of pegylation on monocytic uptake gradually diminish over long incubation 
times (Segat, D. et al. 2011).  
 
Kidneys 
Chemical extraction data for Foscan uptake in the kidneys reflected m-THPC fluorescence 
observed in frozen kidney tissue sections at 72 h (Fig 5.8).  A greater concentration of 
Foscan was observed in the kidneys and a high level of m-THPC fluorescence was 
distributed around the glomeruli at this time, compared to PLGA and PEG-PLGA NPs.  m-
THPC’s hydrophobicity promotes strong serum protein binding and its transformation into 
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hydrophilic liver metabolites (Li, S. D. et al. 2008).  However, results indicate possible 
excretion or partial entrapment of Foscan via the kidneys by 72 h (Fig 5.14), which show 
the highest concentration of m-THPC in comparison to other tissues.  It is unclear as to 
why Foscan concentrations in the kidney should increase over this time (24-72 h).  Renal 
filtration cutoff size has been suggested at 5.5 nm (Choi, H. S. et al. 2007) but with bulky 
serum protein binding m-THPC molecules may become trapped.  Furthermore, cell of the 
RES also reside in the kidneys therefore m-THPC maybe phagocytosed at this site.  
Polymeric NPs used in this study are much larger (~150 nm) and have shown to double in 
size in the presence of serum proteins (Segat, D. et al. 2011).  On account of their size, it is 
more likely particles are cleared via the hepatobiliary (liver and bile) pathway, passing 
through the colon.  Unfortunately no m-THPC biodistribution data for the intestine or 
colon was taken to confirm hepatobiliary excretion of NPs.  By 72 h, biodegradable 
polymeric particles are also likely to have degraded significantly into biologically benign 
components and excreted from the body (Choi, H. S. et al. 2007).  However, it was not 
possible to facilitate the collection of urine or fecal samples.  Collaborators carrying out in 
vivo bioluminescence imaging studies to determine m-THPC biodistribution of m-THPC-
loaded PLGA and PEG-PLGA NPs, following their intravenous administration (0.3 mg kg-
1) into mice, showed little difference between the delivery systems but a greater m-THPC 
uptake in the colon was observed with NPs compared to Foscan.  Unlike here, however, 
this m-THPC distribution pattern was also reflected in the kidneys.  Differences between 
results were attributed to differences in experimental technique, such as quantitative versus 
qualitative measurements of m-THPC and background autofluorescence of tissues from 
endogenous flavoproteins when imaging (Rojnik, M. et al. 2012). 
 
Skin 
Chemical extraction data indicated a greater uptake of m-THPC loaded polymeric NPs in 
the skin at both 24 and 72 h following intravenous administration in comparison to Foscan 
(Fig 5.8).  These concentrations appeared to be retained over a 72 h period for all m-THPC 
formulations.  This may indicate a slow terminal elimination rate from skin tissue that 
cannot be ascertained over this short time series.  Alternatively, fluorescence 
measurements taken of extremely low m-THPC concentrations may reach the detection 
limit of this system. 
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Polymeric m-THPC uptake in vivo: tumour tissue 
In tumour tissue an increase in m-THPC uptake was observed with both PLGA NPs of 
more than two-fold in comparison to Foscan at 24 h.  By 72 h, m-THPC in PLGA NPs 
remains significantly higher than Foscan, by approximately four-fold, whereas PEG-PLGA 
m-THPC concentrations fall to similar levels as Foscan (Fig 5.8).  This possible retention 
of PLGA NPs versus PEG-PLGA NPs at 72 h in the tumour may be on account of their 
~30 nm size difference (Rojnik, M. et al. 2012;Segat, D. et al. 2011).  Also m-THPC-
loaded PLGA NP concentrations in this blood at this time also remain elevated but are 
undetectable for PEG-PLGA NPs.  As previously discussed, it is thought an increased 
blood circulation time increases the probability of NPs reaching target tumour tissues to 
deliver m-THPC, where they are able to passively accumulate through the EPR effect in 
vivo.  Their retention in the tumour parenchyma may also promote intracellular 
internalisation of either intact particles or released drug (Liu, D. et al. 1992;Nagayama, S. 
et al. 2007).   
 
Quantitative chemical extraction measurements do not provide information on the 
distribution and retention of m-THPC throughout tumour tissue, only as a whole organ.  
Fluorescence microscopy was employed to image frozen tumour sections following 
administration of each m-THPC formulation.  A greater fluorescence intensity was 
observed at 72 h (Fig 5.14) for all m-THPC formulations in comparison to 24 h (Fig 5.13) 
in tumour tissue, but noticeably more with PLGA NPs, which corresponded to chemical 
extraction data at this time.  Unfortunately, in comparison to other selected tissues (liver, 
lung, spleen, kidney), tumour tissue demonstrated the lowest m-THPC fluorescence for all 
m-THPC formulations at these times.  However, the heterogeneity of tumour tissue may 
create difficulty in interpreting m-THPC fluorescence. 
 
PDT 
A significant reduction in dark cytotoxicity was reported in vitro with the same pegylated 
and m-THPC-loaded PLGA NPs by collaborators, in comparison to Foscan in A549 cells 
(Rojnik, M. et al. 2012).  Following irradiation with red light (600-700 nm), these cells 
demonstrated a similar phototoxic effect for both Foscan and PEG-PLGA NPs, despite a 
50% reduction in intracellular m-THPC availability with pegylated PLGA NPs.  It was 
concluded that m-THPC delivery via PEG-PLGA NPs resulted in complete conversion of 
particle aggregates into highly photoactive monomers, compensating for the reduction in 
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cellular uptake (Rojnik, M. et al. 2012).  These results were in good agreement with other 
groups showing an enhanced photodynamic activity of meso-tetra(4-
hydroxyphenyl)porphyrin and verteporfin incorporated in PLGA NPs compared to free PS 
(Konan-Kouakou, Y. N. et al. 2005); (Konan, Y. N. et al. 2003). 
 
PDT studies were developed further here with the same PLGA NPs in MC28 subcutaneous 
rat tumours in vivo using 10 J of light at 100 mW following a dose of 0.3 mg kg-1 m-THPC 
equivalent.  Unlike in vitro studies, despite an observed increase in m-THPC tumour 
uptake with both PLGA and PEG-PLGA NPs in comparison to Foscan at both 24 and 72 h 
through biodistribution studies (Fig 5.8) there was no significant difference detected in 
tumour PDT efficacy between each m-THPC formulation at the same selected drug:light 
intervals in this model (Fig 5.16).  Low to negligible levels of necrosis observed in control 
animal tumours were attributed to the development of necrotic cores (hypoxia) from 
untreated, growing tumours or the small incision made to insert the laser fibre into the 
tumour capsule.   
 
PDT results may have been due to limitations of this tumour model, as the maximum 
percentage area of necrosis capable of inducing was 50-60%.  A resistance to PDT of the 
outer tumour capsule has been reported by other groups, which would have significantly 
reduced the total percentage of tumour necrosis (Berg, K. et al. 2011).  It has been 
suggested by Desgrosellier et al., that invading fibroblasts, recognised as promoting the 
growth of fibrous tissue (desmoplasia) during tumour progression, deposit large amounts 
of collagen that might result in resistance to therapy in some tumours (Desgrosellier, J. S. 
et al. 2010).  Alternatively, differences in the subcellular distribution of m-THPC when 
delivered by polymeric NPs versus Foscan at 24 or 72 h may affect photodynamic potential 
on account of differences in the route of entry and subsequent m-THPC localisation inside 
the cell.  For example, Foscan has been shown to preferentially localise around the 
endoplasmic reticulum (ER) and Golgi apparatus (Compagnin, C. et al. 2009;Compagnin, 
C. et al. 2011) whereas Rojnik et al., demonstrated accumulation of m-THPC in 
lysosomal-endosomal compartments as a result of internalisation via clathrin dependent 
endocytosis with PLGA and PEG-PLGA NPs (Rojnik, M. et al. 2012).  Despite these 
temporal differences, Rojnik and co-workers also showed intense m-THPC fluorescence in 
the same subcellular locations as Foscan (ER and Golgi) at shorter NP incubation periods, 
attributed to the high initial ‘burst release rate’ of m-THPC observed from polymeric NPs.  
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This may have accounted for the similarities observed in PDT efficacy between polymeric 
NPs and Foscan observed here at 24 h in vivo.  Earlier DLIs (<24 h) were not selected for 
treatment due to concerns regarding initial rapid release of m-THPC from NPs potentially 
causing predominant vascular PDT damage in vivo.  Furthermore, slow degradation rates 
of polymer NPs indicated by Jain et al., required longer DLIs to ensure total release of m-
THPC from fully degraded NPs intracellularly following uptake (Jain, R. K. et al. 2010).  
At a longer DLI of 72 h, there was a trend or a slight increase in the percentage of PDT 
tumour necrosis induced with both PLGA and PEG-PLGA NPs in comparison to Foscan, 
however, it was not significant.  This longer incubation period in vivo may have also 
favoured preferential m-THPC-NP uptake at the tumour site i.e. parenchyma (neoplastic 
cells) and/or stroma (non-malignant cells), compared to 24 h.   
 
Although differences in PDT efficacy between m-THPC formulations were not significant, 
these findings create promise for the application of these polymeric nanoparticles as PDT 
agents, as they are able to exert the similar phototoxic effects to tumour tissue as Foscan.  
This shows that m-THPC is able to reach tumour tissue following it encapsulation in 
polymeric NPs and is released into its photoactive form for effective PDT.  This is 
encouraging given these are the first in vivo PDT studies to be carried out with PLGA NPs 
to our knowledge. 
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5.5 Conclusion 
The primary objective of the work described in this chapter was to investigate the uptake 
of m-THPC in vivo following intravenous administration of either non-pegylated or 
pegylated poly(lactic-co-glycolic acid) (PEG-PLGA) m-THPC-loaded NPs in comparison 
to standard Foscan.  Non-covalent incorporation of m-THPC into polymeric NPs aimed to 
increase their longevity in the blood circulation by preventing rapid uptake into the RES to 
improve delivery of m-THPC to tumour tissue and enhance PDT efficacy.  Quantitative 
chemical extraction and qualitative fluorescence microscopy were employed to 
demonstrate the biodistribution of m-THPC in selected tissues and fluorescence lifetime 
measurements were carried out on intact ex vivo tissue to determine the presence of m-
THPC self-quenching.  An increase in m-THPC uptake was observed in tumour tissue 
following its encapsulation in PLGA NPs over a 72 h period compared to Foscan; 
however, this was not reflected in PDT results.  Despite observing no significant difference 
in PDT efficacy between m-THPC formulations these results create promise for the 
application of polymeric nanoparticles as PDT agents, as they demonstrated an equal level 
of phototoxicity to tumours in vivo as Foscan.  This is encouraging given these are the first 
in vivo PDT studies to be carried out with PLGA NPs to our knowledge.  Although 
limitations may exist in the in vivo tumour model adopted here, the selectivity of this 
delivery system, and hence PDT, could be further improved following the conjugation of 
active biological molecules to the NP surface that are capable of specifically recognising 
receptors over-expressed on tumour cells. 
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6. Organically Modified Silica Nanoparticles 
6.1 Introduction 
Untargeted ORMOSIL NPs 
Human populations have long been exposed to non-biodegradable or partially 
biodegradable nano-sized components from a variety of sources including aerosols, dust, 
smoke, soot and pollen, which behave like foreign matter in the body.  Non-biodegradable 
nanocarriers have been investigated for biomedical applications due to a number of 
advantageous characteristics; their usage extends to drug or gene delivery vehicles, 
imaging agents and diagnostic tools.  However, problems associated with bioelimination 
and potential toxicity, as a result of their lack of degradation, have led to long-term health 
concerns.  Presently, the degree to which they cause harmful side effects has yet to be fully 
understood or established and is perhaps considered a fundamental requisite for any in vivo 
study with these nanocarriers for translation into the clinic.  
 
Many non-biodegradable nanocarriers have been synthesised from a diverse range of 
materials for applications in biomedicine and each carry their own unique properties; these 
include, metallic NPs, such as gold (Au) and silver (Ag), carbon nanotubes (CNs), 
quantum dots (QDs), ceramic and silica NPs, which have been touched upon in early 
chapters (Chapter 2: Nanotechnology).  Here, we explore the use of silica as a non-
biodegradable nanocarrier.  Silica is an abundant natural compound existing in both 
crystalline and non-crystalline (amorphous) forms (Tavano, R. et al. 2010).  The latter 
occurs naturally and can be synthesised commercially through polymerisation of silicates 
and other inorganic precursors under controlled conditions to produce silica NPs.  Silica 
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NPs are used in a host of industrial practices, from food manufacturing to additives in 
chemical processes (Barik, T. K. et al. 2008).  More recently they have received increased 
attention for their doping capabilities (with organic molecules) for use in therapeutic 
applications. 
 
Owing to their robustness, multimodality and ease of manipulation, silica NPs offer 
distinct advantages over molecular agents.  These include (i) synthesis of an extensive 
range of physical and chemical properties (size, shape, charge, porosity, monodispersity), 
(ii) morphological and chemical stability in extreme environments (pH and temperature), 
(iii) loading and protection of both hydrophilic and lipophilic agents, (iv) controlled release 
of molecules through their porous structure (v) tailored entrapment of monomeric 
molecules (vi) multi-loading of different agents (vii) better control over material 
characteristics (Chatterjee, D. K. et al. 2008a;Paszko, E. et al. 2011;Qian, J. et al. 
2011;Shan, Y. et al. 2011).  Furthermore, these NPs can be modified at their surface to 
improve functionality, such as the incorporation of PEG groups to improve biodistribution 
and the addition of targeted biomolecules for enhanced selectivity. 
 
Figure 6.1. (A) mesoporous silica matrix (B) ~20 nm pegylated organically modified silica (ORMOSIL) 
nanoparticles.  Diagram provided by University of Padova, Italy (Selvestrel, F. et al. 2013). 
 
Organic/inorganic silica hybrid materials have been termed ‘ormocers’ (Schmidt H 1985), 
‘ceramers’ (Wilkes, G. L. et al. 1985) and, more recently ‘ORMOSILs’; ORganically 
MOdified SILica.  A variety of alkylsilane and alkoxysilane precursors have been studied, 
which constitute the fundamental components of these hybrid materials, as they are 
amenable to surface modifications on account of their functional groups (Finnie, P. et al. 
2000;Ulman, A. 1996).  Inorganic and organic groups are connected to Si atoms through –
O-Si-C≡ bonds forming a porous, cross-linked network or a wormhole-like silica matrix 
structure (Sharma, R. K. et al. 2004) (Fig 5.1A).  The addition of these organic moieties to 
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the silica (ORMOSIL) increase its versatility, as different organic components can be 
selected during the production process to synthesise NPs with the desired physical and 
chemical characteristics. 
 
The hydrolysis and polycondensation of organically modified alkoxysilanes, such as vinyl 
triethoxysilane (VTES) conjugated with PEGamine (biocompatible polymer), form 
spherical pegylated ORMOSIL NPs with improved physiochemical and stealth properties 
(Sharma, R. K. et al. 2004) (Fig 6.1B).  Owing to the presence of lipophilic organic groups 
at their core, active hydrophobic molecules can be housed in the interior of ORMOSIL 
NPs, with the potential to form electrostatic complexes with surface ligands on their 
exterior (Diksha et al. 2012).  Particle size can be controlled very precisely, achieving 
narrow size distributions, while still maintaining monodispersity (Dash, S. et al. 2008).  
The mechanical properties, such as hardness and elasticity, can also be tailored by varying 
the degree of alkylation of organosilane precursors (Dash, S. et al. 2008).  Furthermore, 
these ORMOSIL materials are porous and have a tuneable pore size (Box 6.1); making 
them suitable for drug delivery. 
 
Box 6.0. (above) The porosity nomclamenture of a material as stipulated by the International Union of Pure 
& Applied Chemistry (IUPAC). 
 
As a result, ORMOSIL NPs have been used to encapsulate a host of active molecules.  
Reetz et al., immobilised lipase in ORMOSIL of various compositions, observing an 
increase in enzyme activity (Reetz, M. T. et al. 1996).  Delivery of plasmid DNA in 
ORMOSIL NPs as non-viral vectors was demonstrated by Kneuer et al., (Kneuer, C. et al. 
2000).  In the controlled delivery of hydrophobic chemotherapeutic agents, such as 
doxorubicin, Diksha et al., illustrated these anti-cancer drugs could be activated by 
external release factors in vivo (Diksha et al. 2012). 
 
Toxicity 
Silica, as a bulk material, is reported as being biologically inert, however as with many 
materials, its behaviour at the nanoscale level has not yet been established.  Despite silica 
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NPs exhibiting ideal attributes for biomedical applications within in vivo environments; 
such as their monodispersity, lack of precipitation and enhanced biodistribution (Kumar, R. 
et al. 2010), their non-biodegradability causes concern for clinical translation, as these NPs 
cannot be broken down into biologically benign components.  These concerns are largely 
due to the lack of understanding on clearance mechanisms and little available data on the 
potentially harmful long-term effects (>15 d) of silica NP accumulation in the body or 
successive accumulation from repeated doses.  Studies illustrating a renal threshold of 5.5 
nm (Choi, H. S. et al. 2007), suggests the route of clearance is size dependent and the only 
other major route of excretion for non-biodegradable NPs of a larger hydrodynamic 
diameter is the hepatobiliary pathway; via the liver, into bile and faeces.  This is a much 
slower and inefficient process, increasing the exposure-time curve and the likelihood of 
toxicology from adverse side-effects and the creation of tissue abnormalities.  In addition, 
despite dense PEG layers preventing capture and uptake in the liver (RES) to increase the 
blood circulation half-life and therapeutic bioavailability, it may also preclude NPs from 
elimination.  Furthermore, it has been suggested that the retention of some NPs in the body 
could potentially affect other future medical tests (Choi, H. S. et al. 2007).   
 
Applications in PDT 
Important considerations must be taken into account for applications in PDT whereby the 
active photosensitiser molecule is retained in non-biodegradable nanocarriers.  ORMOSIL 
NPs possess specific characteristics ideal for use in PDT (Table 6.1).  Firstly, these NPs are 
transparent therefore allow the transmission of light through the particle surface for 
irradiation and activation of internalised photosensitiser.  Secondly, the size, shape and 
porous structure of the ORMOSIL NP can be exquisitely controlled, allowing the diffusion 
of molecular oxygen into the silica matrix and release of singlet oxygen species out in 
order to elicit phototoxic damage.  Thirdly, the hydrophobic photosensitiser (PS) may be 
incorporated monomerically within the silica shell without drastically altering its structure 
through chemical modification, thereby maintaining its spectrofluorimetric properties and 
singlet oxygen quantum yield.  Lastly, the surface of these NPs can be functionalised with 
biomolecules to further enhance the uptake into cancer cells.  Each of these parameters can 
be manipulated for optimised biodistribution and phototoxicity efficacy (Brevet, D. et al. 
2009); (Zhang, C. et al. 2007).  
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Photosensitisers may be incorporated into ORMOSIL NPs through different mechanisms 
(Chatterjee, D. K. et al. 2008a).  Physical entrapment of the photosensitiser, involves 
immobilisation through non-covalent interactions.  The photosensitiser resides either 
within pores or the silica shell itself and has been achieved by numerous research groups 
using different photosensitisers.  Primary examples included the physical incorporation of 
the photosensitiser, 2-(1-hexyloxyethyl)-2-devinyl pyropheophorbide (HPPH), a PS in 
Phase II clinical trials for oesophageal cancer, into ~30 nm ORMOSIL NPs by Roy et al., 
(Roy, I. et al. 2003).  It was hypothesised that HPPH was encapsulated monomerically and 
the porosity of the silica matrix allowed for the diffusion of oxygen molecules based on the 
ability of the NPs to produce an effective singlet oxygen quantum yield.  Photophysical 
studies with meta-tetra(hydroxyphenyl)chlorin (m-THPC) (Chapter 1: Introduction) in 
non-pegylated silica NPs of ~180 nm by Kopelman et al., in the same year showed there 
was no difference in the fluorescence spectra/intensity of embedded m-THPC and a 
positive effect on singlet oxygen production was observed in comparison to free m-THPC 
(Yan, F. et al. 2003).  The same group encapsulated Methylene Blue (MB), an FDA 
approved photosensitiser, in ORMOSIL NPs of ~160 nm, which produced lower singlet 
oxygen yields that other NPs (Tang, W. et al. 2005).  This was attributed to the 
microenvironment in the double shell ORMOSIL matrix.  In vitro studies in human 
oesophageal squamous carcinoma (KYSE 510) with physically entrapped monomeric m-
THPC in pegylated ORMOSIL NPs of ~30 nm showed low dark toxicity but a strong 
leaching effect (90% m-THPC) in the presence of serum proteins (3%) after 50 mins 
incubation (Compagnin, C. et al. 2009).  It was also determined that there was no 
difference in the subcellular localisation of encapsulated m-THPC versus free m-THPC as 
a result, as serum-m-THPC complexes had formed at the NP surface prior to 
internalisation.  However, the presence of surface PEG groups largely prevented this 
transfer to serum proteins.  Investigations with the photosensitiser phthalocyanine Pc4 
encapsulated in 25 nm ORMOSIL NPs (Zhao, B. et al. 2009) showed encapsulation 
increased the aqueous solubility/stability and delivery of the hydrophobic photosensitiser, 
whilst significantly enhancing the PDT efficacy of Pc4 (through Type II mechanisms) 
following 22.5 J cm2 of light between 600 and 700 nm in vitro in both non-pigmented 
human melanoma (A375) and pigmented mouse melanoma (B16F10) cell lines in 
comparison to free photosensitiser.  Various research groups have used the natural 
photosensitiser protoporphyrin IX, (PpIX) a precursor to haem synthesis, physically 
entrapped in ORMOSIL NPs in vitro in multiple cancer cell lines, including breast, colon, 
6. Organically Modified Silica Nanoparticles 
180 
lung, epidermoid and lymphoblastoid (Qian, J. et al. 2012;Shan, L. 2004;Simon, V. et al. 
2010).  These NPs ranged from ~10-60 nm and a high uptake was preferentially seen in 
some cancer cell lines over others, but all demonstrated greater cellular uptake than free 
PpIX alone.  PDT with these NPs in vitro produced high levels of ROS causing large levels 
of cellular damage.  The same PpIX silica NPs loaded with a tracer dye were used for 
optical imaging in vivo in tumour-bearing nude mice, implanted with either human colon, 
lung or glioblastoma multiforme tumours subcutaneously, to monitor and quantify their 
biodistribution in tissues.  A high tumour uptake was demonstrated in relation to normal 
tissues but maximal accumulation was dependent on the tumour cell line implanted.  High 
accumulation was also observed in the liver, spleen, lungs and lymph nodes of these 
animals following intravenous tail vein injection (Simon, V. et al. 2010).  Studies in nude 
mice xenografted with subcutaneous-Hela tumours were used for in vivo near-infrared 
imaging and PDT studies following an intratumoral injection of MB entrapped in 
ORMOSIL NPs of ~105 nm.  12 hours post injection tumours were exposed to 5 min of 
continuous 635 nm light at 500 mW cm-2.  10 days post-PDT signs of gradual tumour 
necrosis appeared (He, X. et al. 2009). 
 
Problems associated with photosensitiser leaching and premature release of drug loads 
from NPs, particularly in the presence of serum proteins (Compagnin, C. et al. 2009), 
leading to loss of therapeutic bioavailability, reduced efficacy of treatment and side-
effects, has prompted research into other means of incorporating molecules within 
ORMOSIL NPs.  As PDT does not require release of the drug to elicit type I or type II 
phototoxic effects, covalent coupling of photosensitisers inside the silica matrix of 
ORMOSIL NPs has been proposed and performed in an attempt to overcome these 
drawbacks (Couleaud, P. et al. 2010).  Initial concerns on the potential physiochemical 
changes covalent anchorage may induce to the photosensitiser, in terms of reducing its 
spectrofluorimetric properties, singlet oxygen yield, phototoxicity and ultimately PDT 
efficiency were soon alleviated, as discussed below. 
 
Various photosensitisers have been covalently incorporated within silica NPs.  Depending 
on the properties of the silica and/or the PS, covalent bonding can be achieved through 
spacers, linkers (Ohulchanskyy, T. Y. et al. 2007) or coupling (Rossi, L. M. et al. 2008).  
Covalent linking of PpIX in larger silica NPs of 110 nm for PDT studies was demonstrated 
by Mou et al., (Tu, H. L. et al. 2009).  It was shown aggregation and self-quenching of 
PpIX could be avoided due to site-isolation of the PS in the porous structure of the NPs, as 
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there was no change in the absorption spectrum from free PpIX.  Following this, in vitro 
studies found a linear relationship between cellular uptake and NP dosage.  Further studies 
in vitro entrapping metalloporphyrins (Cheng, R. J. et al. 2003), porphyrin derivatives 
(Hocine, O. et al. 2010) , chlorins (Couleaud, P. et al. 2010) and merocyanine (Brevet, D. 
et al. 2009) in silica NPs have shown no influence of covalent incorporation of PS on 
singlet oxygen yield and spectroscopic properties, with some studies noting an increase in 
phototoxic activity with NP delivery in comparison to free PS (Zhao, B. et al. 2009).  This 
is thought to be due to intracellular localisation, in particular, the strong association with 
lysosomes which localises the effect of generated ROS (Zhao, 2009). 
 
Prasad et al., were the first to demonstrate the covalent incorporation of PS molecules 
within ORMOSIL NPs (pegylated) (Ohulchanskyy, T. Y. et al. 2007).  Using a water 
microemulsion and the organosilane precursor VTES they were able to produce a 
monodispersed aqueous dispersion of ultralow size (~20 nm) ORMOSIL NPs with 
covalently linked PS (iodobenzylpyropheophorbide), whilst retaining the spectroscopic and 
functional capabilities of the PS.  In vitro studies (colon-26 cells) with these NPs exhibited 
a phototoxic effect which was positively correlated to the increased loading of PS within 
the ORMOSIL NPs and their cellular uptake.  100% cell kill was observed following 24 h 
incubation with 0.5 µM of PS-ORMOSIL NPs and irradiation with 8 J cm2 of light.  
Subsequently these ORMOSIL NPs have been studies in vivo for bioimaging, 
biodistribution, clearance and toxicity studies (Kumar, R. et al. 2010).  Further 
investigations revealed the greatest uptake of the covalently incorporated fluorophore, 
DY776, in ~20 nm ORMOSIL NPs was observed in the liver, spleen and stomach of mice 
through PS fluorescence and microPET imaging every 24 h for up to 15 days following i.v. 
administration.  The hepatobiliary excretion pathway was proposed as the predominant 
clearance route and no toxicity was identified through histological analysis of tissues.  
However, no further in vivo PDT studies were carried out with these ORMOSIL NPs.  
Many groups have now focused on using multi-modal silica NPs for different platforms.  
Silica NPs functionalised with bioactive molecules (i.e. transferrin, monoclonal Abs) and 
covalently incorporated fluorophores, have been reported for simultaneous imaging and 
therapy (Kumar, R. et al. 2008), in addition to NPs incorporating PpIX for PDT and 
undergoing two-photon irradiation for bioimaging (Qian, J. et al. 2012).  Silica NPs with 
magnetic cores and PS embedded in their shells have been illustrated for MRI imaging in 
diagnostic applications and PDT by Lai et al., (Lai, C. W. et al. 2008). 
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Table 6.1. Summary of silica-based NPs for PDT applications.  Taken from (Couleaud, P. et al. 2010).
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m-THPC is a hydrophobic molecule, which aggregates in aqueous environments, 
hampering its phototoxic activity.  Researchers have shown there was no difference in the 
fluorescence spectra of covalently embedded m-THPC in photophysical studies with m-
THPC physically entrapped (non-covalent) in silica NPs.  Additionally, a positive effect on 
singlet oxygen production was observed in comparison to free m-THPC (Yan, F. et al. 
2003).  However, following its physical entrapment in ORMOSIL NPs (Fig 5.2 A), m-
THPC showed a strong tendency to transfer to serum proteins on the NP surface and as a 
result was heavily leached from ORMOSIL NPs in vitro (Compagnin, C. et al. 2009).  
Although this was largely prevented by the addition of PEG groups on the NP surface, its 
premature leakage is likely to lead to loss of bioavailability, reduced phototoxicity at the 
target site of action and a lowered therapeutic index on account of greater administered 
doses required to exert phototoxic effects in vivo. 
 
 
Figure 6.2. Schematic diagram (A) non-covalently incorporated m-THPC (red) and ORMOSIL groups 
(black) (B) Covalent monosilane m-THPC (C) Covalent tetrasilane m-THPC.  Diagram provided by 
University of Padova, Italy (Selvestrel, F. et al. 2013). 
 
Covalent incorporation of m-THPC into microporous (<2 nm) organically modified silica 
nanoparticles (ORMOSIL NPs) was therefore proposed here (Table 6.4) in order to prevent 
premature m-THPC leakage and facilitate its delivery into target cancerous tissues 
following systemic intravenous injection in vivo.  Mono-silane (Fig 6.2 B) or tetra-silane 
(Fig 6.2 C) linkers were used to covalently anchor m-THPC within small (≤20 nm) or large 
(≥90 nm) ORMOSIL NPs.  Photophysical studies by collaborators who provided 
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untargeted ORMOSIL NPs used here (Dr F Mancin et al.,) showed the silica matrix did not 
significantly deactivate singlet oxygen production from covalently embedded m-THPC 
(Selvestrel, F. et al. 2013).  This suggests key ROS molecules are able to diffuse out of the 
NP to elicit phototoxic damage.  The outer surface of the NP was modified with densely 
packed PEG chains (e.g. PEG2000) to increase stability and prevent rapid clearance by the 
RES (Fig 6.3). 
 
 
Figure 6.3. m-THPC loaded pegylated organically modified silica nanoparticles.  Diagram provided by 
University of Padova, Italy (Selvestrel, F. et al. 2013). 
 
Targeted cRGD-ORMOSIL NPs 
The selectivity of drug molecule uptake into specific tissues has long been an outstanding 
issue in the treatment of disease and the focus of much research.  In the field of oncology, 
addressing this issue is imperative in aiming to reduce drug-associated side effects and 
improving therapeutic efficacy (therapeutic index), in the monitoring, diagnosis and 
treatment of cancer, whilst simultaneously reducing cost.  Through the encapsulation of 
therapeutics and imaging agents, nanotechnology has provided a promising platform in 
which to improve cancer targeting applications by increasing the half-life of circulating 
molecules for passive uptake into tumours (EPR effect).  The opportunity to enhance 
uptake further through the surface engineering of nanocarriers, to preferentially seek 
tumour cells and minimise cytotoxicity to normal tissues, has been pursued over many 
years.  Various ligands, whose complementary receptors are over-expressed on the surface 
of cancer cells, have been targeted in order to exploit the active uptake mechanism into 
malignant cells.  These include transferrin, lectoferrin, lectin, folate, human growth factor 
(EGF, VEGF, TGF-β) receptors and scavenger, nuclear and integrin receptors (Mehra, N. 
K. et al. 2013).  Despite encouraging progress in the targeted delivery of therapeutics and 
positive treatment outcomes at preferential tissue sites, the development of safe, effective 
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and stable targeted therapeutics remains a challenging necessity.  ORMOSIL NPs were 
developed further for targeted studies in an attempt to further enchance tumour uptake and 
PDT efficacy by conjugating the cyclic RGD (Arg-Gly-Asp) peptide to the NP surface 
(Table 6.4), which has a known affinity for the integrin αVβ3 receptor overexpressed on a 
number of cancers.  
 
Integrin targeting 
The integrin are a family of cell adhesion receptors that span the lipid bilayer of cells and 
present themselves as heterodimeric glycoproteins on the cell surface.  They mediate 
adhesion to the extracellular matrix (ECM) and immunoglobulin (Ig) superfamily 
molecules, whilst promoting intracellular signalling.  Their repertoire consists of at least 24 
distinct integrin heterodimers formed by the combination of 18 α-subunits and 8 β-subunits 
(Desgrosellier, J. S. et al. 2010).  Specific integrin heterodimers preferentially bind to 
distinct ECM proteins and a given integrin expressed on a cell dictates the extent to which 
that cell will adhere to and migrate on different matrices.  This mechanism is essential for 
normal cellular progression and tissue growth, but in the case of tumour proliferation, 
provides the necessary means for invasion and migration of cancer cells (Box 6.1). 
 
 
 
Many solid tumours originate from epithelial cells and the integrins expressed by these 
epithelial cells are retained by tumours.  As a consequence, integrins are expressed on a 
wide variety of cancers to different degrees and have been attributed to disease progression 
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(Table 6.2) (Desgrosellier, J. S. et al. 2010).  Integrins αvβ3, α5β1 and αvβ6, are typically 
expressed at low or undetectable levels in most adult epithelia but can be highly up 
regulated in some tumours.  Conversely, some integrin expression, such as α2β1, can be 
down-regulated in tumour cells to increase tumour dissemination (Kren, A. et al. 2007).  
These properties can be exploited for the purposes of cancer therapy and in recent years 
have led to great progression towards the use of integrins as therapeutic targets and 
imaging biomarkers. 
 
Integrins have the ability to either enhance cell survival or induce apoptosis (e.g. p53 
inactivation) in order to maintain the integrity of tissues and prevent cells surviving in an 
improper environment.  This is achieved by drawing upon external environmental factors 
and through constant interaction with the ECM.  Furthermore, the activation of complex 
signal transduction cascades controlling cellular fate are dependent on integrin ligation, as 
ligated integrins relay survival signals and unligated integrins are able to promote 
apoptosis (Desgrosellier, J. S. et al. 2010). 
 
Tumour type Integrins expressed Associated phenotypes
Melanoma αvβ3 and α5β1 Vertical growth phase and lymph node metastasis
Breast α6β4 and αvβ3 Increased tumour size and grade and decreased survival (α6β4) 
Increased bone metastasis (αvβ3)
Prostate αvβ3 Increased bone metastasis
Pancreatic αvβ3 Lymph node metastasis
Ovarian α4β1 and αvβ3 Increased peritoneal metastasis (α4β1)                                      
Tumour proliferation (αvβ3)
Cervical αvβ3 and αvβ6 Decreased patient survival
Glioblastoma αvβ3 and αvβ5 Both are expressed at the tumour–normal tissue margin and 
have a possible role in invasion
Table 6.2. Selection of integrins involved in certain cancers.  Adapted from (Desgrosellier, J. S. et al. 2010). 
 
αv integrins were first identified on the basis of their ability to recognise the RGD (Arg-
Gly-Asp) peptide sequence (Pytela, R. et al. 1985) (Fig 6.4).  Integrin αVβ3 consists of two 
components, integrin alpha V and integrin beta 3 (endothelial cells: CD61), and has shown 
to augment tumour progression.  Integrin αVβ3 is able to regulate cell survival through 
crosstalk with fibroblast growth factor receptor (FGFR) via specific integrin-growth factor 
receptor pairing, which prevents cellular apoptosis through the intrinsic apoptotic pathway 
(Petitclerc, E. et al. 1999).  Targeting of this integrin with antagonists can help to promote 
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endothelial cell death.  In conjunction with integrin αVβ5 (crosstalk with vascular 
endothelial growth factor receptor 2, VEGFR2), integrin αVβ3 has been targeted with cyclic 
RGD pentapeptide, Cilengitide® (Merck KGaA), in Phase II clinical trials and has shown 
effectiveness in blocking tumour progression in the treatment of glioblastoma patients with 
few reported side effects (Mas-Moruno, C. et al. 2010). 
 
This cyclic RGD peptide (cRGD) demonstrated 100 to 1000 times increased activity over 
linear reference peptides and initial positive clinical findings led to the first Phase III 
clinical trial being conducted with an integrin antagonist.  However, in 2013 the trial 
suffered setbacks following disappointing late-stage results (500+ patients), as no 
significant increase in the overall survival of patients was found in comparison to the 
current standard chemo-radiotherapy regimen (i.e. temozolomide and radiotherapy).  This 
highlights the clinical importance of continued research into the role integrins and integrin 
antagonists play as tumour inhibitors. 
 
 
Fig 6.4. Targeted NPs used to deliver therapeutics to tumour tissues with greater efficacy following surface 
conjugation with RGD (Arg-Gly-Asp). Inset: cyclic RGD peptide.  Adapted from (Xu, J. et al. 2012). 
 
αVβ3 integrin: Applications in PDT 
Other early phase clinical trials with integrin antagonists (RGD peptide and monoclonal 
antibodies, mAbs) and preclinical studies have been comprehensively reviewed by 
(Avraamides, C. J. et al. 2008) and (Desgrosellier, J. S. et al. 2010), respectively.  RGD 
studies reviewed here will focus on integrin-targeted therapies for the delivery of 
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photosensitisers for applications in PDT (Table 6.3).  Photosensitiser (PS)–peptide 
conjugates have been developed as a targeting strategy against human umbilical vein 
endothelial cells (HUVEC) overexpressing αvβ3 integrin by conjugating a linear or cyclic 
RGD peptide (cRGD) to 5-(4-carboxyphenyl)-10,15,20-triphenylchlorin (porphyrin) 
(Frochot, C. et al. 2007).  The cellular uptake and phototoxicity of porphyrin was greatly 
enhanced following its conjugation to the RGD peptide in the HUVEC cell line, in 
comparison to free PS.  The internalisation of either PS conjugate (linear or cyclic RGD 
motif) was approximately 80 – 100 greater than porphyrin alone after 24 h.  Furthermore, 
despite a two-fold reduction in the quantum singlet oxygen yield produced by the RGD-
porphyrin conjugates, a greater phototoxicity against HUVEC cells was observed with the 
conjugated versus unconjugated porphyrin.  Some non-specific internalisation was detected 
towards the non-expressing αvβ3 integrin cell line, EMT-6, which was attributed to possible 
conjugate aggregation in the media, however, demonstrated no toxicity to cells (Frochot, 
C. et al. 2007).  An enhanced cellular accumulation was observed in a human cervical 
cancer cell line (SiHa) with similar cyclic RGD peptides conjugated to the PS, 
Protoporphyrin IX (PpIX); precursor to the haem biosynthesis pathway.  Pharmacokinetic 
analysis of PpIX-cRGD in vivo showed accumulation in the liver but significant retention 
of PpIX in tumour tissue, with 2-fold higher tumour: normal tissue ratios than the free PS 
following its administration into a CaNT mammary tumour mouse model (Conway, C. L. 
et al. 2008).  Unfortunately, this was not reflected in the overall in vivo PDT data, at dose-
light intervals of 0 and 6 h, as no significant difference between tumour PDT efficacy was 
observed with conjugated-PpIX versus free PpIX.  This was thought to be due to 
differences in the target environment or in the subcellular localisation of the compounds. 
 
Few studies have been carried out using RGD-targeted NPs incorporating photosensitisers 
for PDT applications in vitro.  Concerns with NP-ligand include the potential for 
denaturation of RGD peptide and other proteins i.e. mAbs, when bound to the NP surface.  
This can affect binding of the ligand to its receptor, increase non-specific interactions, 
promote the production of protein-NP aggregates or stimulate inflammation.  Selvestrel et 
al., has recently investigated cyclic RGD targeted to PEG-ORMOSIL NPs via a 
commercially available MBS (m-Maleimidobenzoyl-N-hydroxysuccinimide ester) 
crosslinker.  These RGD-NPs showed a higher uptake when incubated with HUVEC cells 
(overexpress integrin αvβ3 receptor) in comparison to identically prepared NPs conjugated 
with a control peptide, RAD, whereby the central glycine amino acid was substituted with 
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alanine to prevent integrin recognition and to eliminate the possibility of non-specific 
interactions.  Furthermore, cellular uptake increased with increasing NP surface coating of 
RGD peptide, from 15 to 30% (Selvestrel, F. et al. 2013).  In PDT studies with RGD-NPs, 
a significant reduction in cell viability was found following irradiation of cells, 
demonstrating their ability to induce a phototoxic effect with covalently embedded m-
THPC.  However, no difference in cell kill was observed between RGD and control RAD-
conjugated NPs.  Wang et al., encapsulated lipophilic ZnPc molecules in the hydrophobic 
layers of polymeric lipid micelles, which contained upconversion nanocrystals (NaYF4) at 
the central core.  The surface of these pegylated micelles was targeted with RGD and 
transmembrane peptide Tat and demonstrated a 60% reduction in MCF-7 (αVβ3–positive) 
cell viability with targeted micelles versus untargeted controls following PDT (Wang, H. et 
al. 2014). 
 
To our knowledge, no studies have yet been conducted with RGD-targeted agents in vivo 
for use in PDT but many studies have demonstrated the efficacy and biodistribution of 
RGD-targeted NPs loaded with chemotherapeutics in vivo, in particular liposomal 
doxorubicin (Chen, Z. et al. 2012;Kim, J. W. et al. 2004;Schiffelers, R. M. et al. 
2003;Xiong, X. B. et al. 2005c;Zhang, Y. F. et al. 2010).  Doxorubicin-loaded pegylated 
liposomes targeted with RGD showed a higher uptake and cytotoxicity in vitro in human 
A375 melanoma cells in comparison to free drug or untargeted liposomes and in vivo, 
biodistribution and therapeutic efficacy showed more effective tumour regression in B16 
tumour-bearing mice with RGD-targeted liposomes (Xiong, X. B. et al. 2005c).  In the 
same in vivo model, Zhang et al., demonstrated similar tumour regression following co-
encapsulation of doxorubicin with a vascular disrupting agent in RGD-modified liposomes 
(Zhang, Y. F. et al. 2010).  These results show promise for PS uptake with RGD-targeted 
nanoparticles proposed here.  
 
Despite multiple studies demonstrating the suitability of RGD as a targeting moiety for 
cancer treatment, it is important to consider the crucial, yet contradictory role integrins 
play in both tumour progression and the host’s cellular response to cancer.  For example, in 
addition to certain tumours, integrins are expressed on a vast number of endogenous cells, 
including endothelial cells, fibroblasts, pericytes, bone marrow-derived cells, inflammatory 
cells and platelets, which are involved in numerous host functions, such as angiogenesis 
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and desmoplasia, whilst also comprising a significant proportion of the immune system 
(Fig 6.5).   
 
Typically these integrins are expressed to a lower degree on mature vessels and although 
their presence on many of these cells types creates a greater application for potential 
therapeutic targets, it also raises concerns regarding uptake of RGD-targeted nanosystems 
into cells of the host’s immune system in vivo and associated toxicity.  Abundant 
similarities exist between inflammation and the progression of cancer.  For example,  at a 
tissue level, in both cases, a common phenomenon is the increased infiltration of 
leukocytes, such as neutrophils, macrophages and lymphocytes at the disease site (Maeda, 
H. et al. 2000) and pro-tumorigenic integrin, αvβ3, is also expressed by platelets, dendritic 
cells and monocytes (precursor macrophages) (Fig 6.5).  As such, research groups have 
used targeted RGD-liposomes for drug delivery to monocytes and macrophages (Kelly, C. 
et al. 2011).   
 
Fig 6.5. Role of integrins in the host response to cancer: (1) Integrins regulate the migration, proliferation and 
survival of endothelial cells for angiogenesis.  (2) Integrins promote interaction between cells for the 
stabilisation of newly formed blood vessels (neovasculature).  (3) Monocytes (αvβ3) may enhance disease 
progression by secreting cytokines and growth factors (GFs) to initiate angiogenesis and tumour cell 
migration.  The growth of fibrous or connective tissue (desmoplasia) and (5) deposition of collagen involved 
in tumour progression requires the secretion of further GFs and cytokines from fibroblast infiltration (4).  (6) 
Platelets have also been found to play an important role in possibly aiding metastatic dissemination by 
interacting with tumour cells through a fibrinogen bridge.  Taken from (Desgrosellier, J. S. et al. 2010). 
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The recruitment of macrophages by integrin αvβ3 is important for tumour suppression 
(Taverna, D. et al. 2004), however, could conceivably lead to unfavourable uptake or 
stimulation of phagocytic cells through binding of RGD-targeted therapeutics, causing 
high accumulation or clearance through the liver, where resident macrophages reside under 
steady state conditions (also in the lungs).  Conversely, several studies have shown that 
integrins have an essential role in the homing of myeloid cells and mononuclear 
phagocytes (e.g. monocytes, macrophages, dendritic cells) to tumours, which are also 
intrinsically implicated in innate immunity, primarily phagocytosis, and play a pivotal role 
in inflammation.  Moreover, metastasis can be greatly facilitated by the recruitment of 
these cells to the disease site, leading to potential redistribution of phagocytosed RGD-
targeted therapeutics from circulating monocytes under inflammatory conditions and result 
in an increase uptake in tumour tissue (Ferjancic, S. et al. 2013).  Tumour tissue also 
contains its own associated macrophages (TAMs), which play a complex role in 
tumorigenesis, as they are involved in mechanism to both prevent (M1 macrophages) and 
promote (M2 macrophages) tumour activities.  It was demonstrated through chemical 
extraction and FACS analysis that the PS Photofrin was taken up at greater levels into 
TAMs than into parenchymal ‘tumour cells’ derived from mice bearing squamous cell 
carcinoma (SCCVII) tumours following its administration (Korbelik, M. et al. 1991).   
 
Further to this, the applicability of the integrin αvβ3 as an RGD-targeting moiety for cancer 
therapeutics is demonstrated via its role in tumour angiogenesis, whereby an increase in 
integrin expression on tumour-associated blood vessels is observed unlike well-established 
quiescent endothelium (Brooks, P. C. et al. 1994b).  On account of the blood supply 
tumours demand to rapidly proliferate, vessels are structurally and biologically distinct 
from mature vessels.  Leaky tumour vessels with enlarged fenestrae compromise blood 
flow and vascular drug delivery, whilst promoting fibrosis and tumour cell intravasation 
(Avraamides, C. J. et al. 2008).  It is likely that an increased expression of integrin αvβ3, 
along with αvβ5, allows angiogenic endothelial cells to interact with the ECM and bind 
provisional matrix proteins (i.e. vitronectin, fibrinogen and fibronectin) which have been 
deposited in the tumour microenvironment and provide traction for invading endothelial 
cells.  Angiogenesis at the primary tumour site, not only provides a necessary blood supply 
for sustained progression but also grants access to metastatic tumour cells to travel to 
distant sites, providing a strong rationale for targeting this integrin.   
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Photosensitiser Nano-
carrier 
Targeting 
moiety 
  Tumour model Reference 
     
ZnPc Pegylated lipid 
micelles 
RGD  
Tat 
Human breast cancer (MCF-
7) cells 
(Wang, H. et 
al. 2014) 
     
m-THPC Pegylated 
ORMOSIL 
NPs 
cRGD Human umbilical vein 
endothelial (HUVEC) cells 
(Selvestrel, F. 
et al. 2013) 
     
PpIX 
(5-ALA) 
conjugate cRGD Subcut mouse mammary 
tumour (CaNT) and human 
cervical cells (SiHa) 
(Conway, C. 
L. et al. 2008) 
     
Porphyrin conjugate cRGD 
RGD 
(linear) 
Human umbilical vein 
endothelial (HUVEC) cells 
and mouse mammary cells 
(EMT-6) 
(Frochot, C. et 
al. 2007) 
     
Cy 5.5 conjugate cRGD Human melanoma (HT21), 
breast cancer (MCF-7) and 
fibrosarcoma (HT-1080) 
cells 
(von, W. A. et 
al. 2007) 
 
Table 6.3. Preclinical targeting studies of photosensitisers conjugated to RGD or encapsulated in targeted 
RGD nanocarriers for applications in PDT.  cRGD, cyclic arg-gly-asp peptide: PpIX, protoporphyrin IX; m-
THPC, meta-tetra(hydroxyphenyl)chlorin; NPs, nanoparticles; ZnPc, Zinc phthalocyanine; Tat, peptide 
derived from the transactivator of transcription of HIV; ORMOSIL, organically modified silica. 
 
The utilisation of NPs to deliver therapeutics in the treatment of cancer and other diseases 
is becoming increasingly relevant.  Despite advancements in the field, poor overall 
delivery to the tumour microenvironment and internalisation to the tumour cell cytosol 
remains the greatest challenge towards achieving clinical translation.  Ligands can be 
conjugated to the surface of NPs with the aim of improving selective accumulation into 
cancer cells by exploiting the active uptake mechanism involved in intracellular 
internalisation, targeting complementary receptors over-expressed on the extracellular 
membrane of certain malignant cells.  The aim of studies presented in this chapter was to 
investigate the in vivo biodistribution and PDT efficacy of m-THPC when incorporated in 
non-biodegradable untargeted- and targeted-ORMOSIL NPs.  To our knowledge, these are 
the first in vivo studies to have been carried out using m-THPC covalently incorporated 
within ORMOSIL NPs, of varying size, for anti-tumour PDT efficacy studies.  
Furthermore, few in vivo studies have been conducted involving targeted NPs for 
applications in PDT. 
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Silica NPs size (nm) m-THPC (µM) m-THPC loading (%) silane bonding silica conc (mg mL-1) total silica (mg kg-1)  
IR194 19 421 2.34 mono 16.7 4.34 
IR253 16 555 2.36 mono 21.8 3.47 
IR254 17 505 2.16 mono 21.7 3.82 
IR322 16 499 2.08 mono 22.3 3.92 
IR347 20 431 1.72 mono 23.3 4.72 
GG91UF* 100 470 2 tetra ~ ~ 
SF142UF 95 267 1.2 mono ~ ~ 
SF232UF 90 321 1.23 mono 17.7 4.87 
SF288* 110 270 1.6 tetra 11.4 3.72 
SF311 90 187 1.87 mono 9.3 4.39 
cRGD* (Arg-Gly-Asp) 75 248 - tetra 9.9 4.56 
cRAD*( Arg-Ala-Asp)  75 504 - tetra 20.2 3.03 
Table 6.4. Specifications of ORMOSIL NP preparations used in these investigations (developed at University of Padova, Italy); IR ≤20 nm, SF/GG ≥ 90-100 nm.  Targeted cRGD-
ORMOSIL NPs (receptor: αvβ3 integrin) and corresponding inactive targeted cRAD-ORMOSIL NPs. * indicates tetrasilane m-THPC binding 
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6.2 Materials & Methods 
6.2.1 Chemicals and Photosensitisers 
Microporous (<2 nm) organically modified silica (ORMOSIL) nanoparticles (NPs) were 
synthesised, characterised and supplied by Dr Fabrizio Mancin at the University of Padova 
(Italy).  Particles were prepared using a variation of the well-established Stöber procedure 
(Stober, W. et al. 1968) via reverse microemulsion (oil-in-water) to produce smaller NPs 
(<150 nm).  In a one-pot synthesis method; ammonia-catalysed polymerisation of 
alkoxysilane precursors, vinyltriethoxysilane (VTES), occurred in the hydrophobic core of 
micelles in water (instead of ethanol) in the presence of surfactants (AOT in n-butanol, 
Tween, Brij 35) to control the growth of the nanoparticles (Selvestrel, F. et al. 2013).  The 
addition of trialkoxysilane modified PEG ensured covalent grafting of PEG onto the NP 
surface at high densities (80-85 %) based on weight (see Appendix I – C.1 Synthesis of 
pegylated ORMOSIL NPs).  The reaction mixture was passed through a 0.22 µm 
membrane filter.  The mean diameter of the ORMOSIL NPs was measured using 
transmission electron microscopy (TEM) (see Appendix I - C.6 Transmission electron 
microscopy images).  Dynamic light scattering (DLS) was used to measure the 
corresponding mean hydrodynamic diameter and zeta potential.  The overall surface charge 
was slightly negative with a zeta potential value of ~ -5.2 mV (PBS, pH 7.4).  The content 
of m-THPC was between 1-2 % (w/w).  Particles were supplied in saline buffer.  The 
specifications of individual batches of pegylated ORMOSIL NPs covalently incorporating 
m-THPC used in this investigation are detailed in Table 6.4.  NPs were stored for up to 12 
months (4°C) without any visible aggregation.   
 
Targeted ORMOSIL NPs (PEG 2000: 30 %) and corresponding control ORMOSIL NPs 
(inactive targeted) were synthesised via the same process.  m-THPC was covalently 
incorporated in the silica matrix of NPs via a tetrasilane linker.  The cyclic-RGD peptide 
(Arg-Gly-Asp) (αvβ3 integrin receptor inhibitor) and inactive cyclic-RAD peptide (Arg-
Ala-Asp) were conjugated to the NP surface to produce: m-THPC-loaded SF532 cRGD-
targeted ORMOSIL NPs and SF532 cRAD-untargeted ORMOSIL NPs (Table 6.4).   
 
6.2.2 Absorbance spectra 
The absorbance spectra of m-THPC in each ORMOSIL NP batch were recorded using a 
Lambda 25-UV/Vis spectrophotometer (Perkin-Elmer, UK) between 300 – 700 nm light 
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wavelengths at 1 nm intervals in either storage buffer (saline) or solvent 
(ethanol/methanol) to ensure the characteristics of the absorbance spectrum of m-THPC 
had not been altered following covalent encapsulation.  Spectra were obtained at a 
scanning speed of 480 nm min-1 and recorded through UV Winlab software®.  The 
absorbance spectra of pure m-THPC, monosilane m-THPC, tetrasilane m-THPC, unloaded 
(no m-THPC) ORMOSIL NPs, SF532 cRGD-targeted, SF532 cRAD-untargeted 
ORMOSIL NP spectra were also recorded.  In a separate group, absorbance of m-THPC in 
ORMOSIL NPs was measured following dilution and incubated in Solvable™ to replicate 
tissue chemical extraction conditions and assess any potential shifts in maximum 
absorbance peaks (λmax).  Optimal wavelengths at the highest sensitivity (to minimise 
deviations from Beer’s Law, A = ε l c) were set to obtain measurements (m-THPC λexc = 
423 nm, λem = 652 nm).  Absorbance measurements of each solution were taken in quartz 
cuvettes with a light path-length of 1 cm (Pye Unicam, UK). Cuvettes were rinsed before 
each reading.  Spectra were normalised with background absorbance values of the 
corresponding diluent. 
 
6.2.3 Confocal microscopy in vitro 
For visualisation of untartgeted m-THPC-ORMOSIL NP uptake and intracellular 
localisation confocal microscopy was adopted.  1 x 104 MC28 cells were prepared using 
identical incubation conditions and fluorodish seeding methods as described in Chapter 4: 
Liposomes.  Cells were incubated for 4 h with 1 µM m-THPC (Foscan) or m-THPC 
ORMOSIL NPs; (i) ~20 nm (monosilane m-THPC) and (ii) ~100 nm (tetrasilane m-
THPC).  Control cells, without m-THPC, were incubated with 0.5 µM 4', 6-diemidino- 2-
phenylindole (DAPI) (Sigma, UK) for 10 minutes prior to imaging to identify the presence 
of live cells.  Following incubation, cells were washed twice with PBS before fresh media 
(minus serum and phenol red) was added (see Appendix I – C.4 Preparing Fluorodishes: 
ORMOSIL NPs).  Cells were observed using an inverted Olympus Fluoview 1000 
confocal laser scanning microscope.  Fluorescence confocal images were obtained at x20 
magnification and analysed with Fluoview FV1000 (Olympus)/Image J software.  m-
THPC fluorescence was detected using a 405 nm laser and a set of detection filters with 
400 nm excitation and 640-80 nm emission.  Laser voltage, Gain and Offset were kept 
consistent throughout imaging.  
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As a proof of concept for targeted ORMOSIL NP studies, a cRGD-FITC conjugate was 
provided by the University of Padova (Italy) to identify the expression of αvβ3 integrin on 
selected human cell lines, A549, MC28 and MCF-7, chosen based on previously published 
literature.  The conjugate was administered to cells at a concentration of 50 nM.  Targeted-
NPs were added to cells at a concentration of 2 µM (m-THPC equivalent) and cells were 
cultured under standard conditions.   
 
6.2.4 Animals and tumour model 
Female HL rats (150–220 g) were used for all in vivo tissue pharmacokinetic studies and 
toxicology studies to reduce animal numbers.  The methylcholanthrene-induced 
fibrosarcoma cell line (MC28), syngeneic and transplantable to Hooded Lister (HL) rats 
was cultured under identical conditions as described in Chapter 4: Liposomes.  Animals 
were inoculated subcutaneously in the lower flank with approximately 1–2 × 106 MC28 
cells in 0.1 mL injection volume.  Tumours were monitored continuously and reached an 
optimal size of approximately 10 mm3 after 7–10 days (as described in Chapter 4: 
Liposomes).  Following obtainment of sufficient tumour size between days 7-10,  
ORMOSIL NPs were administered intravenously via a tail vein injection.  Administered 
m-THPC doses were based on availability of compounds; untargeted ORMOSIL NPs (0.3 
mg kg−1 m-THPC), targeted cRGD-ORMOSIL or inactive targeted cRAD-ORMOSIL (0.1 
mg kg−1 m-THPC).  Animals used for time points beyond 72 h were not inoculated with 
tumour cells on account of the maximal tumour growth threshold being exceeded beyond 
this time.  At a specified time point between 2 and 672 h, animals were killed by cervical 
dislocation. 
 
6.2.5 Pharmacokinetic study 
Tissue samples selected for pharmacokinetic analysis included skin (right abdominal wall), 
liver, spleen, kidneys, lung, blood serum and tumour, taken from three animals at each 
time point.  Immediately post-mortem tissues were removed under subdued lighting at 2, 6, 
24, 72, (tumours) and a further 168 h, 2 weeks (336 h) and 28 days (672 h) from HL rats 
after intravenous administration of each untargeted-ORMOSIL NPs (0.3 mg kg−1 m-
THPC)  or at 24 h for targeted-ORMSOSIL NPs (0.1 mg kg−1 m-THPC).  A lower injected 
dose of m-THPC was chosen for targeted studies based on the % m-THPC loading of NPs 
and the quantity of compound provided.  Blood samples (~3 mL) were centrifuged to 
separate the serum at 2000 rpm (~300 g RCF) for 10 min for pharmacokinetic analysis and 
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for toxicological analysis (liver/renal function assays).  Negative control animals at 0 h 
were run simultaneously.  Samples were stored in the dark at −80 °C post-mortem.  m-
THPC extraction from tissues and detection was acquired using the same equipment, under 
identical conditions, following the same methodologies and mathematical models as 
described in Chapter 4: Liposomes.  Solvable™ was capable of completely decomposing 
ORMOSIL NPs upon incubation (see Appendix I - C.6 Transmission Electron 
Microscopy (TEM) Images). 
 
6.2.6 Confocal microscopy ex vivo 
Confocal microscopy was used to obtained images of the localisation of m-THPC in fresh 
ex vivo liver tissue following intravenous administration to HL rats of either  1 mg kg-1 
Foscan or 0.3 mg kg-1 of monosilane m-THPC covalently bound in either ~20 nm or ~90 
nm ORMOSIL NPS.  Tissue samples were removed and observed immediately post-
mortem using an inverted Olympus Fluoview 1000 confocal laser scanning microscope.  
Fluorescence confocal images were obtained using different combinations of magnification 
and objective lens; those imaged at x60 used an oil immersion objective (Olympus).  
Fluoview FV1000 (Olympus) and Image J software were used to analyse images.  m-
THPC fluorescence was detected using a 405 nm laser and a set of detection filters with 
400 nm excitation and 640-80 nm emission.  Laser voltage, Gain and Offset were kept 
consistent throughout imaging. 
 
6.2.7 Fluorescence microscopy (frozen tissue sections) 
Animal tissues were removed post-mortem and snap frozen in liquid nitrogen under 
isopentane (VWR, UK) 24 h post-intravenous injection with 0.3 mg kg-1 m-THPC of ~90 
nm ORMOSIL NPs or 0.1 mg kg-1 m-THPC in targeted ORMOSIL NPS; with m-THPC 
covalently bound by either monosilane or tetrasilane linkers.  For untargeted ORMOISL 
NP studies, 10 micron frozen sections of liver and tumour tissue were cut using a cryostat 
and mounted on glass slide coverslips (VWR, UK).  For targeted ORMOSIL NP studies 
liver, spleen, lung, kidney and tumour tissue were cut and mounted on poly-lysine treated 
glass slides (VWR, UK).  On average five sections were taken per tissue sample from three 
animals.  Sections exposed to blue light for 10 secs using a 405 nm laser (3 mW) to excite 
m-THPC and visualise the extent of dye uptake and diffusion in tissues.  CCD false 
coloured fluorescence microscopy images (512 pixels) were obtained with a PIXI 512 
CCD camera (Princeton Instruments, USA) coupled to an inverted Olympus IMT-2 
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microscope (Olympus).  This system was equipped with a dichroic mirror (505DCLP, 
Omega) and filters were set as follows: 660 nm DF33 colour bandpass filter, 595 nm long 
pass filter and 500 nm ACSP short pass filter.  Sections were imaged using different 
combinations of magnification and objective lens and analysed through WinSpec32 
software (Roper Science Software).  Corresponding confocal images of frozen liver and 
tumour sections with untargeted ORMOSIL NPs were also imaged as described above, 
6.2.6 Confocal Microscopy ex vivo.  The image resolution was 512 x 512 pixels, 
corresponding to 557 x 557 microns. 
 
6.2.8 Toxicology: Biochemical analysis 
For quantitative plasma enzyme measurements of aspartate transaminase (AST) and 
alkaline phosphatase (ALP) to assess liver/renal function, blood samples were collected 
from HL rats immediately following cervical dislocation at each time intervals; 2, 6, 24, 
72, 168 h, 2 weeks and 28 day, after intravenous administration of m-THPC in ORMOSIL 
NPs at a dose of 0.3 mg kg−1.  Blood samples were left to stand at RT for 20 mins then 
centrifuged at 5000 rpm for 10 mins.  Separated plasma was assayed to determine plasma 
enzyme activities using a Roche/Hitachi 912/917/MODULAR analyser (ACN 413, Cobas) 
at The Royal Free Hospital, UCL (London) with reagent kits provided by the manufacturer 
(AST: α-ketoglutarate, malate dehydrogenase, L-aspartate, NADH; ALT: α-ketoglutarate, 
lactate dehydrogenase, L-alanine, NADH) (see Appendix I –  C.7 Toxicology: liver/renal 
enzyme function test). 
 
6.2.9 Toxicology: Histological analysis 
Major organs, including the liver, spleen, lungs and kidneys, were removed post-mortem 
from three animals at 2 weeks post intravenous administration of ~20 nm and ~100 nm m-
THPC-ORMOSIL NPs.  Selected portions of each organ were harvested and immersed in 
4% neutral formalin buffer (4% w/v formaldehyde in phosphate buffered saline) for a 
minimum of 24 h at 20 °C.  Samples were processed by routine histological methods.  
Tissues were embedded face down in paraffin wax blocks.  Four-micrometre sections were 
cut and mounted on Vectabond (Vecta laboratories, UK) treated glass slides.  Three 
sections were taken from each of the tissue samples. Slides were stained with Harris 
haematoxylin and eosin.  Whole slides were scanned with the Hamamatsu Nanozoomer 
(Hamamatsu Photonics UK Ltd) and Hamamatsu virtual microscopy imaging software was 
used to observe any abnormalities in tissues indicative of toxicity at various 
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magnifications.  Tissue histology was assessed by a pathologist ‘blinded’ to the treatment 
groups and liver/renal biochemistry data. 
 
6.2.10 Photodynamic therapy on MC28 tumours 
Injected doses of 0.3 mg kg-1 m-THPC for untargeted-ORMOSIL NP studies and 0.1 mg 
kg-1 m-THPC for targeted-ORMOSIL NP studies were administered to tumour animals 
prior to light delivery.  A drug-light interval of 24 h were chosen based on pharmacokinetic 
data and a second DLI of 6 h was investigated for untargeted ORMOSIL NPs.  Tumours 
were irradiated with red light using a 400 µm bare-cleaved tip optical fibre inserted 
approximately 1 mm into the tumour capsule via a small incision in the overlying skin and 
tumour capsule, to mimic interstitial clinical PDT with Foscan.  A total of 10 J of light at 
100 mW for 100 s was delivered from a 652 nm diode laser.  Treatment with each m-
THPC formulation was initiated when tumours had reached an optimal diameter of 10 mm.  
Each treatment group consisted of four animals.  Animals were killed 24 h after treatment 
by cervical dislocation and whole tumours resected for histological analysis. 
 
6.2.11 Histology and measuring necrosis (Hamamatsu nanozoomer) 
Treated tumour tissue samples were removed post-mortem and prepared by routine 
methods for histological analysis as described in Chapter 4: Liposomes.  The damage was 
calculated from each tumour as a percentage of the whole tumour surface area.  Six 
sections were averaged per tumour (3 from each tumour half).  The mean surface area of 
tumour necrosis was calculated through blind analysis per group of four identically treated 
animals and all data were represented as mean±SD. 
 
6.2.12 Statistical analysis 
Mean and standard deviation was calculated for each animal group (±SD, n=3–5). All data 
were represented as mean±SD.  Statistical analysis was carried out using a two-tailed 
Student's t-test and a Mann–Whitney t-test for PDT data. p≤0.05 was considered 
statistically significant, unless stated otherwise. 
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6.3 Results 
Untargeted ORMOSIL NPs 
Characterisation studies carried out at the University of Padova using dynamic light 
scattering (DLS) indicated unimodal distribution and maximum percentage intensity of 
~20 nm and ~100 nm (data not shown).  It was reported TEM images (see Appendix I C.6 
- TEM images) correlated well with DLS results, showing a narrow size distribution and a 
spherical morphology (Compagnin, C. et al. 2011).  In addition, the overall surface charge 
was found to be slightly negative, with a zeta potential value of ~ -5.2 mV, which can be 
attributed to the presence of PEG groups on the ORMOSIL NP surface and small traces of 
remnant surfactant from particle synthesis (Kumar, R. et al. 2010). 
 
i. Absorption spectra 
An absorbance spectrum of m-THPC and each pegylated ORMOSIL NP batch was taken 
in either, (i) saline buffer (data not shown), (ii) methanol or (iii) Solvable™.  The first was 
to deduce absorbance maxima for NPs administered for in vivo studies (data not shown). 
 
Figure 6.6. Absorbance spectra of m-THPC, monosilane or tetrasilane m-THPC derivatives and m-THPC 
monosilane or tetrasilane derivatives bound inside large (≥90 nm) ORMOSIL NPs diluted in MeOH.  All 
solutions were prepared at 0.5 µM m-THPC equivalent. 
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Secondly, comparisons of free m-THPC, mono- or tetrasilane m-THPC  and mono- or 
tetrasilane-mTHPC covalently bound in pegylated ORMOSIL NPs were carried out in 
methanol (MeOH), as m-THPC is highly hydrophobic, to ensure the spectroscopic 
properties of modified m-THPC and covalently encapsulated m-THPC had not been 
altered (Fig 6.6).  Spectra indicated absorbance peaks characteristic of m-THPC (λ = 423 
nm and 652 nm), which correspond to the literature (Kascakova, S. et al. 2008); (Bonnett, 
R. et al. 1999).  There was no evidence of spectral broadening or dramatic shifts in 
absorbance maxima between m-THPC formulations, suggesting the same photoactive 
species of m-THPC were present.  However, there was a small increase in absorbance 
intensity for both Soret and Q peaks with free versus modified or covalently encapsulated 
m-THPC but this may also be attributed to difference in solution concentrations 
(experimental error) (Fig 6.6 A and B).  The shoulder observed on the Soret band for each 
m-THPC formulation is indicative of highly conjugated systems and is common for 
chlorin-compounds. 
 
An absorbance spectrum of each m-THPC-loaded and unloaded ORMOSIL nanoparticle 
formulation was taken before in vivo studies to deduce peak absorbance wavelengths (Fig 
6.7).   
 
 
Figure 6.7. Absorbance spectra of m-THPC, unloaded ORMOSIL NPs (no m-THPC) and m-THPC 
monosilane or tetrasilane derivatives bound inside large (≥90 nm) or small (≤20 nm) ORMOSIL NPs diluted 
in MeOH.  All solutions were prepared at 10 µM m-THPC equivalent.   
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Absorbance spectra of m-THPC loaded silica NPs in methanol (Fig 6.7) was in good 
agreement with the literature (Compagnin, C. et al. 2009).  As with free m-THPC and 
liposomal encapsulated m-THPC (Chapter 4: Liposomes), the spectra showed two 
absorbance maxima peaks at ~ 420 nm (Soret band) and ~ 652 nm (Q band), suggesting the 
presence of monomerically active m-THPC (non-aggregated).  Unloaded particles have an 
exaggerated light scattering (~300 nm) due to the higher concentration of particles per mL, 
as accurate concentrations could not be calculated without a fluorophore (Fig 6.7). 
 
All ORMOSIL NPs were additionally incubated in Solvable™ for 2 h at 50°C to replicate 
conditions during chemical extraction (Fig 6.8) and ensure the preservation of 
spectroscopic m-THPC characteristics.  There was no difference between absorbance 
spectra of ORMOSIL NPs taken in methanol (Fig 6.7) versus Solvable™ (Fig 6.8), with 
the exception of the loss of the shoulder on the Soret peak (~ 400 nm), which increased the 
peak intensity slightly.  As the m-THPC chromophore is highly conjugated and solvent 
dependent this may be anticipated.  However, this could indicate degradation of 
ORMOSIL NPs in Solvable (confirmed by TEM images, see Appendix I B.C - TEM 
images) and release of m-THPC into its monomeric formation.  Moreover, all ORMOSIL 
NPs diluted in saline buffer, as when administered to animals (data not shown), did not 
indicate any reduction in m-THPC absorbance intensity (652 nm).  Around wavelengths of 
300 – 350 nm, the absorbance spectra of m-THPC loaded particles showed light scattering 
of the ORMOSIL NPs increased with larger nanoparticle diameter size. 
 
Figure 6.8. Absorbance spectra of m-THPC loaded ORMOSIL NPs (mono or tetra) in Solvable.  All 
solutions were prepared at 10 µM.  ORMOSIL NP batches beginning with IR: ~20 nm (mono-mTHPC), SF: 
~100 nm (mono-mTHPC), * indicates ~100 n m ORMOSIL NPs with tetra-mTHPC. 
* 
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ii. Confocal microscopy in vitro 
 
Figure 6.9. Confocal microscopy images of MC28 tumour cells following 4 h incubation with (A) free m-
THPC, (B) Control, no m-THPC, + 0.5 µM DAPI (C) small ORMOSIL NPs of ~20 nm with mono-m-THPC 
(D) or large ORMOSIL NPs of ~100 nm with tetra-m-THPC.  All m-THPC concentrations were 
administered at 1 µM. 
 
In vitro studies were carried out with preliminary batches of pegylated ORMOSIL NPs 
whereby MC28 tumour cells were incubated for 4 h with either ~20 nm ORMOSIL NPs, 
incorporating covalently bound mono-mTHPC (Fig 6.9 C), or ~100 nm ORMOSIL NPs 
with tetrasilane-bound mTHPC (Fig 6.7 D).  Confocal images indicated a higher uptake of 
smaller NPs (~20 nm) in comparison to larger NPs (~100 nm) due to the increase in 
observed red fluorescence.  Free m-THPC (Fig 6.9 A) gave the most intense fluorescence 
signal and indicated uniform distribution throughout the cytoplasm of cells.  This pattern of 
distribution was also demonstrated with the smaller NPs, with the nucleus defined as an 
enclosed black region.  Control cells (without m-THPC) were incubated with DAPI (blue), 
a nuclear fluorescent stain which binds strongly to A-T rich regions of nuclear DNA, used 
to detect live cells (Fig 6.9 B) in the absence of red fluorescence. 
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iii. Pharmacokinetics of m-THPC (Foscan versus pegylated ORMSOIL NPs) 
Pharmacokinetics studies were carried out in a selection of normal tissues and tumour 
tissue with pegylated ORMOSIL NPs, covalently incorporating m-THPC, to investigate 
their uptake and biodistribution in vivo.  As with previously described with liposomal m-
THPC formulations this was carried out through chemical extraction of m-THPC from 
tissues and spectrofluorimetric analysis using identical drug doses (0.3 mg kg-1 m-THPC 
equivalent). 
 
Based on the limited supply of primary ORMOSIL NP batches (Table 6.5), initially only 
one time point was selected for preliminary biodistribution studies, rather than an entire 
time series.  A 24 h time interval was chosen established from pharmacokinetic data of 
pegylated liposomal m-THPC in tumour tissue, which exhibited the greatest uptake of m-
THPC.  Both data sets of pegylated liposomal m-THPC and m-THPC in pegylated 
ORMOSIL NPs have been displayed for direct comparisons in tissue uptake at 24 h (Fig 
6.10).  It is important to consider differences in their biodegradation capabilities. 
 
Sample IR194 SF142UF GG91UF* 
Size (nm) 19 95 100 
m-THPC (µM) 421 267 470 
Loading (%) 2.34 1.5 2.0 
PEG length 2000 2000 2000 
Silane bonding mono mono tetra* 
 
Table 6.5. Specifications of ORMOSIL NP preparations used for preliminary pharmacokinetics studies. 
 
Preliminary data on the uptake of m-THPC in selected tissue of the HL rat at 24 h 
following administration of m-THPC at 0.3 mg kg-1 in either Foscan, FosPEG 2%, FosPEG 
8%, and pegylated ORMOSIL NPs of ~20 nm or ~100 nm covalently incorporating either 
monosilane or tetrasilane bound m-THPC is illustrated in Figure 6.10 (see Appendix I - 
C.2 Quantitative ORMOSIL concentrations at 24 h in vivo).  Injected dose of m-THPC in 
ORMOSIL NPs showed little difference in the accumulation of m-THPC in the blood 
plasma between NP batches at 24 h (avg. ~1.5 µg g-1), however, this was almost than three-
fold the m-THPC concentration observed with pegylated liposomal nanocarriers (~0.5 µg 
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g-1) and more than fifteen times that observed with Foscan (~0.05 µg g-1) (Fig 6.10).  No 
radical differences were identified between pegylated biodegradable liposomes (~1 µg g-1) 
and pegylated non-biodegradable ORMOSIL NPs in the liver (~1.5 µg g-1) versus Foscan 
(~1 µg g-1) at 24 h (Fig 6.8), displaying only a small increase in m-THPC accumulation 
with ORMOSIL NPs.  The same can be said for marginal differences in m-THPC 
accumulation in the kidney and skin following delivery by various pegylated nanocarriers 
in comparison to Foscan.  The most evident difference in normal tissues is m-THPC 
concentrations in the lungs, with small (~20 nm) pegylated ORMOSIL NPs (~2 µg g-1) 
drastically outweighing that of Foscan (~0.1 µg g-1), larger ORMOSIL NPs (~0.7 µg g-1) 
and pegylated liposomes (~1 µg g-1).  It should also be noted that m-THPC accumulation in 
the spleen (data not shown) when delivered by pegylated ORMOSIL NPs, regardless size, 
far surpassed m-THPC accumulation in any other organ or m-THPC formulation (see 
Appendix I - C.3 ORMOSIL NPs in the spleen at 24 h). 
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Figure 6.10. Concentration of m-THPC in tissues following intravenous administration of 0.3 mg kg-1 m-
THPC covalently bound in non-biodegradable pegylated ORMOSIL nanoparticles; ■ ~20 nm (mono-m-
THPC), ■ ~95 nm (mono-m-THPC), ■ ~100 nm (tetra-m-THPC), in comparison to biodegradable pegylated 
liposomal nanocarriers (■ FosPEG 2%, ■ FosPEG 8%) and standard m-THPC formulation (■ Foscan) at 24 
h.  Data points show the mean ± s.d., n=4. 
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In tumour tissue, results with preliminary NP batches appears to show an increase in the 
uptake of m-THPC when incorporated in large (~100 nm) pegylated ORMOSIL NPs (~2 
µg g-1), regardless of covalent encapsulation, in comparison this is almost fourfold > small 
(~20 nm) pegylated ORMOSIL NPs (~0.4 µg g-1), twofold > pegylated liposomal 
nanocarriers (~1 µg g-1) and threefold > Foscan (~0.3 µg g-1) (Fig 6.10).   
 
Sample IR253 IR254 SF232UF 
Size (nm) 16 17 90 
m-THPC (µM) 555 505 321 
Loading (%) 2.36 2.16 1.23 
PEG length 2000 2000 2000 
Silane bonding mono mono mono 
 
Table 6.6. Specifications of ORMOSIL NP preparations used for pharmacokinetic and toxicology studies.   
*In these studies where batches IR253 & IR254 have been employed, samples will be referred to as 20 nm 
(mono) NPs.  Similarly, larger NPs (SF232UF) will be referred to as 90 nm (mono) NPs for simplicity. 
 
Subsequent ORMOSIL nanoparticle composites were redeveloped by our collaborators 
(Table 6.6) and pharmacokinetic studies were extended to assess accumulation and 
retention of non-biodegradable nanocarriers at longer time periods (28 days).  Foscan data 
was acquired from studies in Wistar rats (Chapter 4: Liposomes) and is included as point 
of reference.  Additionally, Foscan data from 168 h ≥ 672 h displayed here is based on 
predicted concentrations calculated using the rate constants of the terminal phase of 
elimination (72 h ≥ 168 h) from liposome studies (also see Appendix I - C.9 %ID/g of m-
THPC in ORMOSIL NPs in different tissues in vivo).   
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Figure 6.11 shows the plasma clearance after a single i.v. injection of 0.3 mg kg-1 m-THPC 
in Foscan, 20 nm or 90 nm pegylated ORMOSIL NPs (with covalently bound monosilane 
m-THPC) into the normal HL rat model between ≤5 min and 672 h.  Foscan was observed 
at the lowest concentrations and was cleared most rapidly from the blood serum relative to 
pegylated ORMOSIL NPs (Fig 6.11).  The greatest m-THPC concentration was observed 
with 20 nm ORMOSIL NPs at t=0 (~1 µg g-1), with 90 nm NPs and Foscan at equal m-
THPC concentrations ~0.5 µg g-1.  Concentrations of m-THPC remained similar between 
pegylated ORMOSIL NPs, despite differences in size, and remained consistently higher 
than Foscan over 672 h, however neither were significant. 
 
 
Figure 6.11. Semi-log plot of mean m-THPC concentration in blood serum after intravenous administration 
of 0.3 mg kg-1 m-THPC in either ■ Foscan or pegylated ORMOSIL nanoparticles ■ ~20 nm (mono-m-
THPC) and ■ ~90 nm (mono-m-THPC) into female HL rats.  Foscan blood data taken from Wistar rats is 
included as a reference.  Data points show the mean ± SD, n = 3. 
 
Following intravenous injection, m-THPC plasma concentrations peaked at the earliest 
time point for each formulation and appeared to decline exponentially.  However, m-THPC 
clearance from plasma fitted multiple exponential decays; therefore data were analysed  
using both a compartmental (Clark B et al. 1981) and  non-compartmental approach 
(Yamaoka, K. et al. 1978), as described in Chapter 4: liposomes. 
BLOOD  
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Pharmacokinetic parameter Foscan ~20 nm ORMOSIL 
~90 nm 
ORMOSIL 
        
Three compartmental model    
Initial dosage (Do, mg kg-1) 0.3 0.3 0.3 
Initial concentration (Co, µg mL-1, t=0) 0.7 1.03 1.55 
Initial volume of distribution (Vd, mL kg-1) 407.4 290.7 194.1 
Vd of first compartment (mL kg-1) 1373.9 528.4 300 
Vd of second compartment (mL kg-1) 640.1 752.0 654.3 
Vd of third compartment (mL kg-1) 6086.2 4596.6 3455.4 
t1/2 of first compartment (h-1) 0.9 1.1 0.4 
t1/2 of second compartment (h-1) 3.3 8.0 1.6 
t1/2 of third compartment (h-1) 90.0 577.6 301.4 
    
Non-compartmental model    
Plasma clearance (Cl, mg kg-1 h-1) 30.0 0.002 0.007 
Mean residence time (MRT, h-1) 61.9 2674.8 158 
Volume of distribution (Vd, mL kg-1) 1875.7 5008 1131 
Half-life (t1/2, h-1) 42.9 1854 109.5 
Elimination rate constant (Kel, h-1) 0.016 0.0001 0.006 
Table 6.7. Plasma pharmacokinetic parameters of m-THPC after an i.v. injected dose of 0.3 m kg-1 m-THPC 
in either ~20 nm or ~90 nm pegylated ORMOSIL NPs incorporating covalently bound monosilane m-THPC 
in female HL rats, calculated using the exponential equations of the three compartment model ( A 
e_αt+Be_βt+Ce_γt), and  the non-compartmental method.  Foscan blood data taken from Wistar rats is included 
as a reference. 
 
Using a compartmental approach (Table 4.4), the data best fit a tri-exponential decay 
curve, described by the equation C = A e-αt + Be-βt + Ce-γt (whereby C = concentration, A, 
B, C = y-intercepts (at t = 0), and α, β, γ = elimination rate constants), which describes the 
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rate of drug flow into and out of the central compartment and gave three compartmental 
half-lives (t1/2) and elimination rate constants for 20 nm and 90 nm ORMOSIL NPs 
covalently incorporating monosilane bound m-THPC (Table 6.7).  Foscan blood data taken 
from Wistar rats is included as a reference. 
 
The non-compartment model (Table 6.6) gives half-lives of 1854 h for 20 nm ORMOSIL 
NPs and 109.5 h for 90 nm ORMOSIL NPs, with elimination rate constants of 0.0001 h-1 
and 0.006 h-1, respectively.  The compartmental model estimates the initial volume of 
distribution (Vd) from the central compartment as 5008 mL kg-1 for 20 nm ORMOSIL NPs 
and 1131 mL kg-1 for 90 nm ORMOSIL NPs.   
 
 
Figure 6.12. Concentration of m-THPC (µg g-1) in the liver of the HL rat as a function of time following an 
intravenous injection of 0.3 mg kg-1 m-THPC in standard ■ Foscan, or pegylated ORMOSIL nanoparticles ■ 
~20 nm (mono-m-THPC) and ■ ~90 nm (mono-m-THPC).  Foscan liver data taken from Wistar rats is 
included as a reference.  Data corrected for negative control tissue.  Data points show the mean ± SD, n = 3.  
Liver data (Fig 6.12) initially show a greater uptake of m-THPC when covalently bound in 
large (90 nm) pegylated ORMOSIL NPs (~7 µg g-1) at the earliest time points compared to 
small (20 nm) pegylated ORMOSIL NPs (~6 µg g-1), both of which are considerably 
LIVER 
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greater than concentrations of Foscan at this time (~4 µg g-1).  Pegylated ORMOSIL NPs 
remained at ~3 µg g-1 in the liver for the duration of the investigation (≥28 days).  In 
comparison, this is the maximal m-THPC concentration observed with pegylated liposomal 
nanocarriers before they and Foscan were almost cleared from the liver ≤168 h. 
 
 
Figure 6.13. Concentration of m-THPC (µg g-1) in the spleen of the HL rat as a function of time following an 
intravenous injection of 0.3 mg kg-1 m-THPC in standard ■ Foscan, or pegylated ORMOSIL nanoparticles ■ 
~20 nm (mono-m-THPC) and ■ ~90 nm (mono-m-THPC).  Foscan spleen data taken from Wistar rats is 
included as a reference.  Data corrected for negative control tissue.  Data points show the mean ± SD, n = 3. 
 
In the spleen m-THPC in ORMOSIL NPs shows a highly similar pattern of uptake to that 
of the liver over 672 h, but at slightly lower m-THPC concentrations (Fig 6.13).  Unlike 
the exponential decay of m-THPC observed with FosPEG formulations, a terminal 
elimination phase does not appear to be obtained with ORMOSIL NPs in the liver or 
spleen over 28 days.  Although m-THPC in ORMOSIL NPs generally shows a negative 
pattern of decline ≥168 h from the liver and spleen, as seen with liposomal formulations, 
the concentrations of m-THPC at the same time points in comparison are far greater with 
ORMOSIL NPs.  
 
SPLEEN 
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In contrast to preliminary biodistribution data at 24 h with initial batches of ORMOSIL 
NPs (Fig 6.10), m-THPC accumulation in the lungs with either 20 nm or 90 nm ORMOSIL 
NPs is much lower, with a maximum m-THPC concentration of ≤0.8 µg g-1 observed at the 
earliest time points (Fig 6.14).  These observed m-THPC concentrations are also much 
lower than those obtained with pegylated liposomal nanocarriers in the lung over 168 h and 
do not particularly correlate to the blood plasma pharmacokinetics of ORMOSIL NPs.  
Over 28 days a favorable decrease in m-THPC accumulation is observed with both small 
and large ORMOSIL NPs (~0.2 µg g-1). 
 
 
Figure 6.14. Concentration of m-THPC (µg g-1) in the lungs of the HL rat as a function of time following an 
intravenous injection of 0.3 mg kg-1 m-THPC in standard ■ Foscan, or pegylated ORMOSIL nanoparticles ■ 
~20 nm (mono-m-THPC) and ■ ~90 nm (mono-m-THPC).  Foscan lung data taken from Wistar rats is 
included as a reference.  Data corrected for negative control tissue.  Data points show the mean ± SD, n = 3. 
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Figure 6.15. Concentration of m-THPC (µg g-1) in the kidneys of the HL rat as a function of time following 
an intravenous injection of 0.3 mg kg-1 m-THPC in standard ■ Foscan, or pegylated ORMOSIL nanoparticles 
■ ~20 nm (mono-m-THPC) and ■ ~90 nm (mono-m-THPC).  Foscan kidney data taken from Wistar rats is 
included as a reference.  Data corrected for negative control tissue.  Data points show the mean ± SD, n = 3. 
 
In the kidneys (Fig 6.15), as with liposomal m-THPC, no significant variation exists in m-
THPC uptake between Foscan or either size pegylated ORMOSIL NP over 672 h.  All m-
THPC formulations appear to plateau from between 168 - 336 h, before a decline to 
baseline is observed with 20 nm ORMOSIL NPs and Foscan.   
 
Figure 6.16 A + B show a direct comparison of m-THPC uptake in selected tissues at 24 h 
culminating all pegylated ORMOSIL NP batches of either small (~20 nm) or large (~90 
nm) particles covalently incorporating monosilane m-THPC or tetrasilane m-THPC*.  
Generally, the greatest uptake of 20 nm pegylated ORMOSIL NPs (mono-m-THPC) is 
observed in the liver at 24 h.  With 90 nm pegylated ORMOSIL NPs there appears to be no 
significant difference on the accumulation of NPs according to the covalent incorporation 
of m-THPC and the greatest m-THPC uptake appears to be in the liver.  However, 
compared to 20 nm ORMOSIL NPs, the greatest m-THPC accumulation also extends to 
the blood plasma and tumour tissue when delivered by 90 nm ORMOSIL NPs at 24 h. 
KIDNEYS 
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Figure 6.16. Direct comparison of small versus large pegylated ORMOSIL NPs on m-THPC accumulation (µg g-1) in all tissues of the HL rat at 24 h following an intravenous injection of 
0.3 mg kg-1 m-THPC covalently bound (monosilane) in pegylated ORMOSIL nanoparticles of either (A) ~20 nm or (B) ~90 nm.  *m-THPC is covalently bound by tetrasilane linkers.  Data 
corrected for negative control tissue.  Data points show the mean ± SD, n = 3. 
 
A B 
6. Organically Modified Silica Nanoparticles 
- 214 - 
 
Figure 6.17. Concentration of m-THPC (µg g-1) in tumour tissue of the HL rat as a function of time 
following an intravenous injection of 0.3 mg kg-1 m-THPC in standard ■ Foscan or pegylated ORMOSIL 
nanoparticles ■ ~20 nm (mono-m-THPC) and ■ ~90 nm (mono-m-THPC).  Foscan tumour data taken from 
HL rats is included as a reference.  Data corrected for negative control tissue.  Data points show the mean ± 
SD, n = 3. 
 
Contrary to Fig 6.17 and preliminary biodistribution studies at 24 h with initial batches of 
pegylated ORMOSIL NPs, there appears to be no significant difference in m-THPC uptake 
between 20 nm and 90 nm ORMOSIL NPs (covalently incorporating monosilane m-
THPC) used for these tumour studies at any time interval over a 96 h period (Fig 6.17).  
There also appears to be no significant difference in m-THPC tumour uptake when 
comparing Foscan to ORMOSIL NPs over a 72 h period. 
 
TUMOUR 
6. Organically Modified Silica Nanoparticles 
- 215 - 
iv. Confocal microscopy ex vivo 
 
Figure 6.18. Confocal microscopy images of ex vivo rat liver tissue at 24 h following i.v. administration of 
0.3 mg kg-1 m-THPC in (A-C) small (20 nm) ORMOSIL NPs (mono-m-THPC) or (D-F) large (90 nm) 
ORMOSIL NPs (mono-m-THPC).  Images on the left indicate liver auto-fluorescence (green), central images 
show m-THPC fluorescence (red) and images on the right after merging of the two channels (green and red) 
to determine m-THPC localisation in liver tissue.  (G-H) Different magnifications of ex vivo rat liver tissue at 
24 h following i.v. administration of 1 mg kg-1 m-THPC in Foscan.  Bright white spots are indicative of m-
THPC fluorescence (I) India ink uptake into the Kupffer cells residing in the sinusoids of the liver (taken 
from (Bowen, R. 2002). 
 
Qualitative confocal microscopy images of ex vivo liver tissue (green) show the 
localisation of m-THPC fluorescence (red) in the Kupffer cells (macrophages), residing in 
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the sinusoids of the liver (Fig 6.18) following intravenous injection of 0.3 mg kg-1 m-
THPC in either 20 nm (Fig 6.18 C) or 90 nm (Fig 6.18 F) pegylated ORMOSIL NPs and 
removal of tissue at 24 h.  The localisation of m-THPC in Kupffer cells is confirmed by 
Bowen et al., who demonstrated phagocytised India ink particles in fixed macrophage cells 
of the liver (black stained cells in Fig 6.18 I) forming part of the RES (Bowen, R. 2002).  
Confocal images (grey) of ex vivo liver tissue acquired following intravenous injection of 1 
mg kg-1 m-THPC in Foscan and removal of tissue at 24 h (Fig 6.18 G & H) show m-THPC 
fluorescence as bright white spots, which appear to be intracellularly localised in liver 
hepatocytes rather than liver macrophages. 
 
v. Fluorescence microscopy frozen tissue 
10 micron frozen sections of liver tissue were imaged using fluorescence microscopy (Fig 
6.19).  Tissues were removed and snap frozen in liquid nitrogen under isopentane from rats 
24 h following intravenous injection with 0.3 mg kg-1 m-THPC in Foscan (Fig 6.19 E-F) or 
90 nm pegylated ORMOSIL NPs incorporating either covalently bound monosilane (Fig 
6.19 A-B) or tetrasilane m-THPC (Fig 6.17 C-D).  Qualitative CCD false coloured 
fluorescent images of m-THPC localisation were obtained at different magnifications (x10 
or x60).  The greatest m-THPC fluorescence (white) was observed with 90 nm pegylated 
ORMOSIL NPs in the liver at 24 h in comparison to Foscan.  This is consistent with 
chemical extraction data of liver tissue. 
 
Localisation of m-THPC fluorescence in ORMOSIL NPs observed with fluorescence 
microscopy was in accordance with corresponding confocal images of ex vivo liver tissue 
(Fig 6.18), suggesting the greatest m-THPC fluorescence is located in the sinusoids 
between the liver hepatocytes where the macrophages (Kupffer cells) reside at 24 h.  
Furthermore, confocal images of the same frozen liver sections used in fluorescence 
microscopy were obtained following excitation of m-THPC and red m-THPC fluorescence 
was also detected in the sinusoids of frozen liver tissue sections (Fig 6.20).   
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Figure 6.19. Fluorescence microscopy: qualitative uptake and localisation of m-THPC in 10 micron frozen 
liver sections at 24 h following intravenous administration of 0.3 mg kg-1 m-THPC in Foscan and covalently 
bound (mono or tetrasilane) in large ORMOSIL NPs (~100 nm).  (A) Large (mono) x10 (B) Large (mono) 
x60 (C) Large (tetra) x10 (D) Large (tetra) x60 (E) Foscan x10 and (F) Foscan x60.  50 micron scale bar on 
each image and the fluorescence intensity scale, top, increases from black (background/no fluorescence) 
through to white (max. fluorescence). 
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Figure 6.20. Confocal microscopy: qualitative uptake and localisation of m-THPC (red) in 10 micron frozen 
liver sections (grey) at 24 h following intravenous administration of 0.3 mg kg-1 m-THPC in Foscan and 
covalently bound (mono or tetrasilane) in large ORMOSIL NPs (~90 nm) at x20.  (A) Large (mono) (B) 
Large (tetra) (C) Control (no m-THPC) (D) Foscan. 
6. Organically Modified Silica Nanoparticles 
- 219 - 
The same fluorescence microscopy and confocal microscopy techniques were employed to 
image 10 micron frozen sections of tumour tissue, obtained from rats under the same 
removal conditions.  0.3 mg kg-1 m-THPC was administered intravenously in either small 
20 nm (monosilane m-THPC) or large 90 nm (mono- or tetrasilane m-THPC) pegylated 
ORMOSIL NPs.  False coloured CCD fluorescent images of frozen tumour tissue sections 
(Fig 6.21) demonstrated the greatest m-THPC fluorescence intensity (white) was observed 
with 90 nm ORMOSIL NPs at 24 h in comparison to 20 nm ORMSIL NPs.  This is 
consistent with chemical extraction data of tumour tissue. 
 
Confocal microscopy images of frozen tumour tissue sections confirmed the greatest m-
THPC red fluorescence signal was observed with 90 nm ORMOSIL NPs at 24 h in 
comparison to 20 nm ORMSIL NPs (Fig 6.22).  The covalent incorporation of m-THPC 
into larger ORMOSIL NPs (mono- or tetrasilane) appeared to have no influence on 
observed red fluorescence intensity.  Images of 20 nm ORMOSIL NPs looked extremely 
similar to images obtained with control tumour tissue which received no m-THPC and 
showed no red fluorescence signal following excitation of tissue. 
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Figure 6.21. Fluorescence microscopy: qualitative uptake and localisation of m-THPC in 10 micron frozen 
tumour sections at 24 h following intravenous administration of 0.3 mg kg-1 m-THPC covalently bound 
(mono or tetrasilane) in small (~20 nm) or large (~90 nm) ORMOSIL NPs.  (A) Large (mono) x10 (B) Large 
(mono) x60 (C) Large (tetra) x10 (D) Large (tetra) x60 (E) Small (mono) x10 and (F) Small (mono) x60.  50 
micron scale bar on each image and the fluorescence intensity scale, top, increases from black 
(background/no fluorescence) through to white (max. fluorescence). 
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Figure 6.22. Confocal microscopy: qualitative uptake and localisation of m-THPC (red) in 10 micron frozen 
tumour sections (grey) at 24 h following intravenous administration of 0.3 mg kg-1 m-THPC in Foscan and 
covalently bound (mono or tetrasilane) in small (~20 nm) or large (~90 nm) ORMOSIL NPs at x20.  (A) 
Large (mono) (B) Large (tetra) (C) Small (mono) (D) Control (no m-THPC). 
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vi. Toxicology 
Biochemical blood tests to assess liver/renal enzyme functions were carried out 
simultaneously on blood serum collected from animals used in pharmacokinetic studies 
over a series of time points ≥28 days (1 M). 
 
 
Figure 6.23. Liver/renal enzyme function assay performed on blood plasma to measure circulating 
concentrations of ALT following intravenous administration of 0.3 mg kg-1 m-THPC in either large (90 nm) 
or small (20 nm) pegylated ORMOSIL NPs covalently incorporating monosilane m-THPC into HL rats.  
Control animals received no m-THPC.  Data points show the mean ± SD, n = 3. 
 
Alanine Transaminase (ALT) is an enzyme which catalyses the two parts of the alanine 
cycle and its increased secretion into the blood circulation is commonly used as an 
indicator to diagnose hepatocellular injury or liver inflammation.  Fig 6.23 A & B show no 
significant difference between levels of ALT in the blood serum of animals that were 
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intravenously administered 0.3 mg kg-1 m-THPC in either 20 nm (small) or 90 nm (large) 
pegylated ORMOSIL NPs with covalently incorporated monosilane m-THPC versus 
control animals, which received no m-THPC.  Data were statistically analysed and this was 
true for animals at all time intervals, except at 6 h (p≤0.05), following administration of 90 
nm pegylated ORMOSIL NPs.  Overall results suggested no predominant signs of 
hepatocellular injury or liver toxicity were caused by the administration of pegylated 
ORMOSIL NPs in vivo over 28 days. 
 
 
Figure 6.24. Liver/renal enzyme function assay performed on blood plasma to measure circulating 
concentrations of AST following intravenous administration of 0.3 mg kg-1 m-THPC in either large (90 nm) 
or small (20 nm) pegylated ORMOSIL NPs covalently incorporating monosilane m-THPC into HL rats.  
Control animals received no m-THPC.  Data points show the mean ± SD, n = 3. 
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Aspartate Transaminase (AST) is an enzyme which catalyses the reversible transfer of an 
α-amino group between aspartate and glutamate and is essential in amino acid metabolism.  
Its increased secretion into the blood circulation is commonly used as an indicator to both 
diagnose liver injury and assess renal function (acute renal disease).  Fig 6.24 A & B show 
no significant difference between levels of AST in the blood serum of animals that were 
intravenously administered 0.3 mg kg-1 m-THPC in either 20 nm (small) or 90 nm (large) 
pegylated ORMOSIL NPs with covalently incorporated monosilane m-THPC versus 
control animals, which received no m-THPC.  Data were statistically analysed and this was 
true for animals at all time intervals.  Overall results suggested no predominant signs of 
liver toxicity or renal impairment were caused by the administration of pegylated 
ORMOSIL NPs in vivo over 28 days. 
 
 
Figure 6.25. H&E stained 4 micron sections of rat liver following intravenous administration of 0.3 mg kg-1 
mono-m-THPC in ORMOSIL NPs or no injection (control).  (A) Control liver x20 (B) Control liver x10 (C) 
m-THPC in small ORMOSIL NPs (~20 nm) following 2 weeks administration (x60) (D) m-THPC in large 
ORMOSIL NPs (~90 nm) following 2 weeks administration (x100). 
6. Organically Modified Silica Nanoparticles 
- 225 - 
Liver tissue acquired from the same HL rats used in pharmacokinetic studies was fixed and 
stained.  H&E sections showed evidence of mild inflammation following intravenous 
injection of 0.3 mg kg-1 m-THPC in 20 nm pegylated ORMOSIL NPs (mono-mTHPC) at 2 
weeks (Fig 6.25 C).  This was indicated by the presence of dense cell bodies (granulomas) 
observed in selected regions of the liver compared to control liver tissue (no ORMOSIL 
NPs).  Liver sections imaged following intravenous injection of 0.3 mg kg-1 m-THPC in 90 
nm pegylated ORMOSIL NPs (mono-mTHPC) at 2 weeks (Fig 6.25 D) also showed 
evidence of mild inflammation due to the presence of granular bodies inside macrophages 
(D). 
 
 
Figure 6.26. H&E stained 4 micron sections of rat lung following intravenous administration of 0.3 mg kg-1 
mono-m-THPC in ORMOSIL NPs or no injection (control).  (A) Control lung x10 (B) m-THPC in small 
ORMOSIL NPs (~20 nm) following 2 weeks administration (x20) (C) m-THPC in large ORMOSIL NPs 
(~90 nm) following 2 weeks administration (x20).  
 
H&E lung tissue sections showed evidence of mild inflammation following intravenous 
injection of 0.3 mg kg-1 m-THPC in both 20 nm and 90 nm pegylated ORMOSIL NPs 
(mono-mTHPC) at 2 weeks (Fig 6.26) versus control lung tissue (no ORMOSIL NPs).  
This was indicated by the thickening and increase in cellularity of the epithelial lining of 
the alveoli with the presence of a large number of foamy macrophages (indicated by black 
arrows).   
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In kidney sections no apparent signs of toxicity were observed following intravenous 
administration of either 20 nm or 90 nm pegylated ORMOSIL NPs (mono-mTHPC) at 2 
weeks (Fig 6.27), with perhaps only a slight increase in cell number with ORMOSIL NPs 
kidney sections in comparison to control kidney tissue (no ORMOSIL NPs). 
 
Figure 6.27. H&E stained 4 micron sections of rat kidney following intravenous administration of 0.3 mg kg-
1
 mono-m-THPC in ORMOSIL NPs or no injection (control).  (A) Control kidney x10 (B) m-THPC in small 
ORMOSIL NPs (~20 nm) following 2 weeks administration (x20) (C) m-THPC in large ORMOSIL NPs 
(~90 nm) following 2 weeks administration (x20). 
 
Spleen H&E sections (Fig 6.28) showed no significant difference in appearance of red or 
white pulp to suggest apparent signs of toxicity following intravenous administration of 
either 20 nm or 90 nm pegylated ORMOSIL NPs (mono-mTHPC) at 2 weeks versus 
control spleen tissue (no ORMOSIL NPs). 
 
Figure 6.28. H&E stained 4 micron sections of rat spleen following intravenous administration of 0.3 mg kg-
1
 mono-m-THPC in ORMOSIL NPs or no injection (control).  (A) Control spleen x10 (B) m-THPC in small 
ORMOSIL NPs (~20 nm) following 2 weeks administration (x20) (C) m-THPC in large ORMOSIL NPs 
(~90 nm) following 2 weeks administration (x20). 
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vii. PDT studies 
 
Figure 6.29. Typical H&E stained MC28 tumour sections scanned with the Hamamatsu Nanozoomer to observe the extent of PDT damage, measured by the area of necrosis (dotted 
perimeter), after 0.3 mg kg-1 of m-THPC was injected i.v  (A) Foscan DLI: 6 h, and pegylated ORMOSIL NPs bound with monosilane m-THPC (B) ~20 nm, DLI: 6 h (C) ~90 nm, DLI: 6 h 
(D) Control (no m-THPC) (E) ~20 nm, DLI: 24 h (F) ~90 nm, DLI: 24 h.  Permission for the use of histological images of PDT was granted courtesy of Dr Josephine Woodhams. 
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Sample IR322 SF311 SF288* 
Size (nm) 16 90 110 
m-THPC (µM) 499 187 270 
Loading (%) 2.08 1.87 1.6 
PEG length 2000 2000 2000 
Silane bonding mono mono tetra* 
 
Table 6.8. Specifications of ORMOSIL NP preparations used for PDT studies. 
 
Table 6.8 identifies pegylated ORMOSIL NPs used in PDT studies.  PDT studies were 
carried out in the MC28 tumour rat model to deduce the efficacy of treatment with 
pegylated ORMOSIL NPs covalently incorporating m-THPC in comparison to Foscan.  
PDT damage was observed through H&E sections cut from treated tumour tissues (Fig 
6.29) and the area of tumour necrosis (mm2) was calculated.  Tumour sections are 
indicative of typical PDT damage observed following intravenous administration of 0.3 mg 
kg-1 of either Foscan or pegylated ORMOSIL NPs with monosilane bound m-THPC in 
either 20 nm or 90 nm sized NPs at DLIs of either 6 or 24 h (Fig 6.29).  These qualitative 
images were quantified and show maximal PDT tumour necrosis was observed with 
Foscan at both DLIs (50 mm2) when tumours were irradiated with 10 J of light delivered at 
100 mW (100 s) interstitially (Fig 6.30).  20 nm ORMOSIL NPs demonstrated equal PDT 
efficacy to Foscan at a DLI of 6 h (50 mm2), however, this decreased twofold at a DLI of 
24 h (Fig 6.29 B & E).  Larger 90 nm ORMOSIL NPs follow the same pattern of PDT 
induced necrosis, with a decrease in observed damage at a DLI of 24 h compared to 6 h 
(Fig 6.29 C & F).  Fig 6.30 additionally illustrates the PDT efficacy of large ORMOSIL 
NPs with tetrasilane bound m-THPC.  Interestingly, these NPs showed an increase in PDT 
tumour damage (50 mm2) to rival that of Foscan at the longer selected DLI (24 h) 
compared to the shorter DLI of 6 h (H&E sections not displayed in Fig 6.29).  Control 
tissues that received either no drug or light showed no response to treatment (Fig 6.29 D).   
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Figure 6.30. The area of PDT tumour necrosis (mm2) following irradiation of tumours in female HL rats 
with 10 J of light at 100 mW at a DLI of either 6 h or 24 h, after intravenous injection of 0.3 mg kg−1 m-
THPC in Foscan or pegylated ORMOSIL NPs; ≤20 nm, mono-m-THPC (IR322), ≥90 nm, mono-m-THPC 
(SF232/311), ≥90 nm, *tetra-m-THPC (SF288).  Negative control tumour tissue (received either no drug or 
light treatment, data not shown).  Data points show the mean±SD, n=4. 
 
* 
* 
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Targeted cRGD ORMOSIL NPs 
i. Absorbance Spectra 
m-THPC covalently linked (tetrasilane) in targeted cRGD- and inactive targeted cRAD-
ORMOSIL NPs (Fig 6.31) demonstrated a slight peak broadening and small bathochromic 
shifts for both absorbance peaks (m-THPC λexc = 425 nm, λem = 654 nm), in comparison 
to Foscan.  There was also a greater amount of light scattering between 300-400 nm likely 
due to the presence of silica, as observed in previous ORMOSIL spectra.  
 
Figure 6.31. Absorbance spectra of m-THPC covalently incorporated (tetrasilane) in targeted cRGD-
ORMOSIL NPs and inactive targeted cRAD-ORMOSIL NPs in PBS.  All solutions prepared at 10 µM m-
THPC concentrations. 
 
  
 
6. Organically Modified Silica Nanoparticles 
- 231 - 
ii. Confocal microscopy in vitro 
Tumour cell lines were incubated with a cRGD-FITC conjugate to assess the presence of the αvβ3 integrin.  This was identified through the expression of a 
positive green fluorescence FITC signal, indicative of conjugate binding to the αvβ3 integrin on the cell surface.  A549 cells are recognised as positively 
expressing αvβ3 integrin, which has been demonstrated here following inbucation with cRGD-FITC conjugate for 4 h (Fig 6.32).  Lower levels of green 
fluorescence were observed with MCF-7 cells (Fig 6.33), in accordance with the literature.  A positive FITC fluorescence was detected with the domestic 
MC28 cells (Fig 6.33), under the same conditions, suggestive of αvβ3 integrin expression. 
 
 
Fig 6.32. Confocal microscopy images in vitro following incubation with 50 nM cRGD-FITC conjugate for 4 h in human A549 adenocarcinoma alveolar basal epithelial cells to determine 
αvβ3 integrin expression. 
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Fig 6.33. Confocal microscopy images in vitro following incubation with 50 nM cRGD-FITC conjugate for 4 h in either human MCF-7 breast adenocarcinoma cells or rat MC28 
fibrosarcoma cells to determine αvβ3 integrin expression. 
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iii. Biodistribution studies in vivo 
Targeted uptake studies with targeted cRGD-ORMOSIL NPs were not carried out in vitro 
here due to more extensive work having been previously published by collaborators.  Due 
to the strong cRGD-FITC fluorescence signal observed with MC28 cells, these cells were 
taken forward for in vivo studies. 
 
Biodistribution studies with m-THPC covalently incorporated in targeted cRGD-
ORMOSIL NPs and inactive targeted cRAD-ORMOSIL NPs were carried out in selected 
tissues.  Doses of 0.1 mg kg-1 (m-THPC drug equivalent) were administered in Hooded 
Lister rats implanted with MC28 subcutaneous tumours for analysis at 24 h to measure 
levels of m-THPC in tissues using chemical extraction.  These studies focused on one time 
interval to compare data with studies on untargeted non-biodegradable pegylated 
ORMOSIL NPs, previously described in this chapter. 
 
A range of organs were selected for quantitative analysis to compare the relative uptake of 
m-THPC to that of tumour tissue when delivered by cRGD- and cRAD-ORMOSIL NPs.  
At 24 h, a trend for m-THPC concentrations in the blood serum were observed as 
approximately two-fold greater when administered in cRAD- ORMOSIL NPs (~0.2 µg 
mL-1) compared to cRGD-ORMOSIL NPs (~0.1 µg mL-1), however, this was not 
significant (Fig 6.34).  The highest m-THPC concentrations were observed in the liver 
(~0.7 µg g-1) and spleen (~1.4 µg g-1) for both ORMOSIL NPs at 24 h, where m-THPC 
uptake was almost identical.  m-THPC uptake in the kidneys, lung and skin were observed 
at the lowest concentrations at this time, with almost negligible m-THPC concentrations 
detected for each NP (≤0.05 µg g-1).  m-THPC accumulation in tumour tissue appeared to 
parallel that of the blood serum, with similar concentrations of m-THPC for both NPs, but 
a greater uptake of cRAD-ORMOSIL NPs observed in comparison to cRGD-NPs, which is 
significant at this time (Fig 6.34).   
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Fig 6.34. Concentration of m-THPC (µg g-1) in selected tissues of the Hooded Lister rat following an 
intravenous injection of 0.1 mg kg-1 m-THPC in targeted cRGD-ORMOSIL NPs (blue) or inactive targeted 
cRAD-ORMOSIL NPs (green) ~75 nm at 24 h.  Data points show the mean ± s.d., n = 4. 
 
 
 
Fig 6.35. Comparing the concentration of m-THPC (µg g-1) in tumour tissue of the Hooded Lister rat 
following an intravenous injection of either 0.1 mg kg-1 m-THPC in targeted cRGD-ORMOSIL NPs or 
inactive targeted cRAD-ORMOSIL NPs (75 nm) versus 0.3 mg kg-1 m-THPC  in Foscan or 90 nm and 20 nm 
untargeted pegylated ORMOSIL NPs at 24 h.  Data points show the mean ± s.d., n = 4. 
* 
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Figure 6.35 demonstrates a primitive comparison between previously discussed untargeted 
pegylated ORMOSIL NPs, both large (90 nm) and small (20 nm), administered at a higher 
m-THPC dose (0.3 mg kg-1) versus targeted cRGD- ORMOSIL NPs (75 nm) administered 
at a lower m-THPC dose (0.1 mg kg-1).  m-THPC was covalently bound inside ORMOSIL 
NPs by a tetrasilane linker in all formulations represented in Fig 6.35.  Despite the 
difference in m-THPC doses, small (20 nm) untargeted pegylated ORMOSIL NPs and 
inactive targeted cRAD-ORMOSIL NPs (75 nm) appear to accumulate at similar 
concentrations in MC28 tumour tissue of the HL rat.  cRGD- ORMOSIL NPs demonstrate 
the lowest uptake in the tumour at 24 h. 
 
iv. Fluorescence microscopy  
Fluorescence microscopy of frozen tissue sections taken from the same animals (MC28 HL 
rats) as used in chemical extraction studies (0.1 mg kg-1 m-THPC intravenous injection in 
cRGD- and cRAD-ORMOSIL NPs at 24 h), shown in Figure 6.36, demonstrated the 
presence of intense bright fluorescence spots in false coloured CCD images, which were 
distributed throughout the liver (Fig 6.36).  This was indicative of high m-THPC uptake 
when covalently (tetrasilane) incorporated in both cRGD- and cRAD-ORMOSIL NPs at 24 
h.  The same high m-THPC fluorescence was also observed for both NP groups in the 
spleen, with m-THPC localisation predominantly in the red pulp of spleen tissue (bulk) 
compared to the clearly visible outline of the darker white pulp.  Lung tissue generally 
showed low levels of m-THPC fluorescence but the incidence of bright white spots, 
suggestive of m-THPC fluorescence, was greater following administration of cRAD- 
versus cRGD-ORMOSIL NPs.  Furthermore, images also revealed high m-THPC 
fluorescence within the kidneys for both particles at this time but the lowest observed 
fluorescence in tumour tissue.   
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Fig 6.36. Typical examples of false coloured fluorescence microscopy CCD images of m-THPC in 10 micron frozen tissue sections following an intravenous injection of 0.1 mg kg-1 m-
THPC in either pegylated RGD targeted (top) or pegylated RAD untargeted ORMOSIL NPs (middle) (75 nm) at 24 h. (Bottom) equivalent frozen tissue sections stained with H&E.  100 
micron scale bar on each image and the fluorescence intensity scale, top, increases from black (background/no fluorescence) through to white (max. fluorescence).
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v. PDT studies  
 
Figure 6.37.  The percentage of MC28 tumour tissue necrosis (%) in the HL rat induced by PDT with 10 J of 
light at 100 mW following intravenous injection of 0.1 mg kg-1 of m-THPC in either Foscan, targeted cRGD-
ORMOSIL NPs and inactive targeted cRAD-ORMOSIL NPs at a drug:light interval of 24 h. 
 
When examined histologically, the percentage area of tumour necrosis (from the total 
tumour tissue section) induced by PDT at a drug light interval of 24 h showed there was no 
significant difference between Foscan, cRGD or cRAD- ORMOSIL NPs following their 
intravenous administration at a dose of 0.1 mg kg-1 m-THPC equivalent (Fig 6.37).  
Results showed there was a trend towards a greater percentage area of tumour necrosis 
induced with Foscan (53%) and cRAD-ORMOSIL NPs (52%), which were almost 15% 
higher than tumour necrosis induced with cRGD-ORMOSIL NPs (39%), however, this 
was not significant.  There was a significant difference in PDT tumour necrosis following 
administration of m-THPC formulations versus the control group, which received light 
treatment but no m-THPC (p≤0.001).   
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6.4 Discussion 
In recent years the use of non-biodegradable NPs, such as silica NPs, offer many 
advantageous properties in fulfilling requirements for applications in PDT and are explored 
in this chapter.  On account of their rigid, porous structures, they are able to covalently 
anchor, rather than physically entrap (non-covalent) photosensitisers, without affecting 
their photophysical and spectroscopic capabilities (Selvestrel, F. et al. 2013).  As the PS 
does not need to be released in order to elicit phototoxic effects, this circumvents the 
problems of premature drug leakage, increases PS bioavailability at the site of action and 
reduces exposure to normal tissues.  Additionally, composite materials can be modified 
(PEG attachment) to avoid rapid capture by the RES (i.e. ORMOSIL), and increase either 
passive tumour uptake via the EPR effect or active tumour uptake through the conjugation 
of surface biomolecules to further improve tumour selectivity.  However, issues associated 
with the retention and long-term toxicity of non-biodegradable NPs must be considered 
upon in vivo investigation and are explored here.  The central aim of these studies was to 
deduce m-THPC biodistribution when covalently incorporated inside non-biodegradable 
ORMOSIL NPs, versus Foscan, and assess PDT efficacy for the first time in vivo with 
these NPs.  Furthermore, the latter section of this chapter explored the potential of 
targeting ORMOSIL NPs with cRGD peptide to enhance these properties further.   
 
Untargeted ORMOSIL NPs 
Photophysical studies 
The absorbance spectra of pegylated ORMOSIL NPs was used to deduce spectroscopic 
characteristics of m-THPC versus covalently encapsulated m-THPC (derivatives).  There 
was little observed difference between free forms of m-THPC and monosilane or 
tetrasilane bound forms of m-THPC in methanol or Solvable.  This is perhaps expected as 
the addition of the silane linker is peripheral to the porphyrin ring of m-THPC and the 
covalent linkage of other photosensitisers into ORMOSILs has been demonstrated by other 
groups without detrimental effect to their photochemical properties due to the low polarity 
of the organosilica matrix (Ohulchanskyy, T. Y. et al. 2007;Selvestrel, F. et al. 2013).  
Moreover, all ORMOSIL NPs diluted in saline buffer, as when administered to animals 
(data not shown), did not indicate any reduction in m-THPC absorbance intensity (652 nm) 
or suggest the presence of hydrophobic aggregates, confirming that the covalently bound 
m-THPC was indeed encapsulated within the particles as monomers.   
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In vitro 
m-THPC release from ORMOSIL NPs 
Release rates of physically entrapped m-THPC (non-covalent) from non-pegylated and 
pegylated ORMOSIL NPs were carried out by collaborators at the University of Padova 
(see Appendix I – Fig C.5 Rate of m-THPC release from ORMOSIL NPs).  These studies 
indicated >90% release of m-THPC following incubation with non-pegylated ORMOSIL 
NPs in 3% FBS compared to ~20% release of m-THPC from pegylated ORMOSIL NPs 
under the same conditions.  This increased to ~30% release of m-THPC in the presence of 
10% FBS and >60% release with 50% FBS and was confirmed by in vitro studies in 
human oesophageal squamous carcinoma cells (KYSE 510), which showed cellular uptake 
of physically entrapped m-THPC in ~30 nm ORMOSIL NPs was mediated by transfer to 
serum proteins, promoting premature release of m-THPC from NPs to the media 
(Compagnin, C. et al. 2009).  As a result, there was little difference exhibited in the 
cellular uptake of free m-THPC or when delivered by the NPs.  This phenomenon was 
significantly reduced using pegylated NPs, where a much smaller (<20%) and slower 
release of mTHPC from the nanoparticles was observed with cell culture medium 
containing 3% FBS.   
 
No such serum release-rate experiments were replicated with covalently incorporated m-
THPC in ORMOSIL NPs in studies here, however, confocal images obtained through in 
vitro studies with MC28 tumour cells, indicated a higher uptake of m-THPC with smaller 
NPs (~20 nm) in comparison to large NPs (~100 nm) following a 4 h incubation period 
(Fig 6.9).  The smaller size of the NPs may be more favourable in promoting intracellular 
internalisation, as larger NPs may be more inhibited from entering the cell due to steric 
hindrance at the cell membrane on account of their size.  It is believed m-THPC 
fluorescence is directly associated with NP uptake in these studies due to the covalent 
anchorage of m-THPC within ORMOSIL NPs, therefore differences in NP size may be a 
greater contributing factor in the total m-THPC cell uptake.  However, no m-THPC release 
rate experiments (+ FBS) have been carried out to date with these NPs to confirm this.  
Differences in covalent m-THPC incorporation within each of the NPs for in vitro 
experiments, i.e. monosilane bound m-THPC in 20 nm NPs versus tetrasilane bound in 100 
nm NPs, may also have contributed to the decrease in observed intracellular fluorescence 
with the larger NPs (Fig 6.9).  There was little difference indicated between the absorbance 
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spectra of mono- versus tetrasilane m-THPC (free or bound in ORMOSIL NPs) in MeOH 
(Fig 6.6), however, in vitro conditions, including incubation with cell media containing 
10% FCS, may have affected their fluorescence properties.  It is unlikely FCS directly 
interacts with the PS to cause aggregation and fluorescence quenching as serum proteins 
are too bulky to enter through silica NP pores.  Furthermore, any decrease in fluorescence 
is unlikely to be due to the formation of hydrophobic aggregates as tetrasilane bound m-
THPC molecules cannot migrate towards each other in aqueous environments on account 
of strong covalent bonding within the NP (Fig 6.2C).  Any reduction in fluorescence signal 
was thought to be attributed to unanticipated perturbation in photophysical properties, such 
as the lack of mobility and restricted rotation of tetrasilane m-THPC due to its anchorage at 
four points to the silica matrix.  As porphyrins are planar molecules, which rotate to 
preferentially maintain this planarity, any forced distortion is likely to induce a reduction in 
fluorescence lifetime as a result of flexing dye molecules, causing quenching.  The 
excessive rigidity of tetrasilane m-THPC to the ORMOSIL framework in highly similar 
NPs was described by collaborators in the presence of water and was thought to potentially 
lead to a reduction in singlet oxygen yield in aqueous environments (Selvestrel, F. et al. 
2013).  This would not apply to the same degree with monosilane bound m-THPC, as its 
single bond to the silica matrix allows for a much greater range of movement.  The greater 
red fluorescence signals observed in cells with 20 nm ORMOSIL NPs, bound with 
monosilane m-THPC, are in accordance with previous studies carried out in our laboratory 
(MacKenzie et al., 2011 – data not published), where no spectroscopic changes were 
observed with monosilane bound m-THPC in ORMOSIL NPs in the presence of FCS.   
 
m-THPC uptake and localisation  
Confocal images presented here also offered information on the intracellular localisation of 
m-THPC, as the fluorescence for each nanocarrier was not detected in the nucleus but 
uniformly dispersed in the cytoplasm (Fig 6.9).  This was also observed upon incubation of 
free m-THPC (Foscan) with MC28 tumour cells but the intracellular fluorescence was 
more intense.  This pattern of uptake is in good accordance with the literature (Marchal, S. 
et al. 2007;Melnikova, V. O. et al. 1999a).  Compagnin et al., have shown red m-THPC 
fluorescence distributed throughout the cytoplasm of when using similar (non-pegylated) 
ORMOSIL NPs but also suggested localisation at the RER and Golgi.  However, this was 
proceeding leaching of m-THPC from NPs mediated by serum proteins and as such was 
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attributed to the localisation of free intracellular m-THPC (Compagnin, C. et al. 2009).  
More recently, the same group investigated the cellular uptake of free m-THPC versus 
pegylated ORMOSIL NPs loaded with tetra-silane bound m-THPC following 24 h 
incubation with lung cancer cells (A549) and normal lung cells (CCD-34Lu) for 24 h 3% 
FCS.  Using a FACS analysis, a much lower uptake of m-THPC embedded in NPs was 
taken up by both cell lines (~5%) in comparison to measurements of free m-THPC 
(Selvestrel, F. et al. 2013).  In this investigation, red fluorescence can be attributed to 
bound m-THPC within ORMOSIL NPs 
 
Preliminary pharmacokinetics at 24 h 
Initial batches of small ORMOSIL NPs of ~20 nm indicated m-THPC remained at 
approximately 1.5 µg g-1 in the blood serum at 24 h, which was much greater than that of 
previous investigated biodegradable pegylated liposomal formulations (Fig 6.10).  
However, despite this high circulating m-THPC concentration with non-biodegradable 
NPs, much lower levels of m-THPC accumulated in corresponding tumour tissue at this 
time.  Conversely, 90 nm ORMOSIL NPs were also retained in the blood at similar high 
concentrations at 24 h and delivered m-THPC at much higher concentrations to tumour 
tissue.  This is thought to be attributed to passive targeting of large NPs in solid tumours.  
No radical differences in m-THPC uptake of tissues were identified between FosPEG and 
ORMOSIL NPs, which is perhaps surprising given the expected differences in their tissue 
retention and routes of elimination from the body as a result of their level of 
biodegradability.  It is probable by 24 h liposomal nanocarriers may have degraded 
therefore liver accumulation at this time solely indicates released m-THPC rather than 
liposomally entrapped m-THPC.  Released m-THPC may be potentially bound by serum 
complexes and transported to the liver to produce similar levels of m-THPC accumulation 
as ORMOSIL NPs.  20 nm ORMOSIL NPs displayed high m-THPC accumulation in lung 
tissue at 24 h (~ 2.2 µg g-1); which was more than threefold greater than 90 nm silica NPs 
(~ 0.6 µg g-1), between 2-3 times greater than FosPEG formulations (~ 0.5 – 1.0 µg g-1) 
and almost fifteen times that of Foscan (~ 0.15 µg g-1).  Unlike FosPEG data in the lung 
(Chapter 4: Liposomes), this did not mimic the concentration of m-THPC in the blood 
plasma at this time.  Increased uptake in the lungs has been identified in a number of 
biodistribution studies with various NPs, such as other ORMOSIL NPs (Kumar, R. et al. 
2010), quantum dots (Choi, H. S. et al. 2007) and silica NPs (Yu, T. et al. 2012b).  Lung 
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accumulation in these studies was believed to be the result of passive entrapment in the 
pulmonary arteries due to the large surface area of lung tissue, its abundant blood supply 
and specialised anatomical structures, and dependency of size and charge on uptake.  
Greater retention was observed with larger (>34 nm) and/or positively charged NPs in 
mice (Choi, H. S. et al. 2010).  It is unclear in the present investigation why initial batches 
of smaller ORMOSIL NPs are preferentially retained in the lungs over larger ORMOSIL 
NPs.  All ORMOSIL NPs used in this investigation were reported as slightly negatively 
charged (-5.2 mV).  It has recently been reported that accumulation of NPs in the lungs 
may be preferential in the treatment of cancer, as this area is notoriously difficult to access 
(Anselmo, A. C. et al. 2013). 
 
Pharmacokinetic analysis 
The plasma clearance pharmacokinetics of m-THPC in redeveloped ORMOSIL NPs of 20 
nm and 90 nm in the HL rat model best fit a three exponential decay and were analsysed by 
methods described in ; Chapter 4: Liposomes.   
 
Compartmental approach 
Compartmental analysis gave a biological half-life (t1/2 third compartment) of 577 h and 
301 h for 20 nm and >90 nm ORMOSIL NPs, respectively, following intravenous 
administration of 0.3 mg kg-1 mTHPC (Table 6.6) compared to 90 h for Foscan (Foscan 
data from Chapter 4: Liposomes).  To our knowledge no other in vivo studies 
investigating the biodistribution of ORMOSIL NPs have reported on pharmacokinetic 
parameters for direct comparisons but biological half-lives calculated for other PEG-
modified non-biodegradable silica NPs have shown much lower half-lives, i.e. t1/2 80 mins 
for RuBYP doped NPs of ~45 nm in mice (He, X. et al. 2008).  These differences could be 
a result of various silica precursors, NP sizes, dye incorporation methods and animal 
models used.  The increase in t1/2 deduced for 20 nm ORMOSIL NPs compared to 90 nm 
NPs is surprising given extensive evidence on the faster clearance and elimination of 
smaller sized NPs from in vivo models (Choi J et al. 2011).  However, both 20 nm and 90 
nm ORMOSIL NPs are equally likely to be cleared by longer excretion pathways on 
account of their non-bioderadability.  The compartmental model estimated the initial Vd 
from the central compartment as 5008 mL kg-1 for 20 nm ORMOSIL NPs and 1131 mL kg-
1
 for 90 nm ORMOSIL NPs.  These values strongly indicate that m-THPC covalently 
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bound in non-biodegradable ORMOSIL NPs is selectively retained in different tissues at 
early time points, as the volumes of distribution are so much greater than the blood volume 
of a rat (50 – 70 mL kg-1) (Jones, H. J. et al. 2003).  Moreover, 20 nm ORMOSIL NPs (20 
nm) have a higher volume of distribution (Vd) indicating a greater uniform migration out of 
the vascular compartment into deep tissues, likely due to their smaller size.  Foscan has a 
much higher volume of distribution than both ORMOSIL NPs in first and third 
compartments, probably due to the fact it is a smaller molecule and is rapidly bound by 
serum proteins (Triesscheijn, M. et al. 2007).  Interestingly, all m-THPC formulations have 
a similar volume of distribution for the second compartment (Vd), which is representative 
of the first phase of migration out of the central blood compartment into tissues.   
 
Non-compartmental approach 
Non-compartmental analysis gave plasma m-THPC clearance rates of 0.002 and 0.007 mg 
kg-1 h-1 and t1/2 lives of, 1854 h (~77 days) and 109 h (~5 days) for 20 nm and 90 nm 
ORMOSIL NPs, respectively.  The large dissimilarity in t1/2 values of m-THPC between 90 
nm NPs and 20 nm NPs implies that with increasing NP size, m-THPC remains in 
circulation for shorter periods.  This is perhaps because larger NPs are not taken up as 
effectively into cells therefore are eliminated more efficiently (as demonstrated with in 
vitro studies).   
 
m-THPC biodistribution and uptake in vivo: normal tissues 
Liver 
Foscan was observed at the lowest concentrations in the blood serum, relative to pegylated 
ORMOSIL NPs (20 nm & 90 nm), which was comparable to biodegradable pegylated 
liposomal m-THPC.  Xie et al. reported a greater uptake of 20 nm silica NPs versus 80 nm 
in the major organs of the RES; liver, spleen and lungs in mice (Xie, G. et al. 2010).  
Accumulation of m-THPC incorporated in ORMOSIL NPs was observed at the earliest 
time points (≤6 h) in the liver and spleen, regardless of size, and was much greater than 
that of biodegradable pegylated liposomal nanocarriers and Foscan, than in all other organs 
over 28 days.  Furthermore, unlike the exponential decay observed with FosPEG 
formulations, a terminal elimination phase does not appear to be obtained with m-THPC in 
ORMOSIL NPs in the liver or spleen over this period.  Qualitative confocal microscopy 
images of ex vivo liver tissue (Fig 6.18) and frozen sections of liver tissue (Fig 6.19-21) in 
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this investigation showed m-THPC localised in the Kupffer cells (macrophages) of the 
liver, following administration of 0.3 mg kg-1 m-THPC in 20 nm and 90 nm pegylated 
ORMOSIL NPs at 24 h, whereas Foscan was internalised and appeared as bright white 
spots, indicative of accumulation in lysosomes in the cytoplasm (Fig 6.16).  Both 
techniques also demonstrated a slightly higher accumulation of m-THPC in 90 nm NPs 
compared to 20 nm NPs in these organs, suggesting their size and case material are 
important contributing factors. 
 
Lungs 
ORMOSIL NPs used in this investigation are known to interact with serum proteins 
(Compagnin, C. et al. 2009).  Other studies have indicated the binding of serum proteins 
can lead to strong RES uptake and increase the hydrodynamic diameter of NPs, which is 
more likely to cause obstruction in vessels, partially explaining any increase in NP 
accumulation in lung tissue (Yu, T. et al. 2012b).  It was also demonstrated that 
nanocarriers were able to redistribute to different tissues of the RES through macrophage 
uptake and smaller silica NPs can aggregate, causing transient embolisms in lung 
capillaries in mice in vivo which are endocytosed by macrophages (Xie, G. et al. 
2010;Zhang, J. S. et al. 2005).  Surprisingly, a lower maximal uptake of m-THPC in 
ORMOSIL NPs was observed in the lungs over 28 days compared to liposomal m-THPC 
formulations (Fig 6.14).  However, ORMOSIL NP accumulation was still greater in the 
lungs than in most other organs over the full time series (Fig 6.18).  This data is in contrast 
with Prasad et al., who showed 20 nm ORMOSIL NPs accumulated at less than 5% of 
similar injected doses in the lungs of mice using an NIR fluorophore DY776 and 
radiolabelled 124I, with the majority of particles (75%) accumulating in the liver and spleen 
at 24 h.  This difference is potentially due to the conjugation of 124I on to the outer surface 
of the ORMOSIL NPs, which the authors claimed may have altered the surface properties.  
Furthermore, the amide linker used to attach the 124I was susceptible to enzymatic cleavage 
in vivo, reducing its half-life and therefore the accuracy of scintillation counting, whereas 
m-THPC was covalently incorporated in the current investigation.  Other reports with 
mesoporous silica NPs (~120 nm) have also shown a preferential accumulation in lung 
tissue compared to nonporous silica NPs in immune-competent CD-1 mice following 
intravenous injection.  However, redistribution of transient NPs from this organ was 
observed by 72 h without significant internalisation (Yu, T. et al. 2012a).  Lung data (Fig 
6.14) presented in this chapter showed redeveloped batches of pegylated ORMOSIL NPs 
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accumulated to a much lesser degree than initial batches at 24 h (Fig 6.10).  Furthermore, 
unlike liposomal NPs, ORMOSIL NP data did not particularly correlate to the blood 
plasma pharmacokinetics.  A sharp decline in m-THPC concentration was observed with 
both ORMOSIL NPs in lung tissue by 28 days, which suggests redistribution or clearance 
at this time (Fig 6.14).   
 
Kidneys 
Recently, silica NPs (~150 nm) have been reported as being capable of dissolving in vivo 
in rat models as 36% of injected doses were eliminated through the urine within four days; 
however, information from these studies was limited with no details on methods used to 
quantify silica NP concentration (Borak, B. et al. 2012).  ORMOSIL NPs used in these 
studies were much larger than suggested renal thresholds (20≥100 nm), indicating 
ineffective clearance through glomerular filtration as it is size dependent.  The kidneys 
showed a much lower uptake of m-THPC in 20 nm and 90 nm ORMOSIL NPs in 
comparison to the liver at the same time intervals.  Decreased excretion rates or extended 
exposure can lead to associated toxicity from the accumulation of non-biodegradable NPs.  
It is more likely ORMOSIL NPs were excreted via the hepatobiliary (liver and bile) 
pathway, passing through the colon (Kumar, R. et al. 2010).  However, this cannot be 
confirmed, as metabolic studies were carried out in these investigations.  
 
m-THPC uptake in vivo: tumour tissue 
Initial batches of pegylated ORMOSIL NPs showed a much higher uptake of m-THPC in 
90 nm particles into tumour tissue at 24 h than 20 nm particles or Foscan, which 
corresponded to the blood serum pharmacokinetics of m-THPC with each formulation (Fig 
6.11).  Moderately elevated levels of tumour accumulation via passive targeting have been 
demonstrated previously using PpIX loaded silica NPs of ~45 nm in tumour-bearing mice 
(Simon, V. et al. 2010).  The use of larger NPs appears to be more effective in optimally 
exploiting this natural EPR phenomenon (Maruyama et al., 1999), but there remains a 
balance between ideal particle size for clearance and for tumour retention.   
 
Pharmacokinetic data of redeveloped ORMOSIL NPs revealed a much longer biological 
half-life for smaller (20 nm) ORMOSIL NPs than larger NPs (90 nm) but showed little 
significant difference in m-THPC accumulation in tumour tissue over 96 h with 90 nm 
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versus 20 nm pegylated ORMOSIL NPs in comparison to Foscan (Fig 6.17), but larger 
NPs levels were consistently higher.  These observations were thought to be related to 
particle size and results were confirmed by confocal (Fig 6.22) and fluorescence 
microscopy (6.21) carried out at 24 h post inoculation.  A much greater uptake of larger 
(90 nm) ORMOSIL NPs was observed, regardless of covalent m-THPC linkage within 
particles (mono or tetra), compared to 20 nm ORMOSIL NPs and controls (no m-THPC).  
m-THPC fluorescence was uniform in distribution throughout heterogeneous tumour 
tissue.  
 
Toxicology 
Many studies have reported on the biological inertness and non-antigenicity of silica-based 
materials, along with their ability to resist microbial attack (Jain, T. K. et al. 1998;Kumar, 
R. et al. 2010).  However, even an inert material in bulk may be active at the nanoscopic 
level (Nel, A. et al. 2006).  The size and surface chemistry of silica NPs, as with other NPs, 
has been widely reported as having a significant influence on their toxicity, as a result of 
different physiological lipoproteins binding to the NP surface upon systemic administration 
and dictating NP clearance from the body (Choi, H. S. et al. 2007;Decuzzi, P. et al. 
2010;Greish, K. et al. 2012).  The medical hazards associated with intravenously injected 
NPs are related to the release of proinflammatory cytokines and ROS upon administration, 
which may trigger systemic hypersensitivity reactions or intravascular coagulation, due to 
recognition by the immune system receptors (Oberdorster, G. 2010).  This is most pertinent 
in the case of non-biodegradable nanoparticles.  Studies investigating the proinflammatory 
effects in vitro on blood leukocytes (human) with bare and pegylated ORMOSIL NPs, as 
used in these investigations, have demonstrated that the latter, if captured, are 
predominantly bound by circulating monocytes, following little interaction with other 
leukocytes (Segat, D. et al. 2011).  ORMOSIL NP size was a significant contributing factor 
in monocyte selectivity, with smaller ORMOSIL NPs (20 nm) appearing to have a higher 
monocyte association than larger NPs (≥100 nm).  High density surface pegylation of 
ORMOSIL NPs helped to inhibit these effects and strongly decreased monocytic uptake 
and the activation of blood coagulation cascades upon incubation compared to bare 
ORMOSIL NPs (~85%).  As monocytes may release significant amounts of 
proinflammatory cytokines/chemokines into the blood when suitably stimulated, causing 
dangerous conditions such as generalised shock, this reduction in NP monocytic uptake 
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from pegylation is certainly advantageous (Segat, D. et al. 2011).  Furthermore, other 
studies using the similar pegylated ORMOSIL NPs showed they were poorly endocytosed 
by macrophages and demonstrated a reduced procoagulant activity in comparison to non-
pegylated ORMOSIL NPs (Tavano, R. et al. 2010).  This suggests prevention of rapid 
phagocytosis by the mononuclear phagocytic system (MPS, or RES) and the potential of 
pegylated ORMOSIL NPs as valuable drug delivery vehicles. 
 
Route of administration 
The route of administration can also play a fundamental role in NP toxicity.  The 
biokinetics of NPs in the body differs depending on the portal of entry, particularly 
between intravenous administration of NPs versus NPs entering the blood circulation via 
translocation from either the respiratory tract, GI-tract or skin (Oberdorster, G. 2010).  The 
interaction of NPs with different media following administration by various routes results 
in different biological secondary coatings.  Subsequently, their entry into the blood 
circulation will occur at different doses, dose rates and blood oxygenation states, all of 
which affect NP biodistribution to secondary target organs.  For example, many naturally 
occurring (i.e. pollen, dust) or man-made (i.e. fuel emissions, soot) foreign agents enter 
humans via the respiratory system undetected but when delivered systemically, these NPs 
may translocate to the central nervous system (CNS) causing more severe damage by 
oxidative stress (Medina, C. et al. 2007).  Although there have been no reports published 
on the uptake of m-THPC specifically into nerve cells when administered intravenously, 
this may not necessary be true for silica NPs.  Lung tissue is commonly the pro-target, 
particularly for nano-sized particles due to their increased surface area (Medina, C. et al. 
2007).  In the gastro-intestinal (GI) tract; the smaller the particle diameter, the faster they 
can diffuse through the GI secretion to reach the colonic enterocytes (Szentkuti, L. 1997).  
However, there is a caveat between particle size and intracellular uptake or clearance.  If 
not renally filtered (cut-off suggested as 5.5 nm by (Choi, H. S. et al. 2007)) NPs may be 
excreted via the hepatobiliary pathway, which increases their exposure to the GI tract.  
Like the lungs, the GI-tract is highly accessible to stimuli that can induce an inflammatory 
response.  These include inflammatory bowel disease (IBD), ulcerative colitis and the 
chronic inflammatory condition, Crohn’s disease (CD).  Non-biodegradable NPs may 
additionally be reabsorbed by the gut wall depending on their size and permeability 
increasing the area under the drug exposure curve over time.  However, to date, there have 
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been no in vivo studies published on the effects of nanoparticles directly on the GI tract 
(Medina, C. et al. 2007). 
 
Undesirable, prolonged retention of non-biodegradable NPs can cause potential problems, 
as eventually substances that cannot be broken down into biologically benign components 
accumulate in the liver (Choi, H. S. et al. 2007), which can lead to liver injury, including 
mononuclear inflammatory infiltrate at the portal area and hepatocyte necrosis at the portal 
triads (Xie, G. et al. 2010).  It has been speculated that the greater the mass of the NP 
absorbed, the greater the toxic effect (Sahu, M. et al. 2010).  In the case of m-THPC 
delivery with ORMOSIL NPs, the injected concentration of silica, in addition to the 
injected concentration of m-THPC, was calculated for each NP batch based on an animal 
weighing ~200 g (Table 6.4).  All quantitative data was obtained through the detection of 
m-THPC and its accumulation in tissues, not direct ORMOSIL concentrations.  Firstly, as 
these NPs are non-biodegradable, it can be assumed they remain fully intact for their 
duration in vivo.  Secondly, as m-THPC is covalently bound in its monomeric form 
through silane linkers (mono- or tetra-silane) to the ORMOSIL matrix, assuming all its 
spectrofluorimetric properties are retained (i.e. minimal quenching or photobleaching), a 
rough estimation of the concentration of silica can be calculated based on the percentage 
loading of m-THPC in each batch of NPs (Table 6.4).  Upon comparison of maximum 
silica concentrations injected for each ORMOSIL NP batch, there appeared to be no 
significant correlation with chemical extraction (Fig 6.11-6.17) and toxicology data 
obtained (Fig 6.23-6.29). 
 
Liver function assay: AST/ALP 
Qualitatively ORMOSIL NPs alone cannot be visualised in vitro or in ex vivo tissue on 
account of their size, transparency and lack of fluorescence to assess the effects and 
localisation of silica itself.  Toxicology studies therefore focused on detecting 
abnormalities in ex vivo rat blood samples following the administration of m-THPC doped 
ORMOSIL NPs, using biochemical markers.  This included liver/renal function assays to 
establish changes in the concentrations of liver and renal enzyme secreted into the blood 
circulation as markers of organ damage.  Aspartate Transaminase (AST) is an enzyme 
which catalyses the reversible transfer of an α-amino group between aspartate and 
glutamate.  Its increased secretion into the blood circulation is commonly used as an 
indicator to diagnose liver injury and assess renal function (acute renal disease).  Results 
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suggested no significant difference (p<0.05) in the levels of AST in the blood (U/L) over 
28 days following the administration of 20 or 90 nm pegylated ORMOSIL NPs (Fig 6.24).  
This may have been due to large variations in animal groups at selected time intervals as a 
result of the quality of blood samples.  Unsurprisingly the pattern of liver enzyme secretion 
was similar for both enzymes, as the two are synonymously linked in amino acid 
metabolism.  Alanine Transaminase (ALT) catalyses the two parts of the alanine cycle and 
its increased secretion into the blood circulation is commonly used as an indicator to 
diagnose hepatocellular injury or liver inflammation (see Appendix I - C.7 Toxicology: 
liver/renal enzyme function test).  Results showed a significant increase in ALT blood 
levels at 6 h (p<0.05) following administration of 90 nm ORMOSIL NPs (Fig 6.23) 
compared to control samples (no m-THPC NP injection), which was consistent with peak 
accumulations observed in the liver through chemical extraction data at this time (Fig 
6.12).  Overall results suggested no predominant signs of hepatocellular injury, liver 
toxicity or renal impairment were caused by the administration of either small or large 
pegylated ORMOSIL NPs in vivo over 28 days, as data were not significant (p<0.05) for 
all other time intervals up to this period.  It should be noted that large variations (s.d.) in 
data may account for this, likely due to small animal numbers per group (n=3), and both 
enzymes generally showed an increase in blood concentration at 6 h, 1 week and 2 weeks. 
 
Histological analysis 
Owing to the longevity of non-biodegradable particles and their suspected accumulation 
from inconclusive biochemical assays, tissue sections from organs involved in major 
clearance pathways (RES), which typically house large numbers of residing macrophages, 
were additionally prepared for histological analysis to identify any signs of toxicity, such 
as, the infiltration of pro-inflammatory cells, pulmonary toxicity or tissue damage 
(necrosis).  Liver, spleen, lung and kidney tissues were removed at two weeks post 
intravenous injection of 0.3 mg kg-1 m-THPC in either 20 nm or 90 nm pegylated 
ORMOSIL NPs (mono-mTHPC).  A two week time interval was chosen based on 
previously published in vivo studies using ORMOSIL NPs, which showed clearance of 
NPs by 15 days through histological assessment without any overt signs of toxicity or 
tissue damage (Kumar, R. et al. 2010).  Control tissues were collected from animals which 
received no m-THPC injection and were housed under the same conditions. 
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The most predominant toxicological effects were observed in histological sections of the 
liver and lungs, where signs of an acute proinflammatory response were observed two 
weeks post ORMOSIL NP administration (Fig 6.25-26).  This correlates with in vivo 
biodistribution studies of normal tissues which showed the highest accumulation of 
ORMOSIL NPs, regardless of size, was in these organs.  Histopathology of the liver by 
Ivanov et al., revealed the presence of granulomas, small collections of macrophages, 
following systemic administration of silica NPs in rats, but demonstrated no significance 
difference in liver biochemical markers in the blood (Ivanov, S. et al. 2012); these findings 
were replicated here (Fig 6.25 C).  This may be due to the sensitivity of the technique, poor 
quality blood samples or differences in physiology.  The presence of granulomas in the 
liver, whose migration and cell number are triggered by the perceived presence of foreign 
bodies, which they are unable to eliminate, is applicable to the anticipated in vivo 
behaviour of non-biodegradable silica NPs.  For examples, macrophages may be able to 
recognise and phagocytise NPs but are unable to degrade them due to their chemical 
stability.  This can lead to potential long-term retention in tissues and has also been 
reported by Xie et al., over 30 days, who observed a greater uptake of 20 nm silica NPs 
(TeOS) versus 80 nm in the major organs of the RES; liver, spleen and lung, compared to 
control samples.  They noted the presence of both silica NPs in phagolysosomes within the 
macrophages of the liver and spleen at 7 days using TEM, with a higher cellular uptake of 
smaller NPs on account of their larger surface area in mice (Xie, G. et al. 2010).  
Histological sections of the same organs at the same time interval showed a mononuclear 
inflammatory infiltrate and hepatocyte necrosis at the portal triads of the liver which was 
observed ≥30 days.  
 
In the lungs, histopathology at two weeks following intravenous administration of both 20 
nm and 90 nm pegylated ORMOSIL NPs showed a thickening and increase in the 
cellularity of the epithelial lining of the alveoli with the presence of a large number of 
foamy macrophages (Fig 6.26) in comparison to control tissue (no NP administration).  
This histology is believed to be similar to that of bronchitis, where an inflammation of the 
mucous membrane is observed.  Brown et al., (Brown, D. M. et al. 2001) demonstrated a 
significantly greater influx of neutrophils into rat lung tissue following direct 
administration of smaller non-biodegradable polystyrene nanoparticles (64-nm) compared 
to larger polystyrene particles (202- and 535-nm) into the trachea.  This size-dependent 
phenomenon was also reflected in other parameters of lung inflammation, including an 
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increase in protein and lactate dehydrogenase production and an increase in 
proinflammatory gene expression (IL-8).  This was attributed to the increase in their 
surface area, however, it should be noted that these effects were observed following 
instillation, not systemic intravenous injection, of NPs and polystyrene particles used were 
not fully characterised (surface charge, chemical surface modifications).   
 
Future toxicology studies 
With advancements in nanotechnology, one of the key concerns with regards to the 
administration of non-biodegradable NPs is their penetration across the blood-brain barrier 
(BBB).  Although the BBB is highly restrictive in nature, it is important to consider 
potential adverse implications (Krol, S. 2012;Oberdorster, G. 2010).  More extensive 
toxicity studies on brain tissue were not carried out here due to time and resource 
constraints, however, future studies would need to strongly consider this possibility and 
note important changes in brain tissue pathology from either PS or non-biodegradable NPs, 
if indeed they occur.  It should also be taken into consideration that removal of tissue 
sections for histological analysis here were not standardised between animals, including 
the perfusion of lung tissue prior to fixation and sectioning of tissues.  Furthermore, 
specialised, expert veterinary histopathologists were not at our disposal for full histological 
examination of animal tissues.  Future toxicology studies would need to entail a much 
broader range of tests including; (i) escalated and/or repeated drug doses to obtain the 
maximum tolerated dose (MTD), (ii) immunological markers for proinflammatory factors 
as these particles are non-biodegradable, (iii) more extensive biochemical assays of quality 
controlled live animal blood serum collection, (iv) brain tissue histology, (v) localisation 
studies and (vi) changes in gene expression from increased immunological infiltration (RT-
PCR). 
 
PDT 
There have been PDT studies conducted in vitro with ORMOSIL NPs by Roy et al., (Roy, 
I. et al. 2003) and Ohulchanskyy et al., (Ohulchanskyy, T. Y. et al. 2007) carried out with 
HPPH doped NPs in human epithelial ovarian carcinoma (UCI-107) cells and colon cells 
(CT26), respectively, with success.  Qian et al., investigated the cytotoxic effects of 
encapsulated PpIX in mesoporous silica NPs on HeLa cells and the use of ORMOSIL NPs 
doped with IR-820 for brain and sentinel lymph node mapping applications in mice (Qian, 
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J. et al. 2009).  Very few studies, to our knowledge, have focused on in vivo work with 
ORMOSIL NPs for applications in PDT.  Prasad et al., carryed out extensive studies in 
mice to assess biodistribution, toxicity and clearance of ORMOSIL NPs following animal 
imaging (Kumar, R. et al. 2010).  This chapter demonstrates the first PDT studies to be 
carried out in vivo using ORMOSIL NPs.  The extent of PDT necrosis was assessed in 
subcutaneous rat tumours following intravenous administration of ORMOSIL NPs (20 nm 
and 90 nm) covalently incorporating (mono or tetrasilane) m-THPC.   
 
m-THPC is able to maintain its phototoxic ability and efficiently produce ROS at lower 
pH, such as those that occur in the microenvironment of tumours (Kascakova, S. et al. 
2008).  In addition, silica NPs are highly resistant to acidic degradation and their 
documented sub-cellular localisation in acidic lysosomes, importantly, should not affect 
ROS production but can influence cell death pathways induced by PDT; apoptotic or 
necrotic (Guo, W. et al. 1999).  Unlike biodegradable liposomes, which release m-THPC 
once inside the cell, silica NPs remain intact, with m-THPC chemically linked within the 
particle.  Absorbance spectra indicate m-THPC is largely in its monomeric form inside 
silica NPs (Fig 6.4) and other characterisation methods show its incorporation into 
ORMOSIL NPs does not affect its ability to produce singlet oxygen (Selvestrel, F. et al. 
2013).  The size of the NP is thought to contribute to its photodynamic efficacy due to size-
dependent interactions of particles, in terms of their biodistribution and cellular uptake.  
Chatterjee et al., (Chatterjee, D. K. et al. 2008a) reported preferable sub-50 nm silica NP 
size for effective phototoxic treatment, which was additionally supported by studies using 
30 nm silica-based NPs in vitro in cellular uptake studies in tumour cell lines by Roy et al., 
(Roy, I. et al. 2003).   
 
Maximal PDT tumour necrosis (50 mm2) was observed with Foscan at both DLIs (6 or 24 
h) (Fig 6.28) and with different sized m-THPC loaded ORMOSIL.  This confirmed 
activated m-THPC was not perturbed following its incorporation into particles through 
chemical covalent linkage (mono- or tetrasilane) to the NP matrix (monomeric formation).  
However, PDT with NPs did appear to be specifically dependent on (i) covalent linkage 
within NPs, (ii) DLIs (6 and 24 h) and (iii) NP size.  All of which appeared to be 
contributing factors in the outcome of PDT induced necrosis.  20 nm ORMOSIL NPs 
incorporating monosilane bound m-THPC demonstrated equal PDT efficacy to Foscan at a 
DLI of 6 h (50 mm2) compared to 90 nm NPs (30-40 mm2) (Fig 6.28).  This was initially 
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attributed to their smaller radii and larger surface area, which allowed for a greater volume 
of distribution.  However, this figure decreased two-fold at a DLI of 24 h (Fig 6.27 B & E), 
suggesting PDT necrosis may have been predominantly induced by effects on the 
vasculature st earlier DLIs (6 h) i.e. vessel collapse, due to higher concentrations in the 
blood at early time points (Schacht, V. et al. 2006).  Interestingly, in vitro studies with 
collaborators showed a low cellular uptake in A549 cells following incubation with 
tetrasilane bound m-THPC in ORMOSIL NPs at 24 h compared to free m-THPC (Foscan), 
whereas in vivo biodistribution studies here, tumour uptake of ORMOSIL NPs was greater 
than Foscan at this time.  This was reflected in PDT studies in vivo, whereby tetrasilane 
bound m-THPC in ORMOSIL NPs demonstrated equal PDT efficacy to Foscan at a DLI of 
24 h (50 mm2).  Therefore despite their poor intracellular uptake into tumour cells, these 
particles were still able to elicit an effective PDT response through damage to the 
extracellular matrix, interstitial space or vasculature, or a combination of all three. 
 
Larger 90 nm ORMOSIL NPs incorporating monosilane bound m-THPC followed a 
similar pattern of PDT induced necrosis, but with slightly lower levels of tumour damage 
in general and therefore a less pronounced decrease in PDT damage between DLIs of 6 and 
24 h (Fig 6.27 C & F).  Lower concentrations of 90 nm were observed in the blood 
compared to 20 nm at early time points (~6 h), which may account for this, if PDT damage 
is vascular-associated.  In addition, a decrease in m-THPC uptake was observed for 90 nm  
ORMOSIL NPs between 6 and 24 h in tumour tissue, but larger NPs were retained to a 
greater degree in tumour tissue compared to smaller NPs at 24 h, both of which are 
reflected in PDT induce tumour damage (Fig 6.28). 
 
Interestingly PDT efficacy for large ORMOSIL NPs with tetrasilane bound m-THPC 
showed an increase in PDT tumour damage (50 mm2), to rival that of Foscan, at a longer 
selected DLI of 24 h compared to 6 h.  As discussed with in vitro studies in MC28 cells 
earlier, any decrease in singlet oxygen yield is unlikely to be due to the formation of 
hydrophobic aggregates as tetrasilane bound m-THPC molecules cannot migrate towards 
each other to form dimers.  However, excessive rigidity of the framework, in the case of 
tetrasilane m-THPC derivative, may cause a reduction in singlet oxygen yield in the 
aqueous environment in vivo compared to monosilane bound m-THPC, as reported by 
collaborators (Selvestrel, F. et al. 2013).  This may be true for DLIs of 6h between both 
large sets of ORMOSIL NPs (mono- vs tetrasilane m-THPC) however; the increase in PDT 
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necrosis at 24 h with large ORMOSIL NPs incorporating tetrasilane bound m-THPC 
compared to all other NP formulations at this time remains unclear.  It has been shown that 
covalently bound m-THPC can induce a greater PDT effect as it can produce highly 
localised ROS generation intracellularly compared to non-localised free m-THPC (Guo, H. 
et al. 2011).  Unfortunately PDT studies with 20 nm ORMOSIL NPs incorporating 
tetrasilane bound m-THPC were not carried out in order to make direct comparisons on the 
effects of covalent m-THPC incorporation and to eliminate any size-related factors.   
Targeted cRGD-ORMOSIL NPs 
Encouraging results of tumour uptake from untargeted ORMOSIL NPs led us to speculate 
as to whether a further increase in m-THPC tumour uptake could be achieved through 
active targeting of nanocarrier formulations to cancerous tissues.  The goal of untargeted 
stealth NPs (i.e. PEG coated) was to maximise the blood circulation half-life, as longer 
circulation periods increase the likelihood of passive tumour accumulation of NPs from 
greater exposure.  However, there may be an over-reliance on the EPR effect as an 
explanation and methodology to deliver NPs into tumours, as this phenomenon may not be 
a universal property of all tumours.  Second, no single NP size can access all areas of the 
tumour and accumulate in significant quantities.  Large NPs do not appear to extravasate 
far beyond the blood vessel and small NPs are more likely to be able to travel deeper into 
tumour tissue but remain there only transiently (~24 h).  Finally, PEG-modified NPs have 
been shown to partially activate the immune system and lose efficacy upon repeated 
administrations (Anselmo, A. C. et al. 2013).  Although active-targeting NPs also rely on 
the EPR effect to access the intratumoral space, targeting moieties can also be used to by 
anchor the nanoparticles onto tumour cells, in addition to triggering intracellular uptake 
(Albanese, A. et al. 2012).   
 
Differences in non-targeted cellular uptake studies are typically dependent on drug loading, 
drug leaching (+/- serum proteins) and the size and/or surface charge of the delivery agent 
being internalised.  The same factors apply with targeted uptake studies; however, uptake 
is directed via specific receptor-mediate pathways.  Once bound to the receptor, the 
targeted NP-receptor complex produces a localised decrease in Gibb’s free energy, which 
causes the membrane to wrap around the NP, forming a closed endocytic-vesicle structure.  
Receptor-mediated endocytosis typically ensures sequestration of the active agent into 
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lysosomes, which are degraded over time, rather than direct delivery to the cytosol.  
Smaller spherical NPs (≤20 nm) have less ligand-to-receptor interactions than larger NPs 
(≥100 nm).  A small ligand-coated NP may interact with only one or two cell receptors and 
must bind to receptors in close proximity to produce enough available energy (Gibb’s) to 
drive membrane folding (Albanese, A. et al. 2012).  Larger targeted-NPs can act as cross-
linking agents to cluster receptors and induce uptake.  The binding strength of multiple 
receptor-ligand complexes (avidity) is greater than the total sum of individual affinities.  
Conversely, low molecular weight drug-ligand conjugates may allow for more efficient 
uptake via receptor-mediated endocytosis due to their smaller size, whereas bulkier NPs 
may not be as effectively internalised by this route on account of steric hindrance at the 
surface due to the nature of their cargo.  Thermodynamically, a large ligand-coated NP 
binding a large number of cell surface receptors may limit further uptake of additional NPs 
due to redistribution of receptors (via diffusion) and receptor recycling required to 
compensate for the local depletion (Albanese, A. et al. 2012).  Despite this apparent 
drawback, it is important to note, a large number of drug molecules (e.g. ~20,000 per 
liposome) may be delivered to the site of interest with very few targeting ligands attached 
to a NP surface i.e. ≤10 per vesicle.  This translates to >1000-fold delivery amplification 
factor when considering the drug: ligand ratio, in comparison to the 1:1 drug-to-ligand 
ratio of smaller drug-conjugates.  For this reason, alongside advantageous stealth 
properties, targeted ORMOSIL NPs were explored in the latter section of this chapter with 
the aim of improving the specificity of m-THPC delivery into tumour tissue for PDT.   
 
cRGD-ORMOSIL NPs 
The αvβ3 integrin is overexpressed on tumour neovasculature in comparison to mature, 
quiescent endothelial cells.  It has shown to be involved in tumour progression, 
angiogenesis and metastasis through expression on proliferating cells (mature osteoclasts, 
angiogenic endothelial cells and tumour cells).  The specific targeting of αvβ3 integrin cell 
adhesion receptor with the most common integrin binding sequence, the cyclic Arg-Gly-
Asp (cRGD) peptide, was investigated following its conjugation to the surface of 
ORMOSIL NPs.  Cyclic peptides have been reported as stronger and more selective 
inhibitors of cell adhesion, compared to linear variants, due to the preservation of less 
exposed sites (Aumailley, M. et al. 1991).  As a result, this motif has been widely reported 
for diagnostic and therapeutic purposes in cancer (Temming, K. et al. 2005).   
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For targeted studies presented here, collaborators conjugated cRGD-ORMOSIL NPs 
loaded with covalently bound m-THPC and assessed their uptake in human umbilical vein 
endothelial cells (HUVEC), which overexpress the αvβ3 integrin, in comparison to inactive 
targeted cRAD-ORMOSIL NPs that have an amino acid substitution (central glycine with 
alanine).  Results showed an increase in targeted cRGD NPs uptake with respect to cRAD 
NPs, largely regardless of size (70 nm versus 40 nm) and percentage ligand coverage of the 
NP (15% vs. 30%) (Selvestrel, F. et al. 2013).  Conversley, studies using cRGD targeted 
liposomes loaded with doxorubicin showed that they were cleared from the blood plasma 
faster than non-targeted liposomes in Sprague-Dawley rats (Chen, Z. et al. 2012) and 
polymeric NPs were excluded from targeted studies due to limited resources and the high 
m-THPC release observed from these NPs at early time periods in in vitro studies by 
collaborators (Rojnik, M. et al. 2012).   
 
cRGD-ORMOSIL NPs: in vitro 
Tumour cell lines were incubated with a cRGD-FITC conjugate to assess the presence of 
the αvβ3 integrin on domestic cell lines to assess their suitablility for in vivo studies 
following implantation of tumours.  Confocal imaging of positive green fluorescence was 
indicative of conjugate binding to the αvβ3 integrin receptors and intracellular uptake.  
A549 and MCF-7 cells, reported to be positive for αvβ3 integrin demonstrated a strong 
green fluorescence following incubation with cRGD-FITC for 4 h (Fig 6.31), with 
fluorescence largely confined to bright spots in the cytoplasm, indicative of receptor-
mediated endocytosis from lyso-endosome formation.  The greatest qualitative FITC 
fluorescence appeared to be detected in rat MC28 fibrosarcoma cells (Fig 6.32).  Although 
higher cell density observed in MC28 cell confocal images may distort results, these 
findings are supported by studies carried out in vitro on human fibrosarcoma (HT-1080) 
cells, which were described as overexpressing the αvβ3 integrin receptor (Garrigues, H. J. et 
al. 2008;von, W. A. et al. 2007).  These cells were therefore deemed appropriate for in vivo 
studies with targeted cRGD- ORMOSIL NPs in syngeneic, fully immune competent 
animals. 
 
cRGD-ORMOSIL NPs: in vivo 
Hooded Lister rats implanted with MC28 subcutaneous tumours were employed for 
biodistribution studies of m-THPC loaded (tetrasilane) targeted cRGD- and inactive 
targeted cRAD-ORMOSIL NPs.  Animals were intravenously injected with low m-THPC 
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doses of 0.1 mg kg-1 due to limited NP batch volumes.  In vivo experiments with 
corresponding low dose Foscan were not repeated in order to keee animal numbers to a 
minimum.  Selected tissues from treatment groups were removed at 24 h for quantitative 
analysis via chemical extraction of m-THPC.  As described in previous chapters, the 
highest m-THPC concentrations were observed in the blood, liver and spleen (>90% ID/g; 
see Appendix I – C.10 %ID/g cRGD-ORMOSIL NPs), however, there was no significant 
difference observed in tissue m-THPC concentrations (µg g-1) between cRGD- or cRAD-
ORMOSIL NPs (Fig 6.34).  This corresponded with in vivo studies carried out by research 
groups Chen et al., and Xiong et al., who used cRGD-pegylated liposomes loaded with 
doxorubicin.  Following intravenous injection, studies showed both targeted and non-
targeted liposomes demonstrated long circulating properties in rat plasma but there was no 
significant difference in t1/2 (~25 h) between formulations (Chen, Z. et al. 2012).   
 
m-THPC uptake in the lungs and skin was observed at the lowest concentrations following 
tareged cRGD- or cRAD-ORMOSIL NP delivery.  Despite the difference in administered 
doses (0.1 vs. 0.3 mg kg-1) between targeted and former untargeted ORMOSIL NP studies 
discussed in this chapter, this was encouraging, as the latter previously demonstrated 
higher accumulation in the lungs and no difference in m-THPC concentrations in the skin 
compared to Foscan.  Surprisingly, m-THPC accumulation in tumour tissue showed a 
significantly greater uptake of inactive targeted cRAD ORMOSIL NPs in comparison to 
cRGD NPs (Fig 7.18).  Other groups that have used RGD-targeted therapies in vivo have 
found prolonged circulation times and increased tumour accumulation compared to free 
drug but have reported little difference in uptake between targeted and untargeted NPs.  
For example Xiong et al., demonstrated no significant difference in biodistribution studies 
with RGD versus untargeted doxorubicin loaded liposomes in B16 tumour-bearing mice 
but managed to observe effective tumour regression (Xiong, X. B. et al. 2005b).   
 
False coloured fluorescence images were obtained from frozen tissue sections and 
confirmed the highest m-THPC accumulation was in the liver and spleen.  m-THPC 
fluorescence in the liver was not localised around blood vessels for either cRGD- or RAD-
ORMOSIL NPs, suggesting NPs may have extravasated out into the surrounding tissue by 
24 h.  Both NPs also demonstrated a preference for the white pulp, rather than the red pulp 
(cords), in the spleen.  The white pulp contains elevated levels of T cells, including 
monocytes that express the αvβ3 integrin, which may promote binding of targeted cRGD-
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NPs (Swirski, F. K. et al. 2009).  Extraordinarily high splenic uptake was also observed by 
Xiong et al., with RGD-targeted liposomes in vivo in mice in comparison to other organs 
(Xiong, X. B. et al. 2005a), however, this can also be said for cRAD- NPs and in previous 
untargeted ORMOSIL studies at 24 h (see Appendix I - C.3 ORMOSIL NPs & C.10 % 
ID/g targeted cRGD-ORMOSIL NPs).  A high fluorescence signal was detected with both 
NPs in the kidneys through fluorescence microscopy compared to other organs.  This does 
not corroborate with quantitative chemical extraction studies; it is unlikely NPs are 
excreted renally through the kidneys due to their size (~75 nm) and the issue remains 
unclear at this time.  Tumour fluorescence images demonstrated a higher uptake with 
cRAD-NPs, in comparison to targeted cRGD-NPs, which corresponded well with chemical 
extraction data of tumour tissue but unfortunately confirmed there was no improvement in 
tumour uptake of targeted NPs in comparison to uptake in other normal tissues and control 
NPs.  Recruitment and redistribution of mononuclear phagocytes to cancer sites from the 
spleen, may improve m-THPC uptake, as tumour tissue areas are typically high in 
macrophage presence. 
 
PDT with cRGD-ORMOSIL NPs 
PDT was performed under the same light treatment parameters as described in untargeted 
ORMOSIL NP studies.  The percentage area of PDT induced tumour necrosis at a drug 
light interval of 24 h showed there was no significant difference between Foscan, targeted 
cRGD or inactive targeted cRAD-ORMOSIL NPs following their intravenous 
administration at a dose of 0.1 mg kg-1 (m-THPC equivalent) (Fig 6.37).  Contrary to 
cRGD NPs improving in vivo efficacy of PDT to tumours, results showed a trend towards a 
greater percentage area of tumour necrosis induced with cRAD-NPs and Foscan alone 
(>50% versus <40%); although this was not significant.   
 
To our knowledge, there have been no studies conducted using targeted cRGD conjugates 
or NPs for in vivo PDT for direct or indirect comparisons.  The RGD peptide targets the 
αvβ3 integrin receptors abundantly expressed on tumour neovasculature (Stromblad, S. et 
al. 1996), despite MC28 tumours being highly vascularised there did not appear to be any 
improvement in tumour uptake or PDT efficacy with cRGD-ORMOSIL NPs.  Conversely, 
cRAD-ORMSOSIL NPs demonstrated a higher uptake in tumour tissue through 
quantitative chemical extraction studies, which was reflected in PDT data.  Despite no 
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significant differences following cRGD targeting, these NPs are still able to elicit an 
effective PDT response, with tumour necrosis ≥50%.  This is comparable to that of Foscan 
alone and PDT results following much higher doses of administered m-THPC (0.3 mg kg-
1) in previous chapters (Chpts: 4 & 5).  There was a significant difference in PDT tumour 
necrosis following administration of m-THPC formulations versus the control group, 
which received light treatment but no m-THPC (p≤0.001).   
 
PDT studies in vitro in HUVEC cells (αvβ3 integrin positive) following incubation with 
cRGD-targeted and inactive targeted cRAD ORMOSIL NPs (tetrasilane m-THPC) found 
no difference in photokill activity between dose-response curves for both NPs.  This was 
attributed to the partial protection of cells by cRGD peptide from PDT-induced 
phototoxicity, such as an anti-oxidant and anti-apoptotic effect, not exhibited by cRAD 
peptide (Allen, C. M. et al. 2002;Selvestrel, F. et al. 2013).  Selvestrel et al., found 
photokill efficiency did not appear to correspond to NP uptake between cell lines.  This 
was thought to be due to differences between each cell type in their ability to resist the 
cytotoxicity of generated ROS (Selvestrel, F. et al. 2013).  Differences in PDT efficacy in 
vitro could also be due to differences in intracellular localisation of free m-THPC 
(Golgi/ER) and when delivered by targeted NPs (endosomes) and the efficiency of singlet 
oxygen (1O2) production at these sites (Compagnin, C. et al. 2011).  In untargeted 
tetrasilane bound m-THPC loaded ORMOSIL NPs PDT studies in vivo, PDT induced 
tumour necrosis was greater than treatment with either monosilane bound m-THPC or 
Foscan, suggesting sufficient 1O2 generation, however, the conjugation of additional 
surface targeting moieties could modify this behaviour.   
 
The difficulty with assessing effective treatment outcome, regardless of the tumour model 
employed, is deciphering underlying mechanisms that contribute to cell death, which 
cannot always be determined through histological analysis alone.  Whilst this may initially 
be regarded ‘irrelevant’ in the clinical, with tumour regression, patient survival and quality 
of life taking a higher precedence, it is important to distinguish between types of cell death; 
necrosis, apoptosis and autophagy.  For example, apoptosis (programmed) and necrosis 
(premature) are irreversible form of cell death, whereas autophagy (self-engulf) can induce 
cell death or paradoxically maintain cell survival.  If cells are able to recover, this creates 
problems in long-term tumour regression and patient prognosis, therefore understanding 
these pathways allows the development of therapeutic strategies that maximise irreversible 
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tumour cell death and/or anti-tumour immunity; sustaining cancer regression.  Although 
this was not the focus of these investigations, differentiating between cellular fates to 
clearly establish the type of cell death induced following in vivo PDT studies would be 
interesting to investigate in future studies and potentially beneficial in treatment outcome.   
 
Summary: cRGD-ORMOSIL NPs 
RGD peptide is more hydrophilic (zwitterionic) therefore attraction by the PEG 
pseudophase was assumed less likely, with αvβ3 integrin cellular receptors purportedly 
remaining available for interaction, however, despite encouraging cellular uptake in in 
vitro studies, targeted cRGD ORMOSIL NPs used here, showed no overall improvement in 
tumour uptake, biodistribution or in PDT tumour damage in vivo in comparison to 
untargeted NPs.  It is speculated that the addition of excess targeting ligands may 
paradoxically increase uptake and clearance by the RES due to the presence of more 
proteins “visible” on the NP surface than with PEG alone.  Furthermore, positive results 
achieved with active targeting may be offset by a ‘barrier effect’ in vivo whereby the 
majority of NPs are not able to migrate beyond the first few layers of tumour cells due to 
adherence with their targeted receptors (Albanese, A. et al. 2012).  Although active 
targeting of NPs appeared to increase internalisation into cancerous cells in vitro, it did not 
translate in vivo. 
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6.5 Conclusions 
The primary objective of the work described in this chapter was to investigate differences 
in the biodistribution of m-THPC when delivered by ORMOSIL NPs (small and larger) 
and targeted cRGD-ORMOSIL NPs, compared to standard Foscan formulation, to 
demonstrate PDT efficacy for the first time in vivo in MC28 tumour-bearing rats.   
 
Pharmacokinetic analysis gave data on their accumulation within different tissues of 
normal and tumour animal models.  It was found that larger (90 nm) pegylated ORMOSIL 
NPs appeared to accumulate to a greater degree in tumour tissue compared to smaller NPs 
(20 nm) and Foscan, which was likely due to passive uptake and retention of larger NPs in 
malignant tissue through the EPR effect.  Conversely, 20 nm particles had a surprisingly 
longer blood plasma half-life than 90 nm in vivo, which was thought to be attributed to 
their larger surface and higher volume of distribution in tissues.  The greatest m-THPC 
uptake with ORMOSIL NPs was observed in the major organs of the RES, particularly the 
liver and spleen, regardless of NP size.  Studies with cRGD-ORMOSIL NPs showed no 
further significant increase in active m-THPC tumour uptake over untargeted NPs. 
 
Clearance of non-biodegradable NPs was most likely via the hepatobiliary excretion 
pathway on account of NP chemical stability and particle size, which was incompatible 
with renal filtration (>5 nm).  Toxicity studies revealed little significant difference in 
biochemical blood markers for liver and renal enzymes over 28 days but potential signs of 
inflammation were observed in histological analysis of the lungs and liver at two weeks 
post NP administration, likely due to their increased uptake in these tissues. 
 
PDT studies carried out in collaboration with biodistribution studies demonstrated an equal 
maximum level of tumour necrosis induced with 20 nm pegylated ORMOSIL NPs and 
Foscan at early DLI (6 h).  This was attributed to potential effects on the vasculature as an 
increase in PDT tumour necrosis was observed at a longer DLI (24 h) with larger NPs (90 
nm), which corresponded to their higher retention in tumour tissue at this time.  These 
results are encouraging as some of the first PDT studies to be carried out in vivo 
investigating the treatment efficacy of ORMOSIL NPs.  Unfortunately, results with 
targeted nanosystems using cRGD-ORMOSIL NPs did not produce any significant 
improvement in PDT efficacy and were largely inconclusive. 
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7. Conclusions and Future Work 
This thesis is a study of photodynamic therapy (PDT) and aimed to determine whether 
encapsulation of the photosensitiser, m-THPC, into different nanocarriers altered its 
delivery to tumour tissue and improved PDT efficacy at the tumour site in vivo.   
 
The biodistribution and accumulation of m-THPC was assessed in vivo.  Primarily, m-
THPC in its standard micellular clinical formulation, Foscan®, was compared to its 
incorporation into biodegradable phospholipid membranes (liposomes) each with varying 
degrees of pegylation, FosPEG 2% and FosPEG 8%.  Intravenously administered, the 
pharmacokinetic parameters of each formulation were established through compartmental 
and non-compartmental analysis in a syngeneic, subcutaneous tumour rat model.  It was 
discovered the longevity of m-THPC in the blood stream increased with liposomal 
encapsulation and further increased with higher surface pegylation.  This was reflected in 
biodistribution data of tumour tissue, which demonstrated a three-fold increase in m-THPC 
uptake between Foscan and liposomal formulations at 24 h.  Normal tissue damage was 
assessed through skin photosensitivity studies over 7 days and revealed minimal damage. 
 
Incorporation of m-THPC into an alternative biodegradable, pegylated nanoparticles, 
comprised of biocompatible polymer subunits (PLGA), was also examined in the same in 
vivo model and demonstrated a similar increase in m-THPC uptake in tumour tissue in 
comparison to Foscan over 72 h. 
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Finally, organically modified silica (ORMOSIL) nanoparticles, with covalently bound m-
THPC (mono- or tetra-silane), were assessed as a non-biodegradable nano-system.  A 
higher uptake of larger ORMOSIL NPs was observed in malignant tissue in comparison to 
smaller ORMOSIL NPs and Foscan alone, attributed to the EPR effect.  Toxicology 
studies in organs involved in major clearance pathways were carried out and showed little 
detectable toxicity over a 28 day period. 
 
In PDT studies with these pegylated nanoparticles, the central methodology employed was 
post mortem histological analysis to determine the extent of tumour PDT necrosis.  Effects 
of dose, light parameters and drug:light intervals on PDT efficacy were assessed.  
Liposomal formulations of m-THPC showed equal percentages of tumour necrosis 
following administration of m-THPC doses three-fold less than clinical doses of Foscan.  
Furthermore, this thesis explored, for the first time, the use of pegylated PLGA and 
ORMOSIL NPs, encapsulating m-THPC, as PDT agents in vivo.  As such, these NPs 
showed encouraging results, with equal PDT efficacy exhibited as standard Foscan. 
 
Encouraging results from these studies lead to the bioconjugation of active targeting 
ligands to pegylated groups on m-THPC-loaded nanoparticles in a bid to further enhance 
uptake and treatment efficacy at the tumour site.  Optimal performing nanoparticles from 
untargeted studies were elected, in addition to their ability to effectively couple bioactive 
molecules, capable of recognising receptors overexpressed by malignant tissues, to their 
surface.  Despite encouraging results observed in vitro by collaborators with these 
nanoparticles, in vivo studies conducted here with targeted cRGD- ORMOSIL NPs, were 
largely inconclusive with minimal differences in m-THPC tumour uptake and PDT 
efficacy detected. 
 
The overall results have established that the selectivity of m-THPC in vivo can be 
improved upon encapsulation in pegylated nanoparticles.  The major clinical advantage of 
this would be the potential to lower injected m-THPC doses to avoid adverse side-effects 
to normal tissues, reducing damage to adjacent tissue during treatment and problems with 
patient management from skin photosensitivity.  This encapsulation and high drug delivery 
payload of administered m-THPC could afford a similar treatment efficacy whilst 
minimising these effects and reducing therapeutic costs. 
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Future work 
Despite promising experimental data from laboratory studies demonstrated here following 
the incorporation of m-THPC into nanoparticles, the complexity of cancer as a disease 
requires time to establish the optimal PDT treatment parameters, which may vary 
significantly between tumour types.  The efficacy of most cancer therapies is dependent on 
accessibility to their site of action, which is often intracellular or vascular; each bringing 
their own set of complexities.  In PDT, tumour destruction can be achieved both by cell 
death and by photodestruction of the tumour vasculature.  Due to the heterogeneity and 
adaptive resistance within a single tumour, combinational therapy or adjuvant therapy may 
be the best approach, as adopted by the clinic for many current cancer treatments.  
Understanding tumour cell kill mechanisms and examining vascular architecture within 
tumours may be fundamental in establishing effective PDT treatment in the future.   
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Appendix I 
SECTION A: Liposomes 
A.1 Dosage Calculations 
Example: 
For a dose of 0.3 mg kg-1 for a 200 g rat from a stock solution of drug at 0.3 mg mL-1 an injection 
volume of 0.2 mL would be administered: 
 0.3 mg kg-1 x 0.2 kg 
= 0.2 mL 
 0.3 mg mL-1 
Injected dose per rat gives a total concentration of approx. 60 µg g-1 of m-THPC. 
A.2 Cell Counts and Calculations 
 
Figure A.2. Haemocytometer and cell counts. Adapted from www40.homepage.villanova.edu/.../pd2.htm. 
 
Viable cells were counted that overlay the grid of the haemocytometer (A) in the centre and on the 
top and left hand borders of the sub squares; 1, 3, 5, 7 and 9, (B) on both sides. 
1 2 3 
4 5 6 
7 8 9 
9 
О = viable cell 
Ø = dead cell 
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Example: Average cell count ≈ (56 + 48) = 52 cells 
                                         2 
10 µl taken from a 5 ml cell suspension and diluted 1:1 in trypan blue therefore; 
Dilution factor = (10 µL + 10 µL) = 2 
                                     10 µL 
Volume of 1 square = 0.1 mm3 
10-4 cm ≈ 10-4 mL 
Number of cells per ml: 52 cells x 2 x 104 = 1.04 x 106 cells mL-1 
A.3 Preparing Fluorodishes: Foscan® and FosPEG2% 
MC28 cells: Require a cell concentration of 1 x 104 cells/200 µL (fluorodish volume). 
1 x 104 cells   x   ____1 mL____  =   9.6 µL of cell suspension 
       1                  1.04 x 106 cells 
200 µL – 9.6 µL = 190.4 µL of supplemented DMEM media (- FCS). 
Foscan® and FosPEG2% supplied in 100 µM stock solution; require final concentration of 1 µM: 
Add 2 µL of 100 µM stock solution to 198 µL of media (comprised of 9.6 µL cell suspension and 
188.4 µL supplemented media (-FCS)) = 1 µM. 
A.4 Chemical Extraction: Raw Data Calculations 
Example: Preparing stock solutions for standard curve: 
Mw m-THPC = 680.24 g mol-1 
Foscan® provided at 4 mg mL-1 from Biolitec, Jena, Germany. 
1. Calculate number of moles mL-1 in stock solution (Foscan). 
 0.004 g 
x 
1 mol 
= 
5.88x10-6 mol 
or 
5.88 µmol 
 1 mL 680.24 g mL mL 
 
2. Calculate number of moles needed to make 20 mL of a 10 µM solution. 
 10 µmol 
x 
1 L 
x 
20 mL 
= 
0.2 µmol 
 1 L 1000 mL   
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3. Calculate the amount of stock solution needed (volume) to make 20 mL of a 10 µM 
solution. 
 0.2 µmol 
x 
1 mL 
= 
34.0 x10-3 mL 
or 
34 µL 
  5.88 µmol   
Table A.4i.  Preparation of Foscan® stock solution. 
FosPEG2% and FosPEG8% provided at 1.5 mg mL-1 from Biolitec, Jena, Germany. 
1. Calculate number of moles mL-1 in stock solution (FosPEG2% & 8%). 
 0.0015 g 
x 
1 mol 
= 
2.205x10-6 mol 
or 
5.88 µmol 
 1 mL 680.24 g mL mL 
 
2. Calculate number of moles needed to make 20 mL of a 10 µM solution. 
 10 µmol 
x 
1 L 
x 
20 mL 
= 
0.2 µmol 
 1 L 1000 mL   
 
3. Calculate the amount of stock solution needed (volume) to make 20 mL of a 10 µM 
solution. 
 0.2 µmol 
x 
1 mL 
= 
90.7 x10-3 mL 
or 
91 µL 
  2.205 µmol   
Table A.4ii.  Preparation of FosPEG 2% and FosPEG8% stock solution. 
A serial dilution was carried out to prepare additional stock solutions of 1 µM and 0.1 µM, 
whereby 1 mL of a 10 µM m-THPC solution was pipetted into 9 mL of Solvable™ and so forth. 
Construction of standard curves: 
Stock solution (uM) 0 0.01 0.1 0.1 0.1 1 1 10 10 
Standard mTHPC uM 0 0.001 0.005 0.01 0.05 0.1 0.5 1 5 
mTHPC uM solution (ml) 0 0.3 0.15 0.3 1.5 0.3 1.5 0.3 1.5 
Tissue 0.1g/2 ml solvable (ml) 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
Solvable (100%) (ml) 1.5 1.2 1.35 1.2 0 1.2 0 1.2 0 
(if no tissue - solvable) 3 2.7 2.85 2.7 1.5 2.7 1.5 2.7 1.5 
Table A.4iii.  Construction of standard curves. 
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Converting µM concentrations into µg g-1: 
 Mw m-THPC = 680.24 g mol-1  
 1 mL ≈ 1 g  
 1 mole = 680.24 g  
 1 µmole = 680.24 x 10-6 g OR 680.24 µg  
 
1 µM (1 µmole L-1) = 
680.24 µg  
 1000 ml  
 1 µM = 0.68024 µg mL-1 OR µg g-1  
 
Calculating the concentration (µg g-1) of m-THPC in each tissue: 
Example: 
Standard curve of Foscan® for liver tissue, which was linear between 0 and 0.5 µM. 
y = 155.68x
R2 = 0.9999
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Figure A.4.  Standard curve of known concentrations of m-THPC in control liver tissue. 
 
Average fluorescence (a.u.) of liver at 2 h after 0.3 mg kg-1 Foscan® dose ≈ 48 a.u. 
Minus averaged negative control values of liver = 48 - 14.36 a.u. = 33.64 a.u. 
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Therefore if y = 155.68x, x = 33.64/155.68 = 0.216 µM 
If 1 µM = 0.68024 µg g-1 
Then 0.216 µM = 0.147 µg g-1 
However, the original tissue sample, 0.1 g wet weight,  was diluted in 2 mL of Solvable™ 
therefore the original dilution factor (x 20) plus the displacement of liquid (~ 1) means the 
concentration is multiplied by 21: 
Concentration of m-THPC (Foscan®) in the liver at 2h, 0.147 µg g-1 x 21 = 3.1 µg g-1 
A.5 Pharmacokinetic Analysis: Compartmental Approach 
The individual sets of plasma m-THPC concentrations for each liposomal formulation, Foscan®, 
FosPEG 2% and FosPEG 8%, were plotted on a semi-logarithmic scale (see Figs A.2, A.3, & A.4) 
for the compartmental analysis. 
The plasma level decline did not follow a mono-exponential decay (see Section 2.3.1; Fig 2.3) and 
instead could fit to multi-exponentials; therefore the graph could be divided in to three phases.  To 
calculate the parameters of the third compartment, the terminal points of the graph (72, 96 and 168 
h) represented the log linear phase, and the gradient of this line could be used to determine the time 
constant γ (see Tables A.5, A.6, & A.7).  This log/linear phase signifies the elimination of m-THPC 
from the second compartment in equilibrium now with the third compartment. 
The t = 0 y-intercept C, represents the apparent concentration if the drug had been distributed 
instantaneously throughout all compartments.  Intercept C could therefore be used to calculate the 
volume of distribution in the third compartment (Vd) i.e. dosage/y-intercept C (t=0). 
The equation of the third compartment line (blue) could then be used to calculate the m-THPC 
concentration at different time points (0 – 168 h).  To deduce the line of the second compartment 
(green), concentrations values which lay on third compartment line were deducted from real values 
of m-THPC concentration (Tables A.5, A.6, & A.7) obtained from original plasma data (see 
Section 2.3.1; Fig 2.3, and raw data; Table A.8).  These values were plotted and the equation of this 
line (green) gave a new set of parameters (β, B) to deduce Vd in the second compartment.  This 
process was repeated to obtain α, A, Vd in the first compartment.  Time constant α is the constant 
that governs the distribution of m-THPC into the second compartment. 
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The biological half-life of m-THPC for each formulation was calculated using the time constants, 
α,β,γ, (Tables A.5, A.6, & A.7) which were substituted with one of the corresponding values for 
each of the decay phases: 
 t1/2 = 
loge 0.5 
= 
0.693  
α α  
The sum of the exponential y-intercept values at t=0 (A, B and C) were used to calculate the initial 
concentration (Co) of m-THPC in each formulation (Tables A.5, A.6, & A.7), in the blood plasma 
at time 0.  This value was used to calculate the theoretical volume into which the drug was initially 
introduced, in the central compartment (initial Vd). 
This compartmental analysis was completed for all liposomal nanocarrier formulations (Figs A.2, 
A.3, A.4 and Tables A.5, A.6, A.7). 
Foscan®: 
y = -0.2072x - 0.7579
R2 = 0.8736
y = -0.0077x - 3.01
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Figure A.5i. The decline of the m-THPC plasma concentrations after i.v. injection of 0.3 mg kg-1 in a Foscan 
formulation.  Data plotted on a semi-logarithmic scale in three phases, representing the three compartments. 
 
Time Constant Y-intercept (t=0) Y-intercept (t=0) Half life Co (µg ml-1) 
α β γ ln(A) ln(B) ln(C) A B C A B C 
0.78 0.21 0.0077 -1.522 -0.7579 -3.01 0.218 0.469 0.049 0.9 3.3 90.0 0.74 
Table A.5i.  Time constants α, β, γ, logged y-intercept values from semi-log plot at t=0 ln(A), ln(B), ln(C), 
inversed log y-intercept values at t=0 A, B, C, calculated compartmental half-lives using each time constant 
and initial concentration, Co (µg ml-1), of m-THPC after 0.3 mg kg-1 i.v. administered dose in Foscan 
formulation. 
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FosPEG 2%: 
y = -0.2975x + 1.4625
R2 = 0.9448
y = -0.007x - 2.0068
R2 = 1
y = -0.7198x + 1.4395
R2 = 1
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Figure A.5ii.  The decline of the m-THPC plasma concentrations after i.v. injection of 0.3 mg kg-1 in a 
FosPEG 2% formulation.  Data plotted on a semi-logarithmic scale in three phases, representing the three 
compartments. 
 
Time Constant Y-intercept (t=0) Y-intercept (t=0) Half life Co (ug ml-1) 
A b c ln(A) ln(B) ln(C) A B C A B C 
0.72 0.3 0.007 1.44 1.4625 -2.007 4.219 4.317 0.134 1.0 2.3 99.0 8.67 
 
Table A.5ii.  Time constants α, β, γ, logged y-intercept values from semi-log plot at t=0 ln(A), ln(B), ln(C), 
inversed log y-intercept values at t=0 A, B, C, calculated compartmental half-lives using each time constant 
and initial concentration, Co (µg ml-1), of m-THPC after 0.3 mg kg-1 i.v. administered dose in FosPEG 2% 
formulation. 
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FosPEG 8%: 
y = -0.1251x + 1.0896
R2 = 0.9944
y = -0.005x - 1.6133
R2 = 1
y = -1.182x + 2.6209
R2 = 1-3
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Figure A.5iii.  The decline of the m-THPC plasma concentrations after i.v. injection of 0.3 mg kg-1 in a 
FosPEG 8% formulation.  Data plotted on a semi-logarithmic scale in three phases, representing the three 
compartments. 
 
 
Time Constant Y-intercept (t=0) Y-intercept (t=0) Half life Co (ug ml-1) 
A b c ln(A) ln(B) ln(C) A B C A B C 
1.18 0.13 0.005 2.621 1.0896 -1.613 13.748 2.973 0.199 0.6 5.5 138.6 16.92 
 
 
Table A.5iii.  Time constants α, β, γ, logged y-intercept values from semi-log plot at t=0 ln(A), ln(B), ln(C), 
inversed log y-intercept values at t=0 A, B, C, calculated compartmental half-lives using each time constant 
and initial concentration, Co (µg ml-1), of m-THPC after 0.3 mg kg-1 i.v. administered dose in FosPEG 8% 
formulation. 
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FOSCAN                     
time (hrs) O ln o ln c c (o-c) ln (o-c) ln b b (c-b) ln (o.b) 
0     -3.010 0.049     -0.758 0.469     
0.083 0.5947 -0.51963 -3.011 0.049 0.545   -0.775 0.461     
2 0.4040 -0.90626 -3.025 0.049 0.355 -1.034 -1.172 0.310 0.046 -3.08258 
4 0.2620 -1.33933 -3.041 0.048 0.214 -1.541 -1.587 0.205 0.010 -4.64353 
6 0.2108 -1.557 -3.056 0.047 0.164 -1.810 -2.001 0.135     
18 0.0462 -3.07498 -3.149 0.043 0.003 -5.720 -4.488 0.011     
24 0.0486 -3.02351 -3.195 0.041 0.008 -4.872 -5.731 0.003     
72 0.0283 -3.56445 -3.564 0.028 0.000   -15.676 0.000     
96 0.0235 -3.74928 -3.749 0.024 0.000   -20.649 0.000     
168 0.0168 -4.08579 -4.304 0.014 0.003   -35.568 0.000     
                      
   
Table A.5iv.  Raw data from compartmental pharmacokinetic analysis for each formulation 
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Table A.5iv.  (continued) Raw data from compartmental pharmacokinetic analysis for each formulation. 
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A.6 Pharmacokinetic Analysis: Non-compartmental Approach 
To calculate the pharmacokinetic parameters using the non-compartmental approach the following 
method was applied for each formulation; Foscan®, FosPEG 2% and FosPEG 8%: 
1) The plasma concentration of m-THPC at time zero (Co) was estimated by extrapolation of the 
log concentration versus time graph back to zero, using the slope of the line for the initial three 
time points (2, 4 and 6 h). 
2) The slope of the log linear (elimination) phase was estimated between 72 & 168 h. 
3) The area under the concentration versus time graph (AUC) was calculated from time zero (t =0) 
to the last time point (168 h) by the trapezoidal rule (A = ½ (a + b) h) (see figure below) and from 
168 h to infinity (∞) the area was approximated as; Area = C(last)/k’, where C(last) is the plasma 
concentration at the last time point (168 h) and k’ is the elimination rate constant (gradient of slope 
between 72 – 168 h). 
  
Figure A.6.  Area under the curve graph for non-compartmental analysis. 
 
4) The area under the moment curve (AUMC; (concentration x time) versus the time curve).  The 
AUMC was calculated from time zero (t = 0) to 168 h by the trapezoidal rule and 168 h to infinity 
∞ as Area = C(last)/(k’)². 
5) Plasma clearance: 
AUC
DOSECL =  
6) Mean residence time: 
AUC
AUMC
MRT =
 
7) Volume of distribution: Vd = CL x MRT 
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8) Half-life: t1/2 = MRT x ln(2) 
9) Elimination rate constant: 
MRT
Kel
1
=
 
A.7 Time and Concentration of Maximal m-THPC Levels 
  Foscan  FosPEG 2%  FosPEG 8% 
Tissue Peak (h) Concentration 
(ug g-1) 
Peak (h) Concentration 
(µg g-1) 
Peak 
(h) 
Concentration 
(µg g-1) 
Plasma < 5min 0.74 ± 0.15 < 5min 8.67 ± 0.24 < 5min 16.92 ± 1.35 
Tumour 6 0.33 ± 0.025 24 1.13 ± 0.15 24 0.98 ± 0.17 
Liver 4 3.61 ± 0.22 2 2.30 ± 0.27 2 3.03 ± 0.26 
Spleen 4 2.38 ± 0.32 6 2.66 ± 0.74 4 1.15 ± 0.34 
Lung 4 0.46 ± 0.05 6 1.40 ± 0.13 6 2.01 ± 0.32 
Skin 24 0.07 ± 0.01 18 0.07 ± 0.01 96 0.1 ± 0.003 
Table A.7.  Time and concentration of maximal levels of m-THPC (µg g-1) in selected tissues with each 
formulation; Foscan, FosPEG 2% or FosPEG8%, after 0.3 mg kg-1 injected dose (data represent mean ± s.d., 
n = 3). 
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A.8 Chemical Extraction: Colon Accumulation 
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Figure A.8.  Concentration of m-THPC (µg g-1) in colon tissue of the Wistar rat at different time intervals 
after intravenous injection of either, Foscan, FosPEG2% or FosPEG8%, at 0.3 mg kg-1.  Data corrected for 
negative control tissue. (Data points show the mean ± s.d., n = 3). 
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A.9 Concentration of m-THPC in blood plasma versus tumour from HL rat tissues: Foscan, 
FosPEG 2% and 8%) 
 
Figure A.9 Concentration of m-THPC in MC28 tumour tissue (µg g-1) of female Hooded Lister rat versus m-
THPC in blood plasma from HL rat (µg mL-1) as a function of time (h) following an intravenous injection of 
0.3 mg kg−1 m-THPC in standard Foscan, FosPEG 2% and FosPEG 8% formulations.  Data points show the 
mean ± SD, n = 4. 
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A.10 Skin Photosensitivity Studies: Solar Simulator Spectra 
 
Figure A.10. Absorption spectrum of light from solar simulator (Olympus CLV-S30) and a 652 nm laser 
(left) in comparison to the spectrum of natural sunlight (right), taken from nature photonics. 
 
A.11 Skin Photosensitivity Studies: Skin scoring model 
 
Figure A.11. Skin scoring system used for skin photosensitivity studies to visually assess skin damage 
following administration of 0.3 mg kg-1 or 0.1 mg kg-1 m-THPC in either Foscan, FosPEG2% and FosPEG 
8% after exposure to either 0, 5, 15 or 30 mins of sunlight (equivalent) at DLIs of either 96 or 168 h.  Model 
taken from Weersink et al., 2005 
eg. Foscan DLI: 96 h 
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A.12 Skin Photosensitivity Studies: Raw skin scoring data 0.3 mg kg-1 
DLI
Exposure
Time
m-THPC
Formulation
Average
Grade
Rank* Description
Foscan 0.00 1 No observable effect
FosPEG2% 0.00 1 No observable effect
FosPEG8% 0.00 1 No observable effect
Foscan 1.67 2 Moderate erythema
FosPEG2% 1.50 1 Moderate erythema
FosPEG8% 2.00 3 Moderate erythema
Foscan 4.00 2 Slight oedema
FosPEG2% 3.67 1 Slight oedema
FosPEG8% 4.67 3 Moderate oedema
Foscan 5.67 2 Severe oedema
FosPEG2% 5.17 1 Moderate oedema
FosPEG8% 5.67 2 Severe oedema
Foscan 0.00 1 No observable effect
FosPEG2% 0.00 1 No observable effect
FosPEG8% 0.00 1 No observable effect
Foscan 1.17 3 Mild erythema
FosPEG2% 1.00 1 Mild erythema
FosPEG8% 1.00 1 Mild erythema
Foscan 2.83 2 Strong erythema
FosPEG2% 2.67 1 Strong erythema
FosPEG8% 3.00 3 Strong erythema
Foscan 4.83 3 Moderate oedema
FosPEG2% 3.33 1 Strong erythema
FosPEG8% 4.17 2 Slight oedema
* based on the average grade; where 1 is the least affected and 3 is most affected.
96 h
0 min
5 min
15 min
30 min
168 h
0 min
5 min
15 min
30 min
 
Table A.12. Skin scoring results following administration of 0.3 mg kg-1 m-THPC in either Foscan, 
FosPEG2% and FosPEG 8% after exposure to either 0, 5, 15 or 30 mins of sunlight (equivalent) at DLIs of 
either 96 or 168 h.  Model taken from Weersink et al., 2005. 
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A.13 Skin Photosensitivity Studies: Raw skin scoring data 0.1 mgkg-1 
DLI
Exposure
Time
m-THPC
Formulation
Average
Grade
Rank* Description
Foscan 0.00 1 No observable effect
FosPEG2% 0.00 1 No observable effect
FosPEG8% 0.00 1 No observable effect
Foscan 0.67 2 Mild erythema
FosPEG2% 0.30 1 Mild erythema
FosPEG8% 0.67 2 Mild erythema
Foscan 1.50 3 Moderate erythema
FosPEG2% 1.33 1 Mild erythema
FosPEG8% 1.33 1 Mild erythema
Foscan 1.50 2 Moderate erythema
FosPEG2% 1.50 2 Moderate erythema
FosPEG8% 1.33 1 Mild erythema
Foscan 0.00 1 No observable effect
FosPEG2% 0.00 1 No observable effect
FosPEG8% 0.00 1 No observable effect
Foscan 0.67 1 Mild erythema
FosPEG2% 0.67 1 Mild erythema
FosPEG8% 0.67 1 Mild erythema
Foscan 1.33 1 Mild erythema
FosPEG2% 1.83 3 Moderate erythema
FosPEG8% 1.33 1 Mild erythema
Foscan 1.17 1 Mild erythema
FosPEG2% 1.67 3 Moderate erythema
FosPEG8% 1.33 2 Mild erythema
* based on the average grade; where 1 is the least affected and 3 is most affected.
168 h
0 min
5 min
15 min
30 min
96 h
0 min
5 min
15 min
30 min
 
Table A.13. Skin scoring results following administration of 0.3 mg kg-1 m-THPC in either Foscan, 
FosPEG2% and FosPEG 8% after exposure to either 0, 5, 15 or 30 mins of sunlight (equivalent) at DLIs of 
either 96 or 168 h.  Model taken from Weersink et al., 2005. 
A.14 Skin Photosensitivity Studies: control skin tissues 
 
Fig.A. 14. . Histological sections of skin tissue removed from the animal 24 h after light treatment. (A) Skin 
control samples at 0 min (no light) and (B) control samples at 30 mins light exposure (no m-THPC), were 
collected and cut through the centre of the treatment area. Adjacent halves of the skin tissue were sectioned 
(4 µm) and stained with H&E. Images were observed with the Hamamatsu Nanozoomer. M—muscle, Ad—
adipocytes, D—dermis, HF—hair follicle, ED—epidermis. 
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A.15 PDT - Hamamatsu Nanozoomer: Calculating the Area of Necrosis 
  
Figure A.15i.  Hamamatsu Nanozoomer software was used to measure a crude surface area of necrosis as a 
percentage of total tissue from PDT tumour tissue damage after 24 h post i.v. injection of m-THPC at 0.3 µg 
g-1 and 0.1 µg g-1 in Foscan, FosPEG2% and FosPEG8%. 
 
 
 
 
Figure A.15ii.  Hamamatsu Nanozoomer software was used to differentiate between healthy tumour tissue 
and non-viable necrotic tumour tissue.  Classic structure changes indicative of necrosis were observed in cells 
of tumour tissue i.e. loss of cell membrane integrity, nuclear changes (pyknosis- small, densely basophilic, 
round, homogenous nucleus) and colour change from swelling/lysis of cells.  
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A.16 PDT to MC28 tumours using 0.1 mgkg-1 m-THPC dose 
PDT was performed to tumours using 0.1 mg kg-1 dose of m-THPC at a DLI of 24 h, however, no 
significant difference in percentage tumour necrosis was observed between 0.3 mg kg-1 m-THPC 
and these reduced doses with a 10J light dose. 
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Figure A.16.   The percentage area of PDT tumour necrosis following administration of either  2 J or 10 J of 
light to female Hooded Lister rats at a DLI of 24 h, after intravenous injection of either 0.3, 0.1 or 0.05 mg 
kg−1 m-THPC in ■ Foscan, ■ FosPEG2%, and ■ FosPEG 8% formulations.  Control tumour tissue (received 
either no drug or light treatment).  Data points show the mean±SD, n=4. 
Appendix I 
- 284 - 
A.17 Release of m-THPC from Liposomes 
Pegylated liposomes (FosPEG) were incubated in (A) 10%, (B) 50% or (C) 90% serum (FCS) to 
assess (i) electrical repulsion and/or interaction between lipids and plasma proteins and (ii) the 
effect on m-THPC release rate/transfer to plasma proteins from liposomes.  The fluorescence of 
mTHPC was investigated photometrically by collaborators using Fluostar (unpublished data).  The 
highest transfer of mTHPC to serum proteins was observed from FosPEG in 90% FCS following 
2h incubation periods at 37°C.   
 
Transfer of mTHPC from Fospeg to serum proteins at 37°C 
 
 
 
Figure A.17.  Concentration of mTHPC (%) in FosPEG mixtures before or after 20 nm pore filtration at RT 
(with or without liposomal fraction) following 2 h incubation at 37°C with increasing concentrations of FCS 
(A:10%, B:50% or C:90%); measured photometrically.  Data courtesy of Dr Scheglmann, Biolitec, Jena, 
Germany. 
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A.18 Stability of m-THPC from Liposomes 
To investigate the stability of pegylated liposomes the size and PDI were measured following 
incubation in 90% FCS at 37°C. Negligible changes in particle size (z-average) and polydispersity 
(PDI) were observed over 28 h. 
 
 
 
Figure A.18.  The stability of pegylated liposomes was measured by changes in particle size (z-average) and 
polydispersity indices (PDI).  Data courtesy of Dr Scheglmann, Biolitec, Jena, Germany. 
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A.19 Phase transition temperature of liposomes 
The phase transition behaviour of pegylated liposomes (DSPE-PEG+ DPPC+DPPG) with or 
without m-THPC was investigated through differential scanning calorimetry (DSC).  Unloaded 
liposomes appear to a phase-transition temperature of 41°C, whereas m-THPC loaded liposomes 
have a phase transition temperature around 37°C.  At lower temperatures lipids are in a gel phase 
(<37°C), above this temperature lipids are in a fluid phase (>40°C). 
 
 
Figure A.19.  The phase transition temperature of pegylated liposomes (DSPE-PEG+ DPPC+DPPG) with or 
without m-THPC.  Data courtesy of Dr Scheglmann, Biolitec, Jena, Germany. 
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A.20 Equation: percentage injected dose g-1 
 
%ID/g =     m-THPC in organ (µg)   * 100 
Injected dose to rat (µg)/ weight of organ (g) 
 
i.e.  Foscan in the liver at 2 h ~3.14 µg g-1 
m-THPC in organ ~3.14 µg 
 
Injected dose to rat: stock solution (mg kg-1) x average weight of rat (kg) 
0.3 mg kg-1 x 0.2 kg = 60 µg 
 
Average weight of the liver ~ 11 g 
 
Therefore, Foscan in the liver at 2 h = 57% ID% g-1 
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A.21 % Injected dose/g of liposomal m-THPC in different tissues in vivo 
 
Figure A.21i.  Semi-log plot of the percentage injected dose of m-THPC (%ID/g) in different tissues of a rat model as a function of time following an intravenous injection of 0.3 mg kg-1 
m-THPC in standard Foscan.  Data calculated from the mean m-THPC concentration (µg g-1) in each organ, hence no S.D.   
  
 
Appendix I 
- 289 - 
 
Figure A.21ii.  Semi-log plot of the percentage injected dose of m-THPC (%ID/g) in different tissues of a rat model as a function of time following an intravenous injection of 0.3 mg kg-1 
liposomal m-THPC in FosPEG 2%.  Data calculated from the mean m-THPC concentration (µg g-1) in each organ, hence no S.D.   
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Figure A.20iii.  Semi-log plot of the percentage injected dose of m-THPC (%ID/g) in different tissues of a rat model as a function of time following an intravenous injection of 0.3 mg kg-1 
liposomal m-THPC in FosPEG 8%.  Data calculated from the mean m-THPC concentration (µg g-1) in each organ, hence no S.D.   
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SECTION B: Polymeric Nanoparticles 
B.1 Nanoprecipitation Method for synthesis PLGA and PEG-PLGA NPs 
 
Fig B.1. Polymer and drug are dissolved in acetone and added to an aqueous solution containing Poloxamer 188 (surface modifier and stabiliser).  The acetone is evaporated at appropriate 
temperatures and reduced pressures leaving behind the polymer encapsulated nanoparticles with drug. Image taken from Dr Kos, University of Ljubljana.
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B.2 Absorbance spectra of PLGA and PEG-PLGA NPs in MeOD 
 
Figure B.2.  Absorbance spectra of m-THPC in Foscan and noncovalently incorporated in PLGA and 
pegylated PLGA nanoparticles in deuterated methanol (MeOD).  All solutions prepared at 10 µM m-THPC 
concentrations. 
Deuterated methanol (MeOD or CH3OD) is a solvent in which hydrogen atoms have been replaced 
with deuterium (heavy hydrogen) isotope, removing water from the solution and permitting 
complete solubilisation of m-THPC into its monomeric form, whilst prolonging the half-life of 
singlet oxygen.  Absorbance spectra of m-THPC in Foscan, PLGA and PEG-PLGA NPs were 
performed in MeOD.  No spectral shifts or peak broadening was detected for m-THPC in PLGA 
and PEG-PLGA NPs compared to Foscan in MeOD (Fig 5.5).  Absorbance maxima for all m-
THPC formulations in MeOD were recorded at 423 nm and 652 nm, respectively.  Slight 
differences in absorbance maxima (Ab = εcl) may be due to experimental error in preparing 
solutions (c = concentration). 
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B.3 Rate of m-THPC release from polymeric NPs 
 
Figure B.3.  The release rate of m-THPC (temoporfin) from pegylated (PEG-PLGA) and non-pegylated 
(PLGA) NPs over time (h) in phosphate-buffered saline (PBS) with 10% foetal bovine serum (FBS).  m-
THPC retained in NPs was measured following ultracentrifugation and dissolution of polymeric NPs in 
dimethyl sulfoxide (DMSO); established by collaborators Rojnik et al., 2012. 
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B.4 % Injected dose/g of m-THPC in polymeric NPs in different tissues in vivo 
 
 
Figure C.4. Semi-log plot of the percentage injected dose of m-THPC (%ID/g) in different tissues of a rat 
model at 24 & 72 h following an intravenous injection of 0.3 mg kg-1 m-THPC in Foscan, PLGA or PEG-
PLGA NPs.  Data calculated from the mean m-THPC concentration (µg g-1) in each organ, hence no S.D. 
  
 
Appendix I 
- 295 - 
SECTION C: Organically Modified Silica Nanoparticles 
C.1 Synthesis of pegylated ORMOSIL NPs 
 
Figure C.1  Pegylated ORMOSIL NPs covalently incorporating m-THPC prepared by the condensation of VTES (proposed by Prasad et al 2008). 
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C.2 Quantitative ORMOSIL concentrations at 24 h in vivo 
Sample IR194 SF142UF GG91UF 
Size 19 nm 95 nm 100 nm 
Fluorophore mTHPC 421 mTHPC 267 mTHPC 470 
Loading (%) 2.34 1.5 2 
PEG length 2000 2000 2000 
Binding to silica Covalent covalent covalent 
 Concentration (µg g-1) of m-THPC at 24 h 
Blood plasma 1.39 ± 0.30 1.95 ± 0.58 1.55 ± 0.63 
Liver 1.37 ± 0.31 1.46 ± 0.36 1.34 ± 0.23 
Spleen 1.25 ± 0.34 8.40 ± 2.40 20.4 ± 6.50 
Lung 2.18 ± 0.21 0.70 ± 0.18 0.54 ± 0.11 
Kidney 0.15 ± 0.05 0.40 ± 0.16 0.26 ± 0.09 
Skin 0.10 ± 0.03 0.14 ± 0.05 0.11 ± 0.03 
Tumour 0.43 ± 0.08 2.34 ± 0.33 ~ 
Table C.2.  Specifications of silica nanoparticle preparations and their uptake into different tissues at 24 h 
after 0.3 mg kg-1 injected dose, measured by concentration (µg g-1) of m-THPC.  (Data points show the mean 
± s.d., n = 4). 
C.3 ORMOSIL NPs in the spleen at 24 h 
 
Figure C.3.  Concentration of m-THPC (µg g-1) in the spleen of the HL rat at 24 h following an intravenous 
injection of 0.3 mg kg-1 m-THPC in pegylated ORMOSIL nanoparticles  ~20 nm (mono-m-THPC) or ~90 
nm (mono- or tetra*-m-THPC).  Data corrected for negative control tissue.  Data points show the mean ± SD, 
n = 3. 
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C.4 Preparing Fluorodishes: ORMOSIL NPs 
Example: eg. MC28 cells 
MC28 cells: Require a cell concentration of 1 x 104 cells/200 µL (fluorodish volume) 
Average cell count ≈ (223 + 157) = 190 cells (from a 5 mL suspension) 
                                         2 
Number of cells per ml: 190 cells x 2 x 104 = 3.8 x 106 cells mL-1 
1 Fluorodish:   1 x 104 cells   x   ____1 mL____  =   2.6 µL of cell suspension 
                                1                  380 x 104 cells 
Require 7 fluorodishes: 200 µL x 7 = 1400 µL ≈ 2 mL 
Total volume = 2 mL x (5 x 104) cells mL-1 = 1 x 105 cells 
Seeding density = 1 x 105 cells = 26.3 µL of original cell suspension 
                             38 x 105 cells 
Total volume 2 mL - 26.3 µL = 1.974 mL of supplemented DMEM media. 
C.5 Rate of m-THPC release from ORMOSIL NPs 
 
Figure C.5.  Rate of m-THPC release (%) from pegylated (blue, green & pink) versus non-pegylated 
ORMOSIL NPs (red), following the physical entrapment (non-covalent) of m-THPC, in the presence of 
different percentages of FCS (%) over time (min); established by collaborators through FRET experiments 
(Dr Mancin, Padova, Italy). 
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C.6 Transmission Electron Microscopy (TEM) Images 
 
Figure C.6.  ORMOSIL NPs were imaged using TEM to assess their size and dispersity by collaborators at 
the University of Padova under the direction of Dr F Mancin.  Fully intact ORMOSIL NPs in saline (A & B) 
≤20 nm, (C & E) 55 nm, (D) 70 nm and (F) 90 nm.  Fully decomposed ORMOSIL structure in the presence 
of Solvable™, used in chemical extraction studies, to ensure all covalently bound m-THPC is released (G & 
H) indicate the presence of silica debris and salt crystals. 
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C.7 Toxicology: liver/renal enzyme function test  
Liver enzymatic markers and reactions (Cobas®-Roche), Royal Free Hospital, UCL: 
1.  ALT – alanine aminotransferase (cytoplasm of hepatocytes): 
 
 
Rate of the NADH decrease α rate of formation of Pyruvate. 
 
2.  AST – aspartate aminotransferase (cytoplasm & mitochondria of hepatocytes): 
 
 
Rate of the NADH decrease α rate of formation of Oxaloacetate. 
Pyruvate + NADH + H
+
  ⇌ LDH ⇌ L-lactate + NAD
+
 
Oxaloacetate + NADH + H
+
  ⇌ MDH ⇌ Malate + NAD
+
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C.8 Calculations: concentration of silica injected 
IR194 IR253 IR254 IR322 IR347
Density of glass (g cm
-3
) 1.5 1.5 1.5 1.5 1.5
Diameter (nm) 19 16 17 16 20
Volume (nm
3
) 3.59E-18 2.14E-18 2.57E-18 2.1449E-18 4.19E-18
Mass of np (g) 5.39E-18 3.22E-18 3.86E-18 3.2174E-18 6.28E-18
Mass of silica (mg mL
-1
) 16.7 21.8 21.7 22.3 23.3
Number of (nps mL
-1
) 3.1E+15 6.78E+15 5.62E+15 6.931E+15 3.66E+15
m-THPC conc NP (µM) 421 555 505 499 431
m-THPC conc injection stock (mg mL
-1
) 0.286 0.378 0.344 0.339 0.293
Injection volume for  0.3 mg kg
-1
 mTHPC (mL) 0.209 0.159 0.176 0.176 0.205
Number of nps for 0.3 mg kg
-1
 mTHPC (nps kg
-1
) 6.48E+14 1.08E+15 9.9E+14 1.2199E+15 7.5E+14
Amount of silica per rat (mg kg
-1
) 3.4903 3.4662 3.8192 3.9248 4.715
Surface area of each silica np (nm
2
) 1134.262 804.352 908.038 804.352 1256.8
GG91UF* SF142UF SF232UF SF288* SF311
Density of glass (g cm
-3
) 1.5 1.5 1.5 110 1.5
Diameter (nm) 110 95 90 55 45
Volume (nm
3
) 6.97E-16 4.49E-16 3.82E-16 6.97E-16 3.82E-16
Mass of np (g) 1.05E-15 6.73E-16 5.73E-16 1.0455E-15 5.73E-16
Mass of silica (mg mL
-1
) ? ? 17.7 11.4 9.3
Number of (nps mL
-1
) ? ? 3.09E+13 1.0904E+13 1.62E+13
m-THPC conc NP (µM) 470 267 321 270 187
m-THPC conc injection stock (mg mL
-1
) 0.32 0.182 0.218 0.184 0.127
Injection volume for  0.3 mg kg
-1
 mTHPC (mL) 0.1875 0.33 0.275 0.326 0.472
Number of nps for 0.3 mg kg
-1
 mTHPC (nps kg
-1
) ? ? 8.5E+12 3.5547E+12 7.67E+12
Amount of silica per rat (mg kg
-1
) ? ? 4.8675 3.7164 4.3896
Surface area of each silica np (nm
2
) 38018.2 28356.55 25450.2 38018.2 25450.2
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C.9 % Injected dose/g of m-THPC in ORMOSIL NPs in different tissues in vivo 
 
Figure C.9. Semi-log plot of the percentage injected dose of m-THPC (%ID/g) in different tissues of a rat 
model as a function of time following an intravenous injection of 0.3 mg kg-1 m-THPC in Foscan or small 
(IR253.4) or larger (SF232UF) ORMOSIL NPs.  Data calculated from the mean m-THPC concentration (µg 
g-1) in each organ, hence no S.D. 
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C.10 % ID/g of m-THPC in targeted cRGD ORMOSIL NPs in different tissues at 24 h in vivo 
 
Figure C.10. Semi-log plot of the percentage injected dose of m-THPC (%ID/g) in different tissues of the 
HL rat at 24 following an intravenous injection of 0.1 mg kg-1 m-THPC in either targeted cRGD-ORMOSIL 
NPs or inactive targeted cRAD-ORMOSIL NPs.  Data calculated from the mean m-THPC concentration (µg 
g-1) in each organ, hence no S.D. 
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MJ Bovis, JH Woodhams, M Loizidou, D Scheglmann, SG Bown, AJ MacRobert (2012).  
Improved in vivo delivery of m-THPC via pegylated liposomes for use in photodynamic 
therapy.  Journal of Controlled Release 157 (2): 196-205.  Impact factor 7.6. 
 
M Rojnik, P Kocbek, F Moret, C Compagnin, L Celotti, MJ Bovis, JH Woodhams, AJ 
Macrobert, D Scheglman, W Helfrich, MJ Verkaik, E Papini, E Reddi, J Kos (2012).  In 
vitro and in vivo characterization of temoporfin-loaded PEGylated PLGA nanoparticles for 
use in photodynamic therapy.  Nanomedicine (5): 663-77.  Impact factor 6.9. 
 
MD Ball, IC Bonzani, MJ Bovis, A Williams, MM Stevens (2011).  Human periosteum is 
a source of cells for orthopaedic tissue engineering: a pilot study.  Clinical Orthopaedics 
and Related Research 469(11):3085-93.  Impact factor 2.78. 
 
Papers being prepared for submission 
 
MJ Bovis, S Noimark, JH Woodhams, CWM Kay, J Weiner, W Peveler, A Correia, M 
Wilson, IP Parkin, AJ MacRobert.  Photosensitised generation of singlet oxygen in silicone 
polymer substrates doped with methylene blue and nanogold for antimicrobial 
applications. (Manuscript in preparation). 
 
MJ Bovis, JH Woodhams, M Rojnik, P Kocbek, R Fisher, J Kos, AJ Macrobert.  Assessing 
the efficacy of photodynamic therapy in vivo using m-THPC loaded PLGA nanoparticles. 
(Manuscript in preparation). 
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tetra(hydroxyphenyl)chlorin entrapped in pegylated ORMOSIL nanoparticles. (Manuscript 
in preparation). 
 
Conference Presentations 
 
12th World Congress of the International Photodynamic Association (IPA), June 2009, 
Seattle, Washington, USA.  MJ Bovis: Improved m-THPC delivery via novel pegylated 
liposomal nano-carriers. 
 
13th Congress of the European Society for Photobiology in conjunction with the 2nd 
Conference of the European Platform for Photodynamic Medicine (EPPM), Sept 2009, 
Wroclaw, Poland.  MJ Bovis: Pharmacokinetics of novel pegylated liposomal nano-carriers 
for improved m-THPC delivery. 
 
8th International Symposium of European Platform of Photodynamic Medicine, Oct 2010, 
Brixen, Italy.  MJ Bovis: Improving the delivery of m-THPC via liposomal nanocarriers. 
 
14th Congress of the European Society of Photobiology, Sept 2011, Geneva, Switzerland.  
MJ Bovis: Using PEGylated PLGA nanoparticles to enhance the delivery of m-THPC for 
in vivo PDT. 
 
36th Congress of the American Society of Photobiology, June 2012, Montreal, Canada.  MJ 
Bovis: Investigating the Delivery of m-THPC incorporated in pegylated PLGA 
nanoparticles for in vivo PDT. 
 
International Conference on Nanotechnology in Medicine, Nov 2012, London, UK.  MJ 
Bovis:  Investigating the Delivery of m-THPC incorporated in Pegylated PLGA 
Nanoparticles for in vivo PDT. 
 
Society of Academic & Research Surgery, Jan 2013, London, UK.  MJ Bovis: m-THPC 
delivery via pegylated PLGA nanoparticles for in vivo photodynamic therapy (PDT). 
 
15th Congress of the European Society of Photobiology, Sept 2013, Liege, Belgium. MJ 
Bovis: Photosensitised generation of singlet oxygen in silicone polymer substrates doped 
with methylene blue for antimicrobial applications. 
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